Letter of Agreement PLAINTIFF TRIAL EXHIBIT Confidential TEVA_MDL_A_00849961 P-28694_00001 P-28694 _ 00001



Cephalon, Inc 41 Moores Road Frazer, PA 19355 tel 610 344 0200

fax 610 344 0065 www.cephalon.com

Pre-Approved Template Archiving Cover Memo

To:	Legal Department – Archives
From:	Kimber Titus x86766
Date:	January 15, 2009
Re:	Fully-Executed Agreement(s) for Archiving in Central Files
I have attached	d hereto a fully-executed
☐Mutual Co ☐Clinical To	ial Disclosure Agreement onfidential Disclosure Agreement rial Agreement inical Trial Agreement t Agreements
I have <u>comple</u>	sted the checklist below in preparation for archiving in Central Files:
1 1	and finalized this agreement in accordance with the most currently approved ted on the Legal Department Intranet Page.
	nges to the template agreement were made, I forwarded the agreement to the Legal or review and approval.
above, or for	ized Cephalon officer has signed the agreement (at the level of Vice President or CDAs, a Director or Senior Director who has a valid Delegation of Authority to file in the Legal Department).
The agreen	ment(s) is fully executed by both parties and both original signatures are attached.
Thank you!	



Cephalon, Inc.
41 Moores Road
PO Box 4011
Frazer, PA 19355
Phone 610 344-0200
Fax 610-344-0065

INDEPENDENT EDUCATIONAL PROGRAM GRANT AGREEMENT

This Agreement is entered into as of this 16th day of December, 2008, by and between Cephalon ("Cephalon"), located at 41 Moores Road, Post Office Box 4011, Frazer, PA 19355, and Montefiore Medical Center ("Provider") located at CCME, 3301 Bainbridge Avenue, Bronx, NY 10467 and Asante Communications, LLC ("Educational Partner") located at 800 Third Avenue, 9th Floor, New York, NY 10022.

WHEREAS, Cephalon has reviewed Provider's grant request to support a medical education program ("Program"); and

WHEREAS, Cephalon has determined that the Program has the potential to address educational gaps and improve patient care; and

WHEREAS, it is the intent of the parties to ensure that the Program will be independent, objective, balanced, scientifically rigorous, and have reasonable expectations of meeting its educational objectives so that it will not be viewed by the United States Food and Drug Administration ("FDA") as promotional and that Cephalon will not be viewed as responsible for its content; and

WHEREAS, Cephalon agrees to provide funding for the Program under the conditions set forth below.

NOW THEREFORE, Provider and Cephalon agree to the following terms under this Agreement:

- <u>Title of Program.</u> The Educational Program is entitled "Persistent and BTP: Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies," and a copy of the grant request for the Program is attached hereto as Exhibit A.
- Type of Program. The Program is:

igtimesaccredited (e.g	g., continuing n	nedical educat	tion or "CME"); or
□an independe⊦	nt program whe	ere CE credits	will not be offered.

- 3. <u>Educational Partner</u> The Provider ⊠shall ☐ shall not use a third party that will provide assistance in support of the Program ("Educational Partner").
- 4. The name of the Educational Partner is Asante Communications, LLC.
- 5. <u>Educational Components</u>. The expected components of the Program (e.g., number of live meetings, CD ROM, web-based, etc.) are as follows:
 - (a) Thirteen Live National Meetings;
 - (b) Two Additional Live Meetings;
 - (c) Five Web Tactics;
 - (d) One Print Piece;

- (e) Three Print Supplements;
- 6. <u>Program Purpose</u>. The Program is for scientific and educational purposes only, and is based on established bona fide and independently verifiable patient and/or practitioner needs or gaps in healthcare performance, and is not intended to promote a Cephalon product, directly or indirectly. The Program is not a repeat performance of a prior program.

7. Grant Amount Funding Arrangements.

- (a) Cephalon will provide support for the Program by means of an educational grant in the total amount of \$1,316,295, as set forth in the budget attached hereto, or a pro rata amount based on the actual work performed and expenses incurred by Provider in accordance with the Budget. If the Program is canceled or terminated prior to completion, Provider shall return the grant, or any unused portion thereof, to Cephalon within thirty (30) days of such termination or cancellation. Provider shall have full responsibility for all funding arrangements of the Program, including any funding to be provided to its Educational Partner. Payment terms of the grant shall be made in accordance with any schedule/criteria provided in the Budget.
- (b) Within ninety (90) days of completion of the Program, Provider shall provide Cephalon with a detailed reconciliation of actual expenses incurred, and to the extent Cephalon has overpaid Provider for same, Provider shall provide a refund to Cephalon within thirty (30) days thereafter. Such detailed reconciliation shall be forwarded to Cephalon at the address above to the attention of Bhaval Shah Bell, PhD, Medical Affairs.
- (c) Provider may not use funds provided by Cephalon to pay travel, lodging, honoraria or personal expenses for non-faculty attendees. Grant funds may be used to reduce the overall registration fees for attendees. Grant funds may not be used to purchase capital equipment or to provide general operational support for an institution. Funds for hospitality shall not be provided, except that funds may be used for modest meals or receptions that are held as part of the Program, but such events shall not compete with, nor take precedence over, educational events. The appropriateness of any reception shall be at the sole discretion of the Provider, and Provider shall have final decision-making authority in connection with any such activities.
- (d) Funds may be used by the Provider to permit medical students, residents, fellows or other health care professionals in training to travel to and attend the Program; provided, however, that the selection of such students, residents or fellows who receive funds is made by either the

academic or training institution, or, if by the Provider, such selection shall be made with the full concurrence of the academic or training institution.

- 8. Objectivity and Balance. Provider shall retain full responsibility for control of the content of the Program and shall ensure that the following requirements are met:
 - (a) The Program material/information will be objective, balanced and free from commercial bias. All topics shall be treated in an impartial, unbiased manner. All discussions shall include a range of views about each class of drug and disease treatment options. Information shall not unfairly represent a spectrum of views favoring a product or class of products marketed by Cephalon or any other company. The title of the Program will fairly and accurately represent the scope of the presentation.
 - (b) Provider agrees that neither Cephalon nor its agents shall control the content of the Program. Provider agrees that there will be no scripting, targeting of points for emphasis, or other activities by Cephalon or its agents that are designed to influence the content of the Program. Cephalon personnel will not attend content development meetings unless requested in writing by the Provider or the Educational Partner make presentations of disease data and/or Cephalon product data to faculty. In this instance, Cephalon personnel may stay only for this portion of the meeting, and the accredited provider must be in attendance.
 - (c) If requested, in writing, by the Provider or Educational Partner, Cephalon Medical personnel may also provide written material on a Cephalon product or compound in development, such as specific product data, manuscripts, posters, product labels and other scientific material (not in slide format) in accordance with internal corporate guidelines based on the level of information that is acceptable to disclose.
 - (d) Cephalon shall not review the Program for medical accuracy or completeness and the Provider and/or Educational Partner (if any) agree that they will not make such a request of Cephalon.
 - (e) If a product marketed by Cephalon is the subject of discussion, the data will be objectively selected and presented, with an accurate reflection of favorable and unfavorable information about the product and shall also include a balanced discussion of prevailing information on alternative products and /or therapies.
 - (f) Any suggestions of superiority of one product or treatment over another will be supported by the body of available data and will not result from selective presentation or emphasis on data favorable to a particular treatment.
 - (g) Provider represents that neither it nor the Educational Partner (if any) has either an open complaint or decision from the Accreditation Council for Continuing Medical Education ("ACCME") or the FDA that a program

provided by the Provider or the Educational Partner failed to meet standards of independence, balance, objectivity, or scientific rigor.

- 9. Risk Minimization Action Plan. Cephalon provides the following Risk Minimization Action Plan ("RiskMAP") information to all Providers. Neither Cephalon nor its agents shall influence or control whether a product marketed by Cephalon is the subject of discussion. A RiskMAP is a strategic safety program designed to meet specific goals and objectives in minimizing known risks of a product while preserving its benefits. Any product marketed by Cephalon that is approved with a RiskMAP, and the key safety-related health outcomes outlined in that RiskMAP, are listed in Exhibit B. Provider agrees that it is aware of the RiskMAP(s) and the key safety messages.
- 10. No Faculty Selection. Provider shall retain full responsibility for the selection of the presenters, authors, moderators, and/or other faculty (hereinafter referred to collectively as "Faculty"). Provider and/or Educational Partner (if any) shall not request recommendations for Faculty from Cephalon
- 11. <u>Disclosures</u>. Provider will ensure meaningful disclosure of limitations of data (e.g., ongoing research, interim analyses, preliminary data, or unsupported opinion). Provider will require that Faculty disclose when a product is not approved in the United States for the use under discussion.
- 12. <u>Question and Answer Session</u>. To the extent the Program is a presentation, Provider will ensure meaningful opportunities for questioning by the audience.
- 13. <u>Financial Relationships</u>. Provider will ensure meaningful disclosure to the audience of Cephalon funding and any significant relationship between individual Faculty and Cephalon. All meaningful disclosure(s) shall also be made in any written materials, including, but not limited to, announcements, brochures, syllabi and enduring material. Disclosures shall not mention product trade names.
- 14. Representations and Warranties. Provider represents that:
 - (a) Neither it nor the Educational Partner, if any, provides marketing, advertising, public relations, market research, medical education services or other consulting services (e.g., support for advisory boards) to any other department within Cephalon ("Marketing Activities");
 - (b) If Provider or the Educational Partner has an affiliated company that provides Marketing Activities to Cephalon, Provider has instituted appropriate controls and safeguards to ensure the Program (i) remains independent, objective, balanced and scientifically rigorous, (ii) is not intended to promote a Cephalon product, directly or indirectly, and (iii) is not in any way biased due to the affliated company's relationship with Cephalon;

- (c) Provider has determined that it is appropriate to use the Educational Partner in light of the requirements under this Agreement; and
- (d) If Provider or its Educational Partner employs a former Cephalon employee who worked at Cephalon at anytime during the most recent year and who had marketing responsibility in the therapeutic area that will be covered by the Program, then that former employee will not have any role in the planning, development or delivery of the Program.
- 15. <u>Invitations/Enduring Materials</u>. The Program audience will be selected by the Provider. The Provider shall be responsible for distributing materials about the Program, including invitations, reminder notices, and business reply cards that can be used by third parties to obtain any enduring Program material from the Provider.
- 16. Ancillary Promotional Activities. To the extent the Program is a live presentation, no promotional activities or product advertisements will be permitted in the same room as, or in an obligate path to, the Program. If the Program is a teleconference or webcast, no product advertisements or promotional activities will be permitted immediately prior to, during, or immediately after the delivery of the Program. If the Program is in print format, no product advertisements or promotional materials will be interleaved within the pages of the Program. If the Program is made available electronically, no product advertisements or promotional materials will appear within the Program material or interleaved between computer windows or screens of the Program, all as stipulated in ACCME Guidelines.

- 17. Compliance with Guidelines. Provider represents that the Program, including development of the Program and Program materials, shall conform to the American Medical Association ("AMA") Guidelines on Gifts to Physicians, the AMA Ethical Opinion on Continuing Medical Education, the ACCME Standards for Commercial Support, the FDA December 3, 1997 Final Guidance for Industry-Supported Scientific and Educational Activities, and the Pharmaceutical Research and Manufacturers Association ("PhRMA") Code on Interactions with Healthcare Professionals.
- 18. <u>Logistical Status Reports</u>. Provider and/or Educational Partner shall provide periodic reports to Cephalon regarding the management and logistics of Program components.

19. Miscellaneous.

- (a) No party shall use the other party's or its affiliates' name or trademarks for publicity or advertising purposes, except with the prior written consent of the other party.
- (b) Provider agrees to obtain all consents, authorizations, approvals and releases that may be necessary for the production of the Program and of any written materials prepared in connection therewith.

(c) No term, condition or other provision of any attachment or addendum to this Agreement shall supersede any term, condition or other provision of this Agreement, and with respect to any inconsistency or ambiguity, the Agreement shall control.

IN WITNESS WHEREOF, the parties, by their duly authorized representatives, agree to comply with all the terms and conditions of this Agreement.

MONTEFIORE MEDICAL CENTER	CEPHALON, INC.
By: Alm Jay Feld Name: <u>STEVEN SAY FELD</u> Title: <u>ASSOCIATE DIRECTOR</u> , CCME	By:
The above signatory is a duly authorized corporate officer of the IEP Provider.	T
Date: 12/23/08 Tax ID#: 13 1740114	Date: PROVED PROVED TO LEGAL FORM LEGAL DEPT. FINANCE F

ASANTE COMMUNICATIONS LLC
6/1/+
By: () et ()
Name: FETER HVRWITZ
Title: PRESIDENT, MANAGING DIRECTOR
The above signatory is a duly authorized corporate officer of the Educational Partner.
Date: 12/24/08
Tax ID#: 80-105/57

Exhibit A

Copy of Grant Request



Albert Einstein College of Medicine of Yeshiya Linversity

Center for Continuing Medical Education

Bridging the Gap Between Education and Practice



The University Hospital and Academic Medical Center for the Athert Earstein College of Medicine

December 8, 2008

Steven Jay Feld Assumate Intector

> Ms. Karen Roy Director of Medical Education Cephalon 41 Moores Road Frazer, PA 19355

Dear Ms. Roy:

Per your request for additional information, please find below a more detailed overview of the Level and Type of data to be collected via the patient questionnaire.

Under the guidance of the Albany Medical Center's Institutional Review Board (IRB), and approved by Albert Einstein College of Medicine, CME, the Stage III Durable Outcomes measurement will be used to gather non-biased, independent and measurable information for the proposed Outcome Study.

As mentioned in the grant, the Stage III patient questionnaire will assess improvements in the management of persistent and breakthrough pain with patients whose physicians participated in the preceptorship program, when compared to patients who were under the care of control group physicians who did not participate in the preceptorship. The questionnaire will consist of 5-multiple choice questions, each inquiring into their perceptions of the clinician's attentiveness to the pain complaint. Sample questions that may be included, pending further discussion and approval by the Albany IRB, Albert Einstein College of Medicine and based on the approach utilized by Dr. Michael Brennan are as follows:

When compared to the beginning of the year has your clinician devoted more time to discuss the "ups-and-downs" in the severity of your chronic pain?

Parameters to be Measured

- 2 Significantly improved
- 1 Improved
- No change

When compared to the beginning of the year has your clinician devoted more time to discuss changes in your pain severity caused by increased activity?

Parameters to be Measured

- Significantly improved
- : 1 Improved
- 0 No change

3364 Barabridge Norme Bronx, NY 10467 Proxit 748 920 6674 Fix 718 798 2336 meeting org. sfeld@monteflore.org

Confidential

TEVA_MDL_A_00849971

P-28694 _ 00011

Page -2-

When compared to the beginning of the year has your clinician devoted more time to discuss how to treat episodes when your pain is at its worst?

Parameters to be Measured

- Significantly improved
- 1 Improved
- 10 No change

Lastly as a point of clarification, the sole data source from patients will be the patient questionnaire. There aren't any needs for the Durable Outcomes Evaluation to review or collect data from patient charts. Patients will participate in this program on a strictly voluntary basis, can decide not to participate at any time, and will be assured of the confidentiality of their responses. Dr. Charles Argoff and the Albany Medical Center IRB will supervise the administration and data analysis of Stage III, in collaboration with Dr. Hatcher (Associate Dean of CME at Einstein and Director of Research and CME at Montefiore) and Asante Communications.

We hope this clarifies the Stage III section of the proposed grant. As always, should you have any further questions, please do not hesitate to contact me with any questions.

Sincerely,

Steven Jay Fold

Mary Bull

ce: Peter Hurwitz

3301 Bambridge Weine Bronx XY 10467 — Proxi 718 920 6674 — FAX 718 798 2336 — inceme.org — sfeld@montefiore.org



Bridging the Gap Between Education and Practice"



The University Hospital and Academic Medical Center for the Albert Einstein College of Medicine

November 20, 2008

Educational Grant Review Committee Cephalon

Dear Sir and/or Madam:

On behalf of the Albert Einstein College of Medicine & Montefiore Medical Center, Center of Continuing Medical Education (CCME) and our Educational Collaborator and Joint Sponsor, Asante Communications LLC, please find the requested clarification information for Grant #2569.

Albert Einstein would like to reaffirm its commitment to providing high quality education. Of particular importance to us is adapting and refining each successive activity as the year unfolds. Applying our learnings from one program to the next invariably improves the substance of the program, and provides up-to-date insights from the faculty and participants alike.

Upon further discussion with our education collaborator, Asante Communications, in lieu of providing a specific book for the participants, originally suggested to be distributed to after the Full-day Regional Meeting and the Preceptorship program, it would be more prudent to provide a Reference Guide to these participants, in addition to quarterly online updates.

In addition, we see considerable benefits in combining the enduring material of the Teleconferences and the Cases and Commentary into a single enduring material, rather than producing two separate activities. This will limit any overlap that may occur from the content of these two activities. We would like to present this as an attractive option.

Enduring materials posted online will be targeted to pain specialists. Websites that are selected will have an audience which consists of pain specialists, including anesthesiologists, oncologists, neurologists, and physiatrists, among others.

In addition to being an accredited activity, the Position Paper that will be developed from the International Experts Forum will be submitted to a peer-reviewed journal for publication. We will request permission from the journal prior to submission of the article to be published as a CME activity in their journal and elsewhere. This will enhance the current BTP literature.

1361 Barrbridge Avenue Bronx, NY 10467 — Phoxi 718 920 6674 — FA 718 798,2336 — mecinic org

- emegraontefiote org

We would also like to comment further on two select items. First, as noted in the grant, nurses, nurse practitioners and physician assistants represent an important target audience and as such we will be making a concerted effort to recruit these pain clinicians for each educational activity. In addition, we would like to propose that a *Cases and Commentary* workshop be held at the Oncology Nurses Society (ONS) in 2009. An enduring activity will be developed from this Workshop and will extend the reach of this very valuable educational activity. This activity will be accredited for continuing education (CE) credit for nurses by an approved academic institution or noted medical center, such as Montefiore Medical Center. Further, as noted in the accompanying materials, one of the workshops will be held at the American Pain Society, a multidisciplinary organization that requires triple accreditation for all programs.

The other items uploaded for clarification purposes include:

- · Timeline on all proposed activities
- Schematic of Chronic Pain Management Preceptorship (CPMP)
- Full-Day Regional Budget (clarification on Reference Guide)
- Preceptorship Budget (clarification on Reference Guide)

If you need any further information, or have any questions that relate to this grant request, please contact me at 718 920-6674, ext. 232.

On behalf of Albert Einstein College of Medicine & Montefiore Medical Center, I would like to thank Cephalon for the continued consideration of this request.

Sincerely,

Steven Jay Feld

(330) Bambridge Avenue Bronx, N.Y. 10467 — Phoxi: 718 920 6674 — Fxv 718 798 2336 — micrate org — crite@monteflore.org





The state of the s

DESCRIPTION / CATEGORY	ASSUMPTIONS		COST	TOTAL COST
	NE ZOBE			
	Rate	Persona		
rotocol Director Honorarium	\$2,000		\$2,000	
aculty Honoraria (Data Review/Interpr	etation \$2,000	4	\$8,000 TOTAL	£40,000,00
The second secon	FOR MANAGEMENT OF A	激 せんたる 経済 一番も	TOTAL	\$10,000.00
Protocol Review and Approval		《红旗》形式即为"水"。	kanda ay seringa kalanda kandid	\$5,000.00
Totocol Review and Approval	Continue to the second	NACIONE A	是我这里家里来 都是	
Technical Programming/Quarterly	Webinars		Maria Carlo Car	\$6,000.00
Online Hosting and Monthly Mainte				\$2,500.00
Email Recruitment Stage II(Control		ups)		\$2,500.00
Data Analysis/Statistician			· · · · · · · · · · · · · · · · · · ·	\$5,000.00
Patient Enrollment for Stage III				\$1,000.00
	SALE HOLE SEEDING			
Miscellaneous expenses				\$1,500.00
TOTAL OOPs				\$33,500.00
Management Fee				\$15,000.00
ncludes;	4. 4			
' Manage design and production of all ma ' Grant/Needs development	neriais			
*Administer outcomes tools (pre-test, pos	t-test and follow up que.	stions)		ŝ
Analyze results from pre-test, post-test a		31.07.07		
*Liaise with IRB and faculty	,			
*Manage all aspects of Patient enrollmen	t under IRB supervision			î
* Final reconciliation				
Internal IRB compliance				\$25,000.00
Content Development/Editorial/Creativ	'e Fee			\$25,000.00
Content Development Includes. * Development of pre-test, post-test and I	follow-up questions			
* Liaise with faculty	onen up queditions			
*Development of Case Vignettes				
*Development of Patient Survey				
*Development of outcomes report	t			
*Development of ideas for future education				
* Editonal/copy editorial review and forms	atting			
Creative Fee includes:				
 Design of evaluation survey All costs associated with project design 	and development			
TOTAL FEES	una development			\$40,000.00
TOTALTELO				
GRAND TOTAL				\$73,500.00
Variance +/- 10%				
SPECIAL NOTE:			ellation of program	

obj. Barbardge Avenue Bron. Na 2016. — Press (1896) cont. — The 1879 - 56 — no me obj. — time montelior obj.



DESCRIPTION / ASSUMPTIONS C	DST	TOTAL COST
Rate Persons Course Director \$3,500 1		\$3,500.
Faculty Honoraria \$2,000 5		\$10,000
Albert Flenklin Annual Mathematical Confliction From	TO A SECTION ASSESSMENT OF THE PARTY OF THE	\$12,500
Albert Einstein Accreditation and Certificate Fee	2.5 hrs.	312,500
List Purchase		\$1,500
	· · · · · · · · · · · · · · · · · · ·	\$500
Survey Distribution Development of		\$500
Participant Database with		
tracking software Cost/Tax/ Persons/ Number of		\$3,250
Food and Beverage Gratuity Quantity Functions	2000	
To Include Breakfast(s) \$40 20 1	\$800 TOTAL	\$800
Production/Prince 150 Bindors	S D S S S S S S S S S S S S S S S S S S	\$1,500
Production/Printing 150 Binders Reference Guide \$ 30 200		\$6,000
Purchase artwork		\$7 <u>5</u> 0
Transcription Services	an en	\$3,000
Participant Communications (Teleconference/E-Communications)		\$2,000
Creative Design for Program Template		\$2,500
Express Mail Shipping (faculty mailings, materials shipping)	通用联系基础(Menory)型	\$1,000
Postage for partiticipant materials 150		\$1,000
Assembly of participant material 150 Miscellaneous expenses other than group		\$500 \$500
OOP TOTAL		\$50,800.
	areni y yeshtub:	enskere in die
Management Fee	an mapalina and the contract of the contract of the	\$32,000
Includes:		
* Timeline development & maintenance		
* Timeline development & maintenance *Manage internal team and project flow		
*Manage internal team and project flow *Coordinate faculty invitational process including invitations, confirmations, and enri		
*Manage internal team and project flow *Coordinate faculty invitational process including invitations, confirmations, and enn *Coordination of participants involvement and gathering of necessary information (E *Coordinate all initial faculty, faculty/participant, and quarterly teleconference calls	lios, etc)	
*Manage internal team and project flow *Coordinate faculty mixitational process including invitations, confirmations, and enri. *Coordination of participants involvement and gathering of necessary information (E. *Coordinate all initial faculty, faculty/participant, and quarterly teleconference calls. *Manage the development of database of program and apprpropriate clinician tracks.	ng	
*Manage internal team and project flow *Coordinate faculty invitational process including invitations, confirmations, and enri- *Coordination of participants involvement and gathering of necessary information (E *Coordinate all initial faculty, faculty/participant, and quarterly teleconference calls *Manage the development of database of program and appripropriate clinician tracki *Manage design and production of all meeting materials/reference binders including *Traffic meeting materials for review and production.	ng	
*Manage internal team and project flow *Coordinate faculty invitational process including invitations, confirmations, and entry *Coordination of participants involvement and gathering of necessary information (E *Coordinate all initial faculty, faculty/participant, and quarterly teleconference calls *Manage the development of database of program and appropriate clinician tracki *Manage design and production of all meeting materials/reference binders including *Traffic meeting materials for review and production *Arrange for honoraria	ng	
*Manage internal team and project flow *Coordination of participants involvement and gathering of necessary informations, and enti- *Coordination of participants involvement and gathering of necessary information (E *Coordination eli initial faculty, faculty/participant, and quarterly teleconference calls *Manage the development of database of program and appropriate clinician tracki *Manage design and production of all meeting materials/reference binders including *Traffic meeting materials for review and production *Arrange for honorarie *Grant/Needs development *Reconciliation management	itos, etc) n g I bios	
*Manage internal team and project flow *Coordinate faculty invitational process including invitations, confirmations, and entry *Coordinate and invital faculty, faculty/participant, and quarterly teleconference calls *Manage the development of database of program and appripropriate clinician tracki *Manage design and production of all meeting materials/reference binders including *Traffic meeting materials for review and production *Arrange for honoraria *Grant/Needs development *Reconciliation management *Certification collaboration (joint sponsorship, comphance review, Albert Einstein liae	itos, etc) n g I bios	
*Manage internal team and project flow *Coordinate faculty minitational process including invitations, confirmations, and enn *Coordination of participants involvement and gathering of necessary information (E *Coordination if initial faculty, faculty/participant, and quarterly teleconference calls *Manage the development of database of program and appripropriate clinician tracki. *Manage design and production of all meeting materials/reference binders including *Traffic meeting materials for review and production *Arrange for honoraria *Grant/Needs development *Reconciliation management *Continication collaboration (joint sponsorship, compliance review, Albert Einstein lia *Internal CME compliance *Content Development**Editorial/Creative Fee	itos, etc) n g I bios	\$35,250
*Manage internal team and project flow *Coordinate faculty minitational process including invitations, confirmations, and enni *Coordination of participants involvement and gathering of necessary information (E *Coordinate all initial faculty, faculty/participant, and quarterly teleconference calls *Manage the development of database of program and appropriate clinician tracki. *Manage design and production of all meeting materials/reference binders including *Traffic meeting materials for review and production *Arrange for honoraria *Grant/Needs development *Reconciliation management *Certification collaboration (joint sponsorship, compliance review, Albert Einstein lia *Internal CME compliance	itos, etc) n g I bios	\$35,250
*Manage internal team and project flow *Coordinate faculty miritational process including invitations, confirmations, and entr. *Coordinate all initial faculty, faculty/participant, and quarterly teleconference calls. *Manage the development of database of program and appripropriate clinician trackit. *Manage design and production of all meeting materials/reference binders including. *Traffic meeting materials for review and production. *Arrange for honoraria. *Grant/Needs development. *Reconciliation management. *Certification collaboration (joint sponsorship, compliance review, Albert Einstein lia. *Internal CME compliance. Content Development/Editorial/Creative Fee. Includes: *Collaboration with faculty on agenda and discussion guide development.	itos, etc) n g I bios	\$35,250
*Manage internal team and project flow *Coordinate faculty invitational process including invitations, confirmations, and entry *Coordinate and invital faculty, faculty/participant, and quarterly teleconference calls *Manage the development of database of program and appropriate clinician trackit *Manage design and production of all meeting materials/reference binders including *Traffic meeting materials for review and production *Arrange for honoraria *Grant/Needs development *Certification collaboration (joint sponsorship, compliance review, Albert Einstein lies *Internal CME compliance Content Development/Editorial/Creative Fee Includes: *Develop learning objectives	itos, etc) n g I bios	\$35,250
*Manage internal team and project flow *Coordinate faculty ministronal process including invitations, confirmations, and entri *Coordinate and initial faculty, faculty/participant, and quarterly teleconference calls *Manage the development of database of program and appropriate clinician tracki. *Manage design and production of all meeting materials/reference binders including *Traffic meeting materials for review and production *Arrange for honoraria *Granti/Needs development *Reconciliation management *Certification collaboration (joint sponsorship, compliance review, Albert Einstein lia *Internal CME compliance Content Development/Editorial/Creative Fee Includes: *Collaboration with faculty on agenda and discussion guide development *Collaboration with faculty on agenda and discussion guide development *Collaboration with faculty on discussion guide for feleconference calls *Lusse with presenters (chair, faculty) *Editonal/copy editoral review and formalting	itos, etc) n g I bios	\$35,250
*Manage internal team and project flow *Coordinate faculty invitational process including invitations, confirmations, and entry *Coordination of participants involvement and gathering of necessary information (E *Coordinate all initial faculty, faculty/participant, and quarterly teleconference calls *Manage the development of database of program and appripropriate clinician trackit *Manage design and production of all meeting materials/reference binders including *Traffic meeting materials for review and production *Arrange for honoraria *Grant/Needs development *Gerification collaboration (joint sponsorship, compliance review, Albert Einstein lia *Internal CME compliance Content Development/Editorial/Creative Fee Includes: *Develop learning objectives *Collaboration with faculty on agenda and discussion guide development *Collaboration with faculty on discussion guide for teleconference calls *Liase with presenters (chair, faculty)	itos, etc) n g I bios	\$35,250
*Manage internal team and project flow *Coordinate faculty ministronal process including invitations, confirmations, and entri *Coordinate faculty ministronal process including invitations, confirmations, and entri *Coordinate all initial faculty, faculty/panticipant, and quarterly teleconference calls *Manage the development of database of program and appropropriate clinician tracki *Manage design and production of all meeting materials/reference binders including *Traffic meeting materials for review and production *Arrange for honoraria *Grant/Needs development *Reconcitation management *Certification collaboration (joint sponsorship, compliance review, Albert Einstein lia *Internal CME compliance *Content Development/Editorial/Creative Fee Includes: *Collaboration with faculty on agende and discussion guide development *Collaborate with faculty on discussion guide for teleconference calls *Lisse with presenters (chair, faculty) *Editonal/copy editorial review and formalting *Development of program logo	itos, etc) n g I bios	
*Manage internal team and project flow *Coordinate faculty initiational process including invitations, confirmations, and entry *Coordination of participants involvement and gathering of necessary information (E *Coordinate all initial faculty, faculty/participant, and quarterly teleconference calls *Manage the development of database of program and appropriate clinician tracki *Manage design and production of all meeting materials/reference binders including *Traffic meeting materials for review and production *Arrange for honoraria *Grant/Needs development *Certification collaboration (joint sponsorship, compliance review, Albert Einstein lia *Internal CME compliance Content Development/Editorial/Creative Fee Includes: *Develop learning objectives *Collaboration with faculty on agenda and discussion guide development *Collaboration with faculty on discussion guide for feleconference calls *Liasse with presenters (chair, faculty) *Editonal/copy editorial review and formatting *Development of program logo *All costs associated with meeting content design and development	itos, etc) n g I bios	\$67,25 0.
*Manage internal team and project flow *Coordinate faculty invitational process including invitations, confirmations, and entry *Coordination of participants involvement and gathering of necessary information (E *Coordination of invital faculty, faculty/participant, and quarterly teleconference calls *Manage the development of database of program and appropriate clinician trackit *Manage design and production of all meeting materials/reference binders including *Traffic meeting materials for review and production *Arrange for honoraria *Grant/Needs development *Reconcitation management *Certification collaboration (joint sponsorship, compliance review, Albert Einstein lia *Internal CME compliance Content Development/Editorial/Creative Fee Includes: *Collaboration with faculty on agenda and discussion guide development *Collaboration with faculty on discussion guide for teleconference calls *Lieise with presenters (chair, faculty) *Editonal/copy editorial review and formalting *Development of program logo *All costs associated with meeting content design and development	itos, etc) n g I bios	\$35,250 \$67,250. \$118,050.0

with the variety $x \in \mathbb{R}^n$, $x \in \mathbb{R}^n$



Bring of a Gar Brianth to war and Fractice.



plo I inversity Toyal it and youlen is Mede at Center for the About Foot on College of More to

All en Emistens en de pend Medicina Os de en miteración

		134.3 法规则				
			Male			
ESCRIPTION /	to the time the contractor, there is a	ASSUMPTI	ONS		cost	TOTAL COST
CATEGORY			135 (99) 11 0 013		Marine 1970 Andrews	
and the second	ilanina kata 1910	Rate	Persons	: "dan kan kan Beri Co" i af	Secular Att attle Statemen a within the	Land St.
ourse Directo	r Honorarium	\$3,500	1		\$3,500	
hair Honorari		\$2,500	1	\times	\$2,500	
aculty Honora	ria	\$2,000	4	$\angle \Delta$	\$8,000	
					TOTAL	\$14,000.0 \$9,500.0
	Accreditation a					\$3,500.0
IDert Einstein	Outcomes Mea	Surement	90 ************************************	co-Alto	a de la companya de	
otel Accomm		ALTONOMICS OF PROPERTY	The School of the State of the	Maria de la companya		
				NII - 1-4-		
To Include		\$275	Persons 6	Nights 1	\$1,650	
To Include.	Accreditor	\$275	 -		\$275	
	Asante	\$275	3	1	\$825	
	Additional					
	Suppliers [\$275	2	1	\$550	62 200 0
				0	TOTAL	\$3,300.0
To Include:	Faculty	\$600	Persons 6	Service Coach	\$3,600	
	Accreditor	\$600	1	Coach	\$600	
	Asante	\$600	0	Coach	\$0	
	Additional					
	Suppliers	\$600	2	Coach	\$1,200	
					TOTAL	\$5,400.0
Fround Trans To Include		Fare & Tax	Persons 6	Service Sedan	\$1,800	
10 include	Accreditor	\$100	1	Taxi	\$100	
	Asante	\$100	3	Taxi	\$300	
	Additional					
	Suppliers	\$100	2	Taxı	\$200	80.400.0
					TOTAL	\$2,400.0
Expenses	Equility	Rate \$100	Persons 6		\$600	
To Include.	Accreditor	\$100	1		\$100	
	Asante	\$100	3	1 X .	\$300	
	Additional					
			1 ^	I/ \	\$200	\$1,200.0
	Suppliers	\$100	22	<u> </u>		31.200.0
		\$100			TOTAL	
		Cost/Tax/	Persons/	Number of	TOTAL	
Food and Bev	Suppliers erage			Number of Functions	TOTAL	
	Suppliers erage Continental	Cost/Tax/ Gratuity	Persons/ Quantity	Functions		
Food and Bev To Include	erage Continental Breakfast	Cost/Tax/ Gratuity \$40	Persons/ Quantity	Functions 1	\$4,000	
	erage Continental Breakfast Lunch	Cost/Tax/ Gratuity	Persons/ Quantity	Functions		
	erage Continental Breakfast	Cost/Tax/ Gratuity \$40 \$55	Persons/ Quantity 100 100	functions f 1 1	\$4,000 \$5,500 \$3,000	
	erage Continental Breakfast Lunch Break Faculty Dinner	Cost/Tax/ Gratuity \$40 \$55	Persons/ Quantity 100 100	functions 1	\$4,000 \$5,500	
	erage Continental Breakfast Lunch Break Faculty Dinner On-site Slide	Cost/Tax/ Gratuity \$40 \$55 \$30 \$100	Persons/ Quantity 100 100 100	functions t 1 1 1	\$4,000 \$5,500 \$3,000 \$1,000	
	erage Continental Breakfast Lunch Break Faculty Dinner	Cost/Tax/ Gratuity \$40 \$65 \$30	Persons/ Quantity 100 100	functions f 1 1	\$4.000 \$5,500 \$3,000 \$1,000 \$250	
To Include	erage Continental Breakfast Lunch Break Faculty Dinner On-site Silde Review	Cost/Tax/ Gratuity \$40 \$55 \$30 \$100	Persons/ Quantity 100 100 100	functions t 1 1 1	\$4,000 \$5,500 \$3,000 \$1,000	\$13,750
	erage Continental Breakfast Lunch Break Faculty Dinner On-site Slide Review n(s) Rental	Cost/Tax/ Gratuity \$40 \$55 \$30 \$100 \$250	Persons/ Quantity 100 100 100 10	### Functions 1	\$4.000 \$5,500 \$3,000 \$1,000 \$250	\$13,750 \$750. \$50.
Meeting Roor	erage Continental Breakfast Lunch Break Faculty Dinner On-site Slide Review n(s) Rental titer otel Staff)	Cost/Tax/ Gratuity \$40 \$55 \$30 \$100 \$250	Persons/ Quantity 100 100 100 10 10	functions 1 1 1 1 1 1 1	\$4.000 \$5,500 \$3,000 \$1,000 \$250	\$13,750 \$750. \$50. \$100.

supplication within them. No this is the second of the first first in a microscopy of the moniton only



State of the Control of the State of the Sta



Hallmann, the perhaps Americal contents of the Americal contents of the con-

	inting						
eference Gui	de		\$ 30	100			\$3,000.00
	,		Quantity	Design			
Services	Distance						
Include:	Printing of syllat (includes printin		1			l	
	assembly charg					1	
	Agenda, Particij						
	Faculty List, col		1				
	evaluations, etc		125	4-Color	\$5,250		
	evaluations, etc	<u> </u>			75,000		
	D		Į.	,	ļ	,	
	Printing of self-r			4-Color	\$2.750		
	sealed invitation	1	8,500	4-000	\$2,750		\$8,000.00
					TOTAL		\$1,375.00
	e Badges, Tent	Cards					\$250.00
ens, Pads				,	·		
ostage for In	vites						\$2,500.00
	eeting material					and the second second	\$250.00
	arch (articles/p						\$750.00
	No. Combi						
	All equipment fo		w and Gener	al Session			\$5,000.00
	pervisor/Suppor						\$1,500.0
	EU/STFOLK					No. 12 A. West	
ATTENDED TO NATIONAL PROPERTY.	Shipping (facul	Charles and the Control of the Contr	the fit was a minder of the fact of			D	\$250.0
				прриту/		 	\$5,000.0
	ruitment tactic	S/purchase i	1515				\$7,000.0
Meeting Plans					. · ·		\$7,000.0
	ign, and Layout						\$1,500.0
Transcription							
	s expenses						
OOP TOTAL							
OOP TOTAL				u 25.22			\$97,575.0
OOP TOTAL							\$97,575.0
OOP TOTAL				ur sezelek			\$97,575.0
OOP TOTAL FIES : Management Includes:			and the second	w seems	(Tricontest		\$97,575.0
OOP TOTAL HEES: Management Includes: * Timeline dev	Garage	ntenance		.u ::274224		524	\$250.0 \$97,575.0 \$25,000.0
OOP TOTAL Management Includes: * Timeline dev *Manage inter	Fee relopment & mair	ntenance oject flow		Sur Service			\$97,575.0 \$25,000.0
OOP TOTAL Management Includes: * Timeline dev *Manage inter	Fee relopment & mair	ntenance oject flow		ons, confirm	ations, final a	nd welcome packet	\$97,575.0 \$25,000.0
OOP TOTAL Management Includes: * Timeline dev *Manage inter * Coordinate fo	Fee relopment & main nal team and pro	ntenance pject flow Il process inci	luding invitati				\$97,575.0 \$25,000.0
Management Includes: * Timeline dev *Manage inter * Coordinate for * Manage atte	Fee relopment & main nal team and pro- acuity invitational nidee recruitmen	ntenance oject flow of process incl of process inc	luding invitati luding invitati	ions, confirm	ations, final lo	nd welcome packet ogistical information	\$97,575.0 \$25,000.0
Management Includes: * Timeline dev *Manage inter * Coordinate fi * Manage atte * Oversee coc	Fee relopment & main and pro- aculty invitational indee recruitmen ardination of ventional formation of ventional indees.	ntenance bject flow il process inci it process inci ue selection,	luding invitati luding invitati negotiation a	ions, confirm and contractir	ations, final lo	ogistical information	\$97,575.0 \$25,000.0
Management Includes: * Timeline dev *Manage inter * Coordinate fi * Manage atte * Oversee coc * Oversee all	Fee relopment & main nal team and pro- aculty invitational indee recruitment ordination of venturavel, hotel, group in the contravel in the co	ntenance oject flow Il process inci it process inci ue selection, und transport	luding invitati luding invitati negotiation a ation, food fu	ions, confirm and contractir anctions and	ations, final lo ig AV both pre-i		\$97,575.0 \$25,000.0
Management Includes: * Timeline dev *Manage inter * Coordinate fi * Manage atte * Oversee coc * Oversee all	Fee relopment & main and pro- aculty invitational indee recruitmen ardination of ventional formation of ventional indees.	ntenance oject flow Il process inci it process inci ue selection, und transport	luding invitati luding invitati negotiation a ation, food fu	ions, confirm and contractir anctions and	ations, final lo ig AV both pre-i	ogistical information	\$97,575.0 \$25,000.0
Management Includes: * Timeline dev *Manage inter * Coordinate fi * Manage atte * Oversee coc * Oversee all i * Manage all o	Fee relopment & main nal team and pro- aculty invitational indee recruitment ordination of venturavel, hotel, group in-site operation.	ntenance oject flow il process inci it process inci ue selection, und transport s of the progr	luding invitati luding invitati negotiation a ation, food fu ram including	ions, confirm ind contractir inctions and i registration	ations, final lo ig AV both pre-i	ogistical information	\$97,575.0 \$25,000.0
Management Includes: * Timeline dev *Manage inter * Coordinate fi * Manage atte * Oversee coc * Oversee all i * Manage des * Manage des	Fee relopment & mair nal team and pro- aculty invitational indee recruitment irrigination of venit trevel, hotel, group on-site operational irgin and productive	ntenance oject flow all process inclusives selection, und transport s of the progr	luding invitati luding invitati negotiation a ation, food fu ram including ting matenali	ions, confirm ind contractir inctions and i registration	ations, final lo ig AV both pre-i	ogistical information	\$97,575.0 \$25,000.0
Management Includes: * Timeline dev *Manage inter * Coordinate fi * Manage atte * Oversee coc * Oversee all * Manage des participant hai	Fee relopment & mail relateam and pro aculty invitational indee recruitmen indination of venit travel, hotel, grou inn-site operation ign and products indouts, badges,	ntenance oject flow il process inci ue selection, und transport s of the progr on of all mee tent cards, et	luding invitati luding invitati negotiation a lation, food fu ram including ting materials	ions, confirm ind contractir inctions and i registration	ations, final lo ig AV both pre-i	ogistical information	\$97,575.0 \$25,000.0
Management Includes: * Timeline dev *Manage inter * Coordinate fi * Manage atte * Oversee coc * Oversee all i * Manage des participant hai * Traffic meeti	Fee relopment & main ral team and pro aculty invitational indee recruitmen ordination of venit travel, hotel, grou on-site operation uign and products indouts, badges, ing materials for	ntenance oject flow il process inci ue selection, und transport s of the progr on of all mee tent cards, et	luding invitati luding invitati negotiation a lation, food fu ram including ting materials	ions, confirm ind contractir inctions and i registration	ations, final lo ig AV both pre-i	ogistical information	\$97,575.0 \$25,000.0
Management Includes: * Timeline dev *Manage inter * Coordinate fi * Manage atte * Oversee coo * Oversee all * Manage all o * Manage des participant hai * Traffic meeti * Arrange for l	Fee relopment & mail nal team and pro aculty invitationa indee recruitmen ordination of vent travel, hotel, grou on-site operation. uign and production douts, badges, ing materials for honoraria	ntenance oject flow il process inci ue selection, und transport s of the progr on of all mee tent cards, et	luding invitati luding invitati negotiation a lation, food fu ram including ting materials	ions, confirm ind contractir inctions and i registration	ations, final lo ig AV both pre-i	ogistical information	\$97,575.0 \$25,000.0
Management Includes: * Timeline dev *Manage inter * Coordinate fi * Manage atte * Oversee all ii * Manage des participant hai * Traffic meeti * Grant/Needs	Fee relopment & main and team and pro- aculty invitational indee recruitment fravel, hotel, ground in an appropriation of the properation of the p	ntenance oject flow il process inci ue selection, und transport s of the progr on of all mee tent cards, et	luding invitati luding invitati negotiation a lation, food fu ram including ting materials	ions, confirm ind contractir inctions and i registration	ations, final lo ig AV both pre-i	ogistical information	\$97,575.0 \$25,000.0
Management Includes: * Timeline dev *Manage inter * Coordinate fi * Manage affe * Oversee coo * Oversee all i * Manage des * Manage des * Manage des * Traffic meeti * Arrange for i * Grant/Needs *Reconciliatio	Fee relopment & main and team and processor in the proces	ntenance oject flow al process inci- ue selection, und transport is of the progr on of all mee tent cards, et review and p.	luding invitati negotiation a iation, food fu ram including ting materials to: roduction	ions, confirm and contractir inctions and a registration s including	ations, final lo g AV both pre-i area	ogistical information	\$97,575.0 \$25,000.0
Management Includes: * Timeline dev *Manage inter * Coordinate fi * Wanage atte * Oversee coo * Oversee all i * Manage des participant hai * Traffic meets * Arrange for i * Grant/Needs * Reconcliatio * Certification	Fee relopment & main and pro- aculty invitational travel, hotel, group and production are the properties of the production and production are the production are the production and production are the production are the production and production are the production are t	ntenance oject flow al process inci- ue selection, und transport is of the progr on of all mee tent cards, et review and p.	luding invitati negotiation a iation, food fu ram including ting materials to: roduction	ions, confirm and contractir inctions and a registration s including	ations, final lo g AV both pre-i area	ogistical information	\$97,575.0 \$25,000.0
Management Includes: * Timeline dev *Manage inter * Coordinate fi * Manage atte * Oversee cod * Oversee all i * Manage des participant hai * Traffic meeti * Arrange for i * Grant/Needs * Certification * Internal CMI * Internal CMI	Fee relopment & mail relater and pro- aculty invitational indee recruitment ordination of vent travel, hotel, grot on-site operation- ign and producti- indouts, badges, ing materials for rhonoraria is development in management collaboration (jo	ntenance oject flow il process inc. ue selection, und transport s of the progr on of all mee tent cards, et review and p.	luding invitati negotiation a iation, food fu ram including ting materials to: roduction	ions, confirm and contractir inctions and a registration s including	ations, final lo g AV both pre-i area	ogistical information	\$97,575.0 \$25,000.0
Management Includes: * Timeline dev *Manage inter * Coordinate fi * Manage atte * Oversee cod * Oversee all i * Manage des participant hai * Traffic meeti * Arrange for i * Grant/Needs * Certification * Internal CMI Content Dev	Fee relopment & main and pro- aculty invitational travel, hotel, group and production are the properties of the production and production are the production are the production and production are the production are the production and production are the production are t	ntenance oject flow il process inc. ue selection, und transport s of the progr on of all mee tent cards, et review and p.	luding invitati negotiation a iation, food fu ram including ting materials to: roduction	ions, confirm and contractir inctions and a registration s including	ations, final lo g AV both pre-i area	ogistical information	\$97,575.0 \$25,000.0
Management Includes: * Timeline dev *Manage inter * Coordinate fi * Manage atte * Oversee coc * Oversee all i * Manage des participant hai * Traffic meeti * Arrange for i * Grant/Needs * Reconcliatio * Internal CMI Content Dev Includes:	Fee relopment & mail mal team and pro aculty invitational indee recruitment ravel, hotel, group- site operational ingen and products indouts, badges, ing materials for thonoraria is development in management collaboration (jo E compliance elopment/Editor	ntenance oject flow al process inc. ue selection, und transport s of the progr on of all mee tent cards, et review and p	luding invitati luding invitati negoriation a lation, food fu tram including ting materiali to. roduction hip, complian	ions, confirm and contractir unctions and a registration s including	ations, final lo ng AV both pre-i area bert Einstein	ogistical information meeting and onsite	\$97,575.0 \$25,000.0
Management Includes: * Timeline dev *Manage inter * Coordinate fi * Manage atte * Oversee coc * Oversee all i * Manage des participant hai * Traffic meeti * Arrange for i * Grant/Needs * Reconciliatio * Internal CMI Content Dev Includes: * Collaborate	Fee relopment & main and team and processing in a contract of the contract of	ntenance oject flow al process inc. ut process inc. und transport s of the progr on of all mee tent cards, et review and p. unt sponsorst rial Fee	luding invitati luding invitati negoriation a lation, food fu tram including ting materiali to. roduction hip, complian	ions, confirm and contractir unctions and a registration s including	ations, final lo ng AV both pre-i area bert Einstein	ogistical information meeting and onsite	\$97,575.0 \$25,000.0
Management Includes: * Timeline dev *Manage inter * Coordinate fi * Manage atte * Oversee coc * Oversee all * Manage all o * Manage all o * Manage for l * Grant/Needs * Reconcliatio * Certification * Internal CMI Content Dev Includes: * Collaborate * Collaborate	Fee relopment & mail mal team and pro aculty invitational male recruitment ravel, hotel, group more site operation right and products modules, badges, mand products modules, badges, mand materials for honoraria is development in management collaboration (to collab	ntenance oject flow al process inc. us selection, und transport s of the progr on of all mee tent cards, et review and p. int sponsorsh rial Fee earning object wesentations	luding invitati negotiation a ation, food fu ram including ting materials to: roduction hip, complian	ions, confirm and contractir unctions and a registration s including	ations, final lo ng AV both pre-i area bert Einstein	ogistical information meeting and onsite	\$97,575.0 \$25,000.0
Management Includes: * Timeline dev *Manage inter * Coordinate fi * Manage atte * Oversee all i * Manage all i * Manage des participant hai * Traffic meeti * Arrange for i * Grant/Needs * Reconciliation * Certification * Internal CMI Content Devid * Collaborate * Collaborate * Liaise with fi	Fee relopment & main all team and procedure invitational moder recruitment fravel, hotel, groot invitational modern products, and products, badges, and materials for honoraria is development in management collaboration (joe compliance elopment/Editor with faculty on paculty and incorp	intenance oject flow all process incluse selection, und transport is of the program on of all mee tent cards, et review and p. rial Fee earning object prosest faculty	luding invitation a pation, food furam including ting materials to. Toduction and the complian tives, agendation comments	ions, confirm and contractir inctions and a registration is including ce review, Ai	ations, final lo ng AV both pre-i area bert Einstein	ogistical information meeting and onsite	\$97,575.0 \$25,000.0
Management Includes: * Timeline dev *Manage inter * Coordinate fi * Manage atte * Oversee cod * Oversee all ii * Manage des participant hai * Traffic meeti * Arrange for * Certification * Internal CMI Content Devi Includes: * Collaborate * Liaise with ai	Fee relopment & main and pro- aculty invitational travel, hotel, group and production and produc	ntenance oject flow al process inc. us selection, und transport is of the progr on of all mee tent cards, et review and p. int sponsorsi rial Fee earning object coresentations porate faculty corporate accepts	luding invitation a station, food furam including ting materials to, roduction tives, agendatives, agendatives, agendatives, agendatives comments creditor comments and invitation comments agendatives agendative	ions, confirm and contractir inctions and a registration is including ce review, Ai	ations, final lo ng AV both pre-i area bert Einstein	ogistical information meeting and onsite	\$97,575.0 \$25,000.0
Management Includes: * Timeline dev *Manage inter * Coordinate fi * Manage atte * Oversee cod * Oversee all i * Manage des participant hai * Traffic meeti * Arrange for i * Grant/Needs * Reconcilatio * Cettification * Internal CMI Content Dev Includes: * Collaborate * Collaborate * Cilaise with fi * Liaise with fi * Editorial/cop	Fee relopment & main and pro- aculty invitational travel, hotel, group and production are also development and production are accordance by the faculty on lease with faculty on paraculty and incorparation and i	ntenance oject flow al process inci us selection, und transport s of the progr on of all mee tent cards, et review and p. rial Fee examing object cresentations porate faculty corporate acc w and formatt	luding invitation invitation and inv	ions, confirm and contractir inctions and a registration is including ce review, Al	ations, final lo ng AV both pre-i area bert Einstein	ogistical information meeting and onsite	\$97,575.0 \$25,000.0
Management Includes: * Timeline dev *Manage inter * Coordinate fi * Manage atte * Oversee coo * Oversee all i * Manage des participant hai * Traffic meeti * Arrange for i * Arrange for i * Grant/Needs * Cedification * Internal CMI Content Devel Includes: * Collaborate * Collaborate * Liaise with fi * Editonal/coo * All costs ass	Fee relopment & main and team and pro- aculty invitational index recruitment ordination of ventificated, hotel, group and production (joe compliance elopment Editor and incorpaction and incorpaction and incorpaction and incorpaction and incorpaction and incorpactical production and incorpaction and incorpact	ntenance oject flow al process inci us selection, und transport s of the progr on of all mee tent cards, et review and p. rial Fee examing object cresentations porate faculty corporate acc w and formatt	luding invitation invitation and inv	ions, confirm and contractir inctions and a registration is including ce review, Al	ations, final lo ng AV both pre-i area bert Einstein	ogistical information meeting and onsite	\$97,575.0 \$25,000.0 \$28,000.0
Management Includes: * Timeline dev *Manage inter * Coordinate file * Manage atte * Oversee cod * Oversee all il * Manage des participant hair * Arrange for il * Grant/Needs * Reconcliatio * Cettification * Internal CMI Content Devi Includes: * Collaborate * Collaborate * Liaise with fall * Editorial/cop	Fee relopment & main and team and pro- aculty invitational index recruitment ordination of ventificated, hotel, group and production (joe compliance elopment Editor and incorpaction and incorpaction and incorpaction and incorpaction and incorpaction and incorpactical production and incorpaction and incorpact	ntenance oject flow al process inci us selection, und transport s of the progr on of all mee tent cards, et review and p. rial Fee examing object cresentations porate faculty corporate acc w and formatt	luding invitation invitation and inv	ions, confirm and contractir inctions and a registration is including ce review, Al	ations, final lo ng AV both pre-i area bert Einstein	ogistical information meeting and onsite	\$97,575.0 \$25,000.0

Said Brinding Assume Brain NY 1946. Pros. The months of the Astronomy accessors accessors as a month notion of a



the second constant and four to



Had him one Boom done to the him between the Control by the Miner Extraction colors of Medicine.




DESCRIPTION / CATEGORY	ASSUMP	TIONS	er om min it Handley of	COST	TOTAL COST
FINE PARTICIPATE DESCRIPTION	Market Street				
Service of the end with the Electric Philadelical the COMMENT And Service Self-Could be	Rate	Persons	A DECEMBER OF THE PARTY OF THE	A SECTION OF THE PROPERTY AND A SECTION OF THE PROPERTY OF THE	
Course Director Honorarium	\$2,500	1		\$2,500	
Chair Honorarium	\$2,500	1		\$2,500	ļ
				TOTAL	\$5,000.00
Albert Einstein Accreditation	and Certific	ate Fee			\$9,500.00
Albert Einstein Outcomes Me	asurement F	ee			\$3,500.00
Libering Caldalasters					
Production/Printing					
		Quantity	Design		
			ŀ		
Printing of self-ma					1
sealed invitation,					
and Awareness C Medscape and Pa		10,000	4-Color	\$3,500	
MCG-THE THE STATE SHAPE STATES				The second section of the sect	
Webification (Medscape of					\$60,000.00
Additional awareness and re-					\$5,000.00
Creative, Design, and Layout					\$7,000.00
Transcription					\$2,000.00
Postage					\$1,500.00
OOP TOTAL					\$93,500.00
GH-SOME STORY		40 to 14.			
Management Fee					\$20,000.00
Includes:					
* Timeline development & mair	ntenance				
*Manage internal team and pro	ject flow				
* Manage attendee recruitment	t process inci	udina invitati	ons, confirma	ations, and awareness campaign	
* Manage design and production	•	-			
* Traffic meeting materials for i			argir aria mee		
* Arrange for honorana	от. от. ат. а р.				
* Grant/Needs development					
*Reconciliation management					
* Certification collaboration (joi	nt sponsorsh	ip, compliand	ce review, All	pert Einstein liaison)	
* Internal CME compliance		·			
Content Development/Editor	ial Fee				\$20,000.00
includes:					
* Collaborate with faculty on le	amıng object	ives, agenda	and discuss	ion guide development	
* Collaborate with faculty on pr	resentations				
* Liaise with faculty and incorp	orate faculty	comments			
* Liaise with accreditor and inc			nents		
* Editorial/copy editorial review		_			
* All costs associated with mee	eting content	developmen	t		¢40.000.00
FEE TOTAL					\$40,000.00
					£400 500 00
GRAND TOTAL					\$133,500.00

Reference Guide

43.1 Handridge Agame Brons, NA 40467 Progr. 718.0 Straight Prog. 18 (98.1726) Increase of the thorotological

TEVA_MDL_A_00849980 P-28694 _ 00020

Chronic Pain Management Preceptorship (CPMP)



*DOE= Durable Outcomes Evaluation

**Control Group for Stage II includes 150 participants from other educational initiatives that do not participate in CPMP





TEVA_MDL_A_00849981

Persistent and Breakthrough Supported Medical Education Initiatives 2009

			1									
o de la carca de Versonovia e co			weke ke									
International Experts Forum	Live Event	30	-	> ♦		1	•					
Cases and Commentary	Live Event	225	+ -	-> (•	•					
Full-Day Regional Meeting	Live Event	75-100	_	→ (: !		
Teleconference Series	Live Event	200-400			→	•						
Cases and Commentary Print Monograph/Online	<i>PMN News</i> PainClinician Pain.edu	45-60,000						*	-	•		
Full-Day Regional Satellite Webcast	International Forum for Pain Experts Pain.edu	20-25,000	1 (1 97)	•	-	> 4	>			1		
Teleconference Print Monogrpaph/Online	<i>PMN News</i> PainClinician Pain.edu	45-60,000	4		•		•					
Pain/Risk Management Compendium	<i>PMN News</i> PainClinician Pain.edu	45-60,000	:	+		-	>					
International Experts Forum Position Paper/Online	<i>PMN News</i> PainClinician Pain.edu	45-60,000			•	•	•	,				
Preceptorship Program		300	+ -						+	-		-







Bridging the Gap Between Education and Practice "



The University Hospital and Academic Medical Center for the Albert Einstein College of Medicine

In order to review your grant request #2569, Cephalon requires the following additional information:

Please explain how HCPs for the outcomes study will be recruited for the Stage I.

The participants for the Stage I outcomes study will be recruited through the live educational initiatives proposed in the grant—namely, the *Cases and Commentary* Workshops, Teleconference Series, Full-day Regional Meeting and potentially the International Expert Forum. The latter will be a closed, invitation only meeting that will be held at the 2009 American Pain Society meeting in San Diego, pending availability of select thought leaders.

2. Will the WebPanel series be accredited?

Yes. The quarterly WebPanel series is a component of the Chronic Pain Management Preceptorship (n=~200, pending approval of proposed activities) and will be accredited through Albert Einstein College of Medicine. Of note, participants will complete a Durable Outcomes Evaluation (DOE)* Stage II structured questionnaire upon completion of the WebPanel series. The questionnaire will measure the evolution of thought and practice since completion of the DOE Stage I questionnaire, as measured against control clinicians who limited their education to an enduring material and/or live event and who did not participate in the Preceptorship (Stage II) WebPanel. Notably, clinicians who chose not to participate in the preceptorship, and who have otherwise successfully completed at least one post-test from any of the educational initiatives (Live, Print, and/or Online), may participate in the WebPanel series. Their educational outcomes will not, however, contribute to the DOE Stage II outcomes, which is restricted to preceptorship clinicians only.

3. How will participants be incentivized to participate in the outcomes study?

Incentivization is largely based on the opportunity to participate in a novel educational outcomes study, the results from which will likely be published in a peer-reviewed journal. Requirements will be minimally time consuming. Clinicians attending the live educational initiatives will necessarily complete a structured questionnaire before and after the event, and will therefore provide DOE Stage I study data. After completing the pre-post questionnaire, participants will confirm their interest in joining the Chronic Pain Management Preceptorship, comprising a quarterly WebPanel series facilitated by expert pain clinicians. Preceptorship clinicians (DOE Stage II participants) will have an opportunity to collaborate with their peers and thought leaders during the WebPanel series. In addition, preceptorship clinicians will be invited to a closed, invitation-only International Expert Forum (See Question 1). Qualified clinicians may also serve as adjunct faculty for activities that may be held in 2010, pending evaluation by program faculty

4. Is the preceptorship a separate activity to the outcomes study? How will participants be recruited for this activity?

Preceptorship participants will be required to complete a Stage II structured questionnaire, providing data on the durability of high level outcomes when integrated within an ongoing educational series. Preceptorship participants will be recruited during the registration period through e-mail

504 Banduage Avorage Brook, NV 10467 Proxi 18920 5071 FAX 18028 236 mecangoing cores muntoflateous

correspondence, and during one of the live events—teleconference call, Cases and Commentary workshop and/or full-day regional meeting— that they are required to complete.

The RFP stated that the proposal could cover educational events at national meetings, however none is proposed. Please clarify.

Pending availability of the expert pain clinicians, the International Pain Expert Forum may take place at a selected National Congress, currently planned to be held at the American Pain Society (APS; May 2009, San Diego). Preceptorship participants who attend the American Pain Society at their own cost and discretion will be invited to this closed, invitation-only satellite (off-agenda) live event.

In addition, as a point of clarification, we are planning to hold at least one of the *Cases and Commentary* programs will be held immediately before or after the APS in May 2009 and/or a Regional Chronic Pain meeting (e.g.; **Emerging Practices in Opioid Prescribing for Chronic Pain**, March 2009).

6. Please clarify the types of HCPS that may take part in the cases workshops.

HCPs that will be recruited to take part in the *Cases and Commentary* workshops are pain clinicians, including, among others, neurologists, psychiatrists, anesthesiologists, oncologists, rheumatologists, psychologists, and other general practitioners with an interest in pain management.

7. Please clarify PainClinician (TM). Is this a quarterly newsletter?

PainClinician™ is a proprietary component of a larger educational initiative, The International Chronic Pain Forum™, to be formally launched in Q1 2009. The PainClinician quarterly newsletter will drive program recruitment, advertisements, and distribution of accredited pain enduring materials. Our PainClinician™ internal database currently includes thousands of practicing pain clinicians who have participated in previous accredited programs, CSNA surveys, or have otherwise expressed an interest in pain education.

8. Please clarify how you will recruit for the teleconferences and satellite webcasts.

Recruitment efforts for the Teleconference and Webcasts will be multifaceted. Reliable tactics include extending invitations to clinicians in our proprietary PainClinician[™] database, to clinicians identified by the Albert Einstein College of Medicine and to the membership of American Academy of Pain Medicine (AAPM), APS and other medical congresses; announcing the programs in relevant print journals, (e.g., Pain Medicine News, the Journal of Pain, PainClinician). and on selected pain-related websites (e.g., WebMD, pain.edu, International Chronic Pain Forum, etc.).

9. Is the literature surveillance included in the grant costs?

The Literature Surveillance program, including monthly written summaries, as detailed in the grant is not included in the total grant costs. However, the Albert Einstein College of Medicine working collaboratively with Asante routinely forwards to the grant supporters select articles from peer-reviewed journals and related reference materials, all of which are relevant to the educational objectives of the proposed grant initiatives.

3301 Bambridge Avenue, Bronx, N.Y. 10467 Prioxe 748.920-6674 FAX 718 798-2-336 mecinclog cmc@monteliorcorg

10. Please include a timeline of when activities will be disseminated.

Please see attached.

11. Additional Information:

Proposed Payment Schedule: If Albert Einstein College of Medicine is fortunate enough to have its grant approved, the proposed payment schedule is 1/3 of program costs upon LOA acceptance, 1/3 of program costs at a time point identified as approximately 50% through the completion of the grant, and the remaining 1/3 payment during the last 1/3 of the scheduled program completion.

3301 Bainbridge Avenue, Bronx, NY 10467 — Phoxe 718 920 6674 — FAV 718 798 2336 — mecme.org — cmc/cmontehorc.org

Confidential TEVA_MDL_A_00849984





A TENER OF

. Dec Erre (1915-1925) Spot a ser a A LEO HER Made of Contract to the A Electronic Contract to the service

DESCRIPTION /	ASSUMPT	TIONS		COST	т	OTAL COST
CATEGORY	in the art	en e	Similar Communication		-145 B-145 B-1	diamental
	Rate	Persons	Alebatulas	The state of the Service representation of the Service service and the Service service and the Service service service and the Service	2000 200 2000 2000 110 1000	
Course Director	\$2,500	1				\$2,500.
Faculty Honoraria	\$1,500	4		SOMEONE STATES TO SELECT AND	Santa - Palaca a Principal	\$6,000.
to the second of the			alika ka k	A TORINGS		
Albert Einstein Accreditation and C		ee				\$9,500.
Albert Einstein Outcomes Measure	ment Fee	**************************************	verilisade£t.g?	SERIOLENVIING AFTIS	42 6 29501674-E.U.Y	\$3,500.
Food and Beverage	Cost/Tax/ Gratuity	Persons/ Quantity	Number of Functions			
To Include: Breakfast(s)	\$40	10	1	\$400		
35. A. J. S. C. T. S. C. Ballaninia and A. T. Levis, or a reconstruction	reference on a second or	ganna magana aran ng ganggan na ang	t more and a contract of the	TOTAL	a probably watered towards of 1 and 1	\$400.
CACTOR OF THE						
	Quantity	Design	(III.com) in an annual and a			
Production & Printing						
of						
Position Paper	35,000	4-Color		\$10,800		
Pain Clinician						
Postage Cost	35,000	n/a		\$11,000		
Purchase Mailing Lists AAPM/APS				\$4,000	l	
				Tetal	\$25,800.00	
	7 . F		70 036 S	10tai	\$25,000.00	
	(P) 1 Y					
Webification of enduring materials	i				\$5,000.00	
Purchase artwork	a tan Kamada ada a	4 191 220 24 24 25		and the second section of the sectio	o a 7 de la companya	\$750.
Selen districted Municipals References/Permissions						\$ 750.
(ivereignicas) Latinisa in 18	4.0					V. 100.
Intercall Teleconference Charges Transcription Services						\$1,000. \$1,500.
Transcription Services	46 ZX3	11/09/12	13121 S.M.S.			\$1,500.
Express Mail Shipping (faculty ma	ilings, mate	rials ship	ping)	and the second s		\$250
OOP TOTAL						\$56,950.
Management Fee	国际对外 基	d Heroe				\$18,000
management ree Includes:						\$10,000

The Pentagon of the High States of the Control of the Control of the States of the Control of th





A state of the sta

* Manage all aspects of program including position paper logistics and trafficking * Manage all on-site needs for meetings with faculty * Manage design and production of all materials relating to position paper * Amange for honorana * Grant/Needs development *Reconciliation management * Certification collaboration (joint sponsorship, compliance review, Albert Einstein Italson) * Internal CME compliance *Content Development/Editorial/Creative Fee Includes: * Develop learning objectives	\$23,500.00
**Collaboration with faculty on teleconference agenda and discussion guide development *Manage all research associated with identification of prospective Journals for Distribution **Collaborate with faculty on position paper	
* Liaise with presenters (chair, faculty) * Editonal/copy editional review and formatting	
FEE TOTAL	\$41,500.00
GRAND TOTAL Variance +/- 10%	\$98,450.00
SPECIAL NOTE: Any change in scope will require an approved revised budget. Cancellation of program will be subject to costs-to-date for all expenses and staff hours.	
Salar	A (

Conserve group British All 1865 - For Monte of British as the conserve of the formation




Box of the State o



DESCRIPTION / CATEGORY		ASSUMPTIO	ONS		COST		TOTAL COST
		galeriai nerii geli					MATE BUNGATE
	100	Rate	Persons				
Course Direct	tor Honorarium	\$1,500	1	• • • • • • • • • • • • • • • • • • • •			
Faculty Hono		\$1,500	2				\$4,500.0
	n Accreditation a			>			\$9,500.00
	n Outcome Mease				L		\$3,500.0
LETERIAL S	Marie Contraction						
Production/P	rinting						
			Quantity	Design	Total		
Services Include	Printing of Referen	nce Tool for					
include	Pain Specialists a	nd Other	05000	4.00.10.1	#110 000		
	Clinicians		35000	4-Color	\$20,000		
	Printing of Envelo	ne	35000	4-Color	\$4,800		
	1				1 · · · · · · · · · · · · · · · · · · ·	TOTAL	\$24,800.0
TOTAL PAR	a ottota kang	445.76.2					
Webification	of Enduring Mate	rial					\$10,000.0
10 June 20 10 10 10 10 10 10 10 10 10 10 10 10 10	in the Colonia	THE COURSE AND MADE WAS DON'T TO MADE	1 7				
三、其敬を記録されるに記ました人の							PP DDD D
Distribution	Costs to AAPM an		ership				\$8,000.0
Distribution (Pain Clinical	Update Costs for		ership		· · · · · · · · · · · · · · · · · · ·		\$4,000.0
Distribution (Pain Clinical Mail house H	Update Costs for andling Fee	Distribtution	ership				
Distribution (Pain Clinical Mail house H	Update Costs for andling Fee	Distribtution	ership				\$4,000.0
Distribution (Pain Clinical Mail house H Creative, Des	Update Costs for andling Fee sign, and Layout	Distribtution	ership			54) Z acili	\$4,000.0 \$1,750.0
Distribution Pain Clinical Mail house H Creative, Des	Update Costs for andling Fee sign, and Layout twork	Distribtution	ership				\$4,000.0 \$1,750.0 \$7,000.0 \$250.0
Distribution Pain Clinical Mail house H Creative, Der Purchase Ar Permissions	Update Costs for andling Fee sign, and Layout twork /Copyrights	Distribtution	ership		The second secon		\$4,000.0 \$1,750.0 \$7,000.0 \$250.0
Distribution Pain Clinical Mail house H Creative, Der Purchase Ar Permissions	Update Costs for andling Fee sign, and Layout twork Copyrights	Distribtution	ership	4 - 14 - 1			\$4,000.0 \$1,750.0 \$7,000.0 \$250.0 \$750.0
Distribution of Pain Clinical Mail house H Creative, Des Purchase Art Clinical Permissions	Update Costs for andling Fee sign, and Layout twork Copyrights	Distribtution	ership				\$4,000.0 \$1,750.0 \$7,000.0 \$250.0 \$750.0
Distribution of Pain Clinical Mail house H Screative, Der Purchase Ar Permissions Misc Expens TOTAL OC	Update Costs for andling Fee Sign, and Layout twork (Copyrights See See See See See See See See See Se	Distribtution	ership				\$4,000.0 \$1,750.0 \$7,000.0 \$250.0 \$750.0
Distribution of Pain Clinical Mail house H Creative, Des Purchase Art Clinical Permissions Misc Expens TOTAL OC	Update Costs for andling Fee Sign, and Layout twork (Copyrights See SOPs	Distribtution	ership				\$4,000.0 \$1,750.0 \$7,000.0 \$250.0 \$750.0
Distribution Pain Clinical Mail house H Creative, Des Purchase Ar Permissions Misc Expens TOTAL OC	Update Costs for andling Fee Sign, and Layout twork (Copyrights See SOPs	Distribtution	ership				\$4,000.0 \$1,750.0 \$7,000.0 \$250.0 \$750.0 \$250.0 \$74,300.0
Distribution Pain Clinical Mail house H Creative, Der Purchase Ar Permissions Misc Expens TOTAL OC Management Includes:	Update Costs for andling Fee Sign, and Layout twork Copyrights es	Distribtution	ership				\$4,000.0 \$1,750.0 \$7,000.0 \$250.0 \$750.0 \$250.0 \$74,300.0
Distribution of Pain Clinical Mail house H Creative, Des Purchase Art Clinical Mail house H Creative, Des Purchase Art Clinical Main Service Management Includes: * Timeline de 'internal tean	Update Costs for andling Fee sign, and Layout twork (Copyrights Pee SPE) I Fee velopment & maintin and project mana	Distribtution Distribtution	ership				\$4,000.0 \$1,750.0 \$7,000.0 \$250.0 \$750.0 \$250.0 \$74,300.0
Distribution of Pain Clinical Mail house H Creative, Des Purchase Art Claude Purchase Art Claude Permissions Misc Expens TOTAL OC Management Includes: * Timeline de 'Internal tean' * Arrange for	Update Costs for andling Fee sign, and Layout twork Copyrights EEE Velopment & mainten and project mana faculty review and	Distribtution Distribtution Distribution Distribution Distribution Distribution					\$4,000.0 \$1,750.0 \$7,000.0 \$250.0 \$750.0 \$250.0 \$74,300.0
Distribution of Pain Clinical Mail house H Creative, Der Purchase Ari Permissions Misc Expens TOTAL OC Management Includes: 'Internal tean 'Arrange for 'Traffic Refe	Update Costs for and ling Fee sign, and Layout twork //Copyrights PPs I Fee velopment & mainten and project mana faculty review and rence Tool for reviewent and for reviewent and for reviewent for the sign of the sign	enance igement honoraria aw and product	ucn.				\$4,000.0 \$1,750.0 \$7,000.0 \$250.0 \$750.0 \$250.0 \$74,300.0
Distribution of Pain Clinical Mail house H Creative, Des Purchase Ari Permissions Misc Expens TOTAL OC Management Includes: * Timeline de 'Internal tean 'In	Update Costs for andling Fee sign, and Layout twork //Copyrights Pee Velopment & maintn and project mana faculty review and rence Tool for reviesign and production	enance germani honoraria ew and product of of reference to foresterior of reference to the control of the contr	ucn.				\$4,000.0 \$1,750.0 \$7,000.0 \$250.0 \$750.0 \$250.0 \$74,300.0
Distribution of Pain Clinical Mail house H Creative, Des Purchase Art Clinical Misc Expens TOTAL OC Management Includes: * Timeline de "Internal tean * Arrange for * Traffic Refe * Manage de * Liaise with de *	Update Costs for and ling Fee sign, and Layout twork //Copyrights PPs I Fee velopment & mainten and project mana faculty review and rence Tool for reviewent and for reviewent and for reviewent for the sign of the sign	enance igement honoraria ever and product or of reference to aculty	lien ool				\$4,000.0 \$1,750.0 \$7,000.0 \$250.0 \$750.0 \$250.0 \$74,300.0
Distribution of Pain Clinical Mail house H Creative, Des Purchase Ar Permissions Misc Expens TOTAL OC Management Includes: 1 Timeline de "Arrange for Traffic Refe" Manage de Liarse with a Cleview and "Develop gra	Update Costs for andling Fee sign, and Layout work Copyrights Essential Copyrights Fee velopment & mainten and project mana faculty review and rence Tool for reviewing and productor & facunage content frant and needs assets	enance gement honoraria ew and product acculty analytical rate of reference traculty analytical rate of sement.	nion ool				\$4,000.0 \$1,750.0 \$7,000.0 \$250.0 \$750.0 \$250.0 \$74,300.0
Distribution of Pain Clinical Mail house H Creative, Der Purchase Ar Permissions Misc Expens TOTAL OC Management Includes: * Timeline de 'Internal tean 'Arrange for 'Traffic Refe 'Manage de Liaise with of 'Review and 'Develop gra' Certification'	Update Costs for andling Fee sign, and Layout twork //Copyrights PPs Fee velopment & mainten and project mana feculty review and feculty review and feculty review and rence Tool for reviesign and production course director & far and and needs asset a collaboration (com	enance gement honoraria ew and product acculty analytical rate of reference traculty analytical rate of sement.	nion ool	ain liaison)			\$4,000.0 \$1,750.0 \$7,000.0 \$250.0 \$750.0 \$250.0 \$74,300.0
Distribution of Pain Clinical Mail house H Creative, Des Purchase Ari Permissions Misc Expens TOTAL OC Management Includes: * Timeline de 'Internal tean 'Internal tean 'Internal tean 'Review and 'Pevelop gra' Certification' Reconciliatic	Update Costs for and ling Fee sign, and Layout twork //Copyrights Pee velopment & maintn and project mana faculty review and fecule Tool for reviesign and production course director & farmanage content in and needs asset to collaboration (compon management)	enance germeni honoraria ew and product of reference traculty ansiation into o same in plance review.	nion ool	ein liaison)			\$4,000.0 \$1,750.0 \$7,000.0 \$250.0 \$750.0 \$250.0 \$74,300.0
Distribution of Pain Clinical Mail house Harman Creative, Des Purchase Arian Mail Expensions Misc Expensions Misc Expensions Misc Expensions TOTAL OC Management Includes: * Timeline de * Internal tean * Arrange for * Traffic Refee * Manage de * Liarse with of * Review and * Develop grade * Certification* Reconciliatic * Ensure internal * Ensure i	Update Costs for and ling Fee sign, and Layout twork (Copyrights Pee Pee Velopment & maintin and project mana faculty review and faculty review and production course director & farmanage content and needs assess a collaboration (company management and CME compliance)	enance igement honorana ew and product or of reference to aculty anslation into assment inpliance review ace	nion ool	ein liaison)			\$4,000.0 \$1,750.0 \$7,000.0 \$250.0 \$750.0 \$250.0 \$74,300.0
Distribution of Pain Clinical Mail house H Creative, Des Purchase Ari Permissions Misc Expens TOTAL OC Management Includes: * Timeline de * Internal tean * Arrange for * Traffic Refee * Manage de * Liaise with of * Review and * Develop gra * Certification* Reconciliatic * Ensure inter * Content Dev	Update Costs for and ling Fee sign, and Layout twork //Copyrights Pee velopment & maintn and project mana faculty review and fecule Tool for reviesign and production course director & farmanage content in and needs asset to collaboration (compon management)	enance igement honorana ew and product or of reference to aculty anslation into assment inpliance review ace	nion ool	ein liaison)			\$4,000.0 \$1,750.0 \$7,000.0 \$250.0 \$750.0 \$250.0 \$74,300.0
Distribution Pain Clinical Mail house H Creative, Des Purchase Ar Permissions Misc Expens TOTAL OC Management Includes: - Timeline de - Arrange for - Traffic Refe - Manage de Liarse with c - Review and - Develop gra - Certification - Reconciliatic - Ensure Inter - Content Dev - Includes:	Update Costs for and ling Fee sign, and Layout twork (Copyrights Pee Pee Velopment & maintin and project mana faculty review and faculty review and production course director & farmanage content and needs assess a collaboration (company management and CME compliance)	enance sigement honoraria ew and product of reference to caristation into o assment impliance review and lateral and the caristation into a series in the caristation in the caristat	tion ool mine format r,Albert Einste		I learning object	tives	\$4,000.0 \$1,750.0 \$7,000.0 \$250.0 \$750.0 \$250.0 \$74,300.0
Distribution of Pain Clinical Mail house H Creative, Der Purchase Art Permissions Misc Expens TOTAL OC Management Includes: * Timeline de 'Internal tean 'Arrange for 'Arrange for 'Preview and 'Develop gra' Certification Reconciliatic 'Ensure inter Content Dev Includes: * Collaborate * Collaborate	Update Costs for and ling Fee sign, and Layout twork (Copyrights PS I Fee velopment & maint: and project mana faculty review and rence Tool for reviewing and production course director & faminance content traint and needs asset a collaboration (commanagement and CME compliancelopment/Editoris	enance germeni honoraria ber and produci no freference traculty assment impliance review the control of the con	nion ool unline format v,Albert Einste	t outline, and		lives	\$4,000.0 \$1,750.0 \$7,000.0 \$250.0 \$750.0 \$250.0 \$250.0
Distribution of Pain Clinical Mail house H Creative, Des Purchase Arive, Des Purchase	Update Costs for and ling Fee sign, and Layout twork Copyrights I Fee Velopment & mainten and project mana faculty review and faculty review and reductor & farmanage content for an in and needs asset to collaboration (comportion of the compliance of the compliance of the comportion of the compliance of the complianc	enance gemeni honorana ew and produci n of reference t aculty anslation into o ssment inpliance review ce al	tion gool miline format r,Albert Einste of the content the referen	t outline, and		tives	\$4,000.0 \$1,750.0 \$7,000.0 \$250.0 \$750.0 \$250.0 \$250.0
Distribution of Pain Clinical Mail house HEART Creative, Det Purchase Art Creative, Det Purchase Art Contact C	Update Costs for andling Fee sign, and Layout twork (Copyrights Fee PPs (Copyrights Fee PPs)	enance igement honorana ewa and product or of reference to aculty anslation into assment impliance review as development is development of efeculty commonate comment or aculty commonate comment.	tion gool miline format y,Albert Einste of the content the reference	t outline, and ce tool manu		tives	\$4,000.0 \$1,750.0 \$7,000.0 \$250.0 \$750.0 \$250.0 \$250.0
Distribution of Pain Clinical Mail house H Creative, Det Purchase Ari Permissions Misc Expens TOTAL OC Management Includes: * Timeline de * Internal tean * Arrange for * Traffic Refee * Manage de * Liarse with of * Peview and * Develop gra * Certification * Reconciliatic * Ensure inter * Content Dev * Includes: * Collaborate * Collaborate * Liarse with of * Editorial/co.	Update Costs for and ling Fee sign, and Layout twork Copyrights I Fee Velopment & mainten and project mana faculty review and faculty review and reductor & farmanage content for an in and needs asset to collaboration (comportion of the compliance of the compliance of the comportion of the compliance of the complianc	enance gement honorana ew and product of reference to aculty ansiation into assment impliance review as development a development of efaculty commonate comment and formatting and formatting	of the content of the reference of reference of the refer	t outline, and ce tool manu		tives	\$4,000.0 \$1,750.0 \$7,000.0 \$250.0 \$750.0 \$250.0 \$250.0

and the second of the second o







No. 1 St. Comments

		3.00 M / Br	ezalikatek		CONTRACTOR OF THE	222
PAPERTIN)		Marian Company of the				
DESCRIPTION / CATEGORY		ASSUMPT	ions		Cost	TOTAL COST
Alamandaya (j. 1864) Karangan	7.360	The same of the same				M. J.
î. wyt wi e ste bilbe		Rate	Persons			
Course Director	Honorarium	\$2,500	1		\$2,500.00	
Faculty Honorar	ium (per call)	\$1,000	1	8	\$8,000.00	
					TOTAL	\$10,500.00
	Accreditation and C					\$15,000.00
	Outcomes Measurer		Property laws 50	NUMBER OF STREET		\$3,500.00
and the second second should		Quantity	Design	ier saeta in leig American	ilians vali poet to april	DELETING AND THE THE CONTROL
		syllabus				
		(includes				
		printing &				
	[assembly charges for]		
	1	Agenda,				
		Participant List, Faculty List.				
		color slides,	400	4-Color	\$15,000.00	
		Printing of self-				
	[mailer, wafer- sealed			į į	
	İ	invitation	45,000	4-Color	\$10,000.00	
					TOTAL	\$25,000.00
Programme and the state of the				1	I IUIAL	
	TATE OF THE PROPERTY OF THE PR	医学科心学部门 海边大学家位	また 11% 2007 実に建物収	建设建设。1994年1997年19 0	Francisco de la compaña de	ENGLISH BUREAU
		3.000				Marie X
Invitation Distrib	oution Costs	306				\$14,000.00
Invitation Distrib Priority mail shi	oution Costs pping of syllabus &					Marie X
Invitation Distrib Priority mail shi	oution Costs	National Property of the				\$14,000.00 \$3,250.00 \$7,500.00
Invitation Distrib Priority mail shi Island Invited Teleconference Transcription S	pution Costs pping of syllabus & Charges (Total for 8)	(\$14,000.00 \$3,250.00
Invitation Distrib Priority mail shi Teleconference Transcription St	pution Costs pping of syllabus & Charges (Total for 8)	(\$14,000.00 \$3,250.00 \$7,500.00 \$1,500.00
Invitation Distrit Priority mail shi Teleconference Transcription S Purchase of Art	pution Costs pping of syllabus & Particle Charges (Total for 8) prices (Total for 8) puties and Reprints	(\$14,000.00 \$3,250.00 \$7,500.00
Invitation Distrit Priority mail shi Teleconference Transcription S S Purchase of Art	pution Costs pping of syllabus & Charges (Total for 8) prvices (Total for 8) cless and Reprints	3)				\$14,000.00 \$3,250.00 \$7,500.00 \$1,500.00
Invitation Distrit Priority mail shi Teleconference Transcription S Purchase of Art Additional recru	pution Costs pping of syllabus & Charges (Total for services (Total for 8) Icles and Reprints	3)				\$14,000.00 \$3,250.00 \$7,500.00 \$1,500.00
Invitation Distrit Priority mail shi Teleconference Transcription S Communication Purchase of Art Additional recru	pution Costs pping of syllabus & Charges (Total for services (Total for 8) Icles and Reprints	3)				\$14,000.00 \$3,250.00 \$7,500.00 \$1,500.00 \$1,500.00
Invitation Distrit Priority mail shi Teleconference Transcription S Purchase of Art Additional recru	pution Costs pping of syllabus & Charges (Total for services (Total for 8) Icles and Reprints	3)				\$14,000.00 \$3,250.00 \$7,500.00 \$1,500.00
Invitation Distrit Priority mail shi Teleconference Transcription S Purchase of Art Additional recru Creative, Design	putton Costs pping of syllabus & Charges (Total for 8) privices (Total for 8) licles and Reprints litment tactics/Purc	hase lists				\$14,000.00 \$3,250.00 \$7,500.00 \$1,500.00 \$1,500.00 \$5,000.00 \$6,500.00
Invitation Distrit Priority mail shi Teleconference Transcription Sc Purchase of Art Additional recru Creative, Design OOP TOTAL Management Fe	putton Costs pping of syllabus & Charges (Total for is prvices (Total for 8) icles and Reprints itiment tactics/Purc	hase lists				\$14,000.00 \$3,250.00 \$7,500.00 \$1,500.00 \$5,000.00 \$5,000.00
Invitation Distrit Priority mail shi Teleconference Transcription St Purchase of Art Additional recru Creative, Design OOP TOTAL Management Fe Includes:	putton Costs pping of syllabus & Charges (Total for 8) ervices (Total for 8) licles and Reprints litment tactics/Purc	hase lists				\$14,000.00 \$3,250.00 \$7,500.00 \$1,500.00 \$1,500.00 \$5,000.00 \$6,500.00
Invitation Distrit Priority mail shi Teleconference Transcription St Purchase of Art Additional recru Creative, Design OOP TOTAL Management Fe Includes: * Timeline devoket	putton Costs pping of syllabus & Charges (Total for 8) privices (Total for 8) licles and Reprints litment tactics/Purc	hase lists inferences)				\$14,000.00 \$3,250.00 \$7,500.00 \$1,500.00 \$1,500.00 \$5,000.00 \$6,500.00
Invitation Distrik Priority mail shi Teleconference Transcription S Purchase of Art Additional recruit Creative, Design OOP TOTAL Management Fe Includes: 'Timeline devoke 'Manage interna 'Arrange for facus	popular Costs pping of syllabus & Charges (Total for 8) privices (Total for 8) licles and Reprints litiment tactics/Purc in, and Layout e (Total for 8 teleco	hase lists inferences)				\$14,000.00 \$3,250.00 \$7,500.00 \$1,500.00 \$1,500.00 \$5,000.00 \$6,500.00
Invitation Distrit Priority mail shi Teleconference Transcription So Purchase of Art Additional recruir Creative, Design OOP TOTAL Management Fe Includes: 'Timeline developed 'Manage in fract 'Arrange for fact 'Coordinate invit	population Costs pping of syllabus & Charges (Total for 8) ervices (Total for 8) licles and Reprints littment tactics/Purc in, and Layout I team and project floutity honoraria ational process including	hase lists inferences)				\$14,000.00 \$3,250.00 \$7,500.00 \$1,500.00 \$1,500.00 \$5,000.00 \$6,500.00
Invitation Distrit Priority mail shi Teleconference Transcription St Purchase of Art Additional recru Creative, Design OOP TOTAL Hanagement Fe Includes: ' Timeline devoke ' Manage interna ' Arrange for face 'Coordinate invit 'Develop call sch	poution Costs pping of syllabus & Charges (Total for a revices (Total for 8) Icles and Reprints Litment tactics/Purc in, and Layout Re (Total for 8 teleco poment & maintenance It eam and project flou interval process included	hase lists inferences) see widing confirmations				\$14,000.00 \$3,250.00 \$7,500.00 \$1,500.00 \$1,500.00 \$5,000.00 \$6,500.00
Invitation Distrit Priority mail shi Teleconference Transcription S Purchase of Art Additional recru Creative, Design OOP TOTAL Management Fe includes: 'Timeline develet 'Manage interna 'Arrange for facc 'Coordinate invit 'Develop call sot 'Coordinate with	population Costs pping of syllabus & Charges (Total for 8) ervices (Total for 8) licles and Reprints littment tactics/Purc in, and Layout I team and project floutity honoraria ational process including	hase lists inferences) se with ding confirmations appropriate project f	low.			\$14,000.00 \$3,250.00 \$7,500.00 \$1,500.00 \$1,500.00 \$5,000.00 \$6,500.00
Invitation Distrit Priority mail shi Teleconference Transcription St. Purchase of Art Additional recruit Creative, Design OOP TOTAL Management Fe Includes: 'Timeline develog 'Manage interna 'Arrange for facu 'Coordinate invit 'Develop meetin faculty bio list, ev	populson Costs pping of syllabus & Charges (Total for 8) privices (Total for 8) icles and Reprints itiment tactics/Purc icles and Layout (Total for 8 teleco populson & maintenance it earn and project flou ilty honoraria altonal process included call center to insure g matenals (invites, a valuation survey)	hase lists inferences) de with the second confirmations appropriate project faminouncement cards	low.			\$14,000.00 \$3,250.00 \$7,500.00 \$1,500.00 \$1,500.00 \$5,000.00 \$6,500.00
Invitation Distrit Priority mail shi Teleconference Transcription S Purchase of Art Additional recru Creative, Design OOP TOTAL Management Fe Includes: 'Timeline develation of fact 'Coordinate invit 'Develop call soft 'Coordinate with 'Develop meetin faculty bio list, et 'Manage design	popular Costs pping of syllabus & Charges (Total for 8) privices (Total for 8) licles and Reprints litiment tactics/Purc in, and Layout le (Total for 8 teleco popment & maintenance it team and project flo inty honoraria ational process incluredule call center to insure g materials (invites, a valuation survey) and production of me	hase lists Inferences) Inferences Infer	low.			\$14,000.00 \$3,250.00 \$7,500.00 \$1,500.00 \$1,500.00 \$5,000.00 \$6,500.00
Invitation Distrit Priority mail shi Teleconference Transcription So Purchase of Art Additional recruir Creative, Design OOP TOTAL Management Fe Includes: 'Timeline develute 'Manage in recruir 'Manage in recruir 'Coordinate vivit 'Develop meetlin 'Develop meetlin faculty bio list, et 'Manage design 'Ship meeting me	poping of syllabus & Charges (Total for 8) ervices (Total for 8) licies and Reprints litiment tactics/Purc in, and Layout I team and project flo altonal process inclusedule call center to insure g g matenals (invites, a valuation survey) and production of maternals to participants	hase lists inferences) ine wing confirmations appropriate project fanouncement cards setting syllabus is & faculty	low.			\$14,000.00 \$3,250.00 \$7,500.00 \$1,500.00 \$1,500.00 \$5,000.00 \$6,500.00
Invitation Distrit Priority mail shi Teleconference Transcription St. Purchase of Art Additional recruit Creative, Design OOP TOTAL Management Fa Includes: 'Timeline develor 'Manage interna 'Arrange for faculty coordinate mint 'Develop meetin faculty bio list, ev 'Manage design 'Ship meeting me 'Lead and mode 'Develop process	poping of syllabus & Charges (Total for 8) revices (Total for 8) icles and Reprints itiment tactics/Purc the (Total for 8 teleco opment & maintenance team and project flo illy honoraria ational process included call center to insure g materials (invites, a valuation survey) and production of maillerials to participant rate 8 teleconferencess and review evalua	hase lists inferences) ine ding confirmations appropriate project fi announcement cards esting syllabus is & faculty a sessions tions & summary rep	llow s, syllabus, agen			\$14,000.00 \$3,250.00 \$7,500.00 \$1,500.00 \$1,500.00 \$5,000.00 \$6,500.00
Invitation Distrit Priority mail shi Teleconference Transcription S Purchase of Art Additional recru Creative, Design OOP TOTAL Management Fe Includes: 'Timeline devoke 'Manage interna 'Arrange for facu 'Coordinate with 'Develop call sof 'Coordinate with 'Develop meeting Iaculty bio list, ev 'Manage design 'Ship meeting m 'Lead and mode 'Develop, proces 'Liaise with inter	poping of syllabus & Charges (Total for 8) priviles (Total for 8 teleconomic (Tot	hase lists inferences) de with the second of the second	llow , syllabus, agen	da, participant list,		\$14,000.00 \$3,250.00 \$7,500.00 \$1,500.00 \$1,500.00 \$5,000.00 \$6,500.00
Invitation Distrit Priority mail shi Teleconference Transcription S Purchase of Art Additional recru Creative, Design OOP TOTAL Management Fe Includes: 'Timeline develation of the Coordinate invit 'Develop call sot 'Coordinate with 'Develop meetin faculty bio list, ex 'Manage design 'Ship meeting m 'Lead and mode "Develop proces 'Liaise with inter 'Cortification co	poping of syllabus & Charges (Total for 8) arvices (Total for 8) is littles and Reprints itiment tactics/Purch, and Layout and project flooding to the form of the	hase lists inferences) ine with a confirmations appropriate project for announcement cards esting syllabus is & faculty is essions tions & summary reprint accreditor insorship, compliance	llow , syllabus, agen	da, participant list,		\$14,000.00 \$3,250.00 \$7,500.00 \$1,500.00 \$1,500.00 \$5,000.00 \$6,500.00
Invitation Distrit Priority mail shi Teleconference Transcription Si Purchase of Art Additional recruit Creative, Design OOP TOTAL Management Fa Includes: 'Timeline develot 'Manage interna 'Arrange for facu 'Coordinate invit 'Develop meetin faculty bio list, ev 'Manage design 'Ship meeting me 'Lead and mode 'Develop proces' 'Liaise with inter 'Certification co 'Develop Grants 'Complete final i	populion Costs pping of syllabus & Charges (Total for 8) privices (Total for 8) Icles and Reprints itiment tactics/Purc itiment ta	hase lists inferences) ine with a confirmations appropriate project for announcement cards esting syllabus is & faculty is essions tions & summary reprint accreditor insorship, compliance	llow , syllabus, agen	da, participant list,		\$14,000.00 \$3,250.00 \$7,500.00 \$1,500.00 \$1,500.00 \$5,000.00 \$93,250.00

of Prioride Acts of Bring VV (after the Priority Support to the reference of the control of the priority of th



Brighting of a long of the second Edward Commence



Part or applied or that on Value of Market Control of Medical Medical Medical

- Angli Program Pangli Program Pangli Program

Includes:

* Collaborate with faculty on learning objectives, agenda and discussion guide development

* Collaborate with faculty on presentations

*Liaise with faculty & incorporate faculty comments

*Liaise with accreditor & incorporate comments *Edit, copyedit, review and format all materials

*Participate in teleconferences

*Pre- and post-teleconference liaise with faculty

FEE TOTAL

\$47,500.00

GRAND TOTAL (8 Teleconferences)

\$140,750.00

to the order with a Period NN to Date of the Control of the Control of the model of the model of the control of





A use g M to a strict the

DESCRIPTION /			en met en met litte.		Septime 1, contraction of the co	
CATEGORY		ASSUMPT	ONS		COST	TOTAL COST
		Rate	Persons			
Course Director Honora	ırium	\$2,500	1		\$2,500	
Faculty Honorarium		\$1,500	2		\$3,000	
					TOTAL	\$5,500.0
Albert Einstein Accredit	tation and Certif	icate Fee				\$9,500.0
Albert Einstein Outcome	es Measuremen	t Fee				\$3,500.0
						A CALL OF A SEC.
Production/Printing			L	لسبسل		
0	M		Quantity	Design	Cost	
Services Include	Printing		45,000	4-Color	\$20,000	
	I sinding		40,000	7-00101	TOTAL	\$20,000.0
SHEPINGMALING	OST-OOP	F Skinderstille				AT VY and JAMES
Distribution Fee Pain Me						\$14,000.0
Express Mail Shipping (\$200.0
ekille zierata						Sant Card
Webification of Monogra				ina. Marko digininah . Ania M		\$10,000.0
WATER CHARGE		Minister Co.		North Print		
Creative, Design and La						\$6,500.0
Purchase Artwork						\$250.0
TOTAL OOPs						\$69,450.0
	5 446444	12:A PA 31	Participal de la companya della companya de la companya della comp			anggara Kalangan dan kalangan
Management Fee						\$17,500.0
Includes:						
* Timeline development &						
*Internal team and Project						
Coordinate faculty revie						
* Arrange for faculty revie	ew and honoraria	!				
* Arrange for honoraria	. d d					
* Manage design and pro * Traffic materials for revi						
* Certification collaboration			ce review. A	lbert Einstein	liaison)	
* Evaluation summary de	• .	• •				
* Grant/Needs developme		noocaamy				
*Reconciliation managen						
Content Development/E						\$25,000.0
Content Development is						
*Develop learning objecti						
Bevelop learning object						
*Develop oulline for an 8	7 44 1 4		ograph man	uscript		
*Develop outline for an 8 *Collaborate with faculty						
*Develop outline for an 8 *Collaborate with faculty *Liaise with faculty & inco	orporate faculty o					
*Develop outline for an 8 *Collaborate with faculty *Liaise with faculty & inco *Liaise with accreditor &	orporate faculty o incorporate comi	ments				
*Develop outline for an 8 *Collaborate with faculty *Liaise with faculty & inco *Liaise with accreditor & *Editorial/copy editorial r	orporate faculty of incorporate comineview and formations.	ments atting of specie		ograph		
*Develop outline for an 8 *Collaborate with faculty *Liaise with faculty & inco *Liaise with accreditor &	orporate faculty of incorporate comineview and formations.	ments atting of specie		ograph		
*Develop outline for an 8 *Collaborate with faculty *Liaise with faculty & inco *Liaise with accreditor & *Editorial/copy editorial r	orporate faculty of incorporate comineview and formations.	ments atting of specie		ograph		\$42,500.0

Control of Artist Print At 1947 - Proceeds of the Artist Print Research of the Artist Print Research





and the state of t

				Company This put in		25 (4)
				Addin		
DESCRIPTION /	W 200 1, 27 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	ASSUM	IPTIONS	2.2.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1	COST	TOTAL COST
CATEGORY	ROME DEL	Majarang	rsy i de jilijah jegan aktobes i s	Preparation of the Control	on the first of the Michigan	
Barrier and Branch, District Lieu	ha historia sanda and an ana an an an an	Rate	Persons	- การการการที่ โดยเกิดเกาะ		
Course Director	Honorarium	\$3,500	1	$\overline{}$	\$3,500	
Chair Honorarius		\$2,500	1	1×1	\$2,500	
Faculty Honorari	a	\$2,000	5	$V \setminus V$	\$10,000	
Albert Finatain A		-10-45-4-5			TOTAL	\$16,000.0
Albert Einstein A Albert Einstein C			ee			\$9,500.0 \$3,500.0
						\$3,500.0
Hotel Accommod					And the Control of th	
		Room & Tax	Persons	Nights		
To Include,		\$275	7	1 1	\$1,925	
l.	Accreditor Asante	\$275 \$275	1 3	1 1	\$275 \$825	
1	Additional	₽ 2/0	 	 	\$625	
1	Suppliers	\$275	2	1	\$550	
					TOTAL	\$3,575.0
Hotel Miscellane Airfare	ous	Enen * T	Days			\$0.0
To Include.	Faculty	Fare & Tax \$600	Persons 7	Service	\$4,200	
	Accreditor	\$600	1 1	Coach	\$600	
	Asante	\$600	0	Coach	\$0	
	Additional					
	Suppliers	\$600	2	Coach	\$1,200 TOTAL	\$6 000 D
Ground Transpo	rtation	Fare & Tax	Persons	Service	IOTAL	\$6,000.0
To Include		\$300	7	Sedan	\$2,100	
	Accreditor	\$100	1	Taxı	\$100	
	Asante	\$100	3	Tax	\$300	
	Additional Suppliers	\$100	2	Taxi	\$200	
		\$100	<u> </u>	1 100	TOTAL	\$2,700.0
Expenses		Rate	Persons			
To Include:		\$100	7	\mathcal{N}	\$700	
	Asante	\$100	3	1 // I	\$300	
	Accreditor Additional	\$100	1	- / \	\$100	
	Suppliers	\$100	2		\$200	
					TOTAL	\$1,300.0
		Cost/Tax/		Number of		
Food and Bevera	ige	Gratuity	Persons/ Quantity			
	Continental					
To Include.	Breakfast Lunch	\$40	70	1 1	\$0	
	Break	\$65 \$30	70	1	\$4,550 \$2,100	
	Faculty		† '-		\$2,100	
	Dinner	\$100	11	1	\$1,100	
	On-site Slide					
	Review	\$250	1	1	\$250	
					TOTAL	\$8,000.0
Meeting Room(s		\$750	********	1		\$750.0
Gratuities (Hotel On-Site Telephore		\$100 \$750				\$100.0 \$750.0
On-Site Internet		\$750				\$750.0
	70日前海湾			the state of		## * ##################################
Production/Print	1		1			

The mattheward Person NA sugar and the transfer of


The state of the s



District of calls of the state
Services Inclu	Printing of syllabus (includes printing & assembly charges for. Agenda, Participant List, Faculty List, color slides, evaluations, etc)	100	4-Color	\$4,500	
	Printing of self-mailer, wafer- sealed invitation	5,000	4-Color	\$3,000	
				TOTAL	\$7,500.00
Pens, Pads	me Badges, Tent Cards				\$1,375.00 \$250.00
Postage for	Invites				\$3,500.00
The Control of the Co	meeting materials			 -	\$500.00
		HEAR SHE TANK	eda Zirodotilaac		
	- All equipment for Slide Review and		n	58.97.85.18.101.18.17.908.86.56.45.17.90.18.1.	\$5,000.00
Technical St	pervisor/Support - Labor/PowerPo	ant Tech	······		\$1,200.00
	ETTER STANDARD				
	Shipping (faculty mailings, mater	ials shipping)			\$250.00
N C.	ecruitment tactics/purchase lists				\$5,000.00
Meeting Plan					\$7,000.00
d - 81 S	sign, and Layout				\$7,000.00
	n (each table)				\$4,000.00
OOP TOTA	us expenses			······	\$250.00 \$95,750.00
The second secon	WE CHI THE MAN DESCRIPTIONS AND ADDRESS OF THE PARTY OF THE PARTY.	riados (ol Hibroloffessor		Lance Southern and Arthur Colored	395,750.00gs
Managemen					\$26,000.00
Includes				······································	*20,000.00
* Timəline de	velopment & maintenance				
*Manage inte	ernal team and project flow				
					\$184401 \$417.18
* Coordinate	faculty invitational process including	invitations, confi	mations, final and we	lcome packets	2.20
Manage att	endee recruitment process including	invitations confi	rmations final logistics	al information	4.00
	ordination of venue selection, negotia			ar milion	
Carl Colored Anti-charge Colored Color	travel, hotel, ground transportation, i		-	g and onsite	
Michigan contraction on whiteness	on-site operations of the program inc			•	
* Manage de	sign and production of all meeting ma	ateriais including			
	andouts, badges, tent cards, etc.				
* Traffic mee	ting materials for review and producti	ion			e it it is
* Arrange for					E TV s
CO. 1 C. 10 C.	ls development				
AND DESCRIPTION OF THE PROPERTY OF THE PROPERT	on management				62.5
	Collaboration (joint sponsorship, co	mpliance review.	Albert Einstein liaisor	7)	
	E compliance		· · · · · · · · · · · · · · · · · · ·		624 550 00 00
English and the State of the St	elopment/Editorial Fee				\$31,500.00
Includes:	with fourth, on location is the st		malan muda da at		
	with faculty on learning objectives, a with faculty on presentations	iyenda and discl	ізгіоп диіав авувіорт	IGIR	
00-7-10-10-10-10-10-10-10-10-10-10-10-10-10-	with raculty on presentations faculty and incorporate faculty comm	ents			
	accreditor and incorporate accreditor				
OF PROOF STREET, CO.	py editonal review and formatting				100 miles
	sociated with meeting content develo	pment			(C)
FEE TOTA		·			\$57,500.00
GRAND 1	TOTAL			\$	153,250.00
					

 $= (1 + 1) \cdot (1 + 2) \cdot (1$



Market Market Market

DESCRIPTION / CATEGORY	24,940 A.a.	ASSUMI	OTIONS		COST	TOTAL COST
GENERAL POSSESSION STATES	America Dem	ASSUMI	- HONS	kerinaa Alb	et et et et et	TOTAL COST
The second secon	a kadendalkot elisatuu kuus erelle e -	Rate	Persons	Security (Security Security)	tertilitiette test il der likeliere – ver die	and trade of the second
Course Director Honorarium		\$0	1	$ \overline{} $	\$0	
Chair Honorarium		\$2,500	1) X [\$2,500	
Faculty Honoraria		\$2,000	5		\$10,000	
	10 45				TOTAL	\$12,500.00
Albert Einstein Accreditation						\$1,000.00
Albert Einstein Outcome Mea	surement Pe		24 2 4 6 7 4 7	ian isti etrisi	MARTILET TO A MARIA CO	\$0.00
Hotel Accommodations				and the Land of the	with red to the leaf.	STATE OF THE STATE
		Room & Tax	Persons	Nights		
To include:	•	\$275	7	1	\$1,925	
	Accreditor	\$275	1	11	\$275	
	Asante	\$275	3	1	\$825	
	Additional Suppliers	\$275	2	1 1	\$550	
		<u> </u>	*	·	TOTAL	\$3,575.00
Hotel Miscellaneous						\$0.00
Airfare		Fare & Tax	Persons	Service		
To Include.	-	\$600	7	Coach	\$4,200	
	Accreditor	\$600	1	Coach	\$600	
	Asante	\$600	33	Coach	\$1,800	
	Additional	\$600	2	0	£1 300	
	Suppliers	\$600		Coach	\$1,200 TOTAL	\$7,800.00
Ground Transportation (arriva	(/departure)	Fare & Tax	Persons	Service	TOTAL	\$7,000.00
To Include.		\$300	7	Sedan	\$2,100	
	Accreditor	\$100	1	Тахі	\$100	
	Asante	\$100	3	Taxı	\$300	
	Additional		_			
	Suppliers	\$100	2	Taxı	\$200 TOTAL	en 700 00
Expenses		Rate	Persons		IOIAL	\$2,700.00
To Include:	Faculty	\$100	7	N /	\$700	
, 5 5 1450.	Asante	\$100	3	$1 \setminus A$	\$300	
	Accreditor	\$100	1	1 X I	\$100	
	Additional			1 / 🖊 [
	Suppliers	\$100	2	V = V	\$200	
					TOTAL	\$1,300.00
		Cost/Tax/	Persons/	Number of		
Food and Beverage		Gratuity	Quantity	Functions		
حاديدا مناعدا ح	Continental	F40			•	
To Include	Breakfast Lunch	\$40 \$65	70	1 1	\$0 \$4,550	
	Break	\$30	70	1 1	\$4,550	
	Faculty	\$30	10	 	\$2,100	
	Dinner	\$100	11	1	\$1,100	
	On-site				1	
	Slide					
	Review	\$250	1	1 1	\$250	A
Mosting Dear-/-\ De/-/		6750		1	TOTAL	\$8,000.00
Meeting Room(s) Rental Gratuities (Hotel Staff)		\$750 \$100		1		\$750.00 \$100.00
		\$ 100		1		
On-Site Telephone/Fax		\$750	P44444			\$750.00

the make were stray Marine to the "Source to the tests of common and are not considered."






$$\begin{split} & \frac{dN_{t-1}}{dt} = \frac{d}{dt} = \frac{1}{2} \left(\frac{1}{2} \left$$

		Quantity	Design		
Services Include	(includes printing &	100	4-Color	\$4,500	
	wafer-sealed invitation	5,000	4-Color	\$3,000	
			·	TOTAL	\$7,500.0
Signage, Name Badges, Tent	Cards				\$1,375.0
Pens, Pads					\$250.0
Postage for Invites					\$3,500.0
Postage for meeting materials					\$500.0
				Statute out	
Audiovisual - All equipment for					\$5,000.0
Technical Supervisor/Suppor			DETTERMENTALIS - L'ESTELL :	Bell a Maria, de designant france (Maria A	\$1,200.0
MARKELLA MEDUSTE FOR					
Express Mail Shipping (facult		ipping)			\$250.0
Additional recruitment tactics Meeting Planner	ipurchase lists				\$5,000.0
Creative, Design, and Layout	~				\$7,000.0 \$5,000.0
Transcription (each table)					\$4,000.0
Miscellaneous expenses					\$250.0
OOP TOTAL		·····			\$80,050.0
	多。据说图由27.W图200	- 524k		aret a trá to	
Management Fee	The standard of the same of th	and the contract of the contra	Pps. Billion 2000 Section	SERVER . FINE 1. OF CHES	\$26,000.0
Includes:					420,000.0
* Timeline development & main	tenance				
*Manage internal team and proj					
* Coordinate faculty invitational		ns confirma	tions final an	d welcome packe	ote
	,				
" Manage attendee recruitment	process including invitation				
	process including invitation as	ns, confirma	tions, final log		
 Oversee coordination of venue 	selection, negotiation ar	ons, confirma ad contracting	tions, final log I	gistical informatio	n
 Oversee coordination of venue Oversee all travel, hotel, groun 	e selection, negotiation ai nd transportation, food fui	ons, confirma nd contracting nctions and A	tions, final log I V both pre-m	gistical informatio	n
* Oversee coordination of venue * Oversee all travel, hotel, groun * Manage all on-site operations	e selection, negotiation ar nd transportation, food ful of the program including	ons, confirma nd contracting nctions and A	tions, final log I V both pre-m	gistical informatio	n
* Oversee coordination of venue * Oversee all travel, hotel, groun * Manage all on-site operations participant handouts, badges, te	e selection, negotiation ai and transportation, food ful of the program including ant cards, etc.	ons, confirma nd contracting nctions and A	tions, final log I V both pre-m	gistical informatio	n
* Oversee coordination of venue * Oversee all travel, hotel, groun * Manage all on-site operations	e selection, negotiation ai and transportation, food ful of the program including ant cards, etc.	ons, confirma nd contracting nctions and A	tions, final log I V both pre-m	gistical informatio	n
 Oversee coordination of venue Oversee all travel, hotel, groui Manage all on-site operations participant handouts, badges, to Traffic meeting materials for re Arrange for honoraria 	e selection, negotiation ai and transportation, food ful of the program including ant cards, etc.	ons, confirma nd contracting nctions and A	tions, final log I V both pre-m	gistical informatio	n
 Oversee coordination of venue Oversee all travel, hotel, groun Manage all on-site operations participant handouts, badges, to Traffic meeting materials for re 	e selection, negotiation ai and transportation, food ful of the program including ant cards, etc.	ons, confirma nd contracting nctions and A	tions, final log I V both pre-m	gistical informatio	n
 Oversee coordination of venue Oversee all travel, hotel, groui Manage all on-site operations participant handouts, badges, to Traffic meeting materials for re Arrange for honoraria Grant/Needs development 	e selection, negotiation ai nd transportation, food fur of the program including ant cards, etc. aview and production	ons, confirma nd contracting nctions and A registration a	tions, final log J V both pre-m rea	gistical informatio	n
* Oversee coordination of venue * Oversee all travel, hotel, groui * Manage all on-site operations participant handouts, badges, to * Traffic meeting materials for re * Arrange for honoraria * Grant/Needs development *Reconciliation management	e selection, negotiation ai nd transportation, food fur of the program including ant cards, etc. aview and production	ons, confirma nd contracting nctions and A registration a	tions, final log J V both pre-m rea	gistical informatio	n
Oversee coordination of venue Oversee all travel, hotel, groui Manage all on-site operations participant handouts, badges, it Traffic meeting materials for re Arrange for honoraria Grant/Needs development Reconciliation management Certification Collaboration (join	e selection, negotiation ai nd transportation, food fur of the program including ant cards, etc. eview and production ant sponsorship, compliant	ons, confirma nd contracting nctions and A registration a	tions, final log J V both pre-m rea	gistical informatio	n
* Oversee coordination of venue * Oversee all travel, hotel, grout * Manage all on-site operations participant handouts, badges, it * Traffic meeting materials for re * Arrange for honoraria * Grant/Needs development * Reconcillation management * Certification Collaboration (joil * Internal CME compliance	e selection, negotiation ai nd transportation, food fur of the program including ant cards, etc. eview and production ant sponsorship, compliant	ons, confirma nd contracting nctions and A registration a	tions, final log J V both pre-m rea	gistical informatio	en
Oversee coordination of venue Oversee all travel, hotel, groui Manage all on-site operations participant handouts, badges, to Traffic meeting materials for re Arrange for honoraria Grant/Needs development Reconciliation management Certification Collaboration (joil Internai CME compliance Content Development/Editorii Includes: Collaborate with faculty on lea	e selection, negotiation and transportation, food fur of the program including ent cards, etc. eview and production ent sponsorship, compliant at Fee eming objectives, agenda	ons, confirma ad contracting actions and A registration a se review, Alb	tions, final log J V both pre-m rea pert Einstein li	gistical informatio leeting and onsite laison)	en
Oversee coordination of venue Oversee all travel, hotel, groui Manage all on-site operations participant handouts, badges, to Traffic meeting materials for re Arrange for honoraria Grant/Needs development Reconciliation management Certification Collaboration (joil Internai CME compliance Content Development/Editoris Includes: Collaborate with faculty on lea	e selection, negotiation and transportation, food fur of the program including ant cards, etc. eview and production at sponsorship, compliant at Fee imming objectives, agendates as a sentations.	ons, confirma ad contracting actions and A registration a se review, Alb	tions, final log J V both pre-m rea pert Einstein li	gistical informatio leeting and onsite laison)	en
Oversee coordination of venue Oversee all travel, hotel, groui Manage all on-site operations participant handouts, badges, to Traffic meeting materials for re Arrange for honoraria Grant/Needs development Reconciliation management Certification Collaboration (joil Internai CME compliance Content DevelopmentEditorii Includes: Collaborate with faculty on lea Collaborate with faculty and incorpo	e selection, negotiation ai not transportation, food fur of the program including ant cards, etc. eview and production int sponsorship, compliance al Fee iming objectives, agendations trate faculty comments	ons, confirma od contracting octions and A registration a se review, Alb and discussion	tions, final log J V both pre-m rea pert Einstein li	gistical informatio leeting and onsite laison)	en
* Oversee coordination of venue. * Oversee all travel, hotel, groui. * Manage all on-site operations participant handouts, badges, it. * Traffic meeting materials for re. * Arrange for honoraria. * Grant/Needs development. *Reconciliation management. * Certification Collaboration (joil. * Internal CME compliance. Content Development/Editorial includes: * Collaborate with faculty on lea. * Collaborate with faculty on pre. * Liaise with faculty and incorpolitudes with faculty and incorpolitudes. * Liaise with faculty and incorpolitudes.	e selection, negotiation ai not transportation, food fur of the program including ant cards, etc. eview and production int sponsorship, compliance al Fee iming objectives, agenda issentations trate faculty comments imporate accreditor comme	ons, confirma od contracting octions and A registration a se review, Alb and discussion	tions, final log J V both pre-m rea pert Einstein li	gistical informatio leeting and onsite laison)	en
* Oversee coordination of venue. * Oversee all travel, hotel, groui. * Manage all on-site operations participant handouts, badges, to * Traffic meeting materials for re. * Arrange for honoraria. * Grant/Needs development. *Reconciliation management. * Certification Collaboration (joil. * Internal CME compliance. * Content Development/Editori. Includes: * Collaborate with faculty on pre. * Collaborate with faculty on pre. * Liaise with faculty and incorpo. * Liaise with accreditor and incorp. * Liaise with accreditor and incorp. * Editonal/copy editonal review.	e selection, negotiation and transportation, food fur of the program including ent cards, etc. eview and production the sponsorship, compliant al Fee imming objectives, agenda issentations interest faculty comments imporate accreditor comment and formatting	ons, confirma od contracting octions and A registration a se review, Alb and discussion	tions, final log J V both pre-m rea pert Einstein li	gistical informatio leeting and onsite laison)	en
Oversee coordination of venue. Oversee all travel, hotel, groui. Manage all on-site operations participant handouts, badges, to a Traffic meeting materials for reference and the site of the seconditation management. Certification Collaboration (joint line). Internal CME compliance. Content DevelopmentEditori. Includes: Collaborate with faculty on presultations with faculty on presultations with faculty and incorpositions. Liaise with accreditor and incorpositions. Editional/copy editional review. All costs associated with meetings.	e selection, negotiation and transportation, food fur of the program including ent cards, etc. eview and production the sponsorship, compliant al Fee imming objectives, agenda issentations interest faculty comments imporate accreditor comment and formatting	ons, confirma od contracting octions and A registration a se review, Alb and discussion	tions, final log J V both pre-m rea pert Einstein li	gistical informatio leeting and onsite laison)	\$15,750.0
* Oversee coordination of venue. * Oversee all travel, hotel, groui. * Manage all on-site operations participant handouts, badges, to * Traffic meeting materials for re. * Arrange for honoraria. * Grant/Needs development. *Reconciliation management. * Certification Collaboration (joil. * Internal CME compliance. * Content Development/Editori. Includes: * Collaborate with faculty on pre. * Collaborate with faculty on pre. * Liaise with faculty and incorpo. * Liaise with accreditor and incorp. * Liaise with accreditor and incorp. * Editonal/copy editonal review.	e selection, negotiation and transportation, food fur of the program including ent cards, etc. eview and production the sponsorship, compliant al Fee imming objectives, agenda issentations interest faculty comments imporate accreditor comment and formatting	ons, confirma od contracting octions and A registration a se review, Alb and discussion	tions, final log J V both pre-m rea pert Einstein li	gistical informatio leeting and onsite laison)	en
Oversee coordination of venue. Oversee all travel, hotel, groui Manage all on-site operations participant handouts, badges, to Traffic meeting materials for re Arrange for honoraria Grant/Needs development Reconciliation management Certification Collaboration (joil Internal CME compliance Content DevelopmentEditoria Includes: Collaborate with faculty on lea Collaborate with faculty on pre Liaise with faculty and incorpo Liaise with acceptor and inco Editional/copy editional review All costs associated with meet FEE TOTAL	e selection, negotiation and transportation, food fur of the program including ent cards, etc. eview and production the sponsorship, compliant al Fee imming objectives, agenda issentations interest faculty comments imporate accreditor comment and formatting	ons, confirma od contracting octions and A registration a se review, Alb and discussion	tions, final log J V both pre-m rea pert Einstein li	gistical informatio eeting and onsite laison)	\$15,750.0 \$41,750.0
Oversee coordination of venue. Oversee all travel, hotel, groui. Manage all on-site operations participant handouts, badges, to a Traffic meeting materials for reference and the site of the seconditation management. Certification Collaboration (joint line). Internal CME compliance. Content DevelopmentEditori. Includes: Collaborate with faculty on presultations with faculty on presultations with faculty and incorpositions. Liaise with accreditor and incorpositions. Editional/copy editional review. All costs associated with meetings.	e selection, negotiation and transportation, food fur of the program including ent cards, etc. eview and production the sponsorship, compliant al Fee imming objectives, agenda issentations interest faculty comments imporate accreditor comment and formatting	ons, confirma od contracting octions and A registration a se review, Alb and discussion	tions, final log J V both pre-m rea pert Einstein li	gistical informatio eeting and onsite laison)	\$15,750.0
Oversee coordination of venue. Oversee all travel, hotel, groui Manage all on-site operations participant handouts, badges, to Traffic meeting materials for re Arrange for honoraria Grant/Needs development Reconciliation management Certification Collaboration (joil Internal CME compliance Content DevelopmentEditoria Includes: Collaborate with faculty on lea Collaborate with faculty on pre Liaise with faculty and incorpo Liaise with acceptor and inco Editional/copy editional review All costs associated with meet FEE TOTAL	e selection, negotiation and transportation, food fur of the program including ent cards, etc. eview and production the sponsorship, compliant al Fee imming objectives, agenda issentations interest faculty comments imporate accreditor comment and formatting	ons, confirma od contracting octions and A registration a se review, Alb and discussion	tions, final log J V both pre-m rea pert Einstein li	gistical informatio eeting and onsite laison)	\$15,750.0 \$41,750.0
Oversee coordination of venue. Oversee all travel, hotel, groui Manage all on-site operations participant handouts, badges, to Traffic meeting materials for re Arrange for honoraria Grant/Needs development Reconciliation management Certification Collaboration (joil Internal CME compliance Content DevelopmentEditoria Includes: Collaborate with faculty on lea Collaborate with faculty on pre Liaise with faculty and incorpo Liaise with acceptor and inco Editional/copy editional review All costs associated with meet FEE TOTAL	e selection, negotiation and transportation, food fur of the program including ent cards, etc. eview and production the sponsorship, compliant al Fee imming objectives, agenda issentations interest faculty comments imporate accreditor comment and formatting	ons, confirma od contracting octions and A registration a se review, Alb and discussion	tions, final log J V both pre-m rea pert Einstein li	gistical informatio eeting and onsite laison)	\$15,750.0 \$41,750.0

The product of the State NA 193 to the Marketine of the State of the S







Professor, Besself of C V of an Mass of over 1 to About Easters Colons of Mode is

DESCRIPTION / CATEGORY	ASSUM	PTIONS	in come from Albertalle	COST	TOTAL COST
			70 AL COMP.		
	Rate	Persons			New Holland Street Color Control of the Street Color Street Color
Course Director Honoranum	\$0	1		\$0	
Chair Honorarium	\$2,500	1	1 X [\$2,500	
Faculty Honoraria	\$2,000	5		\$10,000	
All A FILE A FIL				TOTAL	\$12,500.00
Albert Einstein Accreditation and Cert Albert Einstein Outcome Measurement					\$1,000.00
a man which the region of graduates the beginning the property of the con-	Cree Markana		Distribution Co. History	KATA A	\$0.00
Hotel Accommodations	the transfer of the same of	n ann a fhairt i cheanaidh a	diring the language and to	alah seringan	
	Room & Tax	Persons	Nights		
To Include: Faculty	\$275	7	1	\$1,925	
Accredito		1	1	\$275	
Asante	\$275	3	1	\$825	
Additiona Suppliers		2	1 1	\$550	
Suppliers	Ψ2/3		· · · · · · · · · · · · · · · · · · ·	TOTAL	\$3,575.00
Hotel Miscellaneous					\$0.00
Airfare	Fare & Tax	Persons	Service		
To Include: Faculty	\$600	7	Coach	\$4,200	
Accredito		1	Coach	\$600	
Asante	\$600	3	Coach	\$1,800	
Additiona Suppliers	i i	2	Coach	\$1,200	
5005110110		<u> </u>	000011	TOTAL	\$7,800.00
Ground Transportation (arrival/departur	re) Fare & Tax	Persons	Service		
To Include: Faculty	\$300	7	Sedan	\$2,100	
Accredito		1	Taxi	\$100	
Asante Additiona	\$100	3	Тахі	\$300	
Suppliers		2	Taxi	\$200	
				TOTAL	\$2,700.00
Expenses	Rate	Persons			
To Include: Faculty	\$100	7		\$700	
Asante	\$100	3	\	\$300	
Accredito Additiona		1	$\downarrow \land \downarrow$	\$100	
Suppliers		2		\$200	
			- V	TOTAL	\$1,300.00
Food and Beverage	Cost/Tax/ Gratuity	Persons/ Quantity	Number of Functions		
			T]	
Continen				_ [
To Include, Breakfas		0	1	\$0	
Lunch Brook	\$65 \$30	70 70	1	\$4,550	
Break Faculty	\$30	70	'-	\$2,100	
Dinner	\$100	11	1	\$1,100	
On-site					
Slide					
Review	\$250	11	11	\$250	£0.000.00
Meeting Room(s) Rental	\$750		1 1	TOTAL	\$8,000.00 \$750.00
Gratuities (Hotel Staff)	\$100			-	\$100.00
Giatuities (Hotel Stall)			4		
On-Site Telephone/Fax On-Site Internet Connection	\$750			1	\$750 00

 $3 \times 4 \times \text{cross} \text{ Scener Remains SA 2000} = -20 \times \text{Section } x = 4 \times 218 \times 28 \times 30 \times 10^{10} \text{ or section of the section$





Aborton Consorthin From Advertising Monoral and August 1 of Maria 1 of Caraca 1 of Ca

Production/Printing						
			Quantity	Design		
Services Include			100	4-Color	\$4,500	
	wafer-sealed	dinvitation	5,000	4-Color	\$3,000	
61					TOTAL	\$7,500.0
Signage, Name Badges, Tent	Cards					\$1,375.0
Pens, Pads						\$250.0
Postage for Invites Postage for meeting materials						\$3,500.0
A Die Talback and material		NET ON S CRO	Maritalia atv	Uni miereiae	Bever Cranking was a control	\$500.0
Audiovisual - All equipment for	Side Review	wand Gener	ai Sassian	3 4 . 3 4 4 4 4		\$ 5,000.0
Technical Supervisor/Suppor	t - Labor/Po	werPoint Tec	h			\$1,200.0
CONTRACTOR OF THE CONTRACTOR O						energia di march
Express Mail Shipping (facult	v mailings	materials sh	inning)			\$250.0
Additional recruitment tactics			, p p g/			\$5,000.0
Meeting Planner			****			\$7,000.0
Creative, Design, and Layout						\$5,000.0
Transcription (each table)						\$4,000.0
Miscellaneous expenses						\$250.0
OOP TOTAL						\$80,050.00
(PERT ABURAN						
Management Fee						\$26,000.0
Includes:						
* Timeline development & main	tenance					
*Manage internal team and proj	ect flow					
 Coordinate faculty invitational 	process inclu	iding invitatio	ons, confirma	tions, final an	d weicome packe	ets
* Manage attendee recruitment	process inclu	ıdıng invitatio	ons, confirma	tions, final loc	aistical information	7
* Oversee coordination of venue						
 Oversee all travel, hotel, groui 	nd transporta	tion, food fur	nctions and A	V both pre-m	eeting and onsite	
* Manage all on-site operations						
participant handouts, badges, te	ent cards, etc	;				
* Treffic meeting materials for re	eview and pro	oduction				
* Arrange for honoraria						
* Grant/Needs development						
*Reconciliation management						
* Certification Collaboration (join	nt sponsorshi	ip, compliand	e review, All	ert Einstein li	aison)	
* Internal CME compliance						
Content Development/Editoria	al Fee					\$15,750.0
Includes:						
* Collaborate with faculty on lea		ves, agenda	and discussi	on guide deve	elopment	
* Collaborate with faculty on pre						
* Liaise with faculty and incorpo						
* Liaise with accreditor and inco			ents			
* Editorial/copy editorial review						
* All costs associated with meet	ing content o	ievelopment			-	# 44 mrs s
FEE TOTAL						\$41,750.0
GRAND TOTAL						124 900 00
ALCOHO TOTAL						121,800.00

 $(x_{i+1}, y_{i+1}, \dots, y_{i+1$

apple agreement and a company


Center for Continuing Medical Education

Some state of the


Strate Control of the
The second section is formally the second section Secretaries along Manager

DESCRIPTION /	ASSUMPT	IONS	1	COST	TOTAL COST
CATEGORY		02/14/14/20	a ideograpija i	N. \$4.00 p. 10 10 10 10 10 10 10 10 10 10 10 10 10	A WASSELLE SERVI
ala kalan da tanah kalan kalan da kala	time made in made in the major to applicable the between	A CONTRACTOR OF THE PARTY OF TH		A	i Salar II. da Santania
Course Director Honorarium	\$2,500	Persons 1		\$2,500	
aculty Honorarium	\$1,500	1 2	! ><	\$3,000	
acany monoranani	1 41,500			TOTAL	\$5,500.0
Albert Einstein Accreditation and	Cartificate Fee			IOTAL	\$9,500.0
Albert Einstein Outcome Measur					\$3,500.0
ZTELTOK LEHALLENIZA		3.864.X5	NV CHEN		
Production/Printing					
		Quantity	Design	Cost	
Services Include: Monogra	ph -	45.000		***	
Printing		45,000	4-Color	\$20,000 TOTAL	\$20,000.0
GIRANGADAGNERESSES	The same of the same	Mark Labour		TOTAL	Company and the fact of the contract of the co
Distribution Pain Clinician, Pain	THE PERSON NAMED IN COLUMN TWO IS NOT THE OWNER.	The second secon	s	and the second second	\$14,000.0
xpress Mail Shipping (faculty n			·		\$200.0
可可证的证据					
Webification of Monograph			9.04.000,000		\$10,000.0
eranding of the constant			thankar.	in the second	11.
STEP OF SERVICE STATES OF THE SERVICE STATES	A CONTRACTOR	"阿尔 尔斯尔	其位为农业分1	11100	Delta de la Terra
Creative, Design and Layout					\$6,500.0
Purchase Artwork					\$250.0 \$69.450.0
TOTAL OOPs	Mary Devile, North Little, New	and Table	温物研究であれる人品	and the second second	\$69,450.0
Management Fee	The second of the second secon				\$17,500.0
ncludes:					V 11,000.2
* Timeline development & mainten	ance				
Internal team and Project manage	ment				
* Coordinate faculty review invitati					
Arrange for faculty review and ho	noraria				
Arrange for honorana					
 Manage design and production of Traffic materials for review and p 					
* Certification collaboration (joint s		nce review. Al	bert Einstein l	iaison)	
* Evaluation summary developmen					
* Grant/Needs development	p. 00000g				
*Reconciliation management					
Content Development/Editorial					\$25,000.0
Content Development includes:					
*Develop learning objectives					
*Develop outline for an 8-page mo *Collaborate with faculty in the dev		nograph mani	iscript		
*Liaise with faculty & incorporate fi		grupn mant			
*Liaise with accreditor & incorpora					
* Editorial/copy editorial review an	d formatting of specia	al report mond	ograph		
* All costs associated with meeting	content developme	nt			
TOTAL FEES					\$42,500.0

to Browning Serial Resp. 84 (1967) - Pr. 5 (8800) 1 - 1 + 18 (8) 1 - mondone of the original order of

PERSISTENT AND BREAKTHROUGH PAIN

MULTIDIMENSIONAL ASSESSMENT AND MULTIMODAL OPIOID-BASED TREATMENT STRATEGIES

An Educational Platform Initiative

Medical Education Grant Request

Presented to | Cephalon, Inc.

Submitted by | Albert Einstein College of Medicine

Submitted on | 11/06/2008





Outline of Request

- I. Overview
- II. Platform Sponsorship, Management, and Outcomes Measurement
- III. Educational Platform, Learning Objectives, and Needs Assessment
- IV. Faculty and Programs
- V. Program Recruitment, Awareness, and Distribution
- VI. Budgets

I. Overview

Albert Einstein College of Medicine (Einstein) in association with its educational collaborator, Asante Communications LLC (Asante), respectfully request a grant for the development, certification, production, and distribution of an educational initiative tentatively entitled "Persistent and Breakthrough Pain: Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies." This educational platform is intended to provide continuing medical education (CME) credit to healthcare professionals who treat patients with chronic pain.

The sponsors seek support through an educational grant from Cephalon, Inc. A support statement identifying Cephalon, Inc. as the Grantor will be included in the preamble of each activity, as well as in all announcements regarding the platform and individual activities.

Einstein will certify the initiative for CME credit for physicians.

II. Platform Sponsorship, Management, and Outcomes Measurement

Albert Einstein College of Medicine

For more than 5 decades, Einstein has exemplified excellence in medical research, teaching, and patient care. Established in 1955, and guided by the vision of Professor Albert Einstein, the College was one of the first medical schools to integrate bedside experience with classroom study. Einstein also led the way in the development of bioethics as an accepted academic discipline in medical school curricula and was the first private medical school in New York City to establish an academic Department of Family Medicine as well as a residency program in internal medicine with an emphasis on women's health. Today, Einstein is one of the nation's premier institutions for medical education, basic research, and clinical investigation.

Although education is at the heart of Einstein's mission, biomedical research drives its growth. Einstein has 300 research laboratories, which allow it to consistently be on the forefront of medical breakthroughs via development of cutting-edge techniques and clinical trials. A national leader in biomedical research support from the federal government, Einstein received more than \$150 million in funding from the National Institutes of Health (NIH) in 2006. Einstein ranks sixth in the nation in terms of NIH awards to basic-science departments, and 7 of its programs are designated as NIH "Centers of Excellence."

Einstein and Montefiore Medical Center (the University Hospital and Academic Medical Center for the Albert Einstein College of Medicine) Center for Continuing Medical Education (CCME) was founded in 1976. It is accredited by the Accreditation Council

Page 2 of 30 Confidential

for Continuing Medical Education (ACCME) to provide CME for physicians. CCME is committed to the utilization of resources for the advancement of CME throughout the physician's professional career. CCME's mission is to enhance patient care by bringing diagnostic and therapeutic innovations to the clinical environment through professional medical education for physicians that maintains, develops, and increases their knowledge, skills, and competence.

Independence

CCME does not maintain financial relationships with commercial supporters or educational partners outside of the receipt of normal fee for services. Commercial interests are not involved in the development of content, program planning, or budget-determination. Responsibility for assuring that the CME activities meet the highest requirements and standards of Einstein and the ACCME rests solely with the CCME and is not transferable.

Disclosure and Confrat of Interest

CCME requires written, signed disclosure of the existence of relevant financial interests or relationships with commercial interests from any individual contributing to or in a position to influence the content of a CME activity sponsored by Einstein. Individuals not disclosing relevant financial relationships will be disqualified from an association with the CME activity in question.

CCME has established policies that will identify and resolve all conflicts of interest prior to activity certification by applying the disclosed information and activity subject to ACCME's policies.

Content Vaudeban

All scientific research referred to, reported on, or used in a CME activity certified by Einstein in support or justification of a patient care recommendation will conform to the generally accepted standards of experimental design, data collection, and analysis.

Complessor

Asante has retained Hogan & Hartson LLP, an international law firm, to provide Asante with consultancy and expert insights into current federal and state regulations, ACCME codes of conduct, Pharmaceutical Research and Manufacturers of America (PhRMA) code, and their potential impact on the quality and delivery of our medical education programs.

Experts in all relevant accreditation issues, Hogan & Hartson will ensure that the continuing medical education programs Asante proposes and executes—including such full spectrum communications vehicles as regional meetings, teleconferences, web-based and print activities—will be conducted in an irreproachably compliant fashion. By ensuring that the educational programs faithfully adhere to all relevant law and regulations, Hogan & Hartson will help us meet the educational needs of critical therapeutic areas, develop clinicians' skill sets and improve patient care.

As the 2009 educational year unfolds, Hogan & Hartson will continually monitor our policies and programs and may instruct our team accordingly, facilitating any necessary adjustments. Additionally, the global law firm will help Asante develop employee and faculty educational programs.

Asante Communications, LLC

Asante is a full-service medical education company specializing in physician and patient education for the biopharmaceutical industry. Utilizing proprietary research methodologies, the Asante team of scientists, writers, and strategists delivers high quality CME, tailored to the objectives of our accreditors and grantors, grounded in the science of current and investigational treatment options, and shaped by an expert understanding of adult learning principles. In particular, the company integrates the latest insights into disease management with comprehensive preclinical and clinical data, creating coherent and credible educational platforms. Asante provides strategically sharp content across print, live, video, and Web-based outlets and distribution channels,

Page 3 of 30 Confidential

and leverages its diverse network of pain clinicians to develop, validate and critically review needs assessments and all relevant scientific content. Further, the full spectrum of educational materials proposed in this grant is based on a fundamental tenet that clinicians have idiosyncratic learning preferences and often prefer to self-direct their learning across multiple vehicles. Such a multifaceted, interactive and needs-based approach is critical to instructing clinicians in chronic pain management. Based in New York City, the company is managed by seasoned veterans of the healthcare communications industry.

Platform Management

Asante will be responsible for the development, production, and distribution of the activities within the educational platform under the direction of Einstein. Asante will operate as an extension of the sponsor, working within Einstein's guidelines as well as those of the accrediting organizations and governmental agencies regulating medical education.

Einstein will provide oversight for the development, production, and distribution of the activities within the educational platform as well as the certification for CME credit.

Outcome Levels

Asante reaches Level 4 of Outcomes Measurement as defined by the North American Association of Medical Education and Communication Companies, Inc (NAAMECC) with our standard evaluation process:

- Level 1: Participation (via the participant report)
- Level 2: Satisfaction (via the activity evaluation)
- Level 3: Learning (via the self-assessment exam)
- Level 4: Performance (via the commitment-to-change questions on the activity evaluation)

Durable Outcomes Measurement and Evaluation

Einstein and Asante are committed to providing high quality education associated with durable outcomes that promote best practices in pain management and improve patient care. In addition to traditional outcomes measurements reported and evaluated by Einstein for Level 4 Outcomes as noted above, a randomized controlled study approved by Victor Hatcher, PhD, David Kaufman, MD, of Einstein and the Institutional Review Board (IRB) of Albany Medical Center will be conducted to measure the effectiveness of the educational interventions.

Stage I

In this study, clinicians (N=~300~350) will demonstrate their baseline level of attitudes, awareness, knowledge and current practices by completing a structured questionnaire (20-questions; 10 multiple choice and 10 case-based short answer questions). The questionnaire—a self-developed instrument in early stages of psychometric evaluation—will be based on educational deficits initially identified in the Clinical Survey and Needs Assessment (CSNA). After completing the diagnostic, clinicians will participate in a teleconference program and/or live regional meeting, immediately after which they will again complete a similarly structured questionnaire. Pre and post differences in attitudes, awareness and knowledge will be determined, reflecting the extent to which the participants have achieved the learning objectives. To gain additional context, face-to-face focus group discussions will be conducted immediately after the regional meeting as well. Here, participants will have an opportunity to elaborate on self-reported performance indicators that go beyond the structured questionnaire.

Page 4 of 30 Confidential

Confidential

Stage II

Upon completion of Stage I, a subset of interested clinicians will be randomized to either an intervention group (~n=150), within which clinicians will participate in a monthly WebPanel series with thought leaders for 6 months, or randomized to a control group of clinicians (~n=150), who will receive no further instruction and provide a benchmark against which the effectiveness of continual intervention may be measured. Adult learning principles suggest that such reinforcement helps translate knowledge into practices with enduring value. Clinicians may benefit from the collegial relationship and outcomes-driven mentoring provided by the WebPanel. Outcome variables for Stage II will include the clinicians' confidence in pain management skills and intent-to-change by: (1) employing functional goals to guide patient care (2) implementing structured pain and risk assessment methodologies (3) monitoring breakthrough and persistent pain longitudinally and (4) documenting level of risk.

Stage III

A more precise measure of effectiveness may be obtained in a third and final stage of this study. A subset of clinicians from the Stage II intervention (n=-5 clinicians) and control groups (~n=5 clinicians) will invite as many as 10 patients each to participate in this stage (~N=100 patients; ~n=50 experimental group; ~n=50 control group). Appropriate disclaimers and IRB approval will be secured for each patient upon initiation of Stage II. Once Stage II is completed, patients in each group will complete a brief questionnaire (5 multiple choice questions). Outcome variables for Stage III will be patients' overall satisfaction with the consultations and satisfaction with the clinician's assessment of the quality, severity and temporal components of chronic pain. Differences in patient outcomes will be compared between the Stage II intervention group and control group. The working hypothesis is that those patients treated by clinicians who received ongoing interventions will have sharper assessment skills, translating into discernable and self-reported differences in patient care.

Importantly, this study design and methodology will provide qualitative and quantitative data longitudinally, throughout each stage of the study. Reported outcomes in physician performance and patient care—particularly those demonstrating sustainability—may constitute publishable data for the *Journal of Continuing Education in the Health Professions*, a peer-reviewed journal specializing in CME.

III. Educational Platform, Learning Objectives, and Needs Assessment

Educational Platform

Guided by an expert panel and comprehensive needs assessment, the educational initiatives within this platform are intended to disseminate chronic pain and risk management strategies to a multidisciplinary audience of clinicians who treat patients with chronic pain, including pain specialists, neurologists, rheumatologists, physical medicine and rehabilitation specialists, family practitioners, oncologists, and internal medicine and general practitioners. In a grant proposal to be submitted subsequently, physician assistants, nurse practitioners, and registered nurses will be addressed as an important secondary audience.

Each activity will provide a venue for healthcare professionals to increase their clinical knowledge and awareness of pain and risk-mitigation strategies in the opioid-based treatment of chronic pain. Upon successful completion of the CME activities, healthcare professionals may use the CME credit(s) earned toward their licensure and/or certification requirements.

Einstein and Asante have completed a thorough analysis of the current state of chronic pain education, researching publications and clinical trials, soliciting in-depth thought-leader feedback, and conducting a survey of potential participants regarding current practice patterns, existing educational opportunities, and the need for focused and targeted activities.

Page 5 of 30 Confidential

Asante has developed a proprietary approach to identifying unmet educational needs among clinicians, to tailoring educational programs accordingly, and to developing sensitive outcomes-based approaches to evaluating changes in awareness, knowledge and practice. Briefly, working with Einstein, Asante has employed its CSNA data which helps distinguish among clinicians with various levels of expertise. While the psychometric properties have yet to be fully determined, the questions reveal different approaches to the assessment and treatment of specific disorders. After identifying gaps in understanding among responders, specific replies are shared with thought leaders, who are asked to share their insights into a specific educational deficit and how it may be treated through targeted interventions. Finally, teleconference calls are then conducted to confirm identified gaps among target audiences.

Based on this research and feedback, Einstein and Asante have identified specific educational needs within the therapeutic area and recommend addressing those needs via a series of educational approaches to chronic pain and risk management linking evidence-based medicine with expert perspective.

Intended Audience

These activities are developed for pain specialists, neurologists, rheumatologists, physical medicine and rehabilitation specialists, family practitioners, oncologists, and internal medicine and general practitioners

Activity Goals

It is the goal of these activities to increase their competence and abilities to treat and appropriately manage pain and learn important methods to incorporate risk management strategies into pain management plans.

Learning Objectives

At the conclusion of this program, participants will be better prepared to:

- 1 Define, recognize, and independently assess breakthrough and persistent pain in patients with chronic pain syndromes
- 2. Implement a multidimensional, continual, and vigilant assessment of persistent and breakthrough pain based, in part, on the phenomenology and inferred pathophysiology of the pain syndrome, patient function, goals, and level of risk
- 3. Select appropriate patients for opioid-based management of persistent and breakthrough pain
- 4. Employ multimodal opioid-based therapies tailored to the multidimensional pain assessment of patients with persistent and breakthrough pain
- 5. Explain the respective roles of long-acting, short acting and rapid onset opioids in the management of persistent and breakthrough pain
- 6 Distinguish clinical constructs of physical dependence, tolerance, pseudotolerance, addiction, pseudoaddiction and their impact on medical management of patients with chronic pain syndromes

Clinical Survey and Needs Assessment (CSNA)

Two thousand one hundred and thirty five surveys were e-mailed to U.S. based pain clinicians. One hundred and fifty-seven electronic surveys were completed (7% response rate). Respondents provided answers to several yes/no questions and to openended questions about breakthrough and persistent pain management. Select questions from the survey are included below.

Most (82%) of the sample employed multimodal and multidrug approaches

Page 6 of 30 Confidential

Confidential TEVA_MDL_A_00850003

- Nearly 40% of respondents cited the need for more education on multimodal treatment strategies (eg, behavioral, relaxation strategies, cognitive behavioral therapy)
- Approximately 74% of respondents cited a need to learn more about principles of opioid-based therapy, including when to
 prescribe, how to maintain, and when to discontinue opioids. ("How do I manage a patient with a legitimate pain syndrome
 who has broken the contract?")
- Nearly half (47%) of the respondents agreed that opioid based therapy is time consuming, poorly reimbursed and increasingly
 difficult in this environment. Respondents agreed that guidance on formulating a treatment plan within the current 15-minute
 visit paradigm is needed.
- An estimated 34% of respondents do not risk stratify their patients for problematic opioid use.
- Few subjects (<10%) disagreed with the notion that chronic pain comprises two distinct components (Sample responses below). Rather, the educational need appears to center on definitional issues, and how best to assess and treat the constructs. Operationalizing breakthrough and persistent pain, in other words, appears to be the threshold educational need.
- Most respondents (65%) used the Numeric Rating Scale to evaluate baseline pain, highlighting the need for education on thorough assessment strategies.
- Only 55% of respondents provided an adequate definition of breakthrough pain.

Question: How do you determine whether baseline persistent pain is controlled? Please elaborate as needed.

"Actually, very complex assessment: I begin with comparing both the peak and average pain scores since last encounter, the frequency and duration, comparing these to values from the previous visit; the total daily long-acting and average short-acting (excluding transmucosal fentanyl) opioid dosages are calculated as oral oxycodone equivalents, and the percentage of short-acting medication of the total of the two components is estimated, and compared with last visit. In the interview, adjustments are made in interpretation of these "hard" data points based on any acute injuries or exacerbations which may have disturbed the balance that month, desirable increases in activity vs. overextension, and the end-effect on mood, sleep, energy, motivation, appetite, and perceived areas of improvement or deterioration are assessed. "

Question: How would define breakthrough pain?

Adequate definitions included:

"Sudden onset or rapidly (a relatively soft subjective definition) escalating pain beyond usual tolerable levels (not just above baseline). I do not accept the additional qualification that it is of short duration or even necessarily spontaneously subsides; patients with CRPS I or II, TGN, PHN, or painful MS may experience flares that sustain for hours or even a full day."

"Episodic occurrences, commonly related to changes in activity not well controlled by baseline pain medication use that works the majority of the time."

Page 7 of 30 Confidential

- Disturbing pain despite taking long acting opioid
- I would just say it is an increase over baseline; the pain is getting worse or it still isn't well controlled in the first place
- When a person still has pain on and off, while taking maintenance pain medications
- Pain that occurs at the end of dose drop off of the long acting med regimen before the next dose is due
- BTP is pain occurring in mid-dose regimen with chronic pain controlled by long acting narcotic
- If the baseline pain is not managed then there will be more breakthrough pain. Baseline pain management requires maximizing dosages or other interventions
- Pain that unexpectedly breaks through the baseline pain regimen, as distinct from activity related pain and end-of-dose pain

Critical Assessment of Unmet Educational Needs in Chronic Pain Management

Chronic pain is prevalent, underdiagnosed, often misdiagnosed, and undertreated. (Walid, 2008; Gore, 2006) Previously regarded as a symptom of underlying disorders, the neuroplastic changes that characterize chronic pain constitute a disease state unto itself, a state of peripheral and central sensitization and hyperexcitability that requires comprehensive, continual assessment and treatment. (Woolf, 2007) Chronic pain is a significant burden to the patient, impairing multiple dimensions of function—affective, cognitive, physical, and work-related—which, in turn, adversely affect public health. (McCarberg, 2008) Numerous epidemiologic studies have estimated an annual cost of 80 billion dollars in the United States alone, reflecting the more than 50 million people who have chronic pain syndromes. (APS, 2008) The incidence and prevalence of chronic pain syndromes is projected to increase as the population ages, particularly with such age-related syndromes as osteoporcisis, low back pain, osteoarthritis, and multifocal joint pains. (Robinson, 2007) Many patients with chronic pain will be cancer survivors, a group recently estimated to include more than 10.8 million people. (Ries, 2008) The prevalence and cost of chronic pain, and its debilitating signs and symptoms, have driven pain practitioners, academicians and several medical societies to collaboratively develop screening methodologies, validated assessment tools, and multimodal treatment strategies that provide pain relief and improve patient function. All of these approaches require an ongoing commitment to medical education. (Stanos, 2008; Webster, 2005; Passik, 2008) (CSNA; Learning Objectives 2, 3, 4)

Chronic pain comprises heterogeneous and frequently complex disorders that often require opioid analgesics, a medication class with an equally complex pharmacology and epidemiology. (Pasternak, 2005) Opioids have long been regarded as a cornerstone in the treatment of cancer pain; numerous randomized controlled studies have documented their safety, tolerability and efficacy across a wide variety of cancer-related syndromes. (Pergolizzi, 2008; Ballantyne, 2005; Miaskowski, 2005; Carr, 2004) Over the past 20 years, opioids have gained increasing, though not unqualified, acceptance for noncancer pain as well. (Ballantyne, 2008; Noble, 2008; Riley, 2008; Portenoy, 2007; Furlan, 2006; Coluzzi, 2005; Nicholson, 2003) Concerns about opioids in the management of moderate to severe pain of noncancerous origin, extensively reviewed elsewhere, help explain, at least in part, an unjustifiable undertreatment of pain, especially in the elderly. (Lin, 20007; Robinson, 2007; APS, 2005; Ballantyne and Mao, 2003) Educational programs are urgently needed to help clinicians select appropriate patients with cancer and noncancer pain syndromes for opioid-based pharmacotherapy, and to develop an individualized therapeutic regimen based

Page 8 of 30

on the pain syndrome, level of risk, and goals of each patient. (Portenoy, 2008; Keeney, 2008; Comley, 2000) (CSNA; **Learning Objectives 3, 4**)

Assessment as " Fronk

Multidimensional comprehensive assessment strategies improve patient care and outcomes. (Barbuto, 2008; Breivik H, 2008; Davidson, 2008; Locker, 2007; Yennurajalingam, 2004) Identifying objective findings through a patient work up—including, for example, laboratory electrodiagnostic and imaging studies—remains critical; however, clinicians must operationalize the International Association for the Study of Pain (IASP) definition of pain, which does not require actual tissue damage for pain to be experienced. (Merskey, 1994) Pain is an untestable hypothesis (Fishman, 2008); absent any objective data supporting the pain complaint, clinicians need to rely on patient function and quality of life as goals and benchmarks for success. Listening to the patient is indispensable. By characterizing the quality of the pain, its radiation pattern, and temporal profile—when is the pain minimal, and when is it excruciating?—the patient may help the clinician translate the phenomenology of the pain complaint into a pathophysiology that informs mechanism-based treatment. (Davies, 2008; Maag, 2006; Baron, 2006; Woolf, 2004)

"We need to listen to monitor what's going on with these patients over time, to evaluate the results of therapy, and to control as best we can adherence to the plan of care through a very well thought out monitoring program, and then over time tailor and adjust therapies according to what happens. Because I think if there's one thing we've learned, it is that we really do not have great predictors of either efficacy or safety, except in a very obvious group of high-risk patients."

Perry G. Fine, MD

In time-constrained clinical practice, reducing irreducibly complex chronic pain syndromes is manifestly challenging; their broad phenomenology must therefore be assessed methodically, through a semi-structured approach over time. (Breiveik, 2008; Guarino, 2007; Passik, 2005) There is an urgent need for educational programs addressing practical solutions for ongoing patient assessment, several of which are briefly discussed below. (CSNA; Learning Objective 2)

Assessment is a process that takes time, takes multiple encounters with the patient. And when I discuss with nurses the assessment of pain, I often say for all of us, we have to get the patient's pain story, and in our truncated world of a 15-minute patient visit, that's often a hard thing to achieve, trying to get the patient back with the appropriate frequency so we can detect the subtleties that need to be managed with these types of pain problems."

Christine Miaskowski, PhD, RN

Mechanism Gused Thora; i

First, pain must be correctly classified to drive appropriate treatment selection. (Baron, 2008) Underlying etiologies of chronic pain vary considerably. Cancer pain syndromes may involve soft tissue, bones, or joints, and could be related to a polyneuropathy, plexopathy, or another form of nerve injury. (Berger, 2006) Similarly, noncancer pain syndromes may involve chronic tissue injury, inflammatory disorders, or nerve injury. These disease classifications, although helpful, require additional insights into disease mechanisms. Gradually, clinicians are classifying less by disease than by inferred pathophysiology. (Woolf,

Page 9 of 30 Confidential

2004) Simply, chronic pain syndromes may have a nociceptive (somatic or visceral) component marked by constitutive activation of an otherwise intact nervous system. Inflammatory bowel disease, interstitial cystitis, esteoarthritis, and discogenic back pain are classified as nociceptive. Pain with a predominantly neuropathic component is characterized by reorganization of normal neural circuits, and includes cancer-related neuropathy, complex regional pain syndrome (CRPS), post-laminectomy syndrome, HIV-related neuropathy, central post-stroke pain, post-herpetic neuralgia, diabetic neuropathy, and phantom limb pain, among others. (Argoff, 2006; McMahon & Koltzenburg, 2005) Matching treatment to disease is gradually being eclipsed by matching treatment to mechanism. (Woolf, 2008; de Leon-Casasola, 2008; Baron, 2008) Clinicians require concerted educational efforts to understand this paradigm shift. (CSNA; Learning Objective 2)

femboral Dimensions of Caruna Pala

Second, temporal characteristics of chronic pain must be captured during each visit. Chronic pain is dynamic, ebbing and flowing as a function of movement, stress, and other idiosyncratic factors. (Davies, 2008; Bennett, 2005) The persistent, baseline component of pain, even when controlled, fluctuates; often, the pain breaks through an otherwise effective analgesic regimen. (Bennett, 2007) Breakthrough pain, the second temporal component of chronic pain, is an often overlooked clinical construct. (William, 2008; Swanwick, 2001) Recently discussed by an expert panel, breakthrough pain is a transitory pain more severe than the persistent baseline pain that adversely affects function or quality of life in patients who are receiving analgesic therapy on most days. (Expert Panel on Breakthrough Pain, 2006) The requirement for an adverse functional impact is essential for the management of BTP, and mirrors the increasing focus on function in the Federation of State Medical Boards (FSMB) model policy. (Fishman, 2008) Clinicians require expert guidance on how best to employ patient function as a standard by which to measure treatment success. (CSNA; Learning Objectives 2, 5)

"An important question in pain management: Does an observed reduction in pain intensity translate into clinically relevant functional improvement? That is to say, because a patient says, "Yes, in fact I am experiencing an analgesic effect," does that lead to demonstrable, meaningful accomplishment of certain goals that we may say, other than pain relief, are very important from a clinical or therapeutic standpoint?"

Perry G. Fine, MD

Epidemiologic studies have demonstrated that the majority of patients experience breakthrough pain; the prevalence in cancer patients is estimated at 64%, and that in noncancer pain patients is closer to 74%. (Portenoy 1990; Portenoy, 2006) Patients with breakthrough pain have decreased satisfaction with their analgesic regimen, increased healthcare utilization and associated costs, increased hospital visits and hospitalization, increased mood disturbances, and impaired function. (Abernethy, 2008; Taylor, 2007; Fortner, 2003, Fortner, 2002) Independent assessment and treatment of this clinical entity is therefore critical to patient care. (Taylor, 2007) Clinicians face formidable challenges, however. Breakthrough pain is a highly variable clinical construct—its duration, frequency, severity, and predictability vary among and within patients. (Portenoy, 2006; Mercadante, 2002; Portenoy, 1990; Portenoy, 1989) Continual assessment helps characterize these temporal features and distinguish breakthrough pain from uncontrolled baseline pain. Clinicians require educational programs that help clarify breakthrough pain as a measurable and treatable clinical construct. (CSNA; Learning Objectives 1, 4)

Plak Mideration

Third, a careful consideration of the risk-benefit relationship of opioids in the context of other pharmacologic and nonpharmacologic treatment options is critical to individualized patient care. (Fine and Portency, 2007) Russell K. Portency, MD and colleagues have developed a conceptual framework within which clinicians can decide to initiate, maintain, or discontinue opioid-based therapy. Specifically, the "Portency principles" require identifying the conventional therapeutic approach for the pain syndrome; evaluating the risk-benefit ratios of all feasible treatment options; assessing the risk of opioid-related adverse

Page 10 of 30 Confidential

pharmacologic outcomes (eg. gastrointestinal distress, sedation, endocrine dysfunction); and stratifying the risk of nonmedical opioid use. This approach helps structure opioid-based therapy consistent with risk, an increasingly critical driver of chronic pain management. (Portenoy, 2004) Clinicians can benefit from an educational program that helps them incorporate the principles suggested by Dr Portenoy into their clinical practice. (CSNA; Learning Objective 1, 4)

"Conventional management may not be evidence based and may not be appropriate for the individual person. But we all exist in a network of relationships with other physicians, other health care providers, a regulatory network, a legal network, a managed care network. And you need to have that understanding of conventional practices, within the network, in order to make an informed judgment. If you decide not to do what is conventional, from my perspective, that's totally okay. We do that every day as clinicians. We decide to do something that's not conventional. But, if it's not conventional, you need three things. You need a good reason. You need informed consent. And you need documentation."

Russell K. Portenoy, MD

Understanding the social milieu in which the patient lives and works, and obtaining the personal and/or family history of medical and psychiatric comorbidities, especially substance use disorders, creates a three-dimensional, biopsychosocial representation of the patient. (Wasan, 2007; Adams, 2006; Wool, 2005) Validated screening tools—including the Opioid Risk Tool and the Screener and Opioid Assessment for Patients With Pain—are available to help stratify the risk of inappropriate opioid use. (Belgrade, 2006; Akbig, 2006; Webster, 2005) Such problematic opioid use includes failure to use the opioid as prescribed (misuse), the deliberate use of a drug for nonmedical reasons, in particular for psychotropic effects (abuse), and the willful or accidental transfer of the medication to others (diversion). (Katz, 2008; Katz, 2007) Amid the escalating epidemic of prescription opioid abuse, clinicians need expert insights into balancing the benefits of opioid medications with the risk of abuse, misuse, and diversion. (CASA, 2008; CASA 2005; SAMHSA, 2004) There is an unmet medical and educational need for thorough and careful assessment of biological, psychological, and social dimensions of patients with chronic pain. (Denisco, 2008; Martelli, 2004; Marcus, 2000) (CSNA; Learning Objective 2)

Patients with chronic pain who are assessed as high risk may require a highly structured plan. (Gourlay, 2005) Pill counts, urine drug screening, weekly visits for prescription refills, pharmacy monitoring plans and treatment agreements are all available options. Risk mitigation is an inherently imprecise methodology, as familiar as it is essential. Patients with diabetes, hypertension, or schizophrenia all require careful stratification of risk. The universal applicability of risk stratification to all disciplines of medicine underscores its central importance and the need for ongoing education. (CSNA; Learning Objectives 2, 3)

"In every sector of medicine, we always have to balance the risk or burdens of treatment against the benefits. The benefits in analgesic treatment are going to be pain relief, improved functionality, and decreased or at least more appropriate healthcare utilization. The risks include the side effects of the medication, diminution of quality of life as a result, and abuse behaviors, which can be problematic not only to the patient, but for our society."

Neal E. Slatkin, MD

Page 11 of 30 Confidential

ਲੀਮਸੀਮਾਅਤਰਗ Operad Based Unnage ਪਰ ਨੀ ਵਿੱਚ ਪੰਡਾਵਨ ਜਾਰੀ ਉੱਤੇ ਅਹਨਾਮਯੂਨ ਜੋ ਰਸ

Multidisciplinary, collaborative pain management is often required, particularly for complex chronic pain syndromes with demonstrable biopsychosocial elements. (Stanos, 2007; Wiedemer, 2007) Clinical data and experience support the use of opioids, often in combination with behavioral, psychosocial, rehabilitative, and interventional treatments, customized to the individual patient's pain complaint, risk status, and goals. (Pergolizzi, 2008; de Leon-Casasola, 2008; Soares, 2007; Jensen, 2006) Further, patient care is often improved by combining opioids with nonopioid analgesics—α₂δ, tricyclic antidepressants, serotonin norepinephrine reuptake inhibitors, or nonsteroidal anti-inflammatory drugs. (Gilron, 2008) By targeting therapies at distinct neuraxial sites that transduce, transmit, modulate, and perceive pain signals, patients may receive opioid-sparing and additive analgesic effects. (Baron, 2008)

The rationale for multidrug therapy has considerable face validity, although few randomized controlled studies have been performed to date. (Dworkin, 2007; Backonja, 2006; Kalso, 2005) As discussed, classifying pain as neuropathic or nociceptive significantly influences these combination treatment approaches. (Horowitz, 2007; Argoff, 2006) Recently, Gilron and coworkers reported the benefits of a morphine sulfate-gabapentin combination for neuropathic pain. (Gilron, 2005) Many questions remain. Is there differential benefit to sequential or concurrent combination strategies? Should the maximal tolerated dose for monotherapy be achieved before combining a second agent? How should breakthrough pain be treated within this multidrug treatment paradigm? (Raja, 2005) These and other issues require educational fora to foster peer-to-peer learning and to capture the clinical experience with opioid-based multimodal approaches for persistent and breakthrough pain management. (CSNA; Learning Objectives 4, 5)

Or. Festrating an Opiole That

In his recently published text, *Responsible Opioid Prescribing: A Physician's Guide*, Scott Fishman, MD, describes the model policy of the Federation of State Medical Boards (FSMB) for safe, rational, and transparent prescribing of opioids. (Fishman, 2008) Briefly, the FSMB reinforces the need for thorough assessment and ongoing evaluation of the patient on the formulation and continual refinement of a therapeutic plan. Further, FSMB policy highlights the central importance of tailoring opioid-based therapy commensurate with the degree of risk, and based on a transparent, beneficent, and vigilant relationship with the patient. The paradigm for an opioid trial has been extensively documented, though rarely evaluated in randomized controlled studies. (APS Annual Meeting, 2008) Presently, experts recommend that physicians initiate a trial with predefined functional goals: to achieve control of the baseline pain and to assess and treat fluctuations that break through the multimodal analgesic regimen. (Dy. 2008; Pergolizzi, 2008; Davies, 2008; Portenoy, 2004) There is an urgent need for physicians to integrate this approach into their daily care of patients with chronic pain syndromes. (CSNA; Learning Objectives 1, 4, 5)

"Clinicians should make sure that their records are generally complete, but the key is not to just document everything that's going on, but to be transparent about risk management, to recognize that every patient has risk, whether or not they are taking opioids, whether they are being treated for pain or treated for infections with antibiotics. There is risk in doing nothing, and there is risk in doing the treatment. Recognize the risk and have a plan for follow-up. If there is a problem, then there is a risk management plan."

Scott M. Fishman, MD

Page 12 of 30 Confidential

I do not be a first of the opening and market Proprome a firm on Para

Numerous guidelines and consensus statements recommend the use of regularly scheduled opioid agonists for cancer-related persistent pain. (Pergolizzi, 2008; Moulin, 2007; Trescot, 2006) In addition, "rescue" doses of short-acting and rapid-onset opioids are recommended for the intense fluctuations that often occur despite adequate control of baseline pain—namely, breakthrough pain. (Fishbain, 2008; Aronoff, 2005) For the past 20 years, evidence-based guidelines and empirical decision making in cancer pain management have become the basis by which to evaluate the roles and risks of opioid medications in chronic noncancer pain. (Ballantyne, 2007) Data continue to emerge demonstrating the utility of opioids for common noncancer pain syndromes. (Furlan, 2007; Eisenberg, 2005) Still, more rigorously controlled studies are needed; meanwhile, clinicians must balance evidence-based medicine with practice-based evidence when initiating and maintaining opioid-based therapies. (Davis, 2004; Carr, 2004)

Maintenance of the long-acting opioid (LAO)-based regimen requires continual monitoring and occasional baseline medication adjustments to achieve a measure of dose stability. (Portenoy, 2004) Robust trial data have demonstrated that pharmacologic outcomes—a favorable balance between analgesia and side effects—improve when, during this maintenance phase, breakthrough pain episodes are recognized, assessed, and treated. (Hagen, 2008; Portenoy, 2007; Simpson, 2007; Portenoy, 2006; Zeppetella, 2006; Coluzzi, 2001; Portenoy, 1999; Christie, 1998) Challenges persist, however, and educational programs are required to provide guidance for clinicians to identify well-controlled baseline pain through continual assessment, allowing the independent and tight therapeutic management of breakthrough pain. (CSNA; Learning Objectives 1, 2, 5)

"When clinicians see people who have inadequate pain relief back in their offices, and they're on a long-acting opioid, what it really boils down to during that visit is: Do you decide to raise the background opioid or do you add on another drug, and what drives your decision making at that critical point? And it will depend on how you view the pain phenomenology, the patient, and other factors. And I don't think it's a straightforward question in a disease state in which the best therapies only reduce the background pain by 57 percent."

Steven D. Passik, PhD

Breakthrough pain is not a unitary phenomenon; rather, several subtypes have been evaluated clinically and shown to have telltale characteristics that aid assessment and treatment. (Webster, 2008; Caraceni, 2004; Gutgsell, 2003) First, incident breakthrough pain may be precipitated by volitional (eg, gardening) or nonvolitional (eg, spasm) activity. (Svendsen, 2005) Second, breakthrough pain attributed to end-of-dose failure emerges with a periodicity that coincides roughly with the pharmacokinetic troughs of the baseline medication, typically an LAO. (McCarberg, 2001) Baseline dose adjustments may reduce the frequency and seventy of these episodes, although the LAO may reach dose-limiting toxicities, causing some clinicians to switch opioid baseline medications or to prescribe a short-acting opioid to compensate for the drop in LAO serum levels. (Dy, 2008; De Leon-Casasola, 2008) Finally, idiopathic breakthrough pain is associated with paroxysmal spikes that may reach peak intensity in as little as 3-5 minutes. (Portenoy, 2006; Simon, 2006; Bennett, 2005; Portenoy, 1990)

Clinical studies on the differential phenomenology of breakthrough pain subtypes have been limited. The threshold frequency for breakthrough pain episodes that warrants baseline medication adjustments has not been well established. (Svendsen, 2005) Absent clear experimental evidence, clinicians need guidance on the differential diagnosis of breakthrough pain, and the respective roles of long-acting, short-acting, and rapid-onset opioids. (Davies, 2008; Hagen, 2008; Portenoy, 2008) Case-based workshops, reviews of the evidence, and other expert insights into breakthrough pain management are urgently needed. (CSNA; Learning Objectives 1, 5)

Page 13 of 30 Confidential

"Can we add some questions to the concept of a comprehensive assessment that speak more to clinical meaningfulness of breakthrough pain and treatment selection? So, for instance, the time to onset, time to severe, or time to clinically meaningful effect. And activities you avoid in an attempt to prevent episodes may help define a scope of fluctuations that should be called breakthrough pain that aren't now described as such?"

Russell K. Portenoy, MD

Pain management perspectives continue to evolve. In particular, several concerns are often noted: lack of data supporting long-term opioid therapy; the occurrence of addictive disease in a subset of patients; inexact risk mitigation methodologies; and the potential for hyperalgesia and for endocrine and immune dysfunction with long-term opioid exposure. (Korff, 2008; Ballantyne, 2007) For some patients, opioids are associated with side effects (eg, constipation, pruritis, and sedation), poor tolerability, and serious adverse events such as respiratory depression and, as discussed, misuse, abuse, and diversion. (Harris, 2007) In addition, clinicians need to clarify the nomenclature and clinical constructs of physical dependence, tolerance, pseudotolerance, addiction, and pseudoaddiction. (Jage, 2005; Savage, 2003) (CSNA; Learning Objective 6) These and other safety concerns—identifying opioid-tolerant patients, for instance—rightly rank as paramount among clinicians, and demand continual and comprehensive evaluation of patient compliance and therapeutic response, informed by predefined functional goals. (Rosenblum, 2008) Educational programs should raise awareness of these issues and provide practical guidance to minimize their impact on patient care. (CSNA; Learning Objectives 2, 4)

"For some patients, the therapeutic window is the size of the Texas plains and you can give them medicines without much worry. But there are individuals who are extremely sensitive to medicines and instead of being the size of the Texas plains, the window is the size of a New York City street during rush hour: tight, small, and difficult to manage. When you're trying to treat these patients, you need very precise control of the medications."

Michael J. Brennan, MD

Clearly, patient selection is the linchpin of effective opioid-based therapy. (Portenoy, 2008; Antoin, 2004) Individuals vary across multiple dimensions: in their response to nonpharmacologic and pharmacologic treatment options; in their pain phenomenology; in their affective behavior during therapy; and in their propensity for irresponsible medication use. Despite current and emerging data, no one opioid molecule—oxycodone, fentanyl, or morphine, for instance—has an *a priori* advantage over another. And data delineating the respective roles of long-acting, short-acting, and rapid-onset opioids in managing the persistent and breakthrough components of chronic pain are only beginning to emerge. (Simon, 2005) Clinicians thus need expert input on how best to structure opioid-based therapy in the context of a well orchestrated N-of-1 trial.

Multidimensional assessment governs multimodal therapeutic decision making, but the gap between evidence-based medicine and the practical, day-to-day management of patients with persistent and breakthrough pain is considerable and, for some, even prohibitive. Rational, transparent prescribing of opioids among appropriately selected patients thus presents formidable challenges that can only be met by rigorous educational efforts. (CSNA; Learning Objectives 3, 4)

Page 14 of 30 Confidential

References

Abernethy AP, et al; Am J Manag Care. 2008 May;14(5 Suppl 1):S129-40; A health economic model of breakthrough pain.

Adams N; Psychological approaches to chronic pain management: part 1; J Clin Nurs. 2006 Mar;15(3).290-300.

Akbik H, et al; Validation and clinical application of the Screener and Opioid Assessment for Patients with Pain (SOAPP); J Pain Symptom Manage. 2006 Sep;32(3):287-93.

American Pain Society; Pain: Current Understanding of Assessment, Management and Treatments Section I: Background and Significance; Accessed October, 2008

American Pain Society; Guideline for the Management of Cancer Pain in Adults and Children; 2005.

Antoin H, Beasley RD.; Opioids for chronic noncancer pain. Tailoring therapy to fit the patient and the pain; Postgrad Med. 2004 Sep;116(3):37-40, 43-4.

Argoff CE, et al; Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain; Mayo Clin Proc 2006 Apr;81 (4 Suppl):S12-25.

Aronoff GM; Evidence-based oral transmucosal fentanyl citrate (OTFC) dosing guidelines; Pain Med. 2005 Jul-Aug;6(4):305-14.

Backonja MM; Rational multidrug therapy in the treatment of neuropathic pain; Curr Pain Headache Rep. 2006 Feb;10(1):34-8.

Ballantyne JC; Comparative efficacy of epidural, subarachnoid, and intracerebroventricular opioids in patients with pain due to cancer Cochrane Database Syst Rev. 2005 Jan 25;(1).

Ballantyne JC, Shin NS.; Efficacy of opioids for chronic pain, a review of the evidence; Clin J Pain 2008 Jul-Aug;24(6):469-78.

Ballantyne JC, Mao; J., Opioid therapy for chronic pain, N Engl J Med 2003 Nov 13;349(20):1943-53.

Ballantyne JC.; Opioid analgesia: perspectives on right use and utility; Pain Physician. 2007 May;10(3).479-91

Barbuto JP, et al; Chronic pain: second, do no harm; Am J Phys Med Rehabil. 2008 Jan;87(1):78-83

Baron R.; Mechanisms of disease: neuropathic pain--a clinical perspective; Nat Clin Pract Neurol. 2006 Feb;2(2):95-106.

Baron R, Tölle TR, Assessment and diagnosis of neuropathic pain, Curr Opin Support Palliat Care; 2008 Mar;2(1).1-8.

Belgrade MJ, et al; The DIRE score: predicting outcomes of opioid prescribing for chronic pain; ; J Pain. 2006 Sep;7(9):671-81.

Bennett, et al; Consensus Panel Recommendations for the Assessment and Management of Breakthrough Pain Part I Assessment; P&T, May 2005, Vol. 30 No. 5.

Bennett DS, et al; Prevalence and characteristics of breakthrough pain in patients receiving opioids for chronic back pain in pain specialty clinics.; J Opioid Manag. 2007 Mar-Apr;3(2):101-6.

Benyamın R; Opioid complications and side effects; Pain Physician. 2008 Mar;11(2 Suppl):S105-20.

Berger AM et al; Principles and Practice of Palliative Care and Supportive Oncology; ISBN 0781795958, 9780781795951, Lippincott Williams & Wilkins, 2006

Blick SK; Fentanyl buccal tablet. in breakthrough pain in opioid-tolerant patients with cancer; Drugs. 2006;66(18):2387-93.

Breivik H, et al; Assessment of pain; Br J Anaesth. 2008 Jul;101(1):17-24.

Butler SF, Budman SH, Fernandez K, Jamison RN. Validation of a screener and opioid assessment measure for patients with chronic pain. Pain. 2004; 112:65-75

Caraceni A; Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey; Palliat Med. 2004 Apr;18(3):177-83.

Page 15 of 30 Confidential

Caraceni A; An international survey of cancer pain characteristics and syndromes. IASP TaskForce on Cancer Pain. International Association for the Study of Pain; Pain. 1999 Sep;82(3):263-74.

Carr DB et al, Evidence report on the treatment of pain in cancer patients. J Natl Cancer Inst Monogr. 2004; (32):23-31.

CASA Center on Addiction and Substance Abuse at Columbia University National Survey of American Attitudes on Substance Abuse XIII: Teens and Parents; August 2008.

CASA Center on Addiction and Substance Abuse at Columbia University Under the Counter; The Diversion and Abuse of Controlled Prescription Drugs in the U.S. New York, NY Center on Addiction and Substance Abuse; 2005. (Available at http://www.casacolumbia.org/Absolutenm/articlefiles/380 final_report_not_embargoed pdf).

Cherny et al; Strategies to manage the adverse effects of oral morphine, an evidence-based report; J Clin Oncol. 2001 May 1;19(9):2542-54.

Christie JM; Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain; J Clin Oncol 1998 Oct;16(10):3238-45.

Coluzzi PH; Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR); Pain. 2001 Mar;91(1-2),123-30

Coluzzi F, et al, Opioid therapy for chronic noncancer pain: practice guidelines for initiation and maintenance of therapy; Minerva Anestesiol. 2005 Jul-Aug;71(7-8):425-33.

Comley, et al; Pain management: clinician survey and institutional needs assessment, Proc (Bayl Univ Med Cent). 2000 July; 13(3): 230–235.

Davidson MA, et al; Chronic pain assessment: a seven-factor model; Pain Res Manag. 2008 Jul-Aug;13(4):299-308.

Davis MP; Practical guide to opioids and their complications in managing cancer pain. What oncologists need to know; Oncology (Williston Park). 2007 Sep;21(10):1229-38.

Davis MP; Opioid dose titration for severe cancer pain: a systematic evidence-based review; J Palliat Med. 2004 Jun;7(3):462-8.

Davies AN, et al; An observational study of oncology patients' utilization of breakthrough pain medication; J Pain Symptom Manage. 2008 Apr; 35(4): 406-11.

Davies AN, et al; The management of cancer-related breakthrough pain: Recommendations of a task group of the Science Committee of the Association for Palliative Medicine of reat Britain and Ireland; Eur J Pain. 2008 Aug 14

de Leon-Casasola OA; Current developments in opioid therapy for management of cancer pain; Clin J Pain 2008 May;24 Suppl 10:S3-7.

Denisco RA, Addressing the intersecting problems of opioid misuse and chronic pain treatment; Exp Clin Psychopharmacol. 2008 Oct; 16(5):417-28.

Du Pen SL, Implementing guidelines for cancer pain management: results of a randomized controlled clinical trial, J Clin Oncol. 1999 Jan;17(1).361-70.

Dworkin RH, et al; Pharmacologic management of neuropathic pain: evidence-based recommendations; Pain. 2007 Dec 5;132(3):237-51.

Dy SM; Evidence-based standards for cancer pain management; J Clin Oncol. 2008 Aug 10;26(23):3879-85.

Edlund MJ: Do users of regularly prescribed opioids have higher rates of substance use problems than nonusers?; Pain Med. 2007 Nov-Dec;8(8):647-56.

Eisenberg E, et al; Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials; JAMA. 2005 Jun 22,293(24):3043-52

Expert Panel on Breakthrough Pain, Russell K. Portenoy, Chair; January, 2006, Washington, D.C.

Fishbain DA; Pharmacotherapeutic management of breakthrough pain in patients with chronic

Fishman, S; Responsible Opicid Prescribing: A Physician's Guide; Federation of State Medical Boards; Published by Waterford Life Sciences, Washington D.C., Copyright © 2007.

Page 16 of 30 Confidential

Fortner BV, et al; A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain; J Pain. 2002 Feb;3(1):38-44.

Fortner BV, et al; Description and predictors of direct and indirect costs of pain reported by cancer patients J Pain Symptom Manage. 2003 Jan;25(1):9-18.

Furlan AD, et al; Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects; CMAJ. 2006 May 23;174[11]:1589-94.

Galluzzi KE.; Managing neuropathic pain; J Am Osteopath Assoc. 2007 Nov;107(10 Suppl 6):ES39-48.

Gilron I.; Optimizing neuropathic pain pharmacotherapy: add on or switch over?; Nat Clin Pract Neurol. 2008 Aug;4(8):414-5. Epub 2008 Jun 17.

Gilron I, Max MB.; Combination pharmacotherapy for neuropathic pain: current evidence and future directions.; Expert Rev Neurother. 2005 Nov;5(6):823-30.

Gilron I, et al, Morphine, gabapentin, or their combination for neuropathic pain; N Engl J Med. 2005 Mar 31;352(13).1324-34.

Gore M, et al; Burden of illness in painful diabetic peripheral neuropathy; the patients' perspectives; J Pain. 2006 Dec;7(12):892-900.

Gourlay DL et al; Universal precautions in pain medicine: a rational approach to the treatment of chronic pain, Pain Med 2005 Mar-Apr;6(2):107-12.

Gutgsell T; A prospective study of the pathophysiology and clinical characteristics of pain in a palliative medicine population, Am J Hosp Palliat Care 2003 Mar-Apr; 20(2):140-8.

Hagen NA; Assessment and management of breakthrough pain in cancer patients, current approaches and emerging research; Curr Pain Headache Rep. 2008 Aug;12(4):241-8.

Hagen NA; A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials, J Palliat Med. 2007 Feb;10(1):47-55.

Hagen, et al; The Alberta Breakthrough Pain Assessment Tool for cancer patients: a validation study using a delphi process and patient think-aloud interviews; Journal of Pain and Symptom Management, Feb 2008 Volume 35; Issue 2

Hale M, et al; Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis;

Harris JD; Management of expected and unexpected opioid-related side effects; Clin Ther. 2007 May;29(5):874-88.; Clin J Pain. 2008 May;24 Suppl 10°58-S13.

Horowitz SH; The diagnostic workup of patients with neuropathic pain; Med Clin North Am 2007 Jan;91(1):21-30.

Hwang SS; Cancer breakthrough pain characteristics and responses to treatment at a VA medical center; Pain 2003 Jan;101(1-2):55-64.

Ives TJ, et al; Predictors of opioid misuse in patients with chronic pain; a prospective cohort study; BMC Health Serv Res. 2006 Apr 4,6 46.

Jage J, Opioid tolerance and dependence -- do they matter?; Eur J Pain. 2005 Apr;9(2) 157-62.

Jensen TS, et al; New perspectives on the management of diabetic peripheral neuropathic pain, Diab Vasc Dis Res. 2006 Sep;3(2):108-19.

Korff MV; De facto long-term opioid therapy for noncancer pain; Clin J Pain. 2008 Jul-Aug, 24(6). 521-7.

Kalso E; Opioids in chronic non-cancer pain: systematic review of efficacy and safety; Pain. 2004 Dec, 112(3):372-80.;

Kalso E, Improving opioid effectiveness: from ideas to evidence, Eur J Pain. 2005 Apr., 9(2):131-5.

Katz N; Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep. 2008 Jan; 10(1):11-8.

Katz NP; Challenges in the development of prescription opioid abuse-deterrent formulation; Clin J Pain. 2007 Oct, 23(8):648-60.

Keeney CE, Initiating and sustaining a standardized pain management program in long-term care facilities; J Am Med Dir Assoc. 2008 Jun;9(5):347-53.

Page 17 of 30 Confidential

Lin JJ, Physician attitudes toward opioid prescribing for patients with persistent noncancer pain; Clin J Pain. 2007 Nov-Dec; 23(9):799-803

Locker S; Holistic assessment of cancer patients' pain: reflections on current practice; Int J Palliat Nurs. 2008 Feb;14(2):77-84.

Maag R, Baron R; Neuropathic pain: translational research and impact for patient care; Curr Pain Headache Rep. 2006 Jun;10(3):191-8.

Marcus KS, et al; HIV/AIDS-related pain as a chronic pain condition: implications of a biopsychosocial model for comprehensive assessment and effective management; Pain Med. 2000 Sep;1(3):260-73.

Martelli MF, et al, Psychological, neuropsychological, and medical considerations in assessment and management of pain; J Head Trauma Rehabil. 2004 Jan-Feb; 19(1):10-28.

McCarberg BH et al; The impact of pain on quality of life and the unmet needs of pain management: results from pain sufferers and physicians participating in an Internet survey; Am J Ther. 2008 Jul-Aug; 15(4):312-20.

McMahon, S, Koltzenburg, M; Wall and Melzack's Textbook of Pain, Fifth Edition; Hardbound, 1280 pages, publication date: SEP-2005; ISBN-13: 978-0-443-07287-1; Imprint: Churchill Livingstone.

Mercadante S; Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care; Cancer. 2002 Feb 1;94(3):832-9.

Mercadante S, et al; Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain; Br J Cancer 2007 Jun 18;96(12):1828-33. Epub 2007 May 22.

Mercadante S, et al; Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine; J Pain Symptom Manage. 2006 Aug,32(2):175-9;

Merskey and Bogduk; Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms, Second Edition, International Association for the Study of Pain (IASP) 1994 Task Force on Taxonomy ISBN 978-0-931092-05-3.

Miaskowski C, et al. Cancer Pain Management. Guideline for the Management of Cancer Pain in Adults and Children, APS Clinical Practice Guidelines Reprinted with permission of the American Pain Society. 3rd ed. Glenview, IL; Arnerican Pain Society; 2005. p. 39-48.

Moulin DE, et al; Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society, Pain Res Manag. 2007 Spring;12(1):13-21

Mystakidou K, et al; Oral transmucosal fentanyl citrate; overview of pharmacological and clinical characteristics; Drug Deliv. 2006 Jul-Aug;13(4):269-76.

Nicholson B. Respons ble prescribing of opioids for the management of chronic pain. Drugs. 2003; 63(1):17-32

Noble M, et al; Long-term opioid therapy for chronic noncancer pain, a systematic review and meta-analysis of efficacy and safety; J Pain Symptom Manage, 2008 Feb;35(2):214-28.

Passik SD, Kirsh KL.; The interface between pain and drug abuse and the evolution of strategies to optimize pain management while minimizing drug abuse; Exp Clin Psychopharmacol. 2008 Oct, 16(5):400-4.

Passik SD, et al; Monitoring outcomes during long-term opioid therapy for noncancer pain: results with the Pain Assessment and Documentation Tool; J Opioid Manag. 2005 Nov-Dec;1(5):257-66.

Pasternak GW; Molecular biology of opioid analgesia; J Pain Symptom Manage. 2005 May;29(5 Suppl):S2-9.

Pergolizzi J et al; Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone); Pain Pract 2008 Jul-Aug;8(4):287-313.

Portenoy, RK; American Conference on Pain Medicine 2008; Keynote Address

Portency RK, et al; Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study; Clin J Pain. 2007 May;23(4):287-99.

Page 18 of 30 Confidential

Confidential

Portenoy RK; Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain; J Pain. 2006 Aug.,7(8).583-91.

Portenoy RK; Breakthrough pain: definition, prevalence and characteristics; Pain. 1990 Jun;41(3):273-81.

Portenoy RK; Breakthrough pain definition and management, Oncology (Williston Park). 1989 Aug;3(8 Suppl):25-9.

Portenoy RK.; Appropriate use of opioids for persistent non-cancer pain; Lancet. 2004 Aug 28-Sep 3;364(9436):739-40.

Portency RK; Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study; Pain. 1999 Feb;79(2-3):303-12.

Portency RK; Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain; J Pain. 2006 Aug;7(8):583-91.

Portenoy RK; Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study; Curr Med Res Opin. 2007 Jan;23(1):223-33.

Portency RK; A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer; Clin J Pain. 2006 Nov-Dec.22(9):805-11.

Raja SN, Haythornthwaite JA; Combination therapy for neuropathic pain--which drugs, which combination, which patients?; N Engl J Med. 2005 Mar 31:352(13):1373-5.

Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, Lewis DR, Clegg L, Eisner MP, Reichman M, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER web site, 2008.

Riley JL 3rd, Hastie BA; Individual differences in opioid efficacy for chronic noncancer pain; Clin J Pain. 2008 Jul-Aug;24(6):509-20.

Robinson CL; Relieving pain in the elderly; Health Prog. 2007 Jan-Feb;88(1):48-53, 70.

Rosenblum A. et al.; Opioids and the treatment of chronic pain: Controversies, current status, and future directions, Exp Clin Psychopharmacol. 2008 Oct;16(5):405-16.

Savage SR, et al; Definitions related to the medical use of opioids evolution towards universal agreement; J Pain Symptom Manage. 2003 Jul. 26(1):655-67.

Simon S; Breakthrough pain in opioid-treated patients with neuropathic pain; J Opioid Manag. 2006 Nov-Dec;2(6) 347-52.

Simon S.; Opioids and treatment of chronic pain: understanding pain patterns and the role for rapid-onset opioids; MedGenMed. 2005 Nov 23;7(4):54.

Simpson DM; Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study; Clin Ther. 2007 Apr;29(4):588-601

Soares; The rationale for a multimodal approach in the management of breakthrough cancer pain: a review; Am J Hosp Palliat Carc. 2007 Oct-Nov;24(5):430-9. Epub 2007 Jun 20.

SAMHSA, Substance Abuse and Mental Health Services Administration, Results from the 2004 National Survey on Drug Use and Health: National Findings. NSDUH Series H-28, DHHS Publication No. SMA 05-406,

Soares LG and Chan VW; The rationale for a multimodal approach in the management of breakthrough cancer pain: a review; Am J Hosp Palliat Care. 2007 Oct-Nov;24(5):430-9.

Stanos SP, et al, Physical medicine rehabilitation approach to pain; Anesthesiol Clin. 2007 Dec; 25(4).721-59, v-vi.

Swanwick M; The prevalence of episodic pain in cancer: a survey of hospice patients on Admission; Palliat Med. 2001 Jan; 15(1).9-18.

Svendsen KB, et al; Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms; Eur J Pain. 2005 Apr;9(2):195-206.

Page 19 of 30 Confidential

Taylor DR, et al; Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ); Pain Med. 2007 Apr;8(3):281-8.

Trescot AM; Opioid guidelines in the management of chronic non-cancer pain; Pain Physician. 2006 Jan;9(1):1-39.

Walld MS et al; The Fifth Vital Sign-What Does It Mean? Pain Pract. 2008 Jul 25.

Walsh D; Strategies for pain management: cleveland clinic foundation guidelines for opioid dosing for cancer pain, Support Cancer Ther. 2004 Apr 1;1(3):157-64.

Wasan AD; Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain; Clin J Pain. 2007 May;23(4):307-15.

Wasan AD, Davar G, Jamison R.; The association between negative affect and opioid analgesia in patients with discogenic low back pain; Pain. 2005 Oct;117(3):450-61.

Webster LR; Breakthrough pain in the management of chronic persistent pain syndromes, Am J Manag Care. 2008 May;14(5 Suppl 1):S116-22.

Webster LR, Webster RM Predicting aberrant behaviors in opioid-treated patients, preliminary validation of the Opioid Risk Tool, Pain Med 2005; 6:432-442.

Wiederner, N. L.; The Opioid Renewal Clinic A Primary Care, Managed Approach to Opioid Therapy in Chronic Pain Patients at Risk for Substance Abuse; Pain Medicine; 8 (7):573 - 584

William L, Management of breakthrough pain in patients with cancer; Drugs. 2008;68(7):913-24.

Wool MS, Mor V; A multidimensional model for understanding cancer pain; Cancer Invest. 2005;23(8):727-34.

Woolf CJ.; Central sensitization: uncovering the relation between pain and plasticity; Anesthesiology. 2007 Apr;106(4).864-7.

Woolf CJ.; Dissecting out mechanisms responsible for peripheral neuropathic pain: implications for diagnosis and therapy; Life Sci. 2004 Apr 9;74(21):2605-10.

Yennurajalingam S, et al, Recent developments in cancer pain assessment and management; Support Cancer Ther. 2004 Jan 1;1(2):97-110.

Zeppetella G; Opioids for the management of breakthrough (episodic) pain in cancer patients; Cochrane Database Syst Rev. 2006 Jan 25;(1)

Page 20 of 30

IV. Faculty and Programs

Potential Faculty

Under the direction of David Kaufman, MD, Professor of Neurology and Psychiatry at Albert Einstein College of Medicine, and the Albert Einstein College of Medicine, qualified faculty will be selected and may include the following:

Michael J. Brennan, MD

Chief of Rehabilitation Medicine

Bridgeport Hospital

Bridgeport, Connecticut

David A. Fishbain, MD

Professor of Psychiatry, Adjunct Professor of Anesthesiology and Neurological Surgery

Leonard M. Miller School of Medicine

University of Miami

Miami, Florida

Scott M. Fishman, MD

Professor of Anesthesiology Chief, Division of Pain Medicine University of California, Davis Sacramento, California

Gordon Irving, MD

Medical Director, Swedish Pain Center

747 Broadway

Seattle, Washington Seattle, WA 98122

Bill McCarberg, MD

Founder, Chronic Pain Management Program

Kaiser Permanente Escondido, California

Sebastiano Mercadante, MD

La Maddalena Cancer Center

University of Palermo

Pain Relief & palliative care

Via S. Lorenzo Colli 312

90146 Palermo, ITALY.

Christine Miaskowski, RN, PhD, FAAN

Professor and Chair

Department of Physiological Nursing

UCSF School of Nursing,

San Francisco, California

Judith A. Paice, RN, PhD

Research Professor

Northwestern University Feinberg School of Medicine

Chicago, Illinois

Steven D. Passik, PhD

Clinical Psychologist

Memorial Sloan-Kettering Cancer Center

New York, New York

John Peppin, DO, FACP

Director

Iowa Pain Management Clinic

Des Moines, Iowa

Russell K. Portenoy, MD

Chairman

Department of Pain Medicine and Palliative Care

Beth Israel Medical Center

New York, New York

Neil E. Slatkin, MD, DABPM

Director

Department of Supportive Care, Pain & Palliative Medicine

City of Hope Medical Center

Duarte, California

Lynn R. Webster, MD, FACPM, FASAM

Medical Director

Chief Executive Officer

Lifetree Clinical Research and Pain Clinic

Salt Lake City, Utah

Giovambattista Zeppetella, MD


St Clare Hospice

Hastingwood Road

Hastingwood, Essex CM17 9JX, UK

Page 21 of 30 Confidential

Einstein and Asante recommend developing a comprehensive, accredited, and integrated CME initiative comprising each of the proposed tactics. Further, we recommend folding the educational programs and materials under a unifying and meaningful acronym, linking them conceptually, and assuring clinicians of their quality, accuracy, and clinical relevance.



Chronic Pain Management Preceptorships

In this pilot program, approximately two-hundred (~n=200) US-based pain management clinicians will participate in a preceptorship focusing on opioid-based care of patients with chronic pain. The program will provide a forum for each clinician to interact with national thought leaders via monthly WebPanel series. The interactions will be structured around previously identified areas of educational need and interest, as determined by CSNA and as described in the learning objectives. An initial 30-minute teleconference call with the community-based pain clinicians and national thought leader will launch the pilot program, followed by 15-30 minute quarterly WebPanel calls and, potentially, a meeting at a major medical congress, half-day or full-day regional meeting. Participants will be required to participate in at least three distinct activities; and would be encouraged to participate in a live regional meeting, to be held near to a Pain Center of Excellence identified by the American Pain Society (see below). Upon completion of this program, participants will receive up to 4 hours of CME credit and a complimentary copy of *Rational Opioid Prescribing, A Physician's Guide*, by Scott Fishman, MD, and/or a copy of *Diagnosis and Treatment of Breakthrough Pain*, by Perry Fine, MD. Together, the books effectively summarize the essential elements in developing opioid-based regimens for patients with chronic pain syndromes.

Participants will be encouraged to share their newly acquired knowledge with their colleagues, potentially through a variety of outlets, including, but not limited to, in-services, lectures, and institutional publications. Upon completion of the educational series, and demonstration of improved and durable improvements in awareness, knowledge and performance (see Outcomes Measurement), select clinicians may be invited to participate as adjunct faculty for 2010 educational programs held in their respective regions. Working with national thought leaders, each adjunct faculty member will contribute to educational offerings—some in their local communities—on the assessment, differential diagnosis, and individualization of care for patients with persistent and breakthrough pain, potentially creating regional centers of excellence in pain management.

Page 22 of 30 Confidential

"This proposed preceptorship is superb! This is exactly what many of us have been discussing as a significant need—both for pain and for palliative care. The link to the centers of excellence is great—these are wonderful clinical centers. Some are more academic (NYU, Brigham) and others are more of a private practice model. This would allow participants a wider array of experiences. The outcomes described are perfect."

Judith A. Paice, PhD, RN

Persistent and Breakthrough Pain Management in Cancer Survivors: Mechanism-Based Treatment for a Growing Patient Population (A Full-Day Regional Meeting)

Chronic pain in cancer survivors is an important yet under-studied problem. The prevalence of patients in long-term remission from a variety of cancer syndromes continues to grow, as does the need for guidance on how best to manage their complex pain states, particularly those with other medical and psychiatric comorbidities. Chronic pain and other long-term sequelae related to the disease and to medical, surgical, and radiation treatments significantly impair patient function and healthcare utilization, increasing the burden of illness on patients, their families, and society. This full-day workshop will consist of a morning lecture and panel session with veteran clinicians either currently or formerly associated with Memorial Sloan-Kettering Cancer Center (MSKCC). Their tenure at this premier facility will serve as a backdrop against which cancer survivorship and advances in the care of patients with cancer-related pain will be evaluated. In the afternoon session, participants will engage in a *Cases and Commentary* roundtable discussion.

Participants will receive a complimentary copy of *Rational Opioid Prescribing, A Physician's Guide*, by Scott Fishman, MD, and a copy of *Diagnosis and Treatment of Breakthrough Pain*, by Perry Fine, MD. The activity will be eligible for up to 8 hours of CME credit to physicians. Anticipated attendance is 75-100 physicians.

Satellite Web-Broadcast

Presently, the projection for attendance is 75-100 participants per full-day workshop, drawn primarily from the local and regional communities. To ensure access to other interested clinicians from across the country, a Web cast posted on Medscape or similar pain-related website (eg, www.pain.edu) is proposed. Distance learning is now turnkey, and each participant will be able to access the slide deck, related materials online, and highlights from the meeting. The activity will be eligible for up to 3 hours of CME credit to physicians. Anticipated reach is estimated to be over 20,000 physicians for the online activity.

Cases & Commentary™ Workshop

The Cases & Commentary[™] Workshop format is based, in part, on a small group case-based learning (SGCBL) model, allowing attendees to discuss therapeutic decision making across several case studies. Participants will benefit from the peer-to-peer design of the roundtable discussions, empowering them to listen, to probe, and to proffer solutions with their peers. The workshop provides a forum for exchange of insights into current diagnostic and therapeutic strategies. For those participants whose approach to decision making is aligned with that of their peers and thought leaders, the workshop will validate their own practice. Most participants will acquire knowledge across multiple facets of complicated disease states and patient care.

Eligible for 4 hours of CME credit each, the workshop will include no more than 50-75 participants (total n=~225), who will engage in small group discussions to evaluate best practices in persistent and breakthrough pain management. Each study group may include neurologists, physiatrists, anesthesiologists, and psychologists, and will be facilitated by a key thought leader

Page 23 of 30 Confidential

in pain medicine. In evaluations of previous workshops, most attendees rated the overall activity as "excellent," providing favorable comments regarding both the faculty and learning environment.

The meetings will be presented at regional locations across the country, selected from the 2007 American Pain Society Centers of Excellence. Suggested venues therefore may include the following:

- NYU Medical Center / Hospital for Joint Diseases, Bellevue Hospital Center, Comprehensive Pain Management Center, New York
- The Rosomoff Comprehensive Pain Center, Miami
- Brigham and Women's Hospital, Pain Management Center, Department of Anesthesiology, Perioperative and Pain Medicine, Boston
- UCSF Pain Management Center and UCSF PainCARE, Center for Advanced Research and Education, San Francisco
- Cincinnati Children's Hospital Medical Center, Division of Pain Management

Cases & Commentary Monograph

The case-based discussions will be audiotaped and provide substantial commentary ideally suited for a 4,500 word print monograph. The monograph will be posted on a pain-relevant website (eg www.medscape.com; www.pain.edu), distributed to pain specialists through *Pain Medicine News*, a leading trade journal with a wide readership, and/or through PainClinicianTM, our proprietary database and quarterly distribution vehicle. Written in a narrative style, the case-based monograph will convey best practices in the initial patient presentation, assessment, diagnosis, and formulation and ongoing refinement of therapeutic plans for chronic pain. Successful completion of a 10-question multiple-choice self-assessment examination based on the content presented is necessary to receive a certificate of completion. Participants must score 70% or higher and are allowed 2 attempts to successfully complete the exam. Upon successful completion of the monograph, physicians may use the CME credit earned toward their licensure and/or certification requirements. The activity will be eligible for 1 hour of credit to physicians for 1 year from the issuance date. Anticipated reach is estimated to be over 45,000 physicians for the print monograph in addition to 5,000-10,000 online recipients.

International Expert Forum and Position Paper on Persistent and Breakthrough Pain Management

Davies and coworkers recently published a task force series of recommendations on the management of breakthrough pain. (Davies, 2008) Interestingly, the experts stopped short of making specific treatment recommendations, and instead provided a conceptual framework to guide decision making. Citing the lack of evidence, the experts emphasized a carefully balanced and ongoing assessment and multimodal strategy for the management of breakthrough pain.

In this proposed expert forum, three prominent US based pain clinicians will explore the findings and implications of the Davies report with and two European leaders (eg Giovambattista Zeppetella, MD, Sebastiano Mercadante, MD). The program will consist of several teleconference calls and/or videoconferences, potentially culminating in a meeting at a medical congress. Salient recommendations would provide the substrate for a 6,500-word position paper on persistent and breakthrough pain management, to be posted on a pain-relevant website, and distributed through PainClinicianTM, our proprietary database and quarterly distribution vehicle. Based on the response from pain clinicians who participated in an international forum on persistent and breakthrough pain management recently held in Glasgow, Scotland, this expert panel may receive acknowledgement from the International Association for the Study of Pain (IASP). The activity will be eligible for 1+ hour(s) of credit to physicians for 1 year from the issuance date. Anticipated reach is estimated to be over 35,000 physicians for the print portion in addition to over 15,000-20,000 online recipients.

Page 24 of 30 Confidential

Teleconference Series

A CME audio teleconference brings together the live educational format preferred by many healthcare professionals with the convenience of participating in the activity at home or in the office. Available to a national audience, this format provides clinicians with an opportunity to participate in a lecture led by a thought leader as well as to interact with peers across the country.

This activity will be presented eight (8) times by nationally recognized thought leaders in pain management. Anticipated participation in each broadcast will be 25-50 participants (total n=~200-400), they will be approximately 45 minutes in length, with a 10-minute question-and-answer session completing the program. A teleconference syllabus will be mailed to the participants 48 hours prior to the presentation. Participants will phone in to a reserved line to listen to the lecturer elaborate on the slide content. The activity will be eligible for 1 hour of CME credit to participants.

Teleconference Series Monograph

The teleconferences will be audiotaped and provide commentary ideally suited for a 4,500 word print monograph. The monograph will be posted on a pain-relevant website, distributed to pain specialists through *Pain Medicine News*, a leading trade journal with a wide readership, and direct-mailed to pain practitioners enrolled in PainClinician™, our proprietary database. Written in a narrative style, the case-based monograph will convey best practices in persistent and breakthrough pain management. Successful completion of a 10-question multiple-choice self-assessment examination based on the content presented is necessary to receive a certificate of completion. Participants must score 70% or higher and are allowed 2 attempts to successfully complete the exam. Upon successful completion of the monograph, physicians may use the CME credit earned toward their licensure and/or certification requirements. The activity will be eligible for 1 hour of credit to physicians for 1 year from the issuance date. Anticipated reach is estimated to be over 45,000 physicians for the print monograph in addition to over 5,000-10.000 online recipients.

Albert Einstein's Persistent and Breakthrough Pain Reference Compendium

Editor: Pussell K. Portency, MO Professor of Neurology

Reference manuals provide healthcare professionals with an authoritative educational tool in a condensed format that is easily transported from one clinical setting to another. This reference compendium will provide pain clinicians with practical information in a condensed format for quick reference. Pain and risk screening tools, equianalgesic dosing and other relevant information will be included. This text will include frequently asked questions and answers culled from various fora, including teleconferences and regional meetings. Posed by community pain clinicians, nurses, and psychologists, the questions address the fundamental issues in the management of chronic pain syndromes, from cancer-related pain to osteoarthritis. The responses will be drafted by leading experts in the field; a guest editor for this annual series will provide a preface and additional commentary throughout the text. Exhaustively referenced, this print activity will be available online and eligible for 1-2 hours of continuing education credit to participants. A 10-question multiple-choice self-assessment examination based on the content presented will be included. Successful completion of the posttest is necessary to receive certificate of completion/statement of credit. Anticipated reach is estimated to be over 45,000 physicians for the print monograph in addition to 5,000-10,000 online recipients.

Page 25 of 30

no anderes de la ser e a magazina por

Additional Tactics for Future Consideration

Prinsistent and Biografit partition of the European Saske Proctice and Practice Based Filmburg

In this print and online series, expert thought leaders will elaborate on the seminal studies supporting the management of persistent and breakthrough pain, conducted over the past twenty years, since Drs Portenoy and Hagen published their seminal work in 1990. Abstracts of select studies will be included, and will help frame the discussion on salient issues in chronic pain management. Randomized controlled studies include patient populations with rigorously defined inclusion and exclusion criteria, often precluding generalizable and practical recommendations. Here, clinicians will discuss several landmark study findings, their limitations and implications for current approaches to assessment and individualization of patient care. Particular emphasis will be placed on the soon-to-be published guidelines from the American Pain Society, providing pain clinicians with guidance on how to interpret and implement their recommendations, bridging the gap between what we know and what we don't know with practice based clinical experience and evidence.

Web-Based Decision Tree (Program Name and URL Will Be Provided Upon Request).

This activity purports to integrate the expert clinical experience with the Level 1 Evidence of randomized controlled studies. Two objectives are served. First, clinicians acquire a more in-depth understanding of the evidence-based recommendations in various guidelines. (Of note, the American Pain Society will be publishing its guidelines in the near term.) This knowledge will help clinicians find a more practical expression of guidelines that too often cannot be implemented. Second, clinicians will refine their clinical judgment by engaging in structured decision making—the art of medicine—that drives patient care, particularly when specific evidence is lacking. In this Web-based activity, clinicians will be presented with case studies representative of the myriad issues in managing patients with persistent and breakthrough pain. Case studies may address chronic pain associated with tumor progression, radiation or chemotherapy-related pain in cancer survivors, diabetic peripheral neuropathy, and chronic low back pain.

Upon reviewing salient data—including, for instance, patient history, comorbidities, prior treatment history, pathophysiology, imaging studies, and laboratory findings—the clinicians will develop in step-by-step fashion a course of action. At each step, from assessment and diagnosis; to the initial and revised treatment, the clinician may choose among several options, each informed by well-designed studies and each having risks and benefits. These data will, of course, only be available to the clinicians upon making their selections. With only one "click," clinicians will gain access to a brief abstract summarizing the available evidence and a video of a thought leader roundtable discussion framing the available evidence. Links to seminal scientific and/or randomized controlled studies will be readily accessible and adjacent to each video presentation. When available, evidence-based outcomes—eg, pain reduction and functional improvement—of each treatment selection will be discussed. This self-directed case-based learning provides a familiar educational format for healthcare professionals based on adult learning principles, and consistently rates as a highly effective means by which to educate clinicians.

Case-In-Point and Accompanying Monograph

This roundtable discussion will feature several pain specialists, two from prominent academic centers and another from private practice. Faculty will present several complicated case studies, elaborating on the evidence for various treatment modalities. Twenty-five community-based clinicians—neurologists, psychologists, physician assistants, and nurses—will be invited to listen and to join in the discussion at appropriate times. This "chronic pain-in-the round" program will be video captured to form the basis for podcasts posted on a pain management Web site (eg, www.pain.edu) that includes practical, evidence-based resources for pain specialists

Page 26 of 30		Confidential

The recorded sessions are edited professionally and reduced to 10-minute video vignettes, concise and uninterrupted discussions that capture the thought leaders' expert insights into the management of persistent and breakthrough pain. Print editorials written by community pain clinicians will accompany the video vignettes, reinforcing the major themes and providing an opportunity for academic thought leaders to partner with local clinicians, each managing patients with chronic pain. This innovative Web-based format allows clinicians to participate immediately in each activity at a self-directed pace from their computers—accommodating even the busiest of schedules.

A monograph will be developed to provide additional context for the video case studies. A 10-question multiple-choice self-assessment examination will also be included, reflecting the content discussed in each video vignette and accompanying print editorials. Successful completion of the posttest is necessary to receive a certificate of completion, or a statement of credit. Participants must score 70% or higher and are allowed 2 attempts to successfully complete the exam. Upon successful completion of the examination, healthcare professionals may use the CME credit earned toward their licensure and/or certification requirements. Each vignette—prime examples of which may be e-mail blasted to the target audience of pain specialists—will be eligible for 1 hour of credit for 1 year from the issuance date.

Literature Surveillance

Quarterly reports summarizing in an easy-to-read style results from a formal literature surveillance will be shared with select faculty and preceptorship clinicians. Designed to identify new developments in the management of chronic pain, the reports will monitor clinical trial data, guideline updates, FDA approvals and warnings, and emerging issues in pain medicine.

Page 27 of 30 Confidential

V. Program Recruitment, Awareness, and Distribution

Program Recruitment, Awareness, and Distribution

All live, print, and online programs will have specific recruitment, awareness, and distribution methods contained to ensure that the programs have the best opportunity for educational uptake and acceptance. These recruitment methods have been validated for past programs and have proven cost effective while maximizing reach and distribution to targeted audiences. These methods include live, print, and online components as detailed below.

PainClinician™

PainClinician™ is a compendium of advances in the management of chronic pain, distributed quarterly to pain specialists and other healthcare professionals interested in chronic pain management. Our proprietary database of the same name will ensure distribution to the primary audience of pain practitioners. Distribution methods include direct mail, distribution at AAPM, APS, and other selected pain management meetings throughout the year. Total quarterly distribution is estimated to be over 25,000. In addition to outlining the accredited package contents, each quarter and through an introductory letter, a leading pain management clinician will highlight the most recent and important dialogues and discussions involving pain medicine.

Pain Medicine News

The enduring activity will be a stand alone monograph of 12 journal sized pages distributed with an early 2009 issue of *Pain Medicine News* to its full circulation of approximately 46,500 clinicians. *Pain Medicine News* is a bimonthly publication circulating to physicians in the 12 specialties that most commonly treat patients with pain emergency medicine physicians; neurologists; oncologists; orthopedic surgeons; pain management, pain medicine, and palliative pain medicine specialists; physical medicine and rehabilitation specialists; primary care physicians; and rheumatologists.

Additional copies of the monograph will be distributed from the *Pain Medicine News* exhibit booth at national conferences. *Pain Medicine News* has a presence at 7 conferences throughout the year at which the monograph may be distributed at:

- · American Academy of Pain Medicine
- American Academy of Pain Management
- American Conference on Pain Medicine
- · American Pain Society
- American Society of Regional Anesthesia and Pain Medicine Spring Meeting
- American Society of Regional Anesthesia and Pain Medicine Fall Meeting
- North American Neuromodulation Society

Live and Online Components

Live recruitment, awareness, and distributions campaigns will include attendance at various medical congresses and other relevant satellite pain meetings throughout the year. At these meetings, in addition to recruitment, awareness and distribution of ongoing programs to attendees, enrollment into the *PainClinician* database and program will occur. A thorough online campaign including, but not limited to, MedScape, www.pain.edu, Sermo and other pain-related services, to generate interest in

Page 28 of 30 Confidential

existing and future educational programs will also ensure maximizing the uptake, awareness, acceptance, and ultimately, participation in the ongoing series of educational programs.

Page 29 of 30

ease see attached			

Page 30 of 30

Confidential

.



Center for Continuing Medical Education

Bildging the Gap Between Education and Practice



The Linversity hopital and A side one Medic of the Control of A heat Einstein Control of Medicory

November 6, 2008

Steven Jay Feld

of technology consum

Educational Grant Review Committee Cephalon

Dear Sir and/or Madam:

On behalf of the Albert Einstein College of Medicine & Montefiore Medical Center, Center of Continuing Medical Education (CCME) and our Educational Collaborator and Joint Sponsor. Asante Communications LLC, I am requesting an educational grant from Cephalon in the amount of \$1 462,375.00 to be used to help support several CME accredited activities. These activities will focus on the topic of chronic pain management with the goal of providing clinicians with a learning forum to develop practical methods to appropriately assess and manage pain

CCME, with assistance from its educational collaborator, Asante Communications LLC, an organization with professional staff that have extensive experience in developing and implementing activities such as those being proposed, is planning to develop a series of CME activities to address issues of pain management and to provide physicians with the necessary best-practice skills to be able to better diagnose and treat issues in pain management. The activities will include:

- three (3) cases and commentary live meetings
- one (1) monograph to be developed from materials presented at the cases and commentary meetings
- one (1) on-line monograph (same as above)
- eight (8) live teleconferences available for participation at separate times
- one (1) monograph to be developed from the materials presented during the teleconferences
- one (1) on-line monograph (same as above)
- one (1) live regional meeting
- one (1) satellite webcast which will include highlights from the live regional meeting
- one (1) non-CME international forum of experts, which will be used to develop a CME activity
- one (1) CME position paper developed from the above international forum of experts
- one (1) on-line position paper (same as above)
- one (1) pain/risk management compendium to assist physicians in their clinical settings
- one (1) on-line pain/risk management compendium (same as above)

Each of these activities will include outcomes surveys to measure the practice performance changes of the participants of each activity. A further outcomes study/preceptorship, utilizing a control group to measure and compare the effectiveness of continued educational interventions between the control group's practice performance and the group receiving additional educational interventions will be conducted and will include participants from the cases and commentary, teleconferences and regional meeting. Participants in this outcome study will be given an opportunity to opt in.

(B01 Bambridge Avenue, Brons, NA, 1646) — P. S. (1826) and F. S. (1826) — Barrenera, — Steel (menta free) is

Confidential

As an additional option we are offering to develop and execute a final outcome study, which will poll from a select group of participants from the above outcome study. The physicians would agree to join a final IRB approved study, which will assess patient satisfaction. This study will be developed and overseen by an approved IRB entity and will seek input from patients that agree to be part of the study.

The working title of this comprehensive initiative is, Persistent and Breakthrough Pain. A Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies Initiative.

Faculty for this initiative will be chosen to develop unique learning opportunities, which will enable pain management specialists, which will include, neurologists, rheumatologists, physiatrists, primary care physicians, internal medicine physicians, anesthesiologists and oncologists to increase their competence and abilities to treat and appropriately manage pain and learn important methods to incorporate risk management strategies into pain management plans

We will be using the requested grant for all the expenses related to the organization, capture and development of materials and for the accreditation and assessments of these CME activities

The purpose of this letter is to provide you with information on how CCME is planning to organize all the logistics related to the production and accreditation of these activities

The Albert Einstein College of Medicine and Montefiore Medical Center, Center for Continuing Medical Education and its Educational Collaborator and Joint sponsor, Asante Communications LLC, or our agents, will take full responsibility for both the medical content and logistical aspects of the following.

- Select faculty and topics
- Provide a faculty reviewer to make sure that all materials are free of bias and of professional scientific merit
- Develop a marketing plan to reach an audience of appropriate participants
- Provide sponsorship of the activities and maintain all books and records
- File and prepare all appropriate documentation to allow the activities to be certified by Albert Einstein College of Medicine for AMA PRA credit
- Administrate all financial accounting and bookkeeping
- Prepare, distribute and summarize course evaluations
- Develop, distribute and summarize outcomes surveys
- Maintain records of participants, grade quizzes and provide certificates to requesters
- Review and oversee the development of materials to ensure that the enduring material activities are in compliance with the AMA and ACCME Guidelines

Each of the activities will be reviewed by one of our renowned faculty, who is a specialist in the field of pain management. They will also be responsible for working with Asante Communications LLC to identify needs, learner gaps, objectives, appropriate faculty and determine topics.

Our tax ID number is 13 1740114 (Montefiore Medical Center)

13.3 Bandridge Webba (Brobs, NY 1946) — Phys. 718 (2006) 4 — Fee 748 798 205 — and one one — shelds more from 100.

Page -3-

The provider requires that

- All significant relationships (e.g. consulting, grant recipient, etc.) between Cephalon and faculty members, or any individual in a position to influence content must be disclosed to the participants of its CME activities.
- All commercial interest support be disclosed to participants prior to their participation in its CME activities
- All COIs of faculty, or anyone in a position to influence content will be resolved through mechanisms of resolution developed by Einstein for all its CME activities

Einstein requires that its LOA with Cephalon be signed by Victor B. Hatcher, PhD, Associate Dean of CME at Albert Einstein College of Medicine and Director of CME at Montefiore Medical Center, or Steven Jay Feld, Associate Director of CME at Albert Einstein College of Medicine & Montefiere Medical Center.

Please make checks payable to Montahore Maurical Center

Montefiore Medical Center is the University Hospital for the Albert Einstein College of Medicine and all Albert Einstein College of Medicine, CME finances are handled by Montefiore Medical Center

Check payments should be remitted to CCME 3301 Bainbridge Avenue Bronx, NY 10467 Attn. Steven Feld.

Any unused funds that were received from Cephalon in support of these activities will be retuned to Cephalon upon completion of reconclusion

If you need any further information, or have any questions that relate to this grant request, please contact me at 718 920-6674, ext. 232

On behalf of Albert Einstein College of Medicine & Montefiore Medical Center. I would like to thank Cephalon for consideration or this request.

Sincerely

Steven Jay Feld

cc Asante Communications LLC

3. C. Scabinda, Acemie Breax, XA, 19467. Proxit 718 (2006)74. Pr. 187-82336. Incrementary steads count flore one

-

Exhibit B ACTIQ Risk Management Program

Provider is aware that ACTIQ® (oral transmucosal fentanyl citrate) [C-II] was approved subject to a Risk Management Program (RMP). The RMP includes key safety messages that are essential to the safe use of this product. They are:

- ACTIQ is indicated only for the management of breakthrough cancer pain in patients with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
- ACTIQ is contraindicated in the management of acute or postoperative pain, because life-threatening hypoventilation could occur at any dose in patients not taking chronic opiates.
- This product must not be used in opioid nontolerant patients.
- Patients considered opioid tolerant are those who are taking at least 60 mg Morphine/day, 50 mcg transdermal fentanyl/hour, or an equianalgesic dose of another opioid for a week or longer.
- Instruct patients/caregivers that ACTIQ can be fatal to a child. Keep all units from children and discard properly.
- ACTIQ is intended to be used only in the care of cancer patients and only by oncologists and pain specialists who are knowledgeable of and skilled in the use of Schedule II opioids to treat cancer pain.

FENTORA Risk Management Program

Provider is aware that FENTORA™ (fentanyl buccal tablet) [C-II] was approved subject to a Risk Minimization Action Plan (RiskMAP). The RiskMAP includes key safety messages that are essential to the safe use of this product. They are:

- FENTORA is indicated for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
- FENTORA is contraindicated in the management of acute or postoperative pain, because life-threatening hypoventilation could occur at any dose in patients not taking chronic opiates.
- This product must not be used in opioid nontolerant patients.
- No misuse of FENTORA should occur.
- Unintended (accidental) exposure to FENTORA should not occur.
- Patients considered opioid tolerant are those who are taking at least 60 mg oral morphine/day, at least 25 mcg of transdermal fentanyl/hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.
- Instruct patients/caregivers that FENTORA can be fatal to a child. Keep all units away from children and discard properly.
- FENTORA is intended to be used only in the care of opioid tolerant cancer patients and only by healthcare professionals who are knowledgeable of and skilled in the use of Schedule II opioids to treat cancer pain.



Cephalon, Inc. 41 Moores Road PO Box 4011 Frazer, PA 19355 Phone 613-344-0200

MONTEFIORE)

Check Agreement in TRIM,

Agreement in TRIM,

(ask Counce); Fax 610-344-0065 INDE **ANT AGREEMENT** This Agr December, 2008, by and between Cepha 1, Post Office Box 4011, ") located at CCME, 3301 Frazer, PA 1935 Bainbridge Aven ations, LLC ("Educational Y 10022. Partner") located WHEREAS, Cep. education program WHEREAS . PAIN ___ to ensure t independent, objective, palanced, scientifically rigorous, ____ reasonable expectations of meeting its educational objectives so that it will not be viewed by the United States Food and Drug Administration ("FDA") as promotional and that Cephalon

WHEREAS, Cephalon agrees to provide funding for the Program under the conditions set forth below.

NOW THEREFORE, Provider and Cephalon agree to the following terms under this Agreement:

- 1. <u>Title of Program</u>. The Educational Program is entitled "Persistent and BTP: Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies," and a copy of the grant request for the Program is attached hereto as Exhibit A.
- 2. Type of Program. The Program is:

will not be viewed as responsible for its content; and

⊠accredited (e.g., continuing medical education or "CME"); or
an independent program where CE credits will not be offered

- 3. <u>Educational Partner</u>. The Provider ⊠shall ☐ shall not use a third party that will provide assistance in support of the Program ("Educational Partner").
- 4. The name of the Educational Partner is Asante Communications, LLC.
- 5. <u>Educational Components</u>. The expected components of the Program (e.g., number of live meetings, CD ROM, web-based, etc.) are as follows:
 - (a) Thirteen Live National Meetings;
 - (b) Two Additional Live Meetings;
 - (c) Five Web Tactics:
 - (d) One Print Piece;



Cephalon, Inc.
41 Mocres Road
PO Box 4011
Frazer, PA 19355
Phone 610-344-0200
Fax 610-344-0065

INDEPENDENT EDUCATIONAL PROGRAM GRANT AGREEMENT

This Agreement is entered into as of this 16th day of December, 2008, by and between Cephalon ("Cephalon"), located at 41 Moores Road, Post Office Box 4011, Frazer, PA 19355, and Montefiore Medical Center ("Provider") located at CCME, 3301 Bainbridge Avenue, Bronx, NY 10467 and Asante Communications, LLC ("Educational Partner") located at 800 Third Avenue, 9th Floor, New York, NY 10022.

WHEREAS, Cephalon has reviewed Provider's grant request to support a medical education program ("Program"); and

WHEREAS, Cephalon has determined that the Program has the potential to address educational gaps and improve patient care; and

WHEREAS, it is the intent of the parties to ensure that the Program will be independent, objective, balanced, scientifically rigorous, and have reasonable expectations of meeting its educational objectives so that it will not be viewed by the United States Food and Drug Administration ("FDA") as promotional and that Cephalon will not be viewed as responsible for its content; and

WHEREAS, Cephalon agrees to provide funding for the Program under the conditions set forth below.

NOW THEREFORE, Provider and Cephalon agree to the following terms under this Agreement:

- <u>Title of Program</u>. The Educational Program is entitled "Persistent and BTP: Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies," and a copy of the grant request for the Program is attached hereto as Exhibit A.
- 2. Type of Program. The Program is:

⊠accredited (e.g.,	continuing me	dical educat	ion or "CN	1 E"); or
an independent i	orogram where	e CE credits	will not be	offered.

- 3. <u>Educational Partner</u>. The Provider ⊠shall ☐ shall not use a third party that will provide assistance in support of the Program ("Educational Partner").
- 4. The name of the Educational Partner is Asante Communications, LLC.
- 5. <u>Educational Components</u>. The expected components of the Program (e.g., number of live meetings, CD ROM, web-based, etc.) are as follows:
 - (a) Thirteen Live National Meetings;
 - (b) Two Additional Live Meetings:
 - (c) Five Web Tactics;
 - (d) One Print Piece;

- (e) Three Print Supplements;
- 6. <u>Program Purpose</u>. The Program is for scientific and educational purposes only, and is based on established bona fide and independently verifiable patient and/or practitioner needs or gaps in healthcare performance, and is not intended to promote a Cephalon product, directly or indirectly. The Program is not a repeat performance of a prior program.
- 7. Grant Amount Funding Arrangements.
 - (a) Cephalon will provide support for the Program by means of an educational grant in the total amount of \$1,316,295, as set forth in the budget attached hereto, or a pro rata amount based on the actual work performed and expenses incurred by Provider in accordance with the Budget. If the Program is canceled or terminated prior to completion, Provider shall return the grant, or any unused portion thereof, to Cephalon within thirty (30) days of such termination or cancellation. Provider shall have full responsibility for all funding arrangements of the Program, including any funding to be provided to its Educational Partner. Payment terms of the grant shall be made in accordance with any schedule/criteria provided in the Budget.
 - (b) Within ninety (90) days of completion of the Program, Provider shall provide Cephalon with a detailed reconciliation of actual expenses incurred, and to the extent Cephalon has overpaid Provider for same, Provider shall provide a refund to Cephalon within thirty (30) days thereafter. Such detailed reconciliation shall be forwarded to Cephalon at the address above to the attention of Bhaval Shah Bell, PhD, Medical Affairs.
 - (c) Provider may not use funds provided by Cephalon to pay travel, lodging, honoraria or personal expenses for non-faculty attendees. Grant funds may be used to reduce the overall registration fees for attendees. Grant funds may not be used to purchase capital equipment or to provide general operational support for an institution. Funds for hospitality shall not be provided, except that funds may be used for modest meals or receptions that are held as part of the Program, but such events shall not compete with, nor take precedence over, educational events. The appropriateness of any reception shall be at the sole discretion of the Provider, and Provider shall have final decision-making authority in connection with any such activities.
 - (d) Funds may be used by the Provider to permit medical students, residents, fellows or other health care professionals in training to travel to and attend the Program; provided, however, that the selection of such students, residents or fellows who receive funds is made by either the

- academic or training institution, or, if by the Provider, such selection shall be made with the full concurrence of the academic or training institution.
- 8. <u>Objectivity and Balance</u>. Provider shall retain full responsibility for control of the content of the Program and shall ensure that the following requirements are met:
 - (a) The Program material/information will be objective, balanced and free from commercial bias. All topics shall be treated in an impartial, unbiased manner. All discussions shall include a range of views about each class of drug and disease treatment options. Information shall not unfairly represent a spectrum of views favoring a product or class of products marketed by Cephalon or any other company. The title of the Program will fairly and accurately represent the scope of the presentation.
 - (b) Provider agrees that neither Cephalon nor its agents shall control the content of the Program. Provider agrees that there will be no scripting, targeting of points for emphasis, or other activities by Cephalon or its agents that are designed to influence the content of the Program. Cephalon personnel will not attend content development meetings unless requested in writing by the Provider or the Educational Partner make presentations of disease data and/or Cephalon product data to faculty. In this instance, Cephalon personnel may stay only for this portion of the meeting, and the accredited provider must be in attendance.
 - (c) If requested, in writing, by the Provider or Educational Partner, Cephalon Medical personnel may also provide written material on a Cephalon product or compound in development, such as specific product data, manuscripts, posters, product labels and other scientific material (not in slide format) in accordance with internal corporate guidelines based on the level of information that is acceptable to disclose.
 - (d) Cephalon shall not review the Program for medical accuracy or completeness and the Provider and/or Educational Partner (if any) agree that they will not make such a request of Cephalon.
 - (e) If a product marketed by Cephalon is the subject of discussion, the data will be objectively selected and presented, with an accurate reflection of favorable and unfavorable information about the product and shall also include a balanced discussion of prevailing information on alternative products and /or therapies.
 - (f) Any suggestions of superiority of one product or treatment over another will be supported by the body of available data and will not result from selective presentation or emphasis on data favorable to a particular treatment.
 - (g) Provider represents that neither it nor the Educational Partner (if any) has either an open complaint or decision from the Accreditation Council for Continuing Medical Education ("ACCME") or the FDA that a program

provided by the Provider or the Educational Partner failed to meet standards of independence, balance, objectivity, or scientific rigor.

- 9. Risk Minimization Action Plan. Cephalon provides the following Risk Minimization Action Plan ("RiskMAP") information to all Providers. Neither Cephalon nor its agents shall influence or control whether a product marketed by Cephalon is the subject of discussion. A RiskMAP is a strategic safety program designed to meet specific goals and objectives in minimizing known risks of a product while preserving its benefits. Any product marketed by Cephalon that is approved with a RiskMAP, and the key safety-related health outcomes outlined in that RiskMAP, are listed in Exhibit B. Provider agrees that it is aware of the RiskMAP(s) and the key safety messages.
- 10. No Faculty Selection. Provider shall retain full responsibility for the selection of the presenters, authors, moderators, and/or other faculty (hereinafter referred to collectively as "Faculty"). Provider and/or Educational Partner (if any) shall not request recommendations for Faculty from Cephalon
- 11. <u>Disclosures</u>. Provider will ensure meaningful disclosure of limitations of data (e.g., ongoing research, interim analyses, preliminary data, or unsupported opinion). Provider will require that Faculty disclose when a product is not approved in the United States for the use under discussion.
- 12. <u>Question and Answer Session</u>. To the extent the Program is a presentation, Provider will ensure meaningful opportunities for questioning by the audience.
- 13. <u>Financial Relationships</u>. Provider will ensure meaningful disclosure to the audience of Cephalon funding and any significant relationship between individual Faculty and Cephalon. All meaningful disclosure(s) shall also be made in any written materials, including, but not limited to, announcements, brochures, syllabi and enduring material. Disclosures shall not mention product trade names.
- 14. Representations and Warranties. Provider represents that:
 - (a) Neither it nor the Educational Partner, if any, provides marketing, advertising, public relations, market research, medical education services or other consulting services (e.g., support for advisory boards) to any other department within Cephalon ("Marketing Activities");
 - (b) If Provider or the Educational Partner has an affiliated company that provides Marketing Activities to Cephalon, Provider has instituted appropriate controls and safeguards to ensure the Program (i) remains independent, objective, balanced and scientifically rigorous, (ii) is not intended to promote a Cephalon product, directly or indirectly, and (iii) is not in any way biased due to the affliated company's relationship with Cephalon;

- (c) Provider has determined that it is appropriate to use the Educational Partner in light of the requirements under this Agreement; and
- (d) If Provider or its Educational Partner employs a former Cephalon employee who worked at Cephalon at anytime during the most recent year and who had marketing responsibility in the therapeutic area that will be covered by the Program, then that former employee will not have any role in the planning, development or delivery of the Program.
- 15. <u>Invitations/Enduring Materials</u>. The Program audience will be selected by the Provider. The Provider shall be responsible for distributing materials about the Program, including invitations, reminder notices, and business reply cards that can be used by third parties to obtain any enduring Program material from the Provider.
- 16. Ancillary Promotional Activities. To the extent the Program is a live presentation, no promotional activities or product advertisements will be permitted in the same room as, or in an obligate path to, the Program. If the Program is a teleconference or webcast, no product advertisements or promotional activities will be permitted immediately prior to, during, or immediately after the delivery of the Program. If the Program is in print format, no product advertisements or promotional materials will be interleaved within the pages of the Program. If the Program is made available electronically, no product advertisements or promotional materials will appear within the Program material or interleaved between computer windows or screens of the Program, all as stipulated in ACCME Guidelines.

- 17. Compliance with Guidelines. Provider represents that the Program, including development of the Program and Program materials, shall conform to the American Medical Association ("AMA") Guidelines on Gifts to Physicians, the AMA Ethical Opinion on Continuing Medical Education, the ACCME Standards for Commercial Support, the FDA December 3, 1997 Final Guidance for Industry-Supported Scientific and Educational Activities, and the Pharmaceutical Research and Manufacturers Association ("PhRMA") Code on Interactions with Healthcare Professionals.
- 18. <u>Logistical Status Reports</u>. Provider and/or Educational Partner shall provide periodic reports to Cephalon regarding the management and logistics of Program components.

19. Miscellaneous.

- (a) No party shall use the other party's or its affiliates' name or trademarks for publicity or advertising purposes, except with the prior written consent of the other party.
- (b) Provider agrees to obtain all consents, authorizations, approvals and releases that may be necessary for the production of the Program and of any written materials prepared in connection therewith.

(c) No term, condition or other provision of any attachment or addendum to this Agreement shall supersede any term, condition or other provision of this Agreement, and with respect to any inconsistency or ambiguity, the Agreement shall control.

IN WITNESS WHEREOF, the parties, by their duly authorized representatives, agree to comply with all the terms and conditions of this Agreement.

	Λ _ 🛫 🥨
MONTEFIORE MEDICAL CENTER	CEPHALON, INC.
By: Steven Pay State Name: STELEN TAY FELD Title: ASCCIATE DIRECTOR COME	By: Name: Robert Kaper, MD Title: Vice President, Medical Affairs
The above signatory is a duly authorized corporate officer of the IEP Provider.	T
Date: $\frac{12}{23/65}$	Date: 12/16/08
Tax ID#: <u>/3 174 0//4</u>	· · · · · · · · · · · · · · · · · · ·
	CEPHALON LEGAL DEPT.
ASANTÉ COMMUNICATIONS LLC	
By: 1 1 1	
Name: KERR HURWIR	

7

Title: fres, DENT MANAGING DIRECTOR

The above signatory is a duly authorized

corporate officer of the Educational Partner.

Date: 12/2+/c8

Tax ID#: 80 - 02515 70

(c) No term, condition or other provision of any attachment or addendum to this Agreement shall supersede any term, condition or other provision of this Agreement, and with respect to any inconsistency or ambiguity, the Agreement shall control.

IN WITNESS WHEREOF, the parties, by their duly authorized representatives, agree to comply with all the terms and conditions of this Agreement.

MONTEFIORE MEDICAL CENTER	CEPHALON, INC.
By: Stew Cay Stack Name: STEVEN TAY FELD Title: ASCCIATE DIDECTOR COHE The above signatory is a duly authorized corporate officer of the IEP Provider. Date: 12 23 0.5 Tax ID#: 13 174 0/14	By: Name: Robert Kaper, MD Title: Vice President, Medical Affairs Date: 12 / C. C. APPROVED AS TO LEGAL FORM
ASANTE COMMUNICATIONS LLC By: A THE PROPERTY OF THE PROPERTY	CEPHALON DIN LEGAL CEPT.

Title: PLES, DENT MANAGING DIRECTOR

The above signatory is a duly authorized

corporate officer of the Educational Partner.

Date: 12/24/08

Tax ID #: 80 - 02515 70

Exhibit A

Copy of Grant Request



Albert Einstein

Center for Continuing Medical Education

Bridging the Gap Between Education and Practice



The University Hospital and Academic Medical Center for the Albert Einstein Coffege of Medicine

December 8, 2008

College of Medicine of Yeshiva Litiversity

Steven Jay Feld Associate Director

> Ms. Karen Roy Director of Medical Education Cephalon 41 Moores Road Frazer, PA 19355

Dear Ms. Roy:

Per your request for additional information, please find below a more detailed overview of the Level and Type of data to be collected via the patient questionnaire.

Under the guidance of the Albany Medical Center's Institutional Review Board (IRB), and approved by Albert Einstein College of Medicine, CME, the Stage III Durable Outcomes measurement will be used to gather non-biased, independent and measurable information for the proposed Outcome Study.

As mentioned in the grant, the Stage III patient questionnaire will assess improvements in the management of persistent and breakthrough pain with patients whose physicians participated in the preceptorship program, when compared to patients who were under the care of control group physicians who did not participate in the preceptorship. The questionnaire will consist of 5-multiple choice questions, each inquiring into their perceptions of the clinician's attentiveness to the pain complaint. Sample questions that may be included, pending further discussion and approval by the Albany IRB, Albert Einstein College of Medicine and based on the approach utilized by Dr. Michael Brennan are as follows:

When compared to the beginning of the year has your clinician devoted more time to discuss the "ups-and-downs" in the severity of your chronic pain?

Parameters to be Measured

- 1 Improved
- 11.0 No change

When compared to the beginning of the year has your clinician devoted more time to discuss changes in your pain severity caused by increased activity?

Parameters to be Measured

- 2 Significantly improved
- [] Improved
- 110 No change

3301 Bainbridge Avenue, Bronx, N.Y. 10467 Proxt. 718.020 6674 Fax 718 798 2336 mecane org sfeld@montefiore.org

Page -2-

When compared to the beginning of the year has your clinician devoted more time to discuss how to treat episodes when your pain is at its worst?

Parameters to be Measured

- Significantly improved
- 3.1 Improved
- No change

Lastly as a point of clarification, the sole data source from patients will be the patient questionnaire. There aren't any needs for the Durable Outcomes Evaluation to review or collect data from patient charts. Patients will participate in this program on a strictly voluntary basis, can decide not to participate at any time, and will be assured of the confidentiality of their responses. Dr. Charles Argoff and the Albany Medical Center IRB will supervise the administration and data analysis of Stage III. in collaboration with Dr. Hatcher (Associate Dean of CME at Einstein and Director of Research and CME at Montefiore) and Asante Communications.

We hope this clarifies the Stage III section of the proposed grant. As always, should you have any further questions, please do not hesitate to contact me with any questions.

Sincerely,

Steven Jay Feld

Hanty Sold

cc: Peter Hurwitz

3301 Fambridge Avenue, Branx, N.Y. 10467 Phong 718,920,6674 Fax 718 798 2330 mecmelorg sfeld@montefiere.org



Bridging the Gap Between Education and Practice



The University Hospital and Academic Medical Center for the Albert Einstein College of Medicine

November 20, 2008

Educational Grant Review Committee Cephalon

Dear Sir and/or Madam:

On behalf of the Albert Einstein College of Medicine & Montefiore Medical Center, Center of Continuing Medical Education (CCME) and our Educational Collaborator and Joint Sponsor, Asante Communications LLC, please find the requested clarification information for Grant #2569.

Albert Einstein would like to reaffirm its commitment to providing high quality education. Of particular importance to us is adapting and refining each successive activity as the year unfolds. Applying our learnings from one program to the next invariably improves the substance of the program, and provides up-to-date insights from the faculty and participants alike.

Upon further discussion with our education collaborator, Asante Communications, in lieu of providing a specific book for the participants, originally suggested to be distributed to after the Full-day Regional Meeting and the Preceptorship program, it would be more prudent to provide a Reference Guide to these participants, in addition to quarterly online updates.

In addition, we see considerable benefits in combining the enduring material of the Teleconferences and the Cases and Commentary into a single enduring material, rather than producing two separate activities. This will limit any overlap that may occur from the content of these two activities. We would like to present this as an attractive option.

Enduring materials posted online will be targeted to pain specialists. Websites that are selected will have an audience which consists of pain specialists, including anesthesiologists, oncologists, neurologists, and physiatrists, among others.

In addition to being an accredited activity, the Position Paper that will be developed from the International Experts Forum will be submitted to a peer-reviewed journal for publication. We will request permission from the journal prior to submission of the article to be published as a CME activity in their journal and elsewhere. This will enhance the current BTP literature.

(39) Bambridge Avenue Bronx, VY, 10467 Phost 718 920,6671 FAV 718 798.2436 meetic org.

eniet montefore org

We would also like to comment further on two select items. First, as noted in the grant, nurses, nurse practitioners and physician assistants represent an important target audience and as such we will be making a concerted effort to recruit these pain clinicians for each educational activity. In addition, we would like to propose that a Cases and Commentary workshop be held at the Oncology Nurses Society (ONS) in 2009. An enduring activity will be developed from this Workshop and will extend the reach of this very valuable educational activity. This activity will be accredited for continuing education (CE) credit for nurses by an approved academic institution or noted medical center, such as Montefiore Medical Center. Further, as noted in the accompanying materials, one of the workshops will be held at the American Pain Society, a multidisciplinary organization that requires triple accreditation for all programs.

The other items uploaded for clarification purposes include:

- Timeline on all proposed activities
- Schematic of Chronic Pain Management Preceptorship (CPMP)
- Full-Day Regional Budget (clarification on Reference Guide)
- Preceptorship Budget (clarification on Reference Guide)

If you need any further information, or have any questions that relate to this grant request, please contact me at 718 920-6674, ext. 232.

On behalf of Albert Einstein College of Medicine & Montefiore Medical Center, I would like to thank Cephalon for the continued consideration of this request.

Sincerely,

Steven Jay Feld



SPECIAL NOTE:

date for all expenses and staff hours.

Center for Continuing Medical Education

- manufacture the supplication of the street


He have the Propagation and Laster of Medical tenter for the West Careford ellipse of Neate the

DESCRIPTION / CATEGORY	ASSUMPTIONS COST TOTAL COST					
GENERAL - OOP	1.5	4-77				
		Rate	Persons		- •	
Protocol Director Honorarium)	\$2,000	1	\boxtimes	\$2,000	
Faculty Honoraria (Data Revie	ew/Interpretation	\$2,000	4		\$8,000	
					TOTAL	\$10,000.00
IRB Academic Center Fee	.	10.00				* - * Yes + 400 - 100
Protocol Review and Approve	nl					\$5,000.00
Online - OOP						
Technical Programming/Q	uarterly Webinars					\$6,000.00
Online Hosting and Month						\$2,500.00
Email Recruitment Stage I	(Control and Parti	cipant Grou	ps)			\$2,500.00
Data Analysis/Statistician					_	\$5,000.00
Patient Enrollment for Sta	ge III		~			\$1,000.00
MISCELLANEOUS - OOP	4.7					4 1 1
Miscellaneous expenses						\$1,500.00
TOTAL COPs						\$33,500.00
FEES					100	
Management Fee						\$15,000.00
Includes:						
* Manage design and productio	n of all materials					
* Grant/Needs development						
*Administer outcomes tools (pre			ions)			
*Analyze results from pre-test, p *Liaise with IRB and faculty	oost-test and follow-up	questions				
*Manage all aspects of Patient	oncollment under IPR	supanusian				
* Final reconciliation	eniolinien under ind .	super vision				
* Internal IRB compliance						
Content Development/Editori	al/Creative Fee					\$25,000.00
Content Development include						
* Development of pre-lest, post	test and follow-up que	estions				
* Liaise with faculty						
*Development of Case Vignette						
*Development of Patient Surve						
*Development of outcomes rep						
*Development of ideas for futur						
* Editorial/copy editorial review	and formatting					
Creative Fee Includes:						
* Design of evaluation survey * All costs associated with proje	of docian and dovolor	mont				
	ot design and develop	mon				\$40,000.00
TOTAL FEES						340,000.00
GRAND TOTAL						\$73,500.00

2303 Hamburka Avenue, Brans, N.Y. 1946. — Prox. 718 9 20 6024 — Prox. 718 708 256. — micro-org — em gamous floresoft,

Any change in scope will require an approved revised budget. Cancellation of program will be subject to costs-to-

2 Sec. 19 Sec.	am wanageme	nt Precep	torship Progra	m
DESCRIPTION / CATEGORY	ASSUMPTIONS		COST	TOTAL COST
				1
C	Rate Pers			\$3.500.0
Course Director Faculty Honorana	\$3,500 1 \$2,000 5	_ ~		\$3,500.0 \$10,000.0
ACCREDITATION FEE		4.4		
Albert Einstein Accreditat	tion and Certificate Fee		2.5 hrs.	\$12,500.0
LOGISTICS - OOP				
List Purchase		***************************************		\$1,500.0
Survey Distribution				\$500.0
Development of				
Participant Database with				
tracking software				\$3,250.0
Food and Beverage	Cost/Tax/ Perso Gratuity Quar			
To Include Break	kfast(s) \$40 20) 1	\$800	60001
MATERIALS - OOP			TOTAL	\$800.0
Production/Printing 150 i	Binders			\$1,500.0
Reference Guide Purchase artwork	\$ 30 20	0		\$6,000.0 \$750.0
	CATIONS - OOP		2.20	4 700.
Transcription Services				\$3,000.0
	ERVICES - OOP ons (Teleconference/E-Co	C. A. 4 - Warning-Spin-Boltoni		\$2,000.0
Creative Design for Progr	ram Template			\$2,500.0
	OP aculty mailings, materials :			\$1,000.0
Postage for panticipant m		150		\$1,000.0
Assembly of participant n		150		\$500.0
Miscellaneous expenses of OOP TOTAL	other than group			\$500.0 \$50,800.0
TOTAL				400,000.0
FEES	/# F			
Management Fee				\$32,000 0
* Timeline development & n	maintenance			
*Manage internal team and				
	ional process including invita its involvement and galherin			
	ty, faculty/penticpant, and qu			
	of database of program and			
* Manage design and produ * Traffic meeting materials I	luction of all meeting materia for review and production	ls/reference bind	ers including bios	
* Arrange for honoraria	sa tarion and production			
* Grant/Needs development				
*Reconciliation managemer * Certification collaboration	ent i (joint sponsorship, compliai	nce review. Alber	f Finstein liaison)	
* Internal CME compliance				
Content Development/Edi Includes:	itorial/Creative Fee			\$35,250.0
* Develop learning objective	'es			
*Collaboration with faculty	on agenda and discussion g		nt	
1 * Collaborate with faculty or	n discussion guide for teleco	onference calls		
3				
* Liaise with presenters (cha * Editorial/copy editorial revi	•			
Liaise with presenters (cha Editorial/copy editorial revi Development of program I		development		\$67,250.0
Liaise with presenters (cha Editorial/copy editorial revi Development of program I All costs associated with in	logo meeting content design and			₽ ∪1,∠3U.U
Liaise with presenters (cha Editonal/copy editonal revi Development of program I All costs associated with n FEE TOTAL				
*Liaise with presenters (che *Editional/copy editional rev 'Development of program it 'All costs associated with in FEE TOTAL GRAND TOTAL				\$118,050.00
*Liaise with presenters (chi *Editonal/copy editonal revi *Development of program I *All costs associated with in FEE TOTAL			···	\$118,050.00

a formula trace thought take the solution of a separate that are not the contractions



Renging to San Betaran in action and Practice



The University Heaptial and Acidemic Medical Cercus for the About Executations of Medicine

Albert Einstein and Asante Communications **Full-Day Regional Meeting** New York, NY DESCRIPTION / ASSUMPTIONS COST **TOTAL COST** CATEGORY GENERAL-OOP Persons Course Director Honorarium \$3,500 \$3,500 Chair Honorarium \$2,500 \$2,500 Faculty Honoraria \$2,000 \$8,000 \$14,000.00 TOTAL \$9,500.00 Albert Einstein Accreditation and Certificate Fee Albert Einstein Outcomes Measurement Fee \$3,500.00 LOGISTICS + OOP Hotel Accommodations Room & Tax Persons Nights To Include Faculty \$275 \$1,650 6 1 \$275 Accreditor 1 \$275 Asante \$275 3 1 \$825 Additional \$275 2 \$550 1 Suppliers TOTAL \$3,300.00 Airfare Fare & Tax Persons Service To Include. Faculty \$600 6 Coach \$3,600 Accreditor \$600 1 Coach \$600 Asante \$600 0 Coach \$0 Additional 2 Suppliers \$600 Coach \$1,200 TOTAL \$5,400.00 **Ground Transportation** Fare & Tax Persons Service To Include: Faculty \$300 \$1,800 6 Sedan Accreditor \$100 \$100 Тахі Asante \$100 3 Тахі \$300 Additional Suppliers \$100 \$200 Taxi \$2,400.00 TOTAL Expenses Rate Persons To Include: Faculty \$100 6 \$600 Accreditor \$100 1 \$100 Asante \$100 3 \$300 Additional Suppliers \$100 \$200 \$1,200.00 TOTAL Cost/Tax/ Persons/ Number of Food and Beverage Gratuity Quantity **Functions** Continental To Include. Breakfast \$40 100 \$4,000 Lunch 100 \$5,500 \$55 1 Break \$30 100 \$3,000

250 Broductive Venue drow, NA 1047 Proxi 7880206674 Proxi 38 (26 25) meetro of 2 cmetamoretore of

1

1

\$1,000

\$250

\$13,750.00

\$750.00

\$50.00

\$100.00

\$0.00

Faculty Dinner

On-site Slide

Review

Meeting Room(s) Rental

Gratuities (Hotel Staff)

On-Site Telephone/Fax

On-Site Internet Connection

Business Center

\$100

\$250

\$750

\$50

\$100

\$750

\$750

10





the Constant Boptal and Year nor Medical Construction Anest presence Colored Medicin

		•			
4,1	٠,	r;			
,	4,	500	٠,	10 30	
01 J	×,°	i		ji.ver.	ť

TOGUCUOTI/T	rinting					
Reference Gu	ide		\$ 30	100		\$3,000.0
			Quantity	Design		
Services	Printing of syllal	hile				
Include	(includes printin		i			
	assembly charg]	1		
	Agenda, Particip		Į į		,	
	Faculty List, col		1		İ	
	evaluations, etc	:)	125	4-Color	\$5,250	<u> </u>
	Printing of self-r	nailer, wafer-				
	sealed invitation	1	8,500	4-Color	\$2,750	
					TOTAL	\$8,000.
	e Badges, Tent	Cards				\$1,375.
ens, Pads						\$250.
ostage for Ir						\$2,500.
	neeting materials					\$250.
SCIENTIFIC	COMMUNICAT	IONS - OO	P	10 V		
THE PART OF THE PA	earch (articles/p	ALUENDA PROPERTY AND ADDRESS OF THE PARTY OF				\$750.
	AL = 00P	7	- A	3 400001 20 100 100 100 100 100		
	All equipment for					\$5,000.
TOOLS OF A MARKET WAS AND ADDRESS OF THE PARTY OF THE PAR	pervisor/Suppor		to the same of the	4 - 1		\$1,500.
	EOUS - OOP					
	Shipping (facult			ipping)		\$250.
	cruitment tactics	/purchase I	ists			\$5,000.
Meeting Plani						\$7,000.
Creative, Des	ign, and Layout					\$7,000.
						\$1,500.
Transcription Miscellaneou	s expenses					\$250.
Miscellaneou OOP TOTAL	s expenses					\$250. \$97,575.
Miscellaneou OOP TOTAL FEES	s expenses				5742.	\$250. \$97,575.
Miscellaneou OOP TOTAL FEES Management	s expenses	1, 201		(<u> </u>		\$250. \$97,575.
Miscellaneou OOP TOTAL FEES Management Includes:	s expenses Fee		- 10/A998		n Thatean	\$250. \$97,575.
Miscellaneou OOP TOTAL FEES Management ncludes:	s expenses		. S. 4. 19. S.			\$250. \$97,575.
Miscellaneou OOP TOTAL FEES Management Includes: * Timeline dev	s expenses Fee	tenance	(\$,21¢)(1995).			\$1,500. \$250. \$97,575.
Miscellaneou OOP TOTAL FEES Management Includes: * Timeline dev "Manage inten	s expenses Fee elopment & main	tenance lect flow		5.132.005		\$250. \$97,575. \$25,000.
Miscellaneou OOP TOTAL FEES Management Includes: * Timeline dev "Manage inten	s expenses Fee elopment & main	tenance lect flow		5.132.005	trons, final and welco	\$250. \$97,575. \$25,000.
Miscellaneous OOP TOTAL FEES Management Includes: * Timeline dev "Manage intent * Coordinate fa	s expenses Fee elopment & main nal team and pro aculty invitational	tenance lect flow process incl	uding invitatio	ons, confirma	tions, final and welco	\$250. \$97,575. \$25,000.
Miscellaneous OOP TOTAL FEES Management includes: * Timeline dev Manage intent * Coordinate fa * Manage attei	s expenses Fee elopment & main nal team and pro, aculty invitational	tenance ject flow process inclu process inclu	uding invitatio	ons, confirma ons, confirma	tions, final and welco tions, final logistical	\$250. \$97,575. \$25,000.
Miscellaneous OOP TOTAL FEES Management ncludes: * Timeline dev Manage intent * Coordinate fa * Manage attel * Oversee coo	s expenses Fee elopment & main nal team and pro, aculty invitational ndee recruitment rdination of venu	tenance ject flow process inclu process inclu e selection, r	uding invitatio uding invitatio negotiation ar	ons, confirma ons, confirma nd contracting	tions, final and welco tions, final logistical	\$250. \$97,575. \$25,000. ome packets information
Miscellaneous OOP TOTAL FEES Management includes: * Timeline dev *Manage inten * Coordinate fa * Manage attei * Oversee coo * Oversee all ti	s expenses Fee elopment & main nal team and pro, aculty invitational ndee recruitment rdination of venu ravel, hotel, grou	tenance lect flow process incli process incli e selection, r nd transporte	uding invitatio uding invitatio negotiation ar ation, food fui	ons, confirma ons, confirma nd contracting nctions and A	tions, final and welco tions, final logistical i V both pre-meeting s	\$250. \$97,575. \$25,000. ome packets information
Miscellaneous OOP TOTAL FEES Management includes: * Timeline dev *Manage intent * Coordinate fa * Manage attel * Oversee coo * Oversee all ti * Manage all o	s expenses Fee elopment & main nal team and pro, aculty invitational indee recruitment rdination of venu ravel, hotel, grou in-site operations	tenance lect flow process incli process incli e selection, r nd transporta of the progra	uding invitatio uding invitatio negotiation ar ation, food fui am including	ons, confirma ons, confirma nd contracting nctions and A registration a	tions, final and welco tions, final logistical i V both pre-meeting s	\$250. \$97,575. \$25,000. ome packets information
Miscellaneous OOP TOTAL FEES Management includes: * Timeline dev *Manage inten * Coordinate fa * Manage attel * Oversee coo * Oversee all te * Manage all o * Manage desi	s expenses Fee elopment & main nal team and pro, aculty invitational ndee recruitment rdination of venu ravel, hotel, grou in-site operations gn and productio	tenance ject flow process incling process incling e selection, in the transporte of the progra	uding invitation uding invitation negotiation ar ation, food fur am including ung materials	ons, confirma ons, confirma nd contracting nctions and A registration a	tions, final and welco tions, final logistical i V both pre-meeting s	\$250. \$97,575. \$25,000. ome packets information
Miscellaneous DOP TOTAL FEES Management ncludes: * Timeline dev * Manage inten * Coordinate fa * Manage attei * Oversee coo * Oversee all ti * Manage desi participant har	s expenses Fee elopment & main nal team and pro, aculty invitational indee recruitment rdination of venu ravel, hotel, grou in-site operations ign and production indouts, badges, to	tenance ject flow process incli e selection, r nd transporta of the progra in of all meeti ent cards, etc	uding invitation uding invitation negotiation ar ation, food fur am including ing materials c.	ons, confirma ons, confirma nd contracting nctions and A registration a	tions, final and welco tions, final logistical i V both pre-meeting s	\$250. \$97,575. \$25,000. ome packets information
Miscellaneous DOP TOTAL FEES Management ncludes: * Timeline dev *Manage inten * Coordinate fa * Manage attei * Oversee coo * Oversee all ti * Manage desi participant har * Traffic meetii	s expenses Fee elopment & main nal team and pro, aculty invitational indee recruitment rdination of venu ravel, hotel, grou in-site operations ign and production indouts, badges, to	tenance ject flow process incli e selection, r nd transporta of the progra in of all meeti ent cards, etc	uding invitation uding invitation negotiation ar ation, food fur am including ing materials c.	ons, confirma ons, confirma nd contracting nctions and A registration a	tions, final and welco tions, final logistical i V both pre-meeting s	\$250. \$97,575. \$25,000. ome packets information
Miscellaneous OOP TOTAL FEES Management ncludes: * Timeline dev * Manage inten * Coordinate fe * Oversee all t * Manage all o * Manage desi poarticipant har * Traffic meelit * Arrange for h	Fee elopment & main nal team and pro, aculty invitational indee recruitment rdination of yenu in-site operations gin and production adouts, badges, to ing materials for re	tenance ject flow process incli e selection, r nd transporta of the progra in of all meeti ent cards, etc	uding invitation uding invitation negotiation ar ation, food fur am including ing materials c.	ons, confirma ons, confirma nd contracting nctions and A registration a	tions, final and welco tions, final logistical i V both pre-meeting s	\$250. \$97,575. \$25,000. ome packets information
Miscellaneous OOP TOTAL FEES Management ncludes: * Timeline dev * Manage inten * Coordinate fe * Menage attee * Oversee all t * Manage dist > antique attee * Timeline dev * Timeline dev * Manage attee * Oversee all t * Manage desi > participant har * Traffic meetif * Arrange for h * Grant/Needs	Fee elopment & main nal team and pro, aculty invitational indee recruitment rdination of venu ravel, hotel, grou in-site operations ground production adouts, badges, to ing materials for re ionoraria development	tenance ject flow process incli e selection, r nd transporta of the progra in of all meeti ent cards, etc	uding invitation uding invitation negotiation ar ation, food fur am including ing materials c.	ons, confirma ons, confirma nd contracting nctions and A registration a	tions, final and welco tions, final logistical i V both pre-meeting s	\$250. \$97,575. \$25,000. ome packets information
Miscellaneous DOP TOTAL FEES Management ncludes: Timeline dev Manage intent Coordinate fa Manage attet Oversee all ti Manage all o Manage all o Manage fest Traffic meetur Arrange for h Grant/Needs Reconciliation	Fee elopment & main nal tearn and pro, acuity invitational indee recruitment rdination of venu ravel, hotel, grou in-site operations ign and productio ing materials for in incororana development in management	tenance lect flow process inclusion process incl	uding invitation negotiation ar ation, food fui am including ing materials c. roduction	ons, confirma ons, confirma nd contracting nctions and A registration a including	tions, final and welco tions, final logistical o V both pre-meeting a rea	\$250. \$97,575. \$25,000. ome packets information
Miscellaneous DOP TOTAL FEES Management ncludes: Timeline dev Manage intent Coordinate fa Manage attet Oversee all ti Manage all o Manage all o Manage for h Traffic meetit Arrange for h Grant/Needs Reconciliation Certification	Fee elopment & main mal tearn and pro, acuity invitational modee recruitment rdination of venu ravel, hotel, grou in-site operations ign and productio ing materials for in the monorana development in management collaboration (join	tenance lect flow process inclusion process incl	uding invitation negotiation ar ation, food fui am including ing materials c. roduction	ons, confirma ons, confirma nd contracting nctions and A registration a including	tions, final and welco tions, final logistical o V both pre-meeting a rea	\$250. \$97,575. \$25,000. ome packets information
Miscellaneous DOP TOTAL TEES Management Includes: Timeline dev Manage intent Coordinate fa Manage attel Oversee all ti Manage all o Manage desi Darticipant har Traffic meetur Arrange for h Grant/Needs Reconciliation Certification Internal CME	Fee elopment & main nal tearn and pro aculty invitational indee recruitment rdination of venu ravel, hotel, grou in-site operations ign and productio idouts, badges, to ing materials for re inconoraria development in management collaboration (join Ecompliance	tenance lect flow process inclusion of the program of all meet, eview and profits sponsorships of the program of the program of all meet, ent cards, etc.	uding invitation negotiation ar ation, food fui am including ing materials c. roduction	ons, confirma ons, confirma nd contracting nctions and A registration a including	tions, final and welco tions, final logistical o V both pre-meeting a rea	\$250. \$97,575. \$25,000. prine packets information and onsite
Miscellaneous DOP TOTAL TEES Management Includes: Timeline dev Manage intent Coordinate fa Manage attel Oversee all ti Manage all o Manage desi Darticipant har Traffic meetur Arrange for h Grant/Needs Reconciliation Certification Internal CME	Fee elopment & main mal tearn and pro, acuity invitational modee recruitment rdination of venu ravel, hotel, grou in-site operations ign and productio ing materials for in the monorana development in management collaboration (join	tenance lect flow process inclusion of the program of all meet, eview and profits sponsorships of the program of the program of all meet, ent cards, etc.	uding invitation negotiation ar ation, food fui am including ing materials c. roduction	ons, confirma ons, confirma nd contracting nctions and A registration a including	tions, final and welco tions, final logistical o V both pre-meeting a rea	\$250. \$97,575. \$25,000. ome packets information
Miscellaneous DOP TOTAL TES Management Includes: Timeline dev Manage intent Coordinate fa Manage atter Oversee all ti Manage all o Manage all o Manage desi Darticipant har Traffic meetur Grant/Needs Reconculation Certification Internal CME Content Deve	Fee elopment & main nal team and proj aculty invitational indee recruitment rdination of venu ravel, hotel, grou in-site operations gin and production indouts, badges, to fing materials for in adevelopment in management collaboration (join compliance elopment/Editori	tenance lect flow process incli e selection, r nd transporta of the progra in of all meeti ent cards, et eview and pri nt sponsorshi al Fee	uding invitation and invitation and including including ing materials conduction	ons, confirma ons, confirma nd contracting nctions and A registration a including e review, Alb	tions, final and welco tions, final logistical I V both pre-meeting a rea	\$250. \$97,575. \$25,000. some packets information and onsite \$28,000.
Miscellaneous DOP TOTAL TES Management Includes: Timeline dev Manage intent Coordinate fa Manage atter Oversee all ti Manage all o Manage desi Narticipant har Traffic meetin Grant/Needs Reconcilation Certification Internal CME Content Deve	Fee elopment & main nal team and proj aculty invitational indee recruitment rdination of venu ravel, hotel, grou in-site operations gin and production indouts, badges, to ing materials for in an development in management collaboration (join compliance	tenance lect flow process incli e selection, r nd transporte of the progra in of all meeti ent cards, etc eview and pri al Fee aming objecti	uding invitation and invitation and including including ing materials conduction	ons, confirma ons, confirma nd contracting nctions and A registration a including e review, Alb	tions, final and welco tions, final logistical o V both pre-meeting a rea	\$250. \$97,575. \$25,000. some packets information and onsite \$28,000.
Miscellaneous DOP TOTAL FES Management ncludes: Timeline dev Manage intent Coordinate fe Manage attel Oversee coo Oversee all ti Manage all o Manage desi Participant har Traffic meetil A Grant/Needs Reconciliation Cortification Internal CME Content Deve ncludes: Collaborate v Collaborate v	Fee elopment & main nal team and pro aculty invitational ndee recruitment rdination of venu ravel, hotel, grou in-site operations gin and production douts, badges, to ging materials for in ionoraria development collaboration (join compliance chopment/Editori with faculty on lea with faculty on pre-	tenance lect flow process incli e selection, r nd transporte of the progra in of all meeti ent cards, etc eview and pri al Fee arming objecti esentations	uding invitation and invitation and including and including and including and including materials conduction and including page of the compliance fives, agenda	ons, confirma ons, confirma nd contracting nctions and A registration a including e review, Alb	tions, final and welco tions, final logistical I V both pre-meeting a rea	\$250. \$97,575. \$25,000. some packets information and onsite \$28,000.
Miscellaneous DOP TOTAL FEES Management ncludes: * Timeline dev Manage inten * Coordinate fa * Manage attee * Oversee coo * Oversee all t * Manage desi participant har * Traffic meetin * Arrange for h * Grant/Needs * Reconciliation * Cortification * Cortification * Internal CME Content Deve ncludes: * Collaborate v * Liaisc with fa	Fee elopment & main nal team and proj aculty invitational indee recruitment radination of venu ravel, hotel, grou in-site operations gin and production indouts, badges, to ing materials for in conoraria development in management collaboration (joir compliance inopment/Editori with faculty on lea with faculty on pre- inculty and incorpo-	tenance lect flow process incli e selection, r nd transporte of the progra in of all meeti ent cards, etc eview and pri al Fee arming objecti esentations orate faculty of	uding invitation and invitation and including and including and including and including materials concompliance fives, agenda comments	ons, confirma ons, confirma nd contracting nctions and A registration a including e review, Alb and discussion	tions, final and welco tions, final logistical I V both pre-meeting a rea	\$250. \$97,575. \$25,000. some packets information and onsite \$28,000.
Miscellaneous DOP TOTAL FEES Management ncludes: Timeline dev Manage inten Coordinate fe Manage attee Oversee colo Manage desi Participant har Traffic meetil Arrange for he Grant/Needs Reconciliation Cortification Internal CME Content Deve ncludes: Collaborate w Collaborate w Liurse with ac	Fee elopment & main nal team and proj aculty invitational nidee recruitment ravel, hotel, grou nn-site operations gin and production adouts, badges, ti ng materials for in control of team collaboration (join compliance elopment/Editori with faculty on lea with faculty on pro- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo-	tenance ject flow process incline selection, in nd transportation of the program of all meeting entities and process in the program of all meeting entities and process and process are secretations or the faculty of prograte accretisms.	uding invitation and invitation and including and including and including and including materials conduction and including materials comments are ditor comments are ditor comments.	ons, confirma ons, confirma nd contracting nctions and A registration a including e review, Alb and discussion	tions, final and welco tions, final logistical I V both pre-meeting a rea	\$250. \$97,575. \$25,000. some packets information and onsite \$28,000.
Miscellaneous OOP TOTAL FEES Management ncludes: * Timeline dev * Manage inten * Coordinate fe * Manage attee * Oversee all to * Manage all to * Manage desi * Darticipant har * Traffic meetil * Arrange for he * Grant/Needs * Reconciliation * Certification * Internal CME Content Deve	Fee elopment & main nal team and proj aculty invitational indee recruitment rdination of venu ravel, hotel, grou in-site operations gra and production adouts, badges, to ing materials for re ionoraria development in management collaboration (join compliance elopment/Editori with faculty on lea with faculty on pra ioulty and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo-	tenance lect flow process inclusive selection, rund transporte of the progra on of all meeticent cards, etc eview and pro- al Fee aming objectic esentations orate faculty of proprate accrument flow	uding invitation and invitation and including and includin	ons, confirma ons, confirma nd contracting nctions and A registration a including e review, Alb and discussion	tions, final and welco tions, final logistical I V both pre-meeting a rea	\$250. \$97,575. \$25,000. some packets information and onsite \$28,000
Miscellaneous DOP TOTAL FEES Management ncludes: Timeline dev Manage inten Coordinate fa Manage attee Oversee all ti Manage all to Manage all to Manage all to Manage all to Manage all to Manage desi Manage atte	Fee elopment & main nal team and proj aculty invitational nidee recruitment ravel, hotel, grou nn-site operations gin and production adouts, badges, ti ng materials for in control of team collaboration (join compliance elopment/Editori with faculty on lea with faculty on pro- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo-	tenance lect flow process inclusive selection, rund transporte of the progra on of all meeticent cards, etc eview and pro- al Fee aming objectic esentations orate faculty of proprate accrument flow	uding invitation and invitation and including and includin	ons, confirma ons, confirma nd contracting nctions and A registration a including e review, Alb and discussion	tions, final and welco tions, final logistical I V both pre-meeting a rea	\$250. \$97,575. \$25,000. pome packets information and onsite \$28,000
Miscellaneous DOP TOTAL FEES Management ncludes: Timeline dev Manage inten Coordinate fe Manage attee Oversee call to Manage all to Manage desi Manage desi Manage desi Manage desi Manage desi Manage desi Manage for he Grant/Needs Reconciliation Certification Internal CME Content Deve	Fee elopment & main nal team and proj aculty invitational indee recruitment rdination of venu ravel, hotel, grou in-site operations gra and production adouts, badges, to ing materials for re ionoraria development in management collaboration (join compliance elopment/Editori with faculty on lea with faculty on pra ioulty and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo- coreditor and incorpo-	tenance lect flow process inclusive selection, rund transporte of the progra on of all meeticent cards, etc eview and pro- al Fee aming objectic esentations orate faculty of proprate accrument flow	uding invitation and invitation and including and includin	ons, confirma ons, confirma nd contracting nctions and A registration a including e review, Alb and discussion	tions, final and welco tions, final logistical I V both pre-meeting a rea	\$250. \$97,575. \$25,000. some packets information and onsite \$28,000.

2501 Band ontge Wenne, Brans NY In Pr. — Prose 718 regrent 4 — I vs. 25 f. be., 5 from mercus org. — emos monochore org



Bridging "e Gap Reserve Education and Practice"



More to store
to diego at Medip 199
ed freshe at Judentally


The Lemensus Hospital and Academic Mode al Corner furthe Adaest Europes violeze of Memorine

		L					
	Albe	rt Eins	tein an	id Asar	nte Communic	ations 🔝	
			Sate	llite W	ebCast		-
DESCRIPTION /	th have a star of the state of	ASSUMP	IONE	MANAGEMENT OF THE STREET	COST		TOTAL COST
CATEGORY							IOTAL COST
GENERAL - O)P	ACAT CANADAST AND ASSESSMENT	V- (38 - 194 - 194 - 194 - 194 - 194 - 194 - 194 - 194 - 194 - 194 - 194 - 194 - 194 - 194 - 194 - 194 - 194 -	44.0			
	· · · · · · · · · · · · · · · · · · ·	Rate	Persons			,	
Course Director		\$2,500	1		\$2,500	4	1
Chair Honorariu	ım	\$2,500	1		\$2,500	,	* 5 000 00
Alband Finadala			4		TOTAL	·	\$5,000.00 \$9,500.00
Albert Einstein							\$3,500.00
Albert Einstein					- 10 <u>1</u> 10 1		
MATERIALS -			<u></u>				
Production/Prin	Company of the Compan						
1	g		Quantity	Design			
	rinting of self-ma	der wafer-				1	
	ealed invitation, F			l		1 1	1
	nd Awareness C]	
	ledscape and Pa		10,000	4-Color	\$3,500		
	200 0 4 10 7 10 800000	A. T A A. A	Contract to the second	F-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1		*	\$60,000.00
Webification (website e	g. Pain.edu)		\$5,000.00
Additional awar		ruitment tac	ncs				\$7,000.00
Creative, Design	n, and Layout						\$2,000.00
Transcription Postage							\$1,500.00
OOP TOTAL			•				\$93,500.00
					100 mg/m		AND THE RESIDENCE OF THE OWNER, THE PARTY OF
Management Fe	management of the property of the	* 1. Kittinghaller (47.52)	753 304 - 7.50	S.C. 1989 J.S. 1. 1. 142			\$20,000.00
Includes:	·						
* Timeline develo	opment & maint	tenance					
*Manage internal	team and proj	ect flow					
* Manage attend	ee recruitment	process incli	ıdına ınvitatı	ons. confirma	ations, and awareness cam	paign	
* Manage design			=				
* Traffic meeting				ngri and wed	Scape Liaison		
* Arrange for hor		renow and pro					
* Grant/Needs de							
*Reconciliation n	nanagement						
* Certification col	llaboration (join	it sponsorshi	o, compliand	e review, Alb	ert Einstein Iraison)		
* Internal CME c	ompliance						<u></u>
Content Develo	pment/Editoria	al Fee					\$20,000.00
Includes:							
l .	•		∕es, agenda	and discussi	on guide development		
* Collaborate with							
* Liaise with facu	,	•		,			
* Liaise with acci				ents			
* Editorial/copy e			-				
* All costs associ	iatea with meet	ung content o	ieveiopment				\$40,000.00
I LE TOTAL	 -				-		\$40,000.00
CRAND TO	TAI						1133 500 00
GRAND TO	IAL						133,500.00

Reference Guide

2013 Suidentee Active Brook NA 2040 — Press ASSUMECTA — Exc. 718-756 2450 — mechasists — cinctinionic tore org

Chronic Pain Management Preceptorship (CPMP)



*DOE= Durable Outcomes Evaluation

**Control Group for Stage II includes 150 participants from other educational initiatives that do not participate in CPMP





TEVA_MDL_A_00850052 P-28694 00092

Persistent and Breakthrough Supported Medical Education Initiatives 2009

											4.	
en de la companya de la companya de la companya de la companya de la companya de la companya de la companya de La companya de la co				PRISA				negat	MAN.			WB.
International Experts Forum	Live Event	30	+	> ♦		•						
Cases and Commentary	Live Event	225	+	→ (*		•					
Full-Day Regional Meeting	Live Event	75-100	4	→ (
Teleconference Series	Live Event	200-400	-		→ ♦							
Cases and Commentary Print Monograph/Online	<i>PMN News</i> PainClinician Pain.edu	45-60,000						-	>	•		
Full-Day Regional Satellite Webcast	International Forum for Pain Experts Pain.edu	20-25,000		4		•						
Teleconference Print Monogrpaph/Online	<i>PMN News</i> PainClinician Pain.edu	45-60,000			•	>	•					
Pain/Risk Management Compendium	<i>PMN News</i> PainClinician Pain.edu	45-60,000		+		•						
International Experts Forum Position Paper/Online	<i>PMN News</i> PainClinician Pain.edu	45-60,000			•	-	•					
Preceptorship Program		300	—				+			+		+







of Vestion Lincois is

Center for Continuing Medical Education

Bridging the Gap Between Education and Practice"



The University Hospital and Academic Medical Center for the Albert Earstein College of Medicine

In order to review your grant request #2569, Cephalon requires the following additional information:

1. Please explain how HCPs for the outcomes study will be recruited for the Stage I.

The participants for the Stage I outcomes study will be recruited through the live educational initiatives proposed in the grant—namely, the *Cases and Commentary* Workshops, Teleconference Series, Full-day Regional Meeting and potentially the International Expert Forum. The latter will be a closed, invitation only meeting that will be held at the 2009 American Pain Society meeting in San Diego, pending availability of select thought leaders.

2. Will the WebPanel series be accredited?

Yes. The quarterly WebPanel series is a component of the Chronic Pain Management Preceptorship (n=~200, pending approval of proposed activities) and will be accredited through Albert Einstein College of Medicine. Of note, participants will complete a Durable Outcomes Evaluation (DOE)* Stage II structured questionnaire upon completion of the WebPanel series. The questionnaire will measure the evolution of thought and practice since completion of the DOE Stage I questionnaire, as measured against control clinicians who limited their education to an enduring material and/or live event and who did not participate in the Preceptorship (Stage II) WebPanel. Notably, clinicians who chose not to participate in the preceptorship, and who have otherwise successfully completed at least one post-test from any of the educational initiatives (Live, Print, and/or Online), may participate in the WebPanel series. Their educational outcomes will not, however, contribute to the DOE Stage II outcomes, which is restricted to preceptorship clinicians only.

3. How will participants be incentivized to participate in the outcomes study?

Incentivization is largely based on the opportunity to participate in a novel educational outcomes study, the results from which will likely be published in a peer-reviewed journal. Requirements will be minimally time consuming. Clinicians attending the live educational initiatives will necessarily complete a structured questionnaire before and after the event, and will therefore provide DOE Stage I study data. After completing the pre-post questionnaire, participants will confirm their interest in joining the Chronic Pain Management Preceptorship, comprising a quarterly WebPanel series facilitated by expert pain clinicians. Preceptorship clinicians (DOE Stage II participants) will have an opportunity to collaborate with their peers and thought leaders during the WebPanel series. In addition, preceptorship clinicians will be invited to a closed, invitation-only International Expert Forum (See Question 1). Qualified clinicians may also serve as adjunct faculty for activities that may be held in 2010, pending evaluation by program faculty

4. Is the preceptorship a separate activity to the outcomes study? How will participants be recruited for this activity?

Preceptorship participants will be required to complete a Stage II structured questionnaire, providing data on the durability of high level outcomes when integrated within an ongoing educational series. Preceptorship participants will be recruited during the registration period through e-mail

1391 Rambridge Normic Brons, NY 10467 — Pearl 548 954 6674 — Fix 718 798 2356 — inceme org — emet montefiore org

correspondence, and during one of the live events—teleconference call, *Cases and Commentary* workshop and/or full-day regional meeting—that they are required to complete.

The RFP stated that the proposal could cover educational events at national meetings, however none is proposed. Please clarify.

Pending availability of the expert pain clinicians, the International Pain Expert Forum may take place at a selected National Congress, currently planned to be held at the American Pain Society (APS; May 2009, San Diego). Preceptorship participants who attend the American Pain Society at their own cost and discretion will be invited to this closed, invitation-only satellite (off-agenda) live event.

In addition, as a point of clarification, we are planning to hold at least one of the *Cases and Commentary* programs will be held immediately before or after the APS in May 2009 and/or a Regional Chronic Pain meeting (e.g.; **Emerging Practices in Opioid Prescribing for Chronic Pain,** March 2009).

6. Please clarify the types of HCPS that may take part in the cases workshops.

HCPs that will be recruited to take part in the *Cases and Commentary* workshops are pain clinicians, including, among others, neurologists, psychiatrists, anesthesiologists, oncologists, rheumatologists, psychologists, and other general practitioners with an interest in pain management.

7. Please clarify PainClinician (TM). Is this a quarterly newsletter?

PainClinician™ is a proprietary component of a larger educational initiative, *The International Chronic Pain Forum*™, to be formally launched in Q1 2009. The PainClinician quarterly newsletter will drive program recruitment, advertisements, and distribution of accredited pain enduring materials. Our *PainClinician*™ internal database currently includes thousands of practicing pain clinicians who have participated in previous accredited programs, CSNA surveys, or have otherwise expressed an interest in pain education.

8. Please clarify how you will recruit for the teleconferences and satellite webcasts.

Recruitment efforts for the Teleconference and Webcasts will be multifaceted. Reliable tactics include extending invitations to clinicians in our proprietary *PainClinician*™ database, to clinicians identified by the Albert Einstein College of Medicine and to the membership of American Academy of Pain Medicine (AAPM), APS and other medical congresses; announcing the programs in relevant print journals, (e.g., *Pain Medicine News, the Journal of Pain, PainClinician)*, and on selected pain-related websites (e.g., WebMD, pain.edu, International Chronic Pain Forum, etc.).

9. Is the literature surveillance included in the grant costs?

The Literature Surveillance program, including monthly written summaries, as detailed in the grant is not included in the total grant costs. However, the Albert Einstein College of Medicine working collaboratively with Asante routinely forwards to the grant supporters select articles from peer-reviewed journals and related reference materials, all of which are relevant to the educational objectives of the proposed grant initiatives.

3301 Bambridge Avenue, Bronx, N.Y. 10467 PRONE 718 920.6674 FAX 718.798 2336 mecinc.org cmc/e-montefiorc.org

10. Please include a timeline of when activities will be disseminated.

Please see attached.

11. Additional Information:

Proposed Payment Schedule: If Albert Einstein College of Medicine is fortunate enough to have its grant approved, the proposed payment schedule is 1/3 of program costs upon LOA acceptance, 1/3 of program costs at a time point identified as approximately 50% through the completion of the grant, and the remaining 1/3 payment during the last 1/3 of the scheduled program completion.

 $3301 \; Bainbridge \; Avenue, \; Brons, \; N.S. \; 10467 \qquad \; Prove \; 718.920.6674 \qquad \; Frv. \; 718.798.2336 \qquad \; mecme.org \qquad eme@inontetrore.org$





a talango Si kapenta di kamasa di nata di kamasa di kama

DESCRIPTION / CATEGORY	ASSUMP	TIONS		cost		TOTAL COST
GENERAL - OOP		M-1		and the second second		
	Rate	Persons				
Course Director	\$2,500	1				\$2,500
Faculty Honoraria ACCREDITATION FEE	\$1,500	4				\$6,000
						**
Albert Einstein Accreditation an		ee				\$9,500
Albert Einstein Outcomes Measi	urement Fee					\$3,500
LOGISTICS - DOP				gradient of the street.		
	Cost/Tax/	Persons/	Number of			MARKET CONTRACTOR
Food and Beverage To Include Breakfast(s)	Gratuity \$40	Quantity 10	Functions 1	\$400		
To molado Broanido(o)	Ψ40		· · · · ·	TOTAL		\$400
MATERIALS-OOP	100			and surface of the		
	0	DI				
	Quantity	Design			 	
Production & Printing of						
Position Paper	35.000	4-Color		\$10,800		
Pain Clinician Postage Cost	35,000	n/a		\$11,000		
Purchase Mailing	35,000	1//4	<u>. </u>	<u>Ψ11,000</u>		
Lists AAPM/APS				\$4,000		
				Total	\$25,800.00	
ONLINE CONTENT - OOP		14.7				
ONLINE GOITE III						
Webification of enduring materia	als				\$5,000.00	
Purchase artwork						\$750
SCIENTIFIC COMMUNICATION References/Permissions	NS - OOP		n lei			\$750
			er al e			V 100
Teleconference - OOP			1.1			
Intercall Teleconference Charge	5	_				\$1,000
Transcription Services MISCELLANEOUS - DOP	menicana (1981)	NAC A CONTRACT				\$1,500
Express Mail Shipping (faculty r	1000 Carrier Co. 1 2 2 7 20 1	130737474044 111044			100 mg/mg/mg/mg/mg/mg/mg/mg/mg/mg/mg/mg/mg/m	\$250
OOP TOTAL	g =,ac					\$56,950
FEES	v.			<u> </u>		
Management Fee						\$18,000
Includes: * Timeline development & mainten						







water a Again to

And man Medical Control for the And one Medical Control for the Annual Control of the Annual Control

	* Manage all aspects of program including position paper logistics and trafficking		
	* Manage all on-site needs for meetings with faculty		
enter de la companya de la companya de la companya de la companya de la companya de la companya de la companya	* Manage design and production of all materials relating to position paper		eres en ogen
	* Manage design and production of all materials relating to webification of position paper		
	* Arrange for honorana		1.0
	* Grant/Needs development		
	*Reconcilation management		
	* Certification collaboration (joint sponsorship, compliance review, Albert Einstein liaison)		
	* Internal CME compliance		40000
	Content Development/Editorial/Creative Fee	\$23,500.00	V 7/7/ /-
1.1.2	Includes:		
	* Develop learning objectives		
3.5	* Collaboration with faculty on teleconference agenda and discussion guide development	Ì	
	Manage all research associated with identification of prospective Journals for Distribution		
77 J.	Collaborate with faculty on position paper		
	Liaise with presenters (chair, faculty)		
	* Editorial/copy editorial review and formatting		
	FEE TOTAL	\$41,500.00	
			A
	GRAND TOTAL	\$98,450.00	
_ نسر_	Variance +/- 10%		
	SPECIAL NOTE:		
(- T	Any change in scope will require an approved revised budget.		- 11
	Cancellation of program will be subject to costs-to-date for all expenses and staff hours.		
a distribution of the second			



and the second s



the European Hogula ou A phone Medical Governor for the Aner European Golfon of Medical

Albert Einstein and Asante Communications Pain and Risk Management Reference Compendium DESCRIPTION **ASSUMPTIONS** COST **TOTAL COST** / CATEGORY GENERAL + OOP Persons \$1,500 Course Director Honorarium \$4,500.00 Faculty Honoraria \$1,500 2 \$9,500.00 Albert Einstein Accreditation and Certificate Fee \$3,500.00 Albert Einstein Outcome Measurement Fee MATERIALS - OOP Production/Printing Quantity Design Total Services Printing of Reference Tool for Pain Specialists and Other 35000 \$20,000 4-Color 35000 \$4.800 Printing of Envelope 4-Color TOTAL \$24,800.00 ONLINE - OOP \$10,000.00 Webification of Enduring Material SHIPPING/POSTAGE - OOP \$8,000.00 Distribution Costs to AAPM and APS Membership \$4,000.00 Pain Clinical Update Costs for Distribtution \$1,750.00 Mail house Handling Fee CREATIVE/DESIGN - OOP \$7,000.00 Creative, Design, and Layout Purchase Artwork \$250.00 SCIENTIFIC COMMUNICATIONS -OOP \$750.00 Permissions/Copyrights MISCELLANEOUS-OOP \$250.00 Misc Expenses \$74,300.00 TOTAL OOPs FEES \$22,500.00 Management Fee Timeline development & maintenance *Internal team and project management Arrange for faculty review and honoraria Traffic Reference Tool for review and production Manage design and production of reference tool Liaise with course director & faculty *Review and manage content translation into online format *Develop grant and needs assessment Certification collaboration (compliance review, Albert Einstein liaison) *Reconciliation management *Ensure internal CME compliance \$30,000.00 Content Development/Editorial Includes: Collaborate with faculty on the development of the content outline, and learning objectives Collaborate with faculty on the development of the reference tool manuscript *Liaise with faculty & incorporate faculty comments *Liaise with accreditor & incorporate comments * Editonal/copy editorial review and formatting of reference tool * All costs associated with reference tool content development \$52.500.00 TOTAL FEES \$126,800.00 GRAND TOTAL

The transity decides by the NT tops of the State of the Fred State of the continuous of the state of the stat



A musica this was between four ation and haction



The Engerous Angelol and Anderso Mostro France has the Mark Mostro France of Methods

Albert Einstein and Asante Communications **Teleconference Activity - 8 Presentations DESCRIPTION** / TOTAL COST **ASSUMPTIONS** Cost CATEGORY GENERAL-OOP Rate Persons \$2,500.00 \$2,500 Course Director Honorarium \$8,000.00 \$1,000 Faculty Honorarium (per call) TOTAL \$10,500.00 \$15,000.00 Albert Einstein Accreditation and Certificate Fee Albert Einstein Outcomes Measurement Fee \$3,500.00 PRODUCTION-OOP Design syllabus (includes printing & assembly charges for: Agenda, Participant List Faculty List, color slides, 400 4-Color \$15,000.00 Printing of self mailer, wafersealed 4-Color \$10,000.00 invitation 45,000 TOTAL \$25,000.00 SHIPPING/MAILING COST-OOP \$14,000.00 Invitation Distribution Costs \$3,250.00 Priority mail shipping of syllabus & confirmation letters to participants and faculty AUDIO VISUAL/TRANSCRIPTION-OOP \$7,500.00 Teleconference Charges (Total for 8) \$1.500.00 Transcription Services (Total for 8) SCIENTIFIC COMMUNICATION-OOF \$1,500.00 Purchase of Articles and Reprints RECRUITMENT-00P \$5,000.00 Additional recruitment tactics/Purchase lists CREATIVE/DESIGN-00P Creative, Design, and Layout OOP TOTAL \$93,250.00 FEES Management Fee (Total for 8 teleconferences) \$22,500.00 Includes: Timeline development & maintenance *Manage internal team and project flow *Arrange for faculty honoraria *Coordinate invitational process including confirmations *Develop call schedule *Coordinate with call center to insure appropriate project flow *Develop meeting materials (invites, announcement cards, syllabus, agenda, participant lisi, faculty bio list, evaluation survey) *Manage design and production of meeting syllabus *Ship meeting materials to participants & faculty *Lead and moderate 8 teleconference sessions *Develop, process and review evaluations & summary report *Liaise with internal teams, faculty, and accreditor Certification collaboration (joint sponsorship, compliance review, Albert Einstein liaison) *Develop Grants & Needs Assessment *Complete final reconciliation *Ensure internal CME compliance Content Development/Editorial (Total for 8 teleconferences) \$25,000.00

(1) When pulse shows a Branck NA (b.1) is a Physical Representation of the Association of the Property of t




he open give the Sethere Education and Practice



the statement of the section of the statement of the stat

Includes:	
* Collaborate with faculty on learning objectives, agenda and discussion guide development	
* Collaborate with faculty on presentations	
*Liaise with faculty & incorporate faculty comments	
*Liaise with accreditor & incorporate comments	
*Edit, copyedit, review and format all materials	
*Participate in teleconferences	
*Pre- and post-teleconference liaise with faculty	
FEE TOTAL	\$47,500.00
GRAND TOTAL (8 Teleconferences)	\$140,750.00

the solution was the next the State of the State of the State of the State of the solution of the solution of the State of the solution of the solution of the State of the St





A regard the confidence of marine and bringers



the Encountry doupted and Encountry Face for the March Colors of Molices

		ert Einste	Name and Address of the Owner, where		20 4 4	and the second second	ns .	
10 10		Teleconf	erence	Spin-c	TOTAL TIC	ograph		
	DESCRIPTION / CATEGORY		ASSUMPT	IONS		COST	TOTAL COST	
GEN	IERAL - OOP	L						
				D				
Com	rse Director Honora		Rate \$2,500	Persons		\$2,500		
CONTROL OF THE PROPERTY OF THE	Ity Honorarium	arium	\$1,500	2	\times	\$3,000		. 10.049.000
racu	my nonorarium		\$1,500		\sim			
Alba	-4 Fi -4-1- A11	10.00				TOTAL	\$5,500.00 \$9,500.00	
	nt Einstein Accredi rt Einstein Outcom						\$3,500.00	
	ERIALS - OOP	ies weasurement	ree				\$3,300.00	
	luction/Printing		H 1974	l		Ī		17.00
	actions thing		<u> </u>	Quantity	Design	Cost	_	
	Services Include:	Monograph					-	79 - 17 - 3 T
		Printing		45,000	4-Color	\$20,000		
						TOTAL	\$20,000.00	
SHII	PPING/MAILING	COST-OOP	a cardinate		4.			7.60
Dist	ibution Fee Pain M	ledicine News/Cli	nical Update	es/Congress	es		\$14,000.00	
Ехрг	ess Mail Shipping	(faculty mailings,	materials s	hipping)			\$200.00)
ONL	INE -OOP			, , , , , , , ,				
Web	ification of Monogr	aph					\$10,000.00)
Accessed to the contract of th	ATIVE/DESIGN-C		7			Market 1	(III. a. L. III. a. L. III.	
	tive, Design and La	ayout					\$6,500.00	Position of the Control of the Contr
	hase Artwork						\$250.00	The same of the sa
/ TOT	AL OOPs						\$69,450.00	
	8		# 7 //	22.00		* 1000		
And the second s	agement Fee						\$17,500.00)
	ides:							
	neline development							
The second secon	rnal team and Projec ordinate faculty revie	-						2.00
	ange for faculty revie	•	988					-
SIGNIFICATION TO COMPANY	ange for honoraria	sw and nonorana						
Sales and the sales are a sales and the sales are a sales are a sales are a sales are a sales are a sales are a	nage design and pro	oduction of all mate	ariale					4.0
	iffic materials for rev							
10.00	rtification collaboration			ce review. Al	bert Einstein	liaison)		
9. TANKS	aluation summary de	•				. ,		
	ant/Needs developm							A.V.
	onciliation manager							
	tent Development/f						\$25,000.00	
CONTRACTOR OF THE PROPERTY OF	tent Development i					•		
	elop learning object							
*Dev	elop outline for an 8	-page monograph						
	aborate with faculty			ograph manu	script			Land to the
	se with faculty & inc							
	se with accreditor &							
*Liai			&	I report mone	naranh			
*Liai.	torial/copy editorial i				grapn			
*Liai. * Edi * All	torial/copy editorial i costs associated wit FAL FEES						\$42,500.00	
*Liai. * Edi * All	costs associated wit						\$42,500.00	

(2) Architel Accide Priox NA 1940 — Phose TENROWTE — Pro NATA — do one are close monichore and



ignig the Gap Antheon Education and traitive



The Executary Street day and Lade the United Section 1991 the Line Executy Lade proof Model to

Albert Einstein and Asante Communications Cases and Commentary Workshop #1 DESCRIPTION / **ASSUMPTIONS TOTAL COST** CATEGORY GENERAL - OOP Rate Persons \$3.500 Course Director Honorarium \$3,500 Chair Honorarium \$2,500 \$2,500 \$2,000 5 \$10,000 Faculty Honoraria TOTAL \$16,000.00 Albert Einstein Accreditation and Certificate Fee \$9,500.00 Albert Einstein Outcome Measurement Fee \$3,500.00 LOGISTICS - COP **Hotel Accommodations** Room & Tax Persons Nights \$1,925 To Include: Faculty \$275 Accreditor \$275 \$275 \$825 Asante \$275 3 1 Additional \$550 \$275 2 Suppliers TOTAL \$3,575.00 Hotel Miscellaneous \$0.00 Airfare Fare & Tax Persons Service To Include Faculty \$600 Coach \$4,200 \$600 Accreditor \$600 Coach \$0 0 Asante \$600 Coach Additional 2 \$1,200 Suppliers \$600 TOTAL \$6,000.00 **Ground Transportation** Fare & Tax Persons Service \$2,100 To Include Faculty \$300 Sedan Accreditor \$100 \$100 Тахі \$300 Asante \$100 3 Taxi Additional \$200 2 Suppliers \$100 Taxı \$2,700.00 TOTAL Rate Persons Expenses \$700 To Include Faculty \$100 \$100 3 \$300 \$100 Accreditor \$100 Additional \$200 \$100 2 Suppliers TOTAL \$1,300.00 Cost/Tax/ Food and Beverage Gratuity Persons/ Quantity Functions Continental To Include: Breakfast \$40 \$0 \$65 70 \$4,550 Lunch 1 \$2,100 70 Break \$30 1 Faculty \$1,100 Dinner \$100 11 On-site Slide Review \$250 \$250 TOTAL \$8,000.00 \$750.00 Meeting Room(s) Rental \$750 1 Gratuities (Hotel Staff) \$100 \$100.00 \$750.00 On-Site Telephone/Fax \$750 \$750.00 On-Site Internet Connection \$750 MATERIALS - OOP Production/Printing

1994 December School Drieg Schools, and The Schools and Fast as the control of the control of the control of the

Design

Quantity



The second secon



to twistification with \$ \propto \frac{1}{2}

						•
	GRAND TOTAL				\$153,250.00	
	FEE TOTAL		-		\$57,500.00	
	* All costs associated with meeting content develo	pment	·			ang.
	* Editorial/copy editorial review and formatting	20111101110				
	Liaise with racuity and incorporate racuity commends. * Liaise with accreditor and incorporate accreditor.					
	* Collabcrate with faculty on presentations * Liaise with faculty and incorporate faculty comm	ente				77.00
	* Collaborate with faculty on learning objectives, a	igenda and discu	ission guide de	velopment		
	Includes:					
	Content Development/Editorial Fee				\$31,500.00	
	* Internal CME compliance				******	
	* Certification Collaboration (joint sponsorship, co.	mpliance review,	Albert Einstein	liaison)		3.77
Y 77	*Reconciliation management					
	* Grant/Needs development					
	* Arrange for honoraria					C1669
7 : 4	* Traffic meeting materials for review and product	on				
	participant handouts, badges, tent cards, etc	_				- 1
	* Manage design and production of all meeting ma	aterials including				STATE OF
	* Manage all on-site operations of the program inc	luding registratio	n area			
47.	* Oversee all travel, hotel, ground transportation,			meeting and onsite		
	* Oversee coordination of venue selection, negotia					
	* Manage attendee recruitment process including			ogistical information		
	* Coordinate faculty invitational process including	invitations, confil	rmations, final a	and welcome packets		
	манаус плоттапсать ани project now					11.
	*Manage internal team and project flow					
M.E.	* Timeline development & maintenance					
	Includes:				422,003100	
	Management Fee		H17 H	25.25.25.25.25.20.20.20.20.20.20.20.20.20.20.20.20.20.	\$26,000.00	
		Marie Control			17:115	21/15
	OOP TOTAL				\$95,750.00	The state of the s
washoin asaliwi	Miscellaneous expenses				\$250.00	The second second
	Transcription (each table)				\$4,000 00	Yali Quali
	Creative, Design, and Layout				\$7,000.00	77
L.	Meeting Planner				\$7,000.00	
garager Tandid	Additional recruitment tactics/purchase lists				\$5,000.00	
	Express Mail Shipping (faculty mailings, mater	als shipping)			\$250.00	
			e kalina			
	Technical Supervisor/Support - Labor/PowerPo				\$1,200.00	100
	Audiovisual - All equipment for Slide Review and				\$5,000.00	management at a
171	AUDIOVISUAL - OOP			And the second		
	Postage for meeting materials				\$500.00	
1.	Postage for Invites				\$3,500.00	And the latest the second second
11	Pens, Pads				\$250.00	
	Signage, Name Badges, Tent Cards				\$1,375.00	
				TOTAL	\$7,500.00	
. 77.7	sealed invitation	5,000	4-Color	\$3,000		5-14
-1	Printing of self-mailer, wafer-					
E. C.						
	3333333, 337		1			
	evaluations, etc)	100	4-Color	\$4,500		
4	Faculty List, color slides,					
	printing & assembly charges for Agenda, Participant List,					
	Printing of syllabus (includes					
	Printing of syllabus, (includes				1	J 27 4 5 8

28 Part Provided Artistation of Art 1978 Part Provided Pr



E Byrgire was tonn one to pater and fourther.



Doctor versure Graphic and Sarphora Stormer Sarphora Stormer Sarphora Stormer Sarphora Stormer Sarphora Stormer Sarphora Stormer Sarphora Stormer Sarphora Stormer Sarphora Stormer Sarphora Stormer Sarphora Stormer Sarphora Sarph

Albert Einstein	and A	sante (Commu	nication	S
Cases and			aller a trace and the fittings		
DESCRIPTION / CATEGORY	ASSUM	A particular of the		COST	TOTAL COST
GENERAL - OOP		1 110/10	1 1		TOTAL COOT
	Rate	Persons			
Course Director Henerarium	\$0	1		\$0	
Course Director Honorarium Chair Honorarium	\$2,500	1	\ /	\$2,500	
Faculty Honoraria	\$2,000	5	<u> </u>	\$10,000	
raculty Honoraria	\$2,000	٥.	<u> </u>	TOTAL	\$12,500.00
Athant Finatals Associated as and Contifu	-4- F			TOTAL	\$1,000.00
Albert Einstein Accreditation and Certific Albert Einstein Outcome Measurement Fo					\$0.00
LOGISTICS - OOP					
Hotel Accommodations					
Inotel Accommodations	_				
	Room & Tax	Persons	Nights		
To Include Faculty	\$275	7	1	\$1,925	
Accreditor	\$275	1	1	\$275	
Asante	\$275	3	1	\$825	
Additional					
Suppliers	\$275	2	1	\$550	
				TOTAL	\$3,575.00
Hotel Miscellaneous					\$0.00
Airfare	Fare & Tax	Persons	Service	# 000	
To Include Faculty	\$600	7	Coach	\$4,200	
Accreditor	\$600	1	Coach	\$600	
Asante	\$600	3	Coach	\$1,800	
Additional	\$600	2	0	64 200	
Suppliers	\$600		Coach	\$1,200 TOTAL	\$7,800.00
Cround Turner exterior (organization)	Fare & Tax	Darrage	Service	TOTAL	\$7,500.00
Ground Transportation (arrival/departure) To Include, Faculty	\$300	Persons 7	Sedan	\$2,100	
Accreditor	\$100	1	Taxi	\$100	
Asante	\$100	3	Тахі	\$300	
Additional	- 4,00	<u>`</u>			
Suppliers	\$100	2	Тахі	\$200	
				TOTAL	\$2,700.00
Expenses	Rate	Persons			
To Include. Faculty	\$100	7	$N^{-}A$	\$700	
Asante	\$100	3] \ / [\$300	
Accreditor	\$100	1] X [\$100	
Additional			1 / 1		
Suppliers	\$100	2	<u>/</u>	\$200	
				TOTAL	\$1,300.00
	Cost/Tax/	Persons/	Number of		
Food and Beverage	Gratuity	Quantity	Functions		
			[
Continental					
To include. Breakfast	\$40	0	1	\$0	
Lunch	\$65	70	1	\$4,550	
Break	\$30	70	1	\$2,100	
Faculty		ļ ,. ¯		A. 45-	
Dinner	\$100	11	1	\$1,100	
On-site					
Slide	# 050		,	0.50	
Review	\$250	1	1	\$250	\$8,000.00
Meeting Room(s) Rental	\$750	T	T 1 1	TOTAL	\$8,000.00 \$750.00
Gratuities (Hotel Staff)	\$100				\$100.00
On-Site Telephone/Fax	\$750				\$750.00
On-Site Internet Connection	\$750		 		\$750.00
Tou-one internet compertion	Ψ700	L			\$1.00.00

The state of the property of the tensor of the tensor of the section of the section of the section of





Stantificant interpretation of the state of

		<u> </u>	Quantity	Design		
Services Include	/includes n	rinting &	100	4-Color	\$4,500	
GOTTIOGS ITTOIGGG		ed invitation	5,000	4-Color	\$3,000	
	Iwaici-scale	a miniation	0,000	, 50.0.	TOTAL	\$7,500.0
Signage, Name Badges, Tent	Cards					\$1,375.0
Pens, Pads	-					\$250.0
Postage for Invites						\$3,500.0
Postage for meeting material						\$500.0
AUDIOVISUAL -OOP		and the last	****	64.		
Audiovisual - All equipment fo	r Slide Revie	w and Gener	al Session			\$5,000.0
Technical Supervisor/Suppor				• .		\$1,200.0
MISCELLANEOUS - OOP				17.	7	****
Express Mail Shipping (facult	y mailings,	materials sh	ipping)			\$250.0
Additional recruitment tactics	s/purchase	lists				\$5,000.0
Meeting Planner						\$7,000.0
Creative, Design, and Layout						\$5,000.0
Transcription (each table)						\$4,000.0
Miscellaneous expenses						\$250.0
OOP TOTAL						\$80,050.0
FEES			-	1 to 14 to 1		
Management Fee Includes:						\$26,000.0
* Oversee coordination of venu * Oversee all travel, hotel, grou		-	-			
* Manage all on-site operations participant handouts, badges, t * Traffic meeting materials for r * Arrange for honoraria * Grant/Needs development *Reconciliation management * Certification Collaboration (joi * Internal CME compliance Content Development/Editori Includes: * Collaborate with faculty on lea	ent cards, eleview and p int sponsors. at Fee arning object	ram including to roduction hip, compliant	registration a	rea pert Einstein lia	aison)	
* Manage all on-site operations participant handouts, badges, the Traffic meeting materials for it arrange for honoraria and arrange for honoraria and arrange for honoraria and arrangement are continuous. The transition of transition of the transition of the transition of the transition of the transition of the transition of the transition of the transition of the transition of the transition of the transition of the transition of the transition of the transition of the transition of the transition of the transition of the transition of transition of the transitio	ent cards, every ent cards, every end print sponsors. at Fee arming object esentations orate faculty orporate acc and formatt	ram including to roduction hip, compliant tives, agenda comments reditor comm	registration a ce review, Alt and discussion	rea pert Einstein lia	aison)	\$15,750.0
* Manage all on-site operations participant handouts, badges, t * Traffic meeting materials for r * Arrange for honoraria * Grant/Needs development *Reconciliation management * Certification Collaboration (joi * Internal CME compliance Content Development/Editori Includes: * Collaborate with faculty on let * Collaborate with faculty on pri * Liaise with acculty and incorpe * Liaise with accreditor and inci * Editorial/copy editorial review * All costs associated with mee FEE TOTAL	ent cards, every ent cards, every end print sponsors. at Fee arming object esentations orate faculty orporate acc and formatt	ram including to roduction hip, compliant tives, agenda comments reditor comm	registration a ce review, Alt and discussion	rea pert Einstein lia	aison)	\$15,750.0 \$41,750.0
* Manage all on-site operations participant handouts, badges, the Traffic meeting materials for it arrange for honoraria and arrange for honoraria and arrange for honoraria and arrangement are continuous. The transition of transition of the transition of the transition of the transition of the transition of the transition of the transition of the transition of the transition of the transition of the transition of the transition of the transition of the transition of the transition of the transition of the transition of the transition of transition of the transitio	ent cards, every ent cards, every end print sponsors.	ram including to roduction hip, compliant tives, agenda comments reditor comm	registration a ce review, Alt and discussion	rea pert Einstein lia	aison)	

is someone as -2π none -2π to -4π , -4π constant -4π , -4π constant -4π



to be been Rotzech rose in



Profits spets flows to are Some to Mobile Coppet to the Silent Paper to be an at Mee, con-

Albert Einstein and Asante Communications Cases and Commentary Workshop #3 ASSUMPTIONS TOTAL COST GENERAL - OOP Rate Persons \$0 Course Director Honorarium \$0 Chair Honorarium \$2,500 \$2,500 Faculty Honoraria \$2,000 \$10,000 \$12,500.00 TOTAL Albert Einstein Accreditation and Certificate Fee \$1,000.00 Albert Einstein Outcome Measurement Fee \$0.00 LOGISTICS - COP Hotel Accommodations Nights To Include: Faculty \$275 \$1,925 \$275 \$275 Accreditor \$825 Asante \$275 3 1 Additional Suppliers \$275 \$550 TOTAL \$3,575.00 \$0.00 Hotel Miscellaneous Airfare Fare & Tax Persons Service To Include, Faculty \$600 \$4,200 Coach \$600 \$600 Accreditor 1 Coach Asante \$600 3 Coach \$1,800 Additional Suppliers \$600 \$1,200 Coach TOTAL \$7,800.00 Ground Transportation (arrival/departure) Fare & Tax Persons Service To Include Faculty \$300 \$2,100 \$100 \$100 Accreditor Tax \$300 Asante \$100 3 Taxı Additional Suppliers \$100 Tax \$200 TOTAL \$2,700.00 Expenses Rate Persons To Include: Faculty \$100 \$700 \$100 3 \$300 Asante \$100 \$100 Accreditor Additional Suppliers \$100 \$200 TOTAL \$1,300.00 Cost/Tax/ Persons/ Number of Food and Beverage Gratulty Quantity Functions Continental To Include Breakfast \$40 \$4.550 \$65 70 1 Lunch Break \$30 70 1 \$2,100 Faculty Dinner \$100 11 \$1,100 On-site Slide \$250 \$250 Review TOTAL \$8,000.00 \$750 \$750.00 Meeting Room(s) Rental \$100 \$100.00 Gratuities (Hotel Staff) On-Site Telephone/Fax \$750 ____ \$750.00

to the rody were Property of the programment, the first for continuous and increase of

\$750

On-Site Internet Connection

\$750.00





with Carterian to the following the second and the second are constants on the second and the second and the second are constants on the second and the second are constants on the second and the second are constants on the second are constants.

MATERIALS OOD

the surrous thousing and form to be storage for the Mars times to allow at Medical

	MATERIALS - OOP	-4 ⁻⁷					7
	Production/Printing						
				Quantity	Design		
	Services Include:	(includes pi	rinting &	100	4-Color	\$4,500	
		wafer-seale	ed invitation	5,000	4-Color	\$3,000	
						TOTAL	\$7,500.00
	Signage, Name Badges, Tent	Cards					\$1,375.00
	Pens, Pads	•					\$250.00
	Postage for Invites						\$3,500.00
	Postage for meeting materials	S					\$500.00
	AUDIOVISUAL - OOP						
	Audiovisual - All equipment for	Slide Revie	ew and Gener	al Session			\$5,000.00
ally all	Technical Supervisor/Suppor	t - Labor/Po	owerPoint Ted	h			\$1,200.00
	MISCELLANEOUS - OOP						
	Express Mail Shipping (facult			ipping)			\$250.00
	Additional recruitment tactics	/purchase	lists				\$5,000.00
	Meeting Planner						\$7,000.00
	Creative, Design, and Layout						\$5,000.00
7	Transcription (each table)						\$4,000.00
	Miscellaneous expenses						\$250.00
	OOP TOTAL						\$80,050.00
	FEES		1,442	377		1.0	
	Management Fee						\$26,000.00
r	Includes:						
	* Timeline development & main	tenance					
	*Manage internal team and proj	ect flow					
	* Coordinate faculty invitational	process inc	luding invitation	ons, confirma	tions, final an	d welcome pack	rets
	* Manage attendee recruitment	process inc	luding invitation	ons, confirma	tions, final log	gistical informati	on
<u></u>	* Oversee coordination of venue	e selection,	negotiation ar	nd contracting	7		
ánà	* Oversee all travel, hotel, ground	nd transport	ation, food fur	nctions and A	V both pre-m	eeting and onsit	'e
F	* Manage all on-site operations	of the progr	ram including	registration a	rea		
	participant handouts, badges, te	ent cards, et	tc.				
	* Traffic meeting materials for re	eview and p	roduction				
	* Arrange for honoraria						
JIP.	* Grant/Needs development						
	*Reconciliation management						
#	* Certification Collaboration (joi	nt sponsorsi	hip, compliand	ce review, Alb	ert Einstein li	aison)	
M	* Internal CME compliance						
*****	Content Development/Editori	al Fee					\$15,750.00
(**P*)	Includes:						
	* Collaborate with faculty on lea		tives, agenda	and discussi	on guide deve	elopment	
	* Collaborate with faculty on pre						
Ε.	 Liaise with faculty and incorpo 	rate faculty	comments				
	* Liaise with accreditor and inco	orporate acc	reditor commi	ents			
***	* Editorial/copy editorial review	and formatt	ing				
	* All costs associated with mee	ting content	development				
No.	FEE TOTAL						\$41,750.00
	GRAND TOTAL						\$121,800.00
•							

Local Describing Assume Press NA tone - Prost 7580 9000, to leave 3880 state - meaning - one thousand one

Eraphy, to bed Bother of Theorem the Proce of



Albert Emerges Called Co Med. on About A Cassing



We not note head for the Medical Manager of the Medical Medical Medical Manager of the Medical

	DESCRIPTION /		ASSUMPT	IONS	ŀ	COST	TOTAL COST	100
	CATEGORY GENERAL - OOP							* 1
- 1	GENERAL - DUF						and application of the	- 14 - 14 - 14 - 14 - 14 - 14 - 14 - 14
			Rate	Persons				The state of the s
	Course Director Honor	arium	\$2,500	1		\$2,500		
	Faculty Honorarium		\$1,500	2	\angle	\$3,000	** 500.00	
	Albert Einstein Accredi		4. F.			TOTAL	\$5,500.00 \$9,500.00	
	Albert Einstein Outcom						\$3,500.00	
	MATERIALS - OOP	e weasurement					\$3,300.00	
-	Production/Printing		T			ĺ		
			<u> </u>	Quantity	Design	Cost	··· ··································	
	Services Include	Monograph -	T					***
,		Printing		45,000	4-Color	\$20,000		
ادر "سپ					Trends	TOTAL	\$20,000.00	
	SHIPPING/MAILING							
	Distribution Pain Clinic				s		\$14,000.00	
	Express Mail Shipping		s, materials s	hipping)			\$200.00	
اعـ " **	ONLINE -OOP	69 B 89 89 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1					\$10,000.00	
	Webification of Monog				1000		\$10,000.00	
	CERTIFICATES - 00 CREATIVE/DESIGN-0		100	A control of the control of the	ere erest e	4 1 1 1 1 1	The second second	
	Creative, Design and L			YIA- LUIDISA	<u> </u>		\$6,500.00	
2.0	Purchase Artwork	ayout					\$250.00	
1.7	TOTAL OOPs						\$69,450.00	
							<u> </u>	
	Management Fee	7 . A 2505 Million Business					\$17,500.00	
	Includes:	,,						Arresses
_#	* Timeline development	& maintenance						
	*Internal team and Proje	-						en.
	* Coordinate faculty review							
	* Arrange for faculty revi	ew and honoraria						
	* Arrange for honoraria							
	* Manage design and pro * Traffic materials for rev							46.1
	* Certification collaborati			ce review Al	hert Finstein	liaison)		No.
	* Evaluation summary de	- :		oo rovioti, Ai	SOIL ENGION			
7.4	* Grant/Needs developm		occoming					12.24
	*Reconciliation manager							
1	Content Development/I						\$25,000.00	7 m m - 11
	Content Development i	ncludes:						
	*Develop learning object							
	*Develop outline for an 8							
	*Collaborate with faculty *Liaise with faculty & inci			ograpn manu	iscript			
	*Liaise with accreditor &							
, .	* Editorial/copy editorial	•		l report mone	ogranh			
	* All costs associated will				.g. ap.,			
		g 55///07		 		•	<u> </u>	
	TOTAL FEES						\$42,500.00	1000

1997 Barroninge Arabee, Bring NA 1995 - Prose Theffford Provided Provide Personal Transford Information of the Provide Arabe Provided Arab Provided Arab Pro

PERSISTENT AND BREAKTHROUGH PAIN

MULTIDIMENSIONAL ASSESSMENT AND MULTIMODAL OPIOID-BASED TREATMENT STRATEGIES

An Educational Platform Initiative

Medical Education Grant Request

Presented to | Cephalon, Inc.

Submitted by | Albert Einstein College of Medicine

Submitted on | 11/06/2008





Outline of Request

- Overview
- II. Platform Sponsorship, Management, and Outcomes Measurement
- III. Educational Platform, Learning Objectives, and Needs Assessment
- IV. Faculty and Programs
- V. Program Recruitment, Awareness, and Distribution
- VI. Budgets

I. Overview

Albert Einstein College of Medicine (Einstein) in association with its educational collaborator, Asante Communications LLC (Asante), respectfully request a grant for the development, certification, production, and distribution of an educational initiative tentatively entitled "Persistent and Breakthrough Pain: Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies." This educational platform is intended to provide continuing medical education (CME) credit to healthcare professionals who treat patients with chronic pain.

The sponsors seek support through an educational grant from Cephalon, Inc. A support statement identifying Cephalon, Inc. as the Grantor will be included in the preamble of each activity, as well as in all announcements regarding the platform and individual activities.

Einstein will certify the initiative for CME credit for physicians.

II. Platform Sponsorship, Management, and Outcomes Measurement

Albert Einstein College of Medicine

For more than 5 decades, Einstein has exemplified excellence in medical research, teaching, and patient care. Established in 1955, and guided by the vision of Professor Albert Einstein, the College was one of the first medical schools to integrate bedside experience with classroom study. Einstein also led the way in the development of bioethics as an accepted academic discipline in medical school curricula and was the first private medical school in New York City to establish an academic Department of Family Medicine as well as a residency program in internal medicine with an emphasis on women's health. Today, Einstein is one of the nation's premier institutions for medical education, basic research, and clinical investigation.

Although education is at the heart of Einstein's mission, biomedical research drives its growth. Einstein has 300 research laboratories, which allow it to consistently be on the forefront of medical breakthroughs via development of cutting-edge techniques and clinical trials. A national leader in biomedical research support from the federal government, Einstein received more than \$150 million in funding from the National Institutes of Health (NIH) in 2006. Einstein ranks sixth in the nation in terms of NIH awards to basic-science departments, and 7 of its programs are designated as NIH "Centers of Excellence."

Einstein and Montefiore Medical Center (the University Hospital and Academic Medical Center for the Albert Einstein College of Medicine) Center for Continuing Medical Education (CCME) was founded in 1976. It is accredited by the Accreditation Council

Page 2 of 30 Confidential

for Continuing Medical Education (ACCME) to provide CME for physicians. CCME is committed to the utilization of resources for the advancement of CME throughout the physician's professional career. CCME's mission is to enhance patient care by bringing diagnostic and therapeutic innovations to the clinical environment through professional medical education for physicians that maintains, develops, and increases their knowledge, skills, and competence.

independence

CCME does not maintain financial relationships with commercial supporters or educational partners outside of the receipt of normal fee for services. Commercial interests are not involved in the development of content, program planning, or budget-determination. Responsibility for assuring that the CME activities meet the highest requirements and standards of Einstein and the ACCME rests solely with the CCME and is not transferable.

Discionate and Conflict of Interest

CCME requires written, signed disclosure of the existence of relevant financial interests or relationships with commercial interests from any individual contributing to or in a position to influence the content of a CME activity sponsored by Einstein. Individuals not disclosing relevant financial relationships will be disqualified from an association with the CME activity in question.

CCME has established policies that will identify and resolve all conflicts of interest prior to activity certification by applying the disclosed information and activity subject to ACCME's policies.

Contest: Valid Con-

All scientific research referred to, reported on, or used in a CME activity certified by Einstein in support or justification of a patient care recommendation will conform to the generally accepted standards of experimental design, data collection, and analysis.

Complemen

Asante has retained Hogan & Hartson LLP, an international law firm, to provide Asante with consultancy and expert insights into current federal and state regulations, ACCME codes of conduct, Pharmaceutical Research and Manufacturers of America (PhRMA) code, and their potential impact on the quality and delivery of our medical education programs.

Experts in all relevant accreditation issues, Hogan & Hartson will ensure that the continuing medical education programs Asante proposes and executes—including such full spectrum communications vehicles as regional meetings, teleconferences, webbased and print activities—will be conducted in an irreproachably compliant fashion. By ensuring that the educational programs faithfully adhere to all relevant law and regulations, Hogan & Hartson will help us meet the educational needs of critical therapeutic areas, develop clinicians' skill sets and improve patient care.

As the 2009 educational year unfolds, Hogan & Hartson will continually monitor our policies and programs and may instruct our team accordingly, facilitating any necessary adjustments. Additionally, the global law firm will help Asante develop employee and faculty educational programs.

Asante Communications, LLC

Asante is a full-service medical education company specializing in physician and patient education for the biopharmaceutical industry. Utilizing proprietary research methodologies, the Asante team of scientists, writers, and strategists delivers high quality CME, tailored to the objectives of our accreditors and grantors, grounded in the science of current and investigational treatment options, and shaped by an expert understanding of adult learning principles. In particular, the company integrates the latest insights into disease management with comprehensive preclinical and clinical data, creating coherent and credible educational platforms. Asante provides strategically sharp content across print, live, video, and Web-based outlets and distribution channels,

Page 3 of 30 Confidential

and leverages its diverse network of pain clinicians to develop, validate and critically review needs assessments and all relevant scientific content. Further, the full spectrum of educational materials proposed in this grant is based on a fundamental tenet that clinicians have idiosyncratic learning preferences and often prefer to self-direct their learning across multiple vehicles. Such a multifaceted, interactive and needs-based approach is critical to instructing clinicians in chronic pain management. Based in New York City, the company is managed by seasoned veterans of the healthcare communications industry.

Platform Management

Asante will be responsible for the development, production, and distribution of the activities within the educational platform under the direction of Einstein. Asante will operate as an extension of the sponsor, working within Einstein's guidelines as well as those of the accrediting organizations and governmental agencies regulating medical education.

Einstein will provide oversight for the development, production, and distribution of the activities within the educational platform as well as the certification for CME credit.

Outcome Levels

Asante reaches Level 4 of Outcomes Measurement as defined by the North American Association of Medical Education and Communication Companies, Inc (NAAMECC) with our standard evaluation process:

- Level 1: Participation (via the participant report)
- Level 2: Satisfaction (via the activity evaluation)
- Level 3: Learning (via the self-assessment exam)
- Level 4: Performance (via the commitment-to-change questions on the activity evaluation)

Durable Outcomes Measurement and Evaluation

Einstein and Asante are committed to providing high quality education associated with durable outcomes that promote best practices in pain management and improve patient care. In addition to traditional outcomes measurements reported and evaluated by Einstein for Level 4 Outcomes as noted above, a randomized controlled study approved by Victor Hatcher, PhD, David Kaufman, MD, of Einstein and the Institutional Review Board (IRB) of Albany Medical Center will be conducted to measure the effectiveness of the educational interventions.

Stage I

In this study, clinicians (N=~300~350) will demonstrate their baseline level of attitudes, awareness, knowledge and current practices by completing a structured questionnaire (20-questions; 10 multiple choice and 10 case-based short answer questions). The questionnaire—a self-developed instrument in early stages of psychometric evaluation—will be based on educational deficits initially identified in the Clinical Survey and Needs Assessment (CSNA). After completing the diagnostic, clinicians will participate in a teleconference program and/or live regional meeting, immediately after which they will again complete a similarly structured questionnaire. Pre and post differences in attitudes, awareness and knowledge will be determined, reflecting the extent to which the participants have achieved the learning objectives. To gain additional context, face-to-face focus group discussions will be conducted immediately after the regional meeting as well. Here, participants will have an opportunity to elaborate on self-reported performance indicators that go beyond the structured questionnaire.

Page 4 of 30 Confidential

Stage II

Upon completion of Stage I, a subset of interested clinicians will be randomized to either an intervention group (~n=150), within which clinicians will participate in a monthly WebPanel series with thought leaders for 6 months, or randomized to a control group of clinicians (~n=150), who will receive no further instruction and provide a benchmark against which the effectiveness of continual intervention may be measured. Adult learning principles suggest that such reinforcement helps translate knowledge into practices with enduring value. Clinicians may benefit from the collegial relationship and outcomes-driven mentoring provided by the WebPanel. Outcome variables for Stage II will include the clinicians' confidence in pain management skills and intent-to-change by: (1) employing functional goals to guide patient care (2) implementing structured pain and risk assessment methodologies (3) monitoring breakthrough and persistent pain longitudinally and (4) documenting level of risk.

Stage III

A more precise measure of effectiveness may be obtained in a third and final stage of this study. A subset of clinicians from the Stage II intervention (n=~5 clinicians) and control groups (~n=5 clinicians) will invite as many as 10 patients each to participate in this stage (~N=100 patients; ~n=50 experimental group; ~n=50 control group). Appropriate disclaimers and IRB approval will be secured for each patient upon initiation of Stage II. Once Stage II is completed, patients in each group will complete a brief questionnaire (5 multiple choice questions). Outcome variables for Stage III will be patients' overall satisfaction with the consultations and satisfaction with the clinician's assessment of the quality, severity and temporal components of chronic pain. Differences in patient outcomes will be compared between the Stage II intervention group and control group. The working hypothesis is that those patients treated by clinicians who received ongoing interventions will have sharper assessment skills, translating into discernable and self-reported differences in patient care.

Importantly, this study design and methodology will provide qualitative and quantitative data longitudinally, throughout each stage of the study. Reported outcomes in physician performance and patient care—particularly those demonstrating sustainability—may constitute publishable data for the *Journal of Continuing Education in the Health Professions*, a peer-reviewed journal specializing in CME.

III. Educational Platform, Learning Objectives, and Needs Assessment

Educational Platform

Guided by an expert panel and comprehensive needs assessment, the educational initiatives within this platform are intended to disseminate chronic pain and risk management strategies to a multidisciplinary audience of clinicians who treat patients with chronic pain, including pain specialists, neurologists, rheumatologists, physical medicine and rehabilitation specialists, family practitioners, oncologists, and internal medicine and general practitioners. In a grant proposal to be submitted subsequently, physician assistants, nurse practitioners, and registered nurses will be addressed as an important secondary audience.

Each activity will provide a venue for healthcare professionals to increase their clinical knowledge and awareness of pain and risk-mitigation strategies in the opioid-based treatment of chronic pain. Upon successful completion of the CME activities, healthcare professionals may use the CME credit(s) earned toward their licensure and/or certification requirements.

Einstein and Asante have completed a thorough analysis of the current state of chronic pain education, researching publications and clinical trials, soliciting in-depth thought-leader feedback, and conducting a survey of potential participants regarding current practice patterns, existing educational opportunities, and the need for focused and targeted activities.

Page 5 of 30 Confidential

Asante has developed a proprietary approach to identifying unmet educational needs among clinicians, to tailoring educational programs accordingly, and to developing sensitive outcomes-based approaches to evaluating changes in awareness, knowledge and practice. Briefly, working with Einstein, Asante has employed its CSNA data which helps distinguish among clinicians with various levels of expertise. While the psychometric properties have yet to be fully determined, the questions reveal different approaches to the assessment and treatment of specific disorders. After identifying gaps in understanding among responders, specific replies are shared with thought leaders, who are asked to share their insights into a specific educational deficit and how it may be treated through targeted interventions. Finally, teleconference calls are then conducted to confirm identified gaps among target audiences.

Based on this research and feedback, Einstein and Asante have identified specific educational needs within the therapeutic area and recommend addressing those needs via a series of educational approaches to chronic pain and risk management linking evidence-based medicine with expert perspective.

Intended Audience

These activities are developed for pain specialists, neurologists, rheumatologists, physical medicine and rehabilitation specialists, family practitioners, oncologists, and internal medicine and general practitioners

Activity Goals

It is the goal of these activities to increase their competence and abilities to treat and appropriately manage pain and learn important methods to incorporate risk management strategies into pain management plans.

Learning Objectives

At the conclusion of this program, participants will be better prepared to:

- 1. Define, recognize, and independently assess breakthrough and persistent pain in patients with chronic pain syndromes
- 2. Implement a multidimensional, continual, and vigilant assessment of persistent and breakthrough pain based, in part, on the phenomenology and inferred pathophysiology of the pain syndrome, patient function, goals, and level of risk
- 3. Select appropriate patients for opioid-based management of persistent and breakthrough pain
- 4. Employ multimodal opioid-based therapies tailored to the multidimensional pain assessment of patients with persistent and breakthrough pain
- 5. Explain the respective roles of long-acting, short acting and rapid onset opioids in the management of persistent and breakthrough pain
- 6. Distinguish clinical constructs of physical dependence, tolerance, pseudotolerance, addiction, pseudoaddiction and their impact on medical management of patients with chronic pain syndromes

Clinical Survey and Needs Assessment (CSNA)

Two thousand one hundred and thirty five surveys were e-mailed to U.S. based pain clinicians. One hundred and fifty-seven electronic surveys were completed (7% response rate). Respondents provided answers to several yes/no questions and to openended questions about breakthrough and persistent pain management. Select questions from the survey are included below.

Most (82%) of the sample employed multimodal and multidrug approaches

Page 6 of 30 Confidential

- Nearly 40% of respondents cited the need for more education on multimodal treatment strategies (eg, behavioral, relaxation strategies, cognitive behavioral therapy)
- Approximately 74% of respondents cited a need to learn more about principles of opioid-based therapy, including when to
 prescribe, how to maintain, and when to discontinue opioids. ("How do I manage a patient with a legitimate pain syndrome
 who has broken the contract?")
- Nearly half (47%) of the respondents agreed that opioid based therapy is time consuming, poorly reimbursed and increasingly
 difficult in this environment. Respondents agreed that guidance on formulating a treatment plan within the current 15-minute
 visit paradigm is needed.
- An estimated 34% of respondents do not risk stratify their patients for problematic opioid use.
- Few subjects (<10%) disagreed with the notion that chronic pain comprises two distinct components (Sample responses below). Rather, the educational need appears to center on definitional issues, and how best to assess and treat the constructs. Operationalizing breakthrough and persistent pain, in other words, appears to be the threshold educational need.
- Most respondents (65%) used the Numeric Rating Scale to evaluate baseline pain, highlighting the need for education on thorough assessment strategies.
- Only 55% of respondents provided an adequate definition of breakthrough pain.

Question: How do you determine whether baseline persistent pain is controlled? Please elaborate as needed.

"Actually, very complex assessment: I begin with comparing both the peak and average pain scores since last encounter, the frequency and duration, comparing these to values from the previous visit; the total daily long-acting and average short-acting (excluding transmucosal fentanyl) opioid dosages are calculated as oral oxycodone equivalents, and the percentage of short-acting medication of the total of the two components is estimated, and compared with last visit. In the interview, adjustments are made in interpretation of these "hard" data points based on any acute injuries or exacerbations which may have disturbed the balance that month, desirable increases in activity vs. overextension, and the end-effect on mocd, sleep, energy, motivation, appetite, and perceived areas of improvement or deterioration are assessed."

Question: How would define breakthrough pain?

Adequate definitions included:

"Sudden onset or rapidly (a relatively soft subjective definition) escalating pain beyond usual tolerable levels (not just above baseline). I do not accept the additional qualification that it is of short duration or even necessarily spontaneously subsides; patients with CRPS I or II, TGN, PHN, or painful MS may experience flares that sustain for hours or even a full day."

"Episodic occurrences, commonly related to changes in activity not well controlled by baseline pain medication use that works the majority of the time."

Page 7 of 30 Confidential

- Disturbing pain despite taking long acting opioid
- I would just say it is an increase over baseline; the pain is getting worse or it still isn't well controlled in the first place
- When a person still has pain on and off, while taking maintenance pain medications
- Pain that occurs at the end of dose drop off of the long acting med regimen before the next dose is due
- BTP is pain occurring in mid-dose regimen with chronic pain controlled by long acting narcotic
- If the baseline pain is not managed then there will be more breakthrough pain. Baseline pain management requires maximizing dosages or other interventions
- Pain that unexpectedly breaks through the baseline pain regimen, as distinct from activity related pain and end-of-dose pain

Critical Assessment of Unmet Educational Needs in Chronic Pain Management

Chronic pain is prevalent, underdiagnosed, often misdiagnosed, and undertreated. (Walid, 2008; Gore, 2006) Previously regarded as a symptom of underlying disorders, the neuroplastic changes that characterize chronic pain constitute a disease state unto itself, a state of peripheral and central sensitization and hyperexcitability that requires comprehensive, continual assessment and treatment. (Woolf, 2007) Chronic pain is a significant burden to the patient, impairing multiple dimensions of function—affective, cognitive, physical, and work-related—which, in turn, adversely affect public health. (McCarberg, 2008) Numerous epidemiologic studies have estimated an annual cost of 80 billion dollars in the United States alone, reflecting the more than 50 million people who have chronic pain syndromes. (APS, 2008) The incidence and prevalence of chronic pain syndromes is projected to increase as the population ages, particularly with such age-related syndromes as osteoporosis, low back pain, osteoarthritis, and multifocal joint pains. (Robinson, 2007) Many patients with chronic pain will be cancer survivors, a group recently estimated to include more than 10.8 million people. (Ries, 2008) The prevalence and cost of chronic pain, and its debilitating signs and symptoms, have driven pain practitioners, academicians and several medical societies to collaboratively develop screening methodologies, validated assessment tools, and multimodal treatment strategies that provide pain relief and improve patient function. All of these approaches require an ongoing commitment to medical education. (Stanos, 2008; Webster, 2005; Passik, 2008) (CSNA; Learning Objectives 2, 3, 4)

Chronic pain comprises heterogeneous and frequently complex disorders that often require opioid analgesics, a medication class with an equally complex pharmacology and epidemiology. (Pasternak, 2005) Opioids have long been regarded as a cornerstone in the treatment of cancer pain; numerous randomized controlled studies have documented their safety, tolerability and efficacy across a wide variety of cancer-related syndromes. (Pergolizzi, 2008; Ballantyne, 2005; Miaskowski, 2005; Carr, 2004) Over the past 20 years, opioids have gained increasing, though not unqualified, acceptance for noncancer pain as well. (Ballantyne, 2008; Noble, 2008; Riley, 2008; Portenoy, 2007; Furlan, 2006; Coluzzi, 2005; Nicholson, 2003) Concerns about opioids in the management of moderate to severe pain of noncancerous origin, extensively reviewed elsewhere, help explain, at least in part, an unjustifiable undertreatment of pain, especially in the elderly. (Lin, 20007; Robinson, 2007; APS, 2005; Ballantyne and Mao, 2003) Educational programs are urgently needed to help clinicians select appropriate patients with cancer and noncancer pain syndromes for opioid-based pharmacotherapy, and to develop an individualized therapeutic regimen based

Page 8 of 30 Confidential

on the pain syndrome, level of risk, and goals of each patient. (Portenoy, 2008; Keeney, 2008; Comley, 2000) (CSNA; **Learning Objectives 3, 4**)

Associament as Propinate

Multidimensional comprehensive assessment strategies improve patient care and outcomes. (Barbuto, 2008; Breivik H, 2008; Davidson, 2008; Locker, 2007; Yennurajalingam, 2004) Identifying objective findings through a patient work up—including, for example, laboratory electrodiagnostic and imaging studies—remains critical; however, clinicians must operationalize the International Association for the Study of Pain (IASP) definition of pain, which does not require actual tissue damage for pain to be experienced. (Merskey, 1994) Pain is an untestable hypothesis (Fishman, 2008); absent any objective data supporting the pain complaint, clinicians need to rely on patient function and quality of life as goals and benchmarks for success. Listening to the patient is indispensable. By characterizing the quality of the pain, its radiation pattern, and temporal profile—when is the pain minimal, and when is it excruciating?—the patient may help the clinician translate the phenomenology of the pain complaint into a pathophysiology that informs mechanism-based treatment. (Davies, 2008; Maag, 2006; Baron, 2006; Woolf, 2004)

"We need to listen to monitor what's going on with these patients over time, to evaluate the results of therapy, and to control as best we can adherence to the plan of care through a very well thought out monitoring program, and then over time tailor and adjust therapies according to what happens. Because I think if there's one thing we've learned, it is that we really do not have great predictors of either efficacy or safety, except in a very obvious group of high-risk patients."

Perry G. Fine, MD

In time-constrained clinical practice, reducing irreducibly complex chronic pain syndromes is manifestly challenging; their broad phenomenology must therefore be assessed methodically, through a semi-structured approach over time. (Breiveik, 2008; Guarino, 2007; Passik, 2005) There is an urgent need for educational programs addressing practical solutions for engoing patient assessment, several of which are briefly discussed below. (CSNA; **Learning Objective 2**)

Assessment is a process that takes time, takes multiple encounters with the patient. And when I discuss with nurses the assessment of pain, I often say for all of us, we have to get the patient's pain story, and in our truncated world of a 15-minute patient visit, that's often a hard thing to achieve, trying to get the patient back with the appropriate frequency so we can detect the subtleties that need to be managed with these types of pain problems."

Christine Miaskowski, PhD, RN

Macharism-Bases Therapy

First, pain must be correctly classified to drive appropriate treatment selection. (Baron, 2008) Underlying etiologies of chronic pain vary considerably. Cancer pain syndromes may involve soft tissue, bones, or joints, and could be related to a polyneuropathy, plexopathy, or another form of nerve injury. (Berger, 2006) Similarly, noncancer pain syndromes may involve chronic tissue injury, inflammatory disorders, or nerve injury. These disease classifications, although helpful, require additional insights into disease mechanisms. Gradually, clinicians are classifying less by disease than by inferred pathophysiology. (Woolf,

Page 9 of 30 Confidential

2004) Simply, chronic pain syndromes may have a nociceptive (somatic or visceral) component marked by constitutive activation of an otherwise intact nervous system. Inflammatory bowel disease, interstitial cystitis, osteoarthritis, and discogenic back pain are classified as nociceptive. Pain with a predominantly neuropathic component is characterized by reorganization of normal neural circuits, and includes cancer-related neuropathy, complex regional pain syndrome (CRPS), post-laminectomy syndrome, HIV-related neuropathy, central post-stroke pain, post-herpetic neuralgia, diabetic neuropathy, and phantom limb pain, among others. (Argoff, 2006; McMahon & Koltzenburg, 2005) Matching treatment to disease is gradually being eclipsed by matching treatment to mechanism. (Woolf, 2008; de Leon-Casasola, 2008; Baron, 2008) Clinicians require concerted educational efforts to understand this paradigm shift. (CSNA; **Learning Objective 2**)

Temorgal Dinamsions of Chemica Pain

Second, temporal characteristics of chronic pain must be captured during each visit. Chronic pain is dynamic, ebbing and flowing as a function of movement, stress, and other idiosyncratic factors. (Davies, 2008; Bennett, 2005) The persistent, baseline component of pain, even when controlled, fluctuates; often, the pain breaks through an otherwise effective analgesic regimen. (Bennett, 2007) Breakthrough pain, the second temporal component of chronic pain, is an often overlooked clinical construct. (William, 2008; Swanwick, 2001) Recently discussed by an expert panel, breakthrough pain is a transitory pain more severe than the persistent baseline pain that adversely affects function or quality of life in patients who are receiving analgesic therapy on most days. (Expert Panel on Breakthrough Pain, 2006) The requirement for an adverse functional impact is essential for the management of BTP, and mirrors the increasing focus on function in the Federation of State Medical Boards (FSMB) model policy. (Fishman, 2008) Clinicians require expert guidance on how best to employ patient function as a standard by which to measure treatment success. (CSNA; Learning Objectives 2, 5)

"An important question in pain management: Does an observed reduction in pain intensity translate into clinically relevant functional improvement? That is to say, because a patient says, "Yes, in fact I am experiencing an analgesic effect," does that lead to demonstrable, meaningful accomplishment of certain goals that we may say, other than pain relief, are very important from a clinical or therapeutic standpoint?"

Perry G. Fine, MD

Epidemiologic studies have demonstrated that the majority of patients experience breakthrough pain; the prevalence in cancer patients is estimated at 64%, and that in noncancer pain patients is closer to 74%. (Portenoy 1990; Portenoy, 2006) Patients with breakthrough pain have decreased satisfaction with their analgesic regimen, increased healthcare utilization and associated costs, increased hospital visits and hospitalization, increased mood disturbances, and impaired function. (Abernethy, 2008; Taylor, 2007; Fortner, 2003; Fortner, 2002) Independent assessment and treatment of this clinical entity is therefore critical to patient care. (Taylor, 2007) Clinicians face formidable challenges, however. Breakthrough pain is a highly variable clinical construct—its duration, frequency, severity, and predictability vary among and within patients. (Portenoy, 2006; Mercadante, 2002; Portenoy, 1990; Portenoy, 1989) Continual assessment helps characterize these temporal features and distinguish breakthrough pain from uncontrolled baseline pain. Clinicians require educational programs that help clarify breakthrough pain as a measurable and treatable clinical construct. (CSNA; Learning Objectives 1, 4)

Risk Mit ...tion

Third, a careful consideration of the risk-benefit relationship of opioids in the context of other pharmacologic and nonpharmacologic treatment options is critical to individualized patient care. (Fine and Portenoy, 2007) Russell K. Portenoy, MD and colleagues have developed a conceptual framework within which clinicians can decide to initiate, maintain, or discontinue opioid-based therapy. Specifically, the "Portenoy principles" require identifying the conventional therapeutic approach for the pain syndrome; evaluating the risk-benefit ratios of all feasible treatment options; assessing the risk of opioid-related adverse

Page 10 of 30 Confidential

pharmacologic outcomes (eg, gastrointestinal distress, sedation, endocrine dysfunction); and stratifying the risk of nonmedical opioid use. This approach helps structure opioid-based therapy consistent with risk, an increasingly critical driver of chronic pain management. (Portenoy, 2004) Clinicians can benefit from an educational program that helps them incorporate the principles suggested by Dr Portenoy into their clinical practice. (CSNA; **Learning Objective 1, 4**)

"Conventional management may not be evidence based and may not be appropriate for the individual person. But we all exist in a network of relationships with other physicians, other health care providers, a regulatory network, a legal network, a managed care network. And you need to have that understanding of conventional practices, within the network, in order to make an informed judgment. If you decide not to do what is conventional, from my perspective, that's totally okay. We do that every day as clinicians. We decide to do something that's not conventional. But, if it's not conventional, you need three things. You need a good reason. You need informed consent. And you need documentation."

Russell K. Portenoy, MD

Understanding the social milieu in which the patient lives and works, and obtaining the personal and/or family history of medical and psychiatric comorbidities, especially substance use disorders, creates a three-dimensional, biopsychosocial representation of the patient. (Wasan, 2007; Adams, 2006; Wool, 2005) Validated screening tools—including the Opioid Risk Tool and the Screener and Opioid Assessment for Patients With Pain—are available to help stratify the risk of inappropriate opioid use. (Belgrade, 2006; Akbig, 2006; Webster, 2005) Such problematic opioid use includes failure to use the opioid as prescribed (misuse), the deliberate use of a drug for nonmedical reasons, in particular for psychotropic effects (abuse), and the willful or accidental transfer of the medication to others (diversion). (Katz, 2008; Katz, 2007) Amid the escalating epidemic of prescription opioid abuse, clinicians need expert insights into balancing the benefits of opioid medications with the risk of abuse, misuse, and diversion. (CASA, 2008; CASA 2005; SAMHSA, 2004) There is an unmet medical and educational need for thorough and careful assessment of biological, psychological, and social dimensions of patients with chronic pain. (Denisco, 2008; Martelli, 2004; Marcus, 2000) (CSNA; Learning Objective 2)

Patients with chronic pain who are assessed as high risk may require a highly structured plan. (Gourlay, 2005) Pill counts, urine drug screening, weekly visits for prescription refills, pharmacy monitoring plans and treatment agreements are all available options. Risk mitigation is an inherently imprecise methodology, as familiar as it is essential. Patients with diabetes, hyperlension, or schizophrenia all require careful stratification of risk. The universal applicability of risk stratification to all disciplines of medicine underscores its central importance and the need for ongoing education. (CSNA; **Learning Objectives 2, 3**)

"In every sector of medicine, we always have to balance the risk or burdens of treatment against the benefits. The benefits in analgesic treatment are going to be pain relief, improved functionality, and decreased or at least more appropriate healthcare utilization. The risks include the side effects of the medication, diminution of quality of life as a result, and abuse behaviors, which can be problematic not only to the patient, but for our society."

Neal E. Slatkin, MD

Page 11 of 30 Confidential

*"Browns fair Casuid Dased "Lanagers", a or Persistent and Breakthrough Pain.

Multidisciplinary, collaborative pain management is often required, particularly for complex chronic pain syndromes with demonstrable biopsychosocial elements. (Stanos, 2007; Wiedemer, 2007) Clinical data and experience support the use of opioids, often in combination with behavioral, psychosocial, rehabilitative, and interventional treatments, customized to the individual patient's pain complaint, risk status, and goals. (Pergolizzi, 2008; de Leon-Casasola, 2008; Soares, 2007; Jensen, 2006) Further, patient care is often improved by combining opioids with nonopioid analgesics—α₂δ, tricyclic antidepressants, serotonin norepinephrine reuptake inhibitors, or nonsteroidal anti-inflammatory drugs. (Gilron, 2008) By targeting therapies at distinct neuraxial sites that transduce, transmit, modulate, and perceive pain signals, patients may receive opioid-sparing and additive analgesic effects. (Baron, 2008)

The rationale for multidrug therapy has considerable face validity, although few randomized controlled studies have been performed to date. (Dworkin, 2007; Backonja, 2006; Kalso, 2005) As discussed, classifying pain as neuropathic or nociceptive significantly influences these combination treatment approaches. (Horowitz, 2007; Argoff, 2006) Recently, Gilron and coworkers reported the benefits of a morphine sulfate-gabapentin combination for neuropathic pain. (Gilron, 2005) Many questions remain. Is there differential benefit to sequential or concurrent combination strategies? Should the maximal tolerated dose for monotherapy be achieved before combining a second agent? How should breakthrough pain be treated within this multidrug treatment paradigm? (Raja, 2005) These and other issues require educational fora to foster peer-to-peer learning and to capture the clinical experience with opioid-based multimodal approaches for persistent and breakthrough pain management. (CSNA; Learning Objectives 4, 5)

Dichestraling en Opioid Till.

In his recently published text, *Responsible Opioid Prescribing: A Physician's Guide*, Scott Fishman, MD, describes the model policy of the Federation of State Medical Boards (FSMB) for safe, rational, and transparent prescribing of opioids. (Fishman, 2008) Briefly, the FSMB reinforces the need for thorough assessment and ongoing evaluation of the patient on the formulation and continual refinement of a therapeutic plan. Further, FSMB policy highlights the central importance of tailoring opioid-based therapy commensurate with the degree of risk, and based on a transparent, beneficent, and vigilant relationship with the patient. The paradigm for an opioid trial has been extensively documented, though rarely evaluated in randomized controlled studies. (APS Annual Meeting, 2008) Presently, experts recommend that physicians initiate a trial with predefined functional goals: to achieve control of the baseline pain and to assess and treat fluctuations that break through the multimodal analgesic regimen. (Dy, 2008; Pergolizzi, 2008; Davies, 2008; Portenoy, 2004) There is an urgent need for physicians to integrate this approach into their daily care of patients with chronic pain syndromes. (CSNA; **Learning Objectives 1, 4, 5**)

"Clinicians should make sure that their records are generally complete, but the key is not to just document everything that's going on, but to be transparent about risk management, to recognize that every patient has risk, whether or not they are taking opioids, whether they are being treated for pain or treated for infections with antibiotics. There is risk in doing nothing, and there is risk in doing the treatment. Recognize the risk and have a plan for follow-up. If there is a problem, then there is a risk management plan."

Scott M. Fishman, MD

Page 12 of 30 Confidential

Fractics Based Enfuence for the Oriest Based Mercachians of Persis and Stackthrough Pain

Numerous guidelines and consensus statements recommend the use of regularly scheduled opioid agonists for cancer-related persistent pain. (Pergolizzi, 2008; Moulin, 2007; Trescot, 2006) In addition, "rescue" doses of short-acting and rapid-onset opioids are recommended for the intense fluctuations that often occur despite adequate control of baseline pain—namely, breakthrough pain. (Fishbain, 2008; Aronoff, 2005) For the past 20 years, evidence-based guidelines and empirical decision making in cancer pain management have become the basis by which to evaluate the roles and risks of opioid medications in chronic noncancer pain. (Ballantyne, 2007) Data continue to emerge demonstrating the utility of opioids for common noncancer pain syndromes. (Furlan, 2007; Eisenberg, 2005) Still, more rigorously controlled studies are needed; meanwhile, clinicians must balance evidence-based medicine with practice-based evidence when initiating and maintaining opioid-based therapies. (Davis, 2004; Carr, 2004)

Maintenance of the long-acting opioid (LAO)—based regimen requires continual monitoring and occasional baseline medication adjustments to achieve a measure of dose stability. (Portenoy, 2004) Robust trial data have demonstrated that pharmacologic outcomes—a favorable balance between analgesia and side effects—improve when, during this maintenance phase, breakthrough pain episodes are recognized, assessed, and treated. (Hagen, 2008; Portenoy, 2007; Simpson, 2007; Portenoy, 2006; Zeppetella, 2006; Coluzzi, 2001; Portenoy, 1999; Christie, 1998) Challenges persist, however, and educational programs are required to provide guidance for clinicians to identify well-controlled baseline pain through continual assessment, allowing the independent and tight therapeutic management of breakthrough pain. (CSNA; Learning Objectives 1, 2, 5)

"When clinicians see people who have inadequate pain relief back in their offices, and they're on a long-acting opioid, what it really boils down to during that visit is: Do you decide to raise the background opioid or do you add on another drug, and what drives your decision making at that critical point? And it will depend on how you view the pain phenomenology, the patient, and other factors. And I don't think it's a straightforward question in a disease state in which the best therapies only reduce the background pain by 57 percent."

Steven D. Passik, PhD

Breakthrough pain is not a unitary phenomenon; rather, several subtypes have been evaluated clinically and shown to have telltale characteristics that aid assessment and treatment. (Webster, 2008; Caraceni, 2004; Gutgsell, 2003) First, incident breakthrough pain may be precipitated by volitional (eg, gardening) or nonvolitional (eg, spasm) activity. (Svendsen, 2005) Second, breakthrough pain attributed to end-of-dose failure emerges with a periodicity that coincides roughly with the pharmacokinetic troughs of the baseline medication, typically an LAO. (McCarberg, 2001) Baseline dose adjustments may reduce the frequency and severity of these episodes, although the LAO may reach dose-limiting toxicities, causing some clinicians to switch opioid baseline medications or to prescribe a short-acting opioid to compensate for the drop in LAO serum levels. (Dy, 2008; De Leon-Casasola, 2008) Finally, idiopathic breakthrough pain is associated with paroxysmal spikes that may reach peak intensity in as little as 3-5 minutes. (Portenoy, 2006; Simon, 2006; Bennett, 2005; Portenoy, 1990)

Clinical studies on the differential phenomenology of breakthrough pain subtypes have been limited. The threshold frequency for breakthrough pain episodes that warrants baseline medication adjustments has not been well established. (Svendsen, 2005) Absent clear experimental evidence, clinicians need guidance on the differential diagnosis of breakthrough pain, and the respective roles of long-acting, short-acting, and rapid-onset opioids. (Davies, 2008; Hagen, 2008; Portenoy, 2008) Case-based workshops, reviews of the evidence, and other expert insights into breakthrough pain management are urgently needed. (CSNA; **Learning Objectives 1, 5**)

Page 13 of 30 Confidential

"Can we add some questions to the concept of a comprehensive assessment that speak more to clinical meaningfulness of breakthrough pain and treatment selection? So, for instance, the time to onset, time to severe, or time to clinically meaningful effect. And activities you avoid in an attempt to prevent episodes may help define a scope of fluctuations that should be called breakthrough pain that aren't now described as such?"

Russell K. Portenoy, MD

Pain management perspectives continue to evolve. In particular, several concerns are often noted: lack of data supporting long-term opioid therapy; the occurrence of addictive disease in a subset of patients; inexact risk mitigation methodologies; and the potential for hyperalgesia and for endocrine and immune dysfunction with long-term opioid exposure. (Korff, 2008; Ballantyne, 2007) For some patients, opioids are associated with side effects (eg, constipation, pruritis, and sedation), poor tolerability, and serious adverse events such as respiratory depression and, as discussed, misuse, abuse, and diversion. (Harris, 2007) In addition, clinicians need to clarify the nomenclature and clinical constructs of physical dependence, tolerance, pseudotolerance, addiction, and pseudoaddiction. (Jage, 2005; Savage, 2003) (CSNA; **Learning Objective 6**) These and other safety concerns—identifying opioid-tolerant patients, for instance—rightly rank as paramount among clinicians, and demand continual and comprehensive evaluation of patient compliance and therapeutic response, informed by predefined functional goals. (Rosenblum, 2008) Educational programs should raise awareness of these issues and provide practical guidance to minimize their impact on patient care. (CSNA; **Learning Objectives 2, 4**)

"For some patients, the therapeutic window is the size of the Texas plains and you can give them medicines without much worry. But there are individuals who are extremely sensitive to medicines and instead of being the size of the Texas plains, the window is the size of a New York City street during rush hour: tight, small, and difficult to manage. When you're trying to treat these patients, you need very precise control of the medications."

Michael J. Brennan, MD

Clearly, patient selection is the linchpin of effective opioid-based therapy. (Portenoy, 2008; Antoin, 2004) Individuals vary across multiple dimensions: in their response to nonpharmacologic and pharmacologic treatment options; in their pain phenomenology; in their affective behavior during therapy; and in their propensity for irresponsible medication use. Despite current and emerging data, no one opioid molecule—oxycodone, fentanyl, or morphine, for instance—has an *a priori* advantage over another. And data delineating the respective roles of long-acting, short-acting, and rapid-onset opioids in managing the persistent and breakthrough components of chronic pain are only beginning to emerge. (Simon, 2005) Clinicians thus need expert input on how best to structure opioid-based therapy in the context of a well orchestrated N-of-1 trial.

Multidimensional assessment governs multimodal therapeutic decision making, but the gap between evidence-based medicine and the practical, day-to-day management of patients with persistent and breakthrough pain is considerable and, for some, even prohibitive. Rational, transparent prescribing of opioids among appropriately selected patients thus presents formidable challenges that can only be met by rigorous educational efforts. (CSNA; Learning Objectives 3, 4)

Page 14 of 30 Confidential

References

Abernethy AP, et al; Am J Manag Care. 2008 May;14(5 Suppl 1):S129-40; A health economic model of breakthrough pain.

Adams N; Psychological approaches to chronic pain management: part 1; J Clin Nurs. 2006 Mar;15(3):290-300.

Akbik H, et al; Validation and clinical application of the Screener and Opioid Assessment for Patients with Pain (SOAPP); J Pain Symptom Manage. 2006 Sep;32(3):287-93.

American Pain Society; Pain: Current Understanding of Assessment, Management and Treatments Section I: Background and Significance; Accessed October. 2008.

American Pain Society; Guideline for the Management of Cancer Pain in Adults and Children; 2005.

Antoin H, Beasley RD.; Opioids for chronic noncancer pain. Tailoring therapy to fit the patient and the pain; Postgrad Med. 2004 Sep;116(3):37-40, 43-4.

Argoff CE, et al; Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain; Mayo Clin Proc. 2006 Apr;81 (4 Suppl):S12-25.

Aronoff GM; Evidence-based oral transmucosal fentanyl citrate (OTFC) dosing guidelines; Pain Med. 2005 Jul-Aug;6(4):305-14.

Backonja MM; Rational multidrug therapy in the treatment of neuropathic pain; Curr Pain Headache Rep. 2006 Feb;10(1):34-8.

Ballantyne JC; Comparative efficacy of epidural, subarachnoid, and intracerebroventricular opioids in patients with pain due to cancer. Cochrane Database Syst Rev. 2005 Jan 25. (1).

Ballantyne JC, Shin NS., Efficacy of opioids for chronic pain: a review of the evidence; Clin J Pain. 2008 Jul-Aug;24(6):469-78.

Ballanlyne JC, Mao; J.; Opioid therapy for chronic pain, N Engl J Med. 2003 Nov 13;349(20):1943-53.

Ballantyne JC.; Opioid analgesia: perspectives on right use and utility; Pain Physician. 2007 May;10(3):479-91

Barbuto JP, et al; Chronic pain: second, do no harm; Am J Phys Med Rehabil. 2008 Jan;87(1):78-83.

Baron R.; Mechanisms of disease: neuropathic pain--a clinical perspective; Nat Clin Pract Neurol. 2006 Feb;2(2):95-106.

Baron R, Tölle TR; Assessment and diagnosis of neuropathic pain; Curr Opin Support Palliat Care; 2008 Mar;2(1):1-8

Belgrade MJ, et al; The DIRE score: predicting outcomes of opioid prescribing for chronic pain; J Pain. 2006 Sep;7(9):671-81.

Bennett, et al; Consensus Panel Recommendations for the Assessment and Management of Breakthrough Pain Part I Assessment; P&T, May 2005, Vol. 30 No. 5.

Bennett DS, et al; Prevalence and characteristics of breakthrough pain in patients receiving opioids for chronic back pain in pain specialty clinics.; J Opioid Manag. 2007 Mar-Apr;3(2):101-6.

Benyamin R; Opioid complications and side effects; Pain Physician. 2008 Mar;11(2 Suppl):S105-20.

Berger AM et al; Principles and Practice of Palliative Care and Supportive Oncology; ISBN 0781795958, 9780781795951; Lippincott Williams & Wilkins, 2006

Blick SK; Fentanyl buccal tablet: in breakthrough pain in opioid-tolerant patients with cancer; Drugs. 2006;66(18):2387-93.

Breivik H, et al; Assessment of pain; Br J Anaesth. 2008 Jul;101(1):17-24.

Butler SF, Budman SH, Fernandez K, Jamison RN. Validation of a screener and opioid assessment measure for patients with chronic pain. Pain. 2004; 112:65-75.

Caraceni A; Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey; Palliat Med. 2004 Apr;18(3):177-83.

Page 15 of 30 Confidential

Caraceni A; An international survey of cancer pain characteristics and syndromes. IASP TaskForce on Cancer Pain. International Association for the Study of Pain; Pain. 1999 Sep;82(3):263-74.

Carr DB et al; Evidence report on the treatment of pain in cancer patients. J Natl Cancer Inst Monogr. 2004; (32):23-31.

CASA Center on Addiction and Substance Abuse at Columbia University National Survey of American Attitudes on Substance Abuse XIII: Teens and Parents; August 2008.

CASA Center on Addiction and Substance Abuse at Columbia University. Under the Counter: The Diversion and Abuse of Controlled Prescription Drugs in the U.S. New York, NY: Center on Addiction and Substance Abuse; 2005. (Available at http://www.casacolumbia.org/Absolutenm/articlefiles/380 final_report_not_embargoed.pdf).

Cherny et al; Strategies to manage the adverse effects of oral morphine: an evidence-based report; J Clin Oncol. 2001 May 1;19(9):2542-54.

Christie JM; Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain; J Clin Oncol. 1998 Oct; 16(10):3238-45.

Coluzzi PH; Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR); Pain. 2001 Mar;91(1-2):123-30.

Coluzzi F, et al; Opioid therapy for chronic noncancer pain: practice guidelines for initiation and maintenance of therapy; Minerva Anestesiol. 2005 Jul-Aug;71(7-8):425-33.

Comley, et al; Pain management: clinician survey and institutional needs assessment; Proc (Bayl Univ Med Cent). 2000 July; 13(3): 230-235.

Davidson MA, et al; Chronic pain assessment: a seven-factor model; Pain Res Manag. 2008 Jul-Aug;13(4):299-308.

Davis MP; Practical guide to opioids and their complications in managing cancer pain. What oncologists need to know; Oncology (Williston Park). 2007 Sep;21(10):1229-38.

Davis MP; Opioid dose titration for severe cancer pain: a systematic evidence-based review; J Palliat Med. 2004 Jun;7(3):462-8.

Davies AN, et al; An observational study of oncology patients' utilization of breakthrough pain medication; J Pain Symptom Manage. 2008 Apr;35(4):406-11.

Davies AN, et al; The management of cancer-related breakthrough pain: Recommendations of a task group of the Science Committee of the Association for Palliative Medicine of reat Britain and Ireland; Eur J Pain. 2008 Aug 14.

de Leon-Casasola OA; Current developments in opioid therapy for management of cancer pain; Clin J Pain. 2008 May;24 Suppl 10:S3-7.

Denisco RA, Addressing the intersecting problems of opioid misuse and chronic pain treatment; Exp Clin Psychopharmacol. 2008 Oct;16(5).417-28.

Du Pen SL; Implementing guidelines for cancer pain management: results of a randomized controlled clinical trial; J Clin Oncol. 1999 Jan;17(1):361-70.

Dworkin RH, et al; Pharmacologic management of neuropathic pain: evidence-based recommendations; Pain. 2007 Dec 5;132(3):237-51.

Dy SM; Evidence-based standards for cancer pain management; J Clin Oncol. 2008 Aug 10;26(23):3879-85.

Edlund MJ; Do users of regularly prescribed opioids have higher rates of substance use problems than nonusers?; Pain Med. 2007 Nov-Dec;8(8):647-56.

Eisenberg E, et al; Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin. systematic review and meta-analysis of randomized controlled trials; JAMA. 2005 Jun 22;293(24):3043-52.

Expert Panel on Breakthrough Pain, Russell K. Portenoy, Chair; January, 2006, Washington, D.C.

Fishbain DA; Pharmacotherapeutic management of breakthrough pain in patients with chronic

Fishman, S; Responsible Opioid Prescribing: A Physician's Guide; Federation of State Medical Boards; Published by Waterford Life Sciences, Washington D.C., Copyright © 2007.

Page 16 of 30 Confidential

Fortner BV, et al; A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain; J Pain. 2002 Feb;3(1):38-44.

Fortner BV, et al; Description and predictors of direct and indirect costs of pain reported by cancer patients. J Pain Symptom Manage. 2003 Jan;25(1):9-18.

Furlan AD, et al; Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects; CMAJ. 2006 May 23;174(11):1589-94.

Galluzzi KE.; Managing neuropathic pain; J Am Osteopath Assoc. 2007 Nov;107(10 Suppl 6):ES39-48.

Gilron I.; Optimizing neuropathic pain pharmacotherapy: add on or switch over?; Nat Clin Pract Neurol. 2008 Aug;4(8):414-5. Epub 2008 Jun 17.

Gilron I, Max MB.; Combination pharmacotherapy for neuropathic pain: current evidence and future directions.; Expert Rev Neurother. 2005 Nov;5(6):823-30.

Gilron I, et al; Morphine, gabapentin, or their combination for neuropathic pain; N Engl J Med. 2005 Mar 31;352(13):1324-34.

Gore M, et al; Burden of illness in painful diabetic peripheral neuropathy: the patients' perspectives; J Pain. 2006 Dec;7(12):892-900.

Gourlay DL et al; Universal precautions in pain medicine: a rational approach to the treatment of chronic pain; Pain Med. 2005 Mar-Apr;6(2):107-12.

Gutgsell T; A prospective study of the pathophysiology and clinical characteristics of pain in a palliative medicine population; Am J Hosp Palliat Care. 2003 Mar-Apr;20(2):140-8.

Hagen NA; Assessment and management of breakthrough pain in cancer patients: current approaches and emerging research; Curr Pain Headache Rep 2008 Aug;12(4):241-8.

Hagen NA; A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials; J Palliat Med. 2007 Feb;10(1):47-55.

Hagen, et al; The Alberta Breakthrough Pain Assessment Tool for cancer patients: a validation study using a delphi process and patient think-aloud interviews; Journal of Pain and Symptom Management; Feb 2008 Volume 35; Issue 2

Hale M, et al; Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis;

Harris JD; Management of expected and unexpected opioid-related side effects; Clin Ther. 2007 May;29(5):874-88.; Clin J Pain. 2008 May;24 Suppl 10:S8-S13.

Horowitz SH; The diagnostic workup of patients with neuropathic pain; Med Clin North Am. 2007 Jan;91(1):21-30.

Hwang SS, Cancer breakthrough pain characteristics and responses to treatment at a VA medical center, Pain. 2003 Jan;101(1-2):55-64.

Ives TJ, et al; Predictors of opioid misuse in patients with chronic pain: a prospective cohort study; BMC Health Serv Res. 2006 Apr 4;6:46.

Jage J; Opioid tolerance and dependence -- do they matter?; Eur J Pain. 2005 Apr;9(2):157-62.

Jensen TS, et al; New perspectives on the management of diabetic peripheral neuropathic pain; Diab Vasc Dis Res. 2006 Sep;3(2):108-19.

Korff MV; De facto long-term opioid therapy for noncancer pain; Clin J Pain. 2008 Jul-Aug;24(6):521-7.

Kalso E; Opioids in chronic non-cancer pain: systematic review of efficacy and safety; Pain. 2004 Dec, 112(3):372-80.;

Kalso E; Improving opioid effectiveness; from ideas to evidence; Eur J Pain. 2005 Apr; 9(2):131-5.

Katz N; Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep. 2008 Jan; 10(1):11-8.

Katz NP; Challenges in the development of prescription opioid abuse-deterrent formulation; Clin J Pain. 2007 Oct; 23(8):648-60.

Keeney CE; Initiating and sustaining a standardized pain management program in long-term care facilities; J Am Med Dir Assoc. 2008 Jun;9(5):347-53.

Page 17 of 30 Confidential

Lin JJ, Physician attitudes toward opioid prescribing for patients with persistent noncancer pain; Clin J Pain. 2007 Nov-Dec; 23(9):799-803.

Locker S; Holistic assessment of cancer patients' pain: reflections on current practice; Int J Palliat Nurs. 2008 Feb;14(2):77-84.

Maag R, Baron R.; Neuropathic pain: translational research and impact for patient care; Curr Pain Headache Rep. 2006 Jun; 10(3):191-8.

Marcus KS, et al; HIV/AIDS-related pain as a chronic pain condition: implications of a biopsychosocial model for comprehensive assessment and effective management; Pain Med. 2000 Sep;1(3):260-73.

Martelli MF, et al; Psychological, neuropsychological, and medical considerations in assessment and management of pain; J Head Trauma Rehabil. 2004 Jan-Feb; 19(1):10-28.

McCarberg BH et al. The impact of pain on quality of life and the unmet needs of pain management: results from pain sufferers and physicians participating in an Internet survey; Am J Ther. 2008 Jul-Aug;15(4):312-20.

McMahon, S, Koltzenburg, M; Wall and Melzack's Textbook of Pain, Fifth Edition; Hardbound, 1280 pages, publication date: SEP-2005; ISBN-13: 978-0-443-07287-1; Imprint: Churchill Livingstone.

Mercadante S; Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care; Cancer. 2002 Feb 1;94(3):832-9.

Mercadante S, et al; Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain; Br J Cancer. 2007 Jun 18;96(12):1828-33. Epub 2007 May 22.

Mercadante S, et al; Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine; J Pain Symptom Manage. 2006 Aug;32(2):175-9;

Merskey and Bogduk; Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms, Second Edition; International Association for the Study of Pain (IASP) 1994 Task Force on Taxonomy ISBN 978-0-931092-05-3.

Miaskowski C, et al. Cancer Pain Management. Guideline for the Management of Cancer Pain in Adults and Children, APS Clinical Practice Guidelines Reprinted with permission of the American Pain Society. 3rd ed. Glenview, IL; American Pain Society; 2005. p. 39-48.

Moulin DE, et al; Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society; Pain Res Manag. 2007 Spring;12(1):13-21.

Mystakıdou K, et al; Oral transmucosal fentanyl citrate: overview of pharmacological and clinical characteristics; Drug Deliv. 2006 Jul-Aug; 13(4).269-76

Nicholson B. Responsible prescribing of opioids for the management of chronic pain. Drugs 2003; 63(1):17-32.

Noble M, et al, Long-term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety; J Pain Symptom Manage. 2008 Feb;35(2):214-28.

Passik SD, Kirsh KL.; The interface between pain and drug abuse and the evolution of strategies to optimize pain management while minimizing drug abuse; Exp Olin Psychopharmacol. 2008 Oct;16(5):400-4.

Passik SD, et al; Monitoring outcomes during long-term opioid therapy for noncancer pain: results with the Pain Assessment and Documentation Tool; J Opicid Manag. 2005 Nov-Dec;1(5):257-66.

Pasternak GW; Molecular biology of opioid analgesia; J Pain Symptom Manage. 2005 May;29(5 Suppl):S2-9.

Pergolizzi J et al; Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone); Pair Pract. 2008 Jul-Aug;8(4):287-313.

Portenoy, RK; American Conference on Pain Medicine 2008; Keynote Address

Portenoy RK, et al; Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study; Clin J Pain. 2007 May;23(4):287-99.

Page 18 of 30 Confidential

Portenoy RK; Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain; J Pain. 2006 Aug;7(8):583-91.

Portenoy RK; Breakthrough pain: definition, prevalence and characteristics; Pain. 1990 Jun;41(3):273-81.

Portenoy RK; Breakthrough pain: definition and management; Oncology (Williston Park). 1989 Aug;3(8 Suppl):25-9.

Portenoy RK.; Appropriate use of opioids for persistent non-cancer pain; Lancet. 2004 Aug 28-Sep 3;364(9436):739-40.

Portenoy RK; Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study; Pain. 1999 Feb;79(2-3):303-12.

Portency RK; Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain; J Pain. 2006. Aug;7(8):583-91.

Portenoy RK; Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study; Curr Med Res Opin. 2007 Jan;23(1):223-33.

Portenoy RK; A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer; Clin J Pain. 2006 Nov-Dec;22(9):805-11.

Raja SN, Haythornthwaite JA.; Combination therapy for neuropathic pain--which drugs, which combination, which patients?; N Engl J Med. 2005 Mar 31:352(13):1373-5.

Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, Lewis DR, Clegg L, Eisner MP, Reichman M, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER web site, 2008.

Riley JL 3rd, Hastie BA; Individual differences in opioid efficacy for chronic noncancer pain; Clin J Pain. 2008 Jul-Aug;24(6):509-20.

Robinson CL; Relieving pain in the elderly; Health Prog. 2007 Jan-Feb;88(1):48-53, 70.

Rosenblum A, et al; Opioids and the treatment of chronic pain: Controversies, current status, and future directions; Exp Clin Psychopharmacol. 2008 Oct;16(5):405-16.

Savage SR, et al; Definitions related to the medical use of opioids: evolution towards universal agreement; J Pain Symptom Manage. 2003 Jul;26(1):655-67.

Simon S; Breakthrough pain in opioid-treated patients with neuropathic pain; J Opioid Manag. 2006 Nov-Dec;2(6):347-52.

Simon S.; Opioids and treatment of chronic pain; understanding pain patterns and the role for rapid-onset opioids; MedGenMed. 2005 Nov 23;7(4):54.

Simpson DM; Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study; Clin Ther. 2007 Apr;29(4):588-601.

Soares; The rationale for a multimodal approach in the management of breakthrough cancer pain: a review; Am J Hosp Palliat Care. 2007 Oct-Nov;24(5):430-9. Epub 2007 Jun 20.

SAMHSA; Substance Abuse and Mental Health Services Administration. Results from the 2004 National Survey on Drug Use and Health: National Findings. NSDUH Series H-28, DHHS Publication No. SMA 05-406.

Soares LG and Chan VW; The rationale for a multimodal approach in the management of breakthrough cancer pain: a review; Am J Hosp Palliat Care. 2007 Oct-Nov;24(5):430-9.

Stanos SP, et al; Physical medicine rehabilitation approach to pain; Anesthesiol Clin 2007 Dec; 25(4):721-59, v-vi.

Swanwick M; The prevalence of episodic pain in cancer: a survey of hospice patients on Admission; Palliat Med. 2001 Jan; 15(1):9-18.

Svendsen KB, et al; Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms; Eur J Pain. 2005 Apr;9(2):195-206.

Page 19 of 30 Confidential

Taylor DR, et al; Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ); Pain Med. 2007 Apr;8(3):281-8.

Trescot AM; Opioid guidelines in the management of chronic non-cancer pain; Pain Physician. 2006 Jan;9(1):1-39.

Walid MS et al; The Fifth Vital Sign-What Does It Mean? Pain Pract. 2008 Jul 25.

Walsh D; Strategies for pain management: cleveland clinic foundation guidelines for opioid dosing for cancer pain; Support Cancer Ther. 2004 Apr 1;1(3):157-64

Wasan AD; Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain; Clin J Pain. 2007 May;23(4):307-15.

Wasan AD, Davar G, Jamison R.; The association between negative affect and opioid analgesia in patients with discogenic low back pain; Pain. 2005 Oct;117(3):450-61.

Webster LR; Breakthrough pain in the management of chronic persistent pain syndromes; Am J Manag Care. 2008 May;14(5 Suppl 1):S116-22.

Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2005; 6:432-442.

Wiedemer, N. L; The Opioid Renewal Clinic: A Primary Care, Managed Approach to Opioid Therapy in Chronic Pain Patients at Risk for Substance Abuse; Pain Medicine; 8 (7):573 - 584

William L; Management of breakthrough pain in patients with cancer; Drugs. 2008;68(7):913-24.

Wool MS, Mor V; A multidimensional model for understanding cancer pain; Cancer Invest. 2005;23(8):727-34.

Woolf CJ.; Central sensitization: uncovering the relation between pain and plasticity; Anesthesiology. 2007 Apr;106(4):864-7.

Woolf CJ.; Dissecting out mechanisms responsible for peripheral neuropathic pain: implications for diagnosis and therapy; Life Sci. 2004 Apr 9;74(21):2605-10.

Yennurajalingam S, et al; Recent developments in cancer pain assessment and management; Support Cancer Ther. 2004 Jan 1;1(2):97-110.

Zeppetella G; Opioids for the management of breakthrough (episodic) pain in cancer patients; Cochrane Database Syst Rev. 2006 Jan 25;(1)

Page 20 of 30 Confidential

IV. Faculty and Programs

Potertial Foculty

Under the direction of David Kaufman, MD, Professor of Neurology and Psychiatry at Albert Einstein College of Medicine, and the Albert Einstein College of Medicine, qualified faculty will be selected and may include the following:

Michael J. Brennan, MD

Chief of Rehabilitation Medicine

Bridgeport Hospital

Bridgeport, Connecticut

David A. Fishbain, MD

Professor of Psychiatry, Adjunct Professor of Anesthesiology and Neurological Surgery

Leonard M. Miller School of Medicine

University of Miami

Miami, Florida

Scott M. Fishman, MD

Professor of Anesthesiology Chief, Division of Pain Medicine University of California, Davis

Sacramento, California

Gordon Irving, MD

Medical Director, Swedish Pain Center

747 Broadway

Seattle, Washington Seattle, WA 98122

Bill McCarberg, MD

Founder, Chronic Pain Management Program

Kaiser Permanente

Escondido, California

Sebastiano Mercadante, MD

La Maddalena Cancer Center

University of Palermo

Pain Relief & palliative care

Via S. Lorenzo Colli 312

90146 Palermo, ITALY.

Christine Miaskowski, RN, PhD, FAAN

Professor and Chair

Department of Physiological Nursing

UCSF School of Nursing,

San Francisco, California

Judith A. Paice, RN, PhD

Research Professor

Northwestern University Feinberg School of Medicine

Chicago, Illinois

Steven D. Passik, PhD

Clinical Psychologist

Memorial Sloan-Kettering Cancer Center

New York, New York

John Peppin, DO, FACP

Director

Iowa Pain Management Clinic

Des Moines, Iowa

Russell K. Portenoy, MD

Chairman

Department of Pain Medicine and Palliative Care

Beth Israel Medical Center

New York, New York

Neil E. Slatkin, MD, DABPM

Director

Department of Supportive Care, Pain & Palliative Medicine

City of Hope Medical Center

Duarte, California

Lynn R. Webster, MD, FACPM, FASAM

Medical Director

Chief Executive Officer

Lifetree Clinical Research and Pain Clinic

Salt Lake City, Utah

Giovambattista Zeppetella, MD

St Clare Hospice

Hastingwood Road


Hastingwood, Essex CM17 9JX, UK

Page 21 of 30

Confidential

Education a Programs and Materials

Einstein and Asante recommend developing a comprehensive, accredited, and integrated CME initiative comprising each of the proposed tactics. Further, we recommend folding the educational programs and materials under a unifying and meaningful acronym, linking them conceptually, and assuring clinicians of their quality, accuracy, and clinical relevance.



Chronic Pain Management Preceptorships

In this pilot program, approximately two-hundred (~n=200) US-based pain management clinicians will participate in a preceptorship focusing on opioid-based care of patients with chronic pain. The program will provide a forum for each clinician to interact with national thought leaders via monthly WebPanel series. The interactions will be structured around previously identified areas of educational need and interest, as determined by CSNA and as described in the learning objectives. An initial 30-minute teleconference call with the community-based pain clinicians and national thought leader will launch the pilot program, followed by 15-30 minute quarterly WebPanel calls and, potentially, a meeting at a major medical congress, half-day or full-day regional meeting. Participants will be required to participate in at least three distinct activities; and would be encouraged to participate in a live regional meeting, to be held near to a Pain Center of Excellence identified by the American Pain Society (see below). Upon completion of this program, participants will receive up to 4 hours of CME credit and a complimentary copy of *Rational Opioid Prescribing, A Physician's Guide*, by Scott Fishman, MD, and/or a copy of *Diagnosis and Treatment of Breakthrough Pain*, by Perry Fine, MD. Together, the books effectively summarize the essential elements in developing opioid-based regimens for patients with chronic pain syndromes.

Participants will be encouraged to share their newly acquired knowledge with their colleagues, potentially through a variety of outlets, including, but not limited to, in-services, lectures, and institutional publications. Upon completion of the educational series, and demonstration of improved and durable improvements in awareness, knowledge and performance (see Outcomes Measurement), select clinicians may be invited to participate as adjunct faculty for 2010 educational programs held in their respective regions. Working with national thought leaders, each adjunct faculty member will contribute to educational offerings—some in their local communities—on the assessment, differential diagnosis, and individualization of care for patients with persistent and breakthrough pain, potentially creating regional centers of excellence in pain management.

Page 22 of 30 Confidential

"This proposed preceptorship is superb! This is exactly what many of us have been discussing as a significant need—both for pain and for palliative care. The link to the centers of excellence is great—these are wonderful clinical centers. Some are more academic (NYU, Brigham) and others are more of a private practice model. This would allow participants a wider array of experiences. The outcomes described are perfect."

Judith A. Paice, PhD, RN

Persistent and Breakthrough Pain Management in Cancer Survivors: Mechanism-Based Treatment for a Growing Patient Population (A Full-Day Regional Meeting)

Chronic pain in cancer survivors is an important yet under-studied problem. The prevalence of patients in long-term remission from a variety of cancer syndromes continues to grow, as does the need for guidance on how best to manage their complex pain states, particularly those with other medical and psychiatric comorbidities. Chronic pain and other long-term sequelae related to the disease and to medical, surgical, and radiation treatments significantly impair patient function and healthcare utilization, increasing the burden of illness on patients, their families, and society. This full-day workshop will consist of a morning lecture and panel session with veteran clinicians either currently or formerly associated with Memorial Sloan-Kettering Cancer Center (MSKCC). Their tenure at this premier facility will serve as a backdrop against which cancer survivorship and advances in the care of patients with cancer-related pain will be evaluated. In the afternoon session, participants will engage in a *Cases and Commentary* roundtable discussion.

Participants will receive a complimentary copy of *Rational Opioid Prescribing, A Physician's Guide*, by Scott Fishman, MD, and a copy of *Diagnosis and Treatment of Breakthrough Pain*, by Perry Fine, MD. The activity will be eligible for up to 8 hours of CME credit to physicians. Anticipated attendance is 75-100 physicians.

Satellite Web-Broadcast

Presently, the projection for attendance is 75-100 participants per full-day workshop, drawn primarily from the local and regional communities. To ensure access to other interested clinicians from across the country, a Web cast posted on Medscape or similar pain-related website (eg, www.pain.edu) is proposed. Distance learning is now turnkey, and each participant will be able to access the slide deck, related materials online, and highlights from the meeting. The activity will be eligible for up to 3 hours of CME credit to physicians. Anticipated reach is estimated to be over 20,000 physicians for the online activity.

Cases & Commentary™ Workshop

The Cases & CommentaryTM Workshop format is based, in part, on a small group case-based learning (SGCBL) model, allowing attendees to discuss therapeutic decision making across several case studies. Participants will benefit from the peer-to-peer design of the roundtable discussions, empowering them to listen, to probe, and to proffer solutions with their peers. The workshop provides a forum for exchange of insights into current diagnostic and therapeutic strategies. For those participants whose approach to decision making is aligned with that of their peers and thought leaders, the workshop will validate their own practice. Most participants will acquire knowledge across multiple facets of complicated disease states and patient care.

Eligible for 4 hours of CME credit each, the workshop will include no more than 50-75 participants (total n=~225), who will engage in small group discussions to evaluate best practices in persistent and breakthrough pain management. Each study group may include neurologists, physiatrists, anesthesiologists, and psychologists, and will be facilitated by a key thought leader

Page 23 of 30 Confidential

in pain medicine. In evaluations of previous workshops, most attendees rated the overall activity as "excellent," providing favorable comments regarding both the faculty and learning environment.

The meetings will be presented at regional locations across the country, selected from the 2007 American Pain Society Centers of Excellence. Suggested venues therefore may include the following:

- NYU Medical Center / Hospital for Joint Diseases, Bellevue Hospital Center, Comprehensive Pain Management Center, New York
- The Rosomoff Comprehensive Pain Center, Miami
- Brigham and Women's Hospital, Pain Management Center, Department of Anesthesiology, Perioperative and Pain Medicine, Boston
- UCSF Pain Management Center and UCSF PainCARE, Center for Advanced Research and Education, San Francisco
- · Cincinnati Children's Hospital Medical Center, Division of Pain Management

Cases & Commentary Monograph

The case-based discussions will be audiotaped and provide substantial commentary ideally suited for a 4,500 word print monograph. The monograph will be posted on a pain-relevant website (eg www.medscape.com; www.pain.edu), distributed to pain specialists through *Pain Medicine News*, a leading trade journal with a wide readership, and/or through PainClinician™, our proprietary database and quarterly distribution vehicle. Written in a narrative style, the case-based monograph will convey best practices in the initial patient presentation, assessment, diagnosis, and formulation and ongoing refinement of therapeutic plans for chronic pain. Successful completion of a 10-question multiple-choice self-assessment examination based on the content presented is necessary to receive a certificate of completion. Participants must score 70% or higher and are allowed 2 attempts to successfully complete the exam. Upon successful completion of the monograph, physicians may use the CME credit earned toward their licensure and/or certification requirements. The activity will be eligible for 1 hour of credit to physicians for 1 year from the issuance date. Anticipated reach is estimated to be over 45,000 physicians for the print monograph in addition to 5,000-10,000 online recipients.

International Expert Forum and Position Paper on Persistent and Breakthrough Pain Management

Davies and coworkers recently published a task force series of recommendations on the management of breakthrough pain. (Davies, 2008) Interestingly, the experts stopped short of making specific treatment recommendations, and instead provided a conceptual framework to guide decision making. Citing the lack of evidence, the experts emphasized a carefully balanced and ongoing assessment and multimodal strategy for the management of breakthrough pain.

In this proposed expert forum, three prominent US based pain clinicians will explore the findings and implications of the Davies report with and two European leaders (eg Giovambattista Zeppetella, MD, Sebastiano Mercadante, MD). The program will consist of several teleconference calls and/or videoconferences, potentially culminating in a meeting at a medical congress. Salient recommendations would provide the substrate for a 6,500-word position paper on persistent and breakthrough pain management, to be posted on a pain-relevant website, and distributed through PainClinician™, our proprietary database and quarterly distribution vehicle. Based on the response from pain clinicians who participated in an international forum on persistent and breakthrough pain management recently held in Glasgow, Scotland, this expert panel may receive acknowledgement from the International Association for the Study of Pain (IASP). The activity will be eligible for 1+ hour(s) of credit to physicians for 1 year from the issuance date. Anticipated reach is estimated to be over 35,000 physicians for the print portion in addition to over 15,000-20,000 online recipients.

Page 24 of 30 Confidentia

Confidential

Teleconference Series

A CME audio teleconference brings together the live educational format preferred by many healthcare professionals with the convenience of participating in the activity at home or in the office. Available to a national audience, this format provides clinicians with an opportunity to participate in a lecture led by a thought leader as well as to interact with peers across the country.

This activity will be presented eight (8) times by nationally recognized thought leaders in pain management. Anticipated participation in each broadcast will be 25-50 participants (total n=~200-400), they will be approximately 45 minutes in length, with a 10-minute question-and-answer session completing the program. A teleconference syllabus will be mailed to the participants 48 hours prior to the presentation. Participants will phone in to a reserved line to listen to the lecturer elaborate on the slide content. The activity will be eligible for 1 hour of CME credit to participants.

Teleconference Series Monograph

The teleconferences will be audiotaped and provide commentary ideally suited for a 4,500 word print monograph. The monograph will be posted on a pain-relevant website, distributed to pain specialists through *Pain Medicine News*, a leading trade journal with a wide readership, and direct-mailed to pain practitioners enrolled in PainClinician[™], our proprietary database. Written in a narrative style, the case-based monograph will convey best practices in persistent and breakthrough pain management. Successful completion of a 10-question multiple-choice self-assessment examination based on the content presented is necessary to receive a certificate of completion. Participants must score 70% or higher and are allowed 2 attempts to successfully complete the exam. Upon successful completion of the monograph, physicians may use the CME credit earned toward their licensure and/or certification requirements. The activity will be eligible for 1 hour of credit to physicians for 1 year from the issuance date. Anticipated reach is estimated to be over 45,000 physicians for the print monograph in addition to over 5,000-10,000 online recipients.

Albert Einstein's Persistent and Breakthrough Pain Reference Compendium

Editor: Russell K. Portenoy, MO Professor of Neurology

Reference manuals provide healthcare professionals with an authoritative educational tool in a condensed format that is easily transported from one clinical setting to another. This reference compendium will provide pain clinicians with practical information in a condensed format for quick reference. Pain and risk screening tools, equianalgesic dosing and other relevant information will be included. This text will include frequently asked questions and answers culled from various fora, including teleconferences and regional meetings. Posed by community pain clinicians, nurses, and psychologists, the questions address the fundamental issues in the management of chronic pain syndromes, from cancer-related pain to osteoarthritis. The responses will be drafted by leading experts in the field; a guest editor for this annual series will provide a preface and additional commentary throughout the text. Exhaustively referenced, this print activity will be available online and eligible for 1-2 hours of continuing education credit to participants. A 10-question multiple-choice self-assessment examination based on the content presented will be included. Successful completion of the posttest is necessary to receive certificate of completion/statement of credit. Anticipated reach is estimated to be over 45,000 physicians for the print monograph in addition to 5,000-10,000 online recipients.

Pace 25 of 30 Confidential

Additional Tactics for Future Consideration

Pursished and Preakfire (c) Paint Evidence-Point Practice and Practice Basild Evidence

In this print and online series, expert thought leaders will elaborate on the seminal studies supporting the management of persistent and breakthrough pain, conducted over the past twenty years, since Drs Portenoy and Hagen published their seminal work in 1990. Abstracts of select studies will be included, and will help frame the discussion on salient issues in chronic pain management. Randomized controlled studies include patient populations with rigorously defined inclusion and exclusion criteria, often precluding generalizable and practical recommendations. Here, clinicians will discuss several landmark study findings, their limitations and implications for current approaches to assessment and individualization of patient care. Particular emphasis will be placed on the soon-to-be published guidelines from the American Pain Society, providing pain clinicians with guidance on how to interpret and implement their recommendations, bridging the gap between what we know and what we don't know with practice based clinical experience and evidence.

Web-Based Decision Tree (Program Name and URL Will Be Provided Upon Request).

This activity purports to integrate the expert clinical experience with the Level 1 Evidence of randomized controlled studies. Two objectives are served. First, clinicians acquire a more in-depth understanding of the evidence-based recommendations in various guidelines. (Of note, the American Pain Society will be publishing its guidelines in the near term.) This knowledge will help clinicians find a more practical expression of guidelines that too often cannot be implemented. Second, clinicians will refine their clinical judgment by engaging in structured decision making—the art of medicine—that drives patient care, particularly when specific evidence is lacking. In this Web-based activity, clinicians will be presented with case studies representative of the myriad issues in managing patients with persistent and breakthrough pain. Case studies may address chronic pain associated with tumor progression, radiation or chemotherapy-related pain in cancer survivors, diabetic peripheral neuropathy, and chronic low back pain.

Upon reviewing salient data—including, for instance, patient history, comorbidities, prior treatment history, pathophysiology, imaging studies, and laboratory findings—the clinicians will develop in step-by-step fashion a course of action. At each step, from assessment and diagnosis; to the initial and revised treatment, the clinician may choose among several options, each informed by well-designed studies and each having risks and benefits. These data will, of course, only be available to the clinicians upon making their selections. With only one "click," clinicians will gain access to a brief abstract summarizing the available evidence and a video of a thought leader roundtable discussion framing the available evidence. Links to seminal scientific and/or randomized controlled studies will be readily accessible and adjacent to each video presentation. When available, evidence-based outcomes—eg, pain reduction and functional improvement—of each treatment selection will be discussed. This self-directed case-based learning provides a familiar educational format for healthcare professionals based on adult learning principles, and consistently rates as a highly effective means by which to educate clinicians.

Case-In-Point and Accompanying Monograph

This roundtable discussion will feature several pain specialists, two from prominent academic centers and another from private practice. Faculty will present several complicated case studies, elaborating on the evidence for various treatment modalities. Twenty-five community-based clinicians—neurologists, psychologists, physician assistants, and nurses—will be invited to listen and to join in the discussion at appropriate times. This "chronic pain-in-the round" program will be video captured to form the basis for podcasts posted on a pain management Web site (eg, www.pain.edu) that includes practical, evidence-based resources for pain specialists.

Page 26 of 30 Confidential

The recorded sessions are edited professionally and reduced to 10-minute video vignettes, concise and uninterrupted discussions that capture the thought leaders' expert insights into the management of persistent and breakthrough pain. Print editorials written by community pain clinicians will accompany the video vignettes, reinforcing the major themes and providing an opportunity for academic thought leaders to partner with local clinicians, each managing patients with chronic pain. This innovative Web-based format allows clinicians to participate immediately in each activity at a self-directed pace from their computers—accommodating even the busiest of schedules.

A monograph will be developed to provide additional context for the video case studies. A 10-question multiple-choice self-assessment examination will also be included, reflecting the content discussed in each video vignette and accompanying print editorials. Successful completion of the posttest is necessary to receive a certificate of completion, or a statement of credit. Participants must score 70% or higher and are allowed 2 attempts to successfully complete the exam. Upon successful completion of the examination, healthcare professionals may use the CME credit earned toward their licensure and/or certification requirements. Each vignette—prime examples of which may be e-mail blasted to the target audience of pain specialists—will be eligible for 1 hour of credit for 1 year from the issuance date.

Literature Surveillance

Quarterly reports summarizing in an easy-to-read style results from a formal literature surveillance will be shared with select faculty and preceptorship clinicians. Designed to identify new developments in the management of chronic pain, the reports will monitor clinical trial data, guideline updates, FDA approvals and warnings, and emerging issues in pain medicine.

Page 27 of 30 Confidential

Confidential

V. Program Recruitment, Awareness, and Distribution

Program Recruitment, Awareness, and Distribution

All live, print, and online programs will have specific recruitment, awareness, and distribution methods contained to ensure that the programs have the best opportunity for educational uptake and acceptance. These recruitment methods have been validated for past programs and have proven cost effective while maximizing reach and distribution to targeted audiences. These methods include live, print, and online components as detailed below.

PainClinician™

PainClinician™ is a compendium of advances in the management of chronic pain, distributed quarterly to pain specialists and other healthcare professionals interested in chronic pain management. Our proprietary database of the same name will ensure distribution to the primary audience of pain practitioners. Distribution methods include direct mail, distribution at AAPM, APS, and other selected pain management meetings throughout the year. Total quarterly distribution is estimated to be over 25,000. In addition to outlining the accredited package contents, each quarter and through an introductory letter, a leading pain management clinician will highlight the most recent and important dialogues and discussions involving pain medicine.

Pain Medicine News

The enduring activity will be a stand alone monograph of 12 journal sized pages distributed with an early 2009 issue of *Pain Medicine News* to its full circulation of approximately 46,500 clinicians. *Pain Medicine News* is a bimonthly publication circulating to physicians in the 12 specialties that most commonly treat patients with pain: emergency medicine physicians; neurologists; oncologists; orthopedic surgeons; pain management, pain medicine, and palliative pain medicine specialists; physical medicine and rehabilitation specialists; primary care physicians; and rheumatologists.


Additional copies of the monograph will be distributed from the *Pain Medicine News* exhibit booth at national conferences. *Pain Medicine News* has a presence at 7 conferences throughout the year at which the monograph may be distributed at:

- American Academy of Pain Medicine
- American Academy of Pain Management
- American Conference on Pain Medicine
- American Pain Society
- American Society of Regional Anesthesia and Pain Medicine Spring Meeting
- American Society of Regional Anesthesia and Pain Medicine Fall Meeting
- North American Neuromodulation Society

Live and Online Components

Live recruitment, awareness, and distributions campaigns will include attendance at various medical congresses and other relevant satellite pain meetings throughout the year. At these meetings, in addition to recruitment, awareness and distribution of ongoing programs to attendees, enrollment into the *PainClinician* database and program will occur. A thorough online campaign including, but not limited to, MedScape, www.pain.edu, Sermo and other pain-related services, to generate interest in

Page 28 of 30 Confidential



Page 29 of 30

Confidential

VI. Budgets

Please see attached

Page 30 of 30

Confidential



Center for Continuing Medical Education

Bridging the Gap Between Education and Practice



Fig. 1 mrers N. Hospital, and Acidenic Medical Center for the Albert Einstein College of Medicine

November 6, 2008

Steven Jay Feld

Educational Grant Review Committee Cephalon

Dear Sir and/or Madam:

On behalf of the Albert Einstein College of Medicine & Montefiore Medical Center, Center of Continuing Medical Education (CCME) and our Educational Collaborator and Joint Sponsor, Asante Communications LLC, I am requesting an educational grant from Cephalon in the amount of \$1,462,375 00 to be used to help support several CME accredited activities. These activities will focus on the topic of chronic pain management with the goal of providing clinicians with a learning forum to develop practical methods to appropriately assess and manage pain

CCME, with assistance from its educational collaborator, Asante Communications LLC, an organization with professional staff that have extensive experience in developing and implementing activities such as those being proposed, is planning to develop a series of CME activities to address issues of pain management and to provide physicians with the necessary best-practice skills to be able to better diagnose and treat issues in pain management. The activities will include:

- three (3) cases and commentary live meetings
- one (1) monograph to be developed from materials presented at the cases and commentary meetings
- one (1) on-line monograph (same as above)
- eight (8) live teleconferences available for participation at separate times
- one (1) monograph to be developed from the materials presented during the teleconferences
- one (1) on-line monograph (same as above)
- one (1) live regional meeting
- one (1) satellite webcast which will include highlights from the live regional meeting
- one (1) non-CME international forum of experts, which will be used to develop a CME activity
- one (1) CME position paper developed from the above international forum of experts
- one (1) on-line position paper (same as above)
- one (1) pain/risk management compendium to assist physicians in their clinical settings
- one (1) on-line pain/risk management compendium (same as above)

Each of these activities will include outcomes surveys to measure the practice performance changes of the participants of each activity. A further outcomes study/preceptorship, utilizing a control group to measure and compare the effectiveness of continued educational interventions between the control group's practice performance and the group receiving additional educational interventions will be conducted and will include participants from the cases and commentary, teleconferences and regional meeting. Participants in this outcome study will be given an opportunity to opt in.

2301 Bandundge Avenue, Bronx NA 40467 — Pr. 48 (200674 — 10x 718 798 2016 — ala chie org — sfield gmontefiote occ

As an additional option we are offering to develop and execute a final outcome study, which will poll from a select group of participants from the above outcome study. The physicians would agree to join a final IRB approved study, which will assess patient satisfaction. This study will be developed and overseen by an approved IRB entity and will seek input from patients that agree to be part of the study.

The working title of this comprehensive initiative is, Persistent and Breakthrough Pain: A Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies Initiative.

Faculty for this initiative will be chosen to develop unique learning opportunities, which will enable pain management specialists, which will include: neurologists, rheumatologists, physiatrists, primary care physicians, internal medicine physicians, anesthesiologists and oncologists to increase their competence and abilities to treat and appropriately manage pain and learn important methods to incorporate risk management strategies into pain management plans.

We will be using the requested grant for all the expenses related to the organization, capture and development of materials and for the accreditation and assessments of these CME activities

The purpose of this letter is to provide you with information on how CCME is planning to organize all the logistics related to the production and accreditation of these activities

The Albert Einstein College of Medicine and Montefiore Medical Center, Center for Continuing Medical Education and its Educational Collaborator and Joint sponsor, Asante Communications LLC, or our agents, will take full responsibility for both the medical content and logistical aspects of the following:

- Select faculty and topics
- Provide a faculty reviewer to make sure that all materials are free of bias and of professional scientific merit
- Develop a marketing plan to reach an audience of appropriate participants
- Provide sponsorship of the activities and maintain all books and records
- File and prepare all appropriate documentation to allow the activities to be certified by Albert Einstein College of Medicine for AMA PRA credit
- Administrate all financial accounting and bookkeeping
- Prepare, distribute and summarize course evaluations
- Develop, distribute and summarize outcomes surveys
- Maintain records of participants, grade quizzes and provide certificates to requesters
- Review and oversee the development of materials to ensure that the enduring material activities are in compliance with the AMA and ACCME Guidelines

Each of the activities will be reviewed by one of our renowned faculty, who is a specialist in the field of pain management. They will also be responsible for working with Asante Communications LLC to identify needs, learner gaps, objectives, appropriate faculty and determine topics.

Our tax ID number is 13 1740114 (Montefiore Medical Center).

15af Pandyndge Wenne, Bronx, NY 1046 — Phox. 718420.6674 — Pxx 718.795.2556 — mechaloge — sfelds/meatefiou ora

The provider requires that:

- All significant relationships (e.g. consulting, grant recipient, etc.) between Cephalon and faculty members, or any individual in a position to influence content must be disclosed to the participants of its CME activities
- All commercial interest support be disclosed to participants prior to their participation in its CME activities
- All COIs of faculty, or anyone in a position to influence content will be resolved through machanisms of resolution developed by Einstein for air its CME activities

Einstein requires that its LOA with Cephalon be signed by Victor B. Hatcher, PhD, Associate Dean of CME at Albert Einstein College of Medicine and Director of CME at Monteflore Medical Center, or Steven Jay Feld, Associate Director of CME at Albert Einstein College of Medicine & Monteflore Medical Center.

Please make checks payable to Montefiore Medical Center.

Montefiore Medical Center is the University Hospital for the Albert Einstein College of Medicine and all Albert Einstein College of Medicine, CME finances are handled by Montefiore Medical Center.

Check payments should be remitted to: CCME 3301 Bainbridge Avenue Bronx, NY 10467 Attn. Steven Feld

Any unused funds that were received from Cephalon in support of these activities will be retuned to Cephalon upon completion of reconcliation

If you need any further information, or have any questions that relate to this grant request please contact me at 718 929-6674, ext. 232.

On behalf of Albert Einstein College of Medicine & Montefiore Medical Center, I would like to thank Cephalon for consideration of this request.

Sincerely

Steven Jay Feld

co: Asante Communications LLC

The British was a second from the first the second of the British

Exhibit B ACTIQ Risk Management Program

Provider is aware that ACTIQ® (oral transmucosal fentanyl citrate) [C-II] was approved subject to a Risk Management Program (RMP). The RMP includes key safety messages that are essential to the safe use of this product. They are:

- ACTIQ is indicated only for the management of breakthrough cancer pain in patients with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
- ACTIQ is contraindicated in the management of acute or postoperative pain, because life-threatening hypoventilation could occur at any dose in patients not taking chronic opiates.
- This product must not be used in opioid nontolerant patients.
- Patients considered opioid tolerant are those who are taking at least 60 mg Morphine/day, 50 mcg transdermal fentanyl/hour, or an equianalgesic dose of another opioid for a week or longer.
- Instruct patients/caregivers that ACTIQ can be fatal to a child. Keep all units from children and discard properly.
- ACTIQ is intended to be used only in the care of cancer patients and only by oncologists and pain specialists who are knowledgeable of and skilled in the use of Schedule II opioids to treat cancer pain.

FENTORA Risk Management Program

Provider is aware that FENTORA™ (fentanyl buccal tablet) [C-II] was approved subject to a Risk Minimization Action Plan (RiskMAP). The RiskMAP includes key safety messages that are essential to the safe use of this product. They are:

- FENTORA is indicated for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
- FENTORA is contraindicated in the management of acute or postoperative pain, because life-threatening hypoventilation could occur at any dose in patients not taking chronic opiates.
- This product must not be used in opioid nontolerant patients.
- · No misuse of FENTORA should occur.
- Unintended (accidental) exposure to FENTORA should not occur.
- Patients considered opioid tolerant are those who are taking at least 60 mg oral morphine/day, at least 25 mcg of transdermal fentanyl/hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.
- Instruct patients/caregivers that FENTORA can be fatal to a child. Keep all units away from children and discard properly.
- FENTORA is intended to be used only in the care of opioid tolerant cancer patients and only by healthcare professionals who are knowledgeable of and skilled in the use of Schedule II opioids to treat cancer pain.



Cephalon, Inc.

2569

Multimodal Gradula Responsible Strategies

An Educational Platform Initiative









Persistent and Breakthrough Pain

Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies



Table of Contents

- I. Introduction Letter
- II. **Teleconference Series**

Program Overview

Evaluation Summary

III. Persistent and Breakthrough Pain Cases and Commentary™ Workshops

Boston

Program Overview

Evaluation Summary

San Francisco

Program Overview

Evaluation Summary

Jacksonville (ASPMN)

Program Overview

Evaluation Summary

IV. **Full-Day Regional Meeting**

New York

Program Overview

Evaluation Summary

٧. International Experts Forum

Program Overview

VI. Full-Day Regional Meeting Satellite Webcast

Program Overview

VII. **Durable Outcomes Study Webcast Series**

Program Overview

VIII. PAINClinician.com™

Overview

Editorial board

Video interviews

IX. **Contact Information** Compendium.
Release. 2009
APS
AAPM
APMR.
Painchinician
deta.

Confidential

Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies



October 26, 2009

Educational Grant Review Committee Cephalon, Inc.

Dear Sir and/or Madam:

On behalf of the Albert Einstein College of Medicine & Montefiore Medical Center, Center of Continuing Medical Education (CCME) and our Educational Collaborator and Joint Sponsor, Asante Communications LLC, I wish to present some information for Grant #2569, titled *Persistent and Breakthrough Pain: Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies*.

Please find enclosed synopses and/or evaluation summaries from these educational tactics that have been completed to date: 1 Teleconference Series (April 2009), 3 Cases and Commentary™ Workshops (April, May, and September 2009), 1 Full-Day Regional Meeting (June 2009), 3 Live-Streaming Web-Based Tutorials (August and September 2009), 1 International Experts Forum (September 2009), and 1 Spin-off Satellite Webcast (October 2009). These documents will serve as reference materials for this meeting.

Kindly please note that based on faculty recommendations and/or availability, the timing for several initiatives has been revised from the timeline included in the original grant request. The following schematic reflects the revised timeline of the platform deliverables.

Programs	Distribution	Total reach	Q	uarte	r 1	(Juai	rter 2		Qı	uarter	3	Q	u arter	4
			J	F	M	А		vi	J	J	Α	S	0	N	D
International Experts Forum	Live Event	30							4	() (Carrier 18)	-	*		*	
Cases and Commentary	Live Event	225	-	NAME OF STREET	NEWS TABLE	-	*	*				٠			
Full-Day Regional Meeting	Live Event	75-100	*		*****		OFFICE AND ADDRESS OF THE ADDRESS OF		- 4	>					
Teleconference Series	Live Event	200-400	-	· · · · · · · · · · · · · · · · · · ·		>	*								
Full-Day Regional Satellite Webcast	PAINClinician.com [™]	20-25,000						_		•)	era kanana	▶ (>	
Teleconference Print Monograph/Online	APS, AAPM, AAPM&R PAINClinician.com™	45-60,000									\$	as de servición de la constante de la constante de la constante de la constante de la constante de la constante		> +	
Pain/Risk Management Compendium	APS, AAPM, AAPMER PAINClinician.com**	45-60,000									фин	SANCHARDOUT	ent in the second		•
International Experts Forum Position Paper/Online	APS, AAPM, AAPM&R PAINCImician.com™	45-60,800			-						49.0	1982086	and the first		•
Preceptorship Program		300	4	DESCRIPTION OF THE PARTY OF THE	MARK PROPERTY	-saka:		nes eron i	ĝ.		ENGRICAL CHICAGO	-	GENERAL NA	-	-

Finally, the following educational tactics are in development and will be delivered in Q4 2009: 1 Cases and Commentary™/Teleconference Series Spin-off Monograph, 1 International Experts Forum Monograph, 1 Pain and Risk Compendium.

Sincerely,

Steven Jay Feld

pyself

Confidential Page 2 of 39

Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies



Teleconference Schedule

Date	Time	Faculty
Monday, April 20, 2009	Noon-1:00 PM	Perry G. Fine, MD
Monday, April 20, 2009	6:30 PM-7:30 PM	Perry G. Fine, MD
Tuesday, April 21, 2009	6:30 рм-7:30 рм	Lynn R. Webster, MD
Tuesday, April 21, 2009	8:00 PM-9:00 PM	Michael J. Brennan, MD
Wednesday, April 22, 2009	Noon-1:00 PM	Michael J. Brennan, MD
Wednesday, April 22, 2009	6:30 PM-7:30 PM	Lynn R. Webster, MD
Thursday, April 23, 2009	Noon-1:00 PM	David M. Simpson, MD
Thursday, April 23, 2009	8:00 PM-9:00 PM	David M. Simpson, MD

Faculty

Perry G. Fine, MD—PROGRAM CHAIR Salt Lake City, Utah

Michael J. Brennan, MD Fairfield, Connecticut

David M. Simpson, MD New York, New York

Lynn R. Webster, MD Salt Lake City, Utah

CCME Reviewer

David M. Kaufman, MD

Bronx, New York

Learning Objectives

At the completion of this initiative, participants should be better prepared to:

- Implement a continuous, multidimensional, and vigilant assessment of persistent and breakthrough pain based, in part, on the phenomenology and inferred pathophysiology of the pain syndrome, patient function, goals, and level
- Select appropriate patients for opioid-based management of persistent and breakthrough pain
- Employ multimodal treatment strategies tailored to the multidimensional pain assessment of patients with persistent and breakthrough pain
- Explain the respective roles of long-acting, short-acting, and rapid-onset opioids in the management of persistent and breakthrough pain

Participation and Metrics

Total registrants and certifications issued to date: 280

Confidential Page 3 of 39

Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies



Course Evaluation

April 20-23, 2009

Number of Registrants: 280

1. Did the learning objectives, which clarify specific steps to address educational gaps (current vs best practices, meet the overall purpose of the activity?

Response Rate

Objective 1: Implement a continuous, multidimensional, and vigilant assessment of persistent and breakthrough

pain based, in part, on the phenomenology and inferred pathophysiology of the pain syndrome,

patient function, goals, and level of risk

Yes 97.22% No 2.78%

Objective 2: Select appropriate patients for opioid-based management of persistent and breakthrough pain

Yes 98.61% No 1.39%

Objective 3: Employ multimodal treatment strategies tailored to the multidimensional pain assessment of

patients with persistent and breakthrough pain

Yes 97.22% No 2.78%

Objective 4: Explain the respective roles of long-acting, short-acting, and rapid-onset opioids in the

management of persistent and breakthrough pain

Yes 98.59% No 1.41%

2. What percentage of the presentation was effective in teaching you something new?

 90%
 11.27%

 70%
 26.76%

 50%
 28.17%

 30%
 23.94%

 10%
 9.86%

This activity provided evidence-based information that will be useful to me in my job or practice.

Yes 97.26% No 2.74%

4. Did the information received today confirm how you treat/manage patients?

Yes 95.89% No 4.11%

5. Will you make changes that will benefit patient care as a result of information received? If yes, please describe.

Yes 80.95% No 19.05%

Confidential Page 4 of 39

Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies



Comments

- 1. Teach other professionals
- 2. Education
- 3. Include education materials
- 4. Better counseling
- 5. Identify opioid tolerant patients
- 6. Get the opioid agreements instituted in any office
- 7. More aware of BTP
- 8. Will reevaluate my use of opioids in my clinical practice
- 9. Screening patients more often
- 10. Better prepared to share this info with my patients and peers
- 11. Get additional assistance managing medium-risk patients
- 12. Consider rapid-onset opioids for breakthrough pain in more circumstances
- 13. Ratio between long- and short-acting opioids
- 14. Better assessment and management of BTP
- 15. Assessment of BTP
- 16. Drug rotation
- 17. Carefully consider benefits and risks of opioid therapy for chronic pain
- 18. Better assessment/asking about BTP
- 19. Consider other options
- 20. More accurate categorization of patient's status
- 21. SOAPP-R score outcome
- 22. Risk stratification
- 24. Better techniques for BTP assessment
- 25. Update assessment on chronic pain patients
- 26. Assess and listen to patient
- 27. Consider using fentanyl for BTP
- 28. Reaffirmation of current practice parameters
- 29. Evaluate patients more thoroughly before prescribing
- 30. Use combination therapies more frequently
- 31. Better assess and follow patient on pain treatments
- 32. Use of newer delivery forms of fentanyl for breakthrough pain
- 33. Prescribe more TCAs than SSRIs for neuropathic pain

6. What subject matter not presented in this activity do you think should be included in future activities?

Comments

- 1. More highlights about fentanyl
- 2. Complex & difficult topic, managing the uninsured a terrible problem
- 3. Focus on the pediatric patient
- 4. Methods of opioid rotation, side effect management
- 5. More focus on etiology of BTP
- 6. More detail about dosing rapid-onset fentanyl for patients including starting doses
- 7. More case studies
- 8. How to handle pain in methadone clinic patients
- 9. Pain management in a patient with consistent multiple medical problems
- 10. Pain management in psychiatric patients
- 11. More detailed discussion of specific drugs

Confidential Page 5 of 39

Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies



- 12. Management of addicted patients
- 13. Side effects
- 14. Opioid rotation/Dose conversion
- 15. Details regarding prescribed monitoring program
- 16. In depth review of non-pharmacological modalities effective for treatment of neuropathic pain or BTP
- 17. Pediatric pain
- 18. Dosages for medications
- 19. Integrate/share risk assessment (Universal Precaution Paradigm) in chronic pain setting
- 20. Factors in opting for long-acting opioids when a patient is controlled by short acting opioids
- 21. Non-addictive, non-toxic naturalization medications as in

German literature "Lipoic Acid", "Tumeric" for pain

- 22. Use of breakthrough medications in patients on intrathecal therapies
- 7. Was this CME activity "free of commercial bias" for or against any product?

Yes

87.88%

No

12.12%

Optional Questions

8. In comparison with other similar activities, how would you rate this activity?

Excellent: 55.88%
Good: 35.29%
Average: 7.35%
Fair: 1.47%
Poor: 0.00%

9. How would you rate this activity in the quality of its organization and professional manner in which it was conducted?

Excellent: 65.22%
Good: 31.88%
Average: 2.90%
Fair: 0.00%
Poor: 0.00%

My Customer Service Experience

10. Pre-/Off-site Registration

Excellent:	76.12%
Good:	23.88%
Average:	0.00%
Fair:	0.00%
Poor:	0.00%

Confidential

Page 6 of 39

Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies



11. Other:

 Excellent:
 67.65%

 Good:
 23.53%

 Average:
 2.94%

 Fair:
 5.88%

 Poor:
 0.00%

12. I wash my hands before and after each patient encounter.

 Always:
 64.18%

 Most of the Time:
 31.34%

 Sometimes:
 4.48%

 Never:
 0.00%

13. As of today, I will wash my hands before and after each patient encounter.

 Always:
 78.79%

 Most of the Time:
 15.15%

 Sometimes:
 6.06%

 Never:
 0.00%

Confidential Page 7 of 39



Speaker Evaluation

April 20-23, 2009

	Ability to Communicate	How Well Was Topic Covered?	Objectivity, Balance, & Scientific Rigor	Relevance to Your Practice
Michael J. Brennan	, MD			
Superior	40%	43.48%	33.33%	34.78%
Excellent	52%	43.48%	58.33%	52.17%
Satisfactory	8%	13.04%	8.33%	13.04%
Unsatisfactory	0%	0%	0%	0%
Presentation Addres	sed Gaps in Changing	Your		
Competence:	29.03%			
Performance:	32.26%			
Patient Outcomes:	38.71%			
Perry G. Fine, MD				
Superior	41.67%	54.55%	54.55%	27.27%
Excellent	41.67%	18.18%	18.18%	36.36%
Satisfactory	8.33%	27.27%	18.18%	36.36%
Unsatisfactory	8.33%	0%	9.09%	0%
Presentation Addres	sed Gaps in Changing	Your		
Competence:	22.22%			
Performance:	44.44%			
Patient Outcomes:	33.33%			
David M. Simpson,	MD			
Superior	42.86%	38.46%	38.46%	53.85%
Excellent	50%	61.54%	53.85%	38.46%
Satisfactory	7.14%	0%	7.69%	7.69%
Unsatisfactory	0%	0%	0%	0%
Presentation Addres	sed Gaps in Changing	Your		
Competence:	30%			
Performance:	50%			
Patient Outcomes:	20%			

Confidential Page 8 of 39



	Ability to Communicate	How Well Was Topic Covered?	Objectivity, Balance, & Scientific Rigor	Relevance to Your Practice
Lynn R. Webster, N	ID			
Superior	47.62%	52.38%	57.14%	52.38%
Excellent	42.86%	42.86%	38.10%	42.86%
Satisfactory	9.52%	4.76%	4.76%	4.76%
Unsatisfactory	0%	0%	0%	0%
Presentation Address	sed Gaps in Changing	Your		
Competence:	30.77%			
Performance:	38.46%			
Patient Outcomes:	30.77%			

Confidential Page 9 of 39

Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies



Cases and Commentary™ Workshop

Saturday, April 25, 2009 | 8:00 am–12:00 pm
The Westin Copley Place | Boston, Massachusetts

Faculty

Charles E. Argoff, MD—PROGRAM CHAIR Albany, New York

Daniel Brookoff, MD, PhD Denver, Colorado

Michael G. Byas-Smith, MD Atlanta, Georgia

CCME Reviewer David M. Kaufman, MD Bronx, New York James P. Rathmell, MD Boston, Massachusetts

B. Todd Sitzman, MD, MPH Hattiesburg, Mississippi

Learning Objectives

At the completion of this initiative, participants should be better prepared to:

- Define, recognize, and independently assess breakthrough and persistent pain in patients with chronic pain syndromes
- Implement a multidimensional, continual, and vigilant assessment of persistent and breakthrough pain based, in
 part, on the phenomenology and inferred pathophysiology of the pain syndrome, patient function, goals, and level
 of risk
- Select appropriate patients for opioid-based management of persistent and breakthrough pain
- Employ multimodal opioid-based therapies tailored to the multidimensional pain assessment of patients with persistent and breakthrough pain
- Explain the respective roles of long-acting, short-acting, and rapid-onset opioids in the management of persistent and breakthrough pain

Participation and Metrics

Total attendee and certifications issued to date: 38

Confidential Page 10 of 39

Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies



Course Evaluation

April 25, 2009 | Boston, Massachusetts
Total Number of Attendees: 38

1. Did the learning objectives, which clarify specific steps to address educational gaps (current vs best practices), meet the overall purpose of the activity?

Response Rate

Objective 1: Define, recognize, and independently assess breakthrough and persistent pain in patients with

chronic pain syndromes

Yes 100% No 0%

Objective 2: Implement a multidimensional, continual, and vigilant assessment of persistent and breakthrough

pain based, in part, on the phenomenology and inferred pathophysiology of the pain syndrome,

patient function, goals, and level of risk Yes 100% No 0%

Objective 3: Select appropriate patients for opioid-based management of persistent and breakthrough pain

Yes 100% No 0%

Objective 4: Employ multimodal opioid-based therapies tailored to the multidimensional pain assessment of

patients with persistent and breakthrough pain

Yes 100% No 0%

Objective 5: Explain the respective roles of long-acting, short-acting, and rapid-onset opioids in the

management of persistent and breakthrough pain

Yes 100% No 0%

2. What percentage of the presentation was effective in teaching you something new?

0% 45% 70% 20% 50% 20% 30% 15% 10% 0%

3. This activity provided evidence-based information that will be useful to me in my job or practice.

Yes 100% No 0%

4. Did the information received today confirm how you treat/manage patients?

Yes 100% No 0%

Confidential Page 11 of 39

Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies



5. Will you make changes that will benefit patient care as a result of information received?

Yes 100% No 0%

If yes, please describe.

Comments

- 1. Better use of standardized risk assessment tools
- 2. Prescribe opioids
- 3. More formal upfront assessment using a tool to assess for potential dependence and/or abuse
- 4. More patient education regarding issues
- 5. Better viewpoint of where opioids fit on a continuum of care
- 6. Use of charts
- 6. What subject matter not presented in this activity do you think should be included in future activities?

Comments

- 1. Urine drug testing
- 2. Pharmacodynamics and pharmacokinetics of pain drugs
- 3. A little more interdisciplinary approach, although I realize this was not purpose of program
- 4. Alternative pain therapies
- 5. Interventional role-IT/SCS
- 6. Apply and document risk stratification
- 7. Was this CME activity "free of commercial bias" for or against any product?

Yes 100% No 0%

Optional Questions

8. In comparison with other similar activities, how would you rate this activity?

 Excellent:
 90%

 Good:
 10%

 Average:
 0%

 Fair:
 0%

 Poor:
 0%

9. How would you rate this activity in the quality of its organization and professional manner in which it was conducted?

 Excellent:
 80%

 Good:
 20%

 Average:
 0%

 Fair:
 0%

 Poor:
 0%

Confidential Page 12 of 39



My Customer Service Experience

10. Pre-/Off-site Registration

Excellent:	89.47%
Good:	10.53%
Average:	0%
Fair:	0%
Poor:	0%

11. Onsite Registration

Excellent:	100%
Good:	0%
Average:	0%
Fair:	0%
Poor:	0%

12. Interaction With Staff/Workshop Facilitators

Excellent:	89.47%
Good:	10.53%
Average:	0%
Fair:	0%
Poor:	0%

13. Conference Facilities

Excellent:	90%
Good:	10%
Average:	0%
Fair:	0%
Poor:	0%

14. Other:

Excellent:	100%
Good:	0%
Average:	0%
Fair:	0%
Poor:	0%

Comments

I did not expect this format to be as useful as it was—very practical. I can use this information.

15. I wash my hands before and after each patient encounter.

Always:	75%
Most of the Time:	25%
Sometimes:	0%
Novor	Λ0/

16. As of today, I will wash my hands before and after each patient encounter.

Always:	75%
Most of the Time:	25%
Sometimes:	0%
Never:	0%

Confidential Page 13 of 39



Speaker Evaluation

April 25, 2009 | Boston, Massachusetts

	Ability to Communicate	How Well Was Topic Covered?	Objectivity, Balance, & Scientific Rigor	Relevance to Your Practice
Charles E. Argoff, I	MD			
Superior	100%	100%	100%	100%
Excellent	0%	0%	0%	0%
Satisfactory	0%	0%	0%	0%
Unsatisfactory	0%	0%	0%	0%
Presentation Address	sed Gaps in Changing	Your		
Competence:	33%			
Performance:	34%			
Patient Outcomes:	33%			
Daniel Brookoff, MI	D, PhD			
Superior	100%	100%	100%	100%
Excellent	0%	0%	0%	0%
Satisfactory	0%	0%	0%	0%
Unsatisfactory	0%	0%	0%	0%
Presentation Address	sed Gaps in Changing	Your		
Competence:	33%			
Performance:	34%			
Patient Outcomes:	33%			
Michael G. Byas-Sr	nith, MD			
Superior	100%	100%	100%	100%
Excellent	0%	0%	0%	0%
Satisfactory	0%	0%	0%	0%
Unsatisfactory	0%	0%	0%	0%
Presentation Address	sed Gaps In Changing	Your		
Competence:	34%			
Performance:	33%			
Patient Outcomes:	33%			

Confidential Page 14 of 39

全球点上最后的一个企业。 第一次,一个企业,是一个企业,是一个企业,是一个企业,是一个企业,是一个企业,是一个企业,是一个企业,是一个企业,是一个企业,是一个企业,是一个企业,是一个企业,是

	Ability to Communicate	How Well Was Topic Covered?	Objectivity, Balance, & Scientific Rigor	Relevance to Your Practice
James P. Rathmell,	MD			
Superior	100%	100%	100%	100%
Excellent	0%	0%	0%	0%
Satisfactory	0%	0%	0%	0%
Unsatisfactory	0%	0%	0%	0%
Presentation Address	sed Gaps in Changing	Your		
Competence:	40%			
Performance:	30%			
Patient Outcomes:	30%			
B. Todd Sitzman, N	ID, MPH			
Superior	80%	67%	78%	75%
Excellent	20%	33%	11%	13%
Satisfactory	0%	0%	11%	12%
Unsatisfactory	0%	0%	0%	0%
Presentation Address	sed Gaps in Changing	Your		
Competence:	38%			
Performance:	31%			

Confidential Page 15 of 39

Patient Outcomes:

31%

Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies



Cases and Commentary™ Workshop

Saturday, May 30, 2009 | 8:00 AM-12:00 PM Parc 55 Hotel | San Francisco, California

Faculty

Perry G. Fine, MD—PROGRAM CHAIR Salt Lake City, Utah

Michael J. Brennan, MD Fairfield, Connecticut

Scott M. Fishman, MD Sacramento, California

CCME Reviewer

David M. Kaufman, MD

Bronx, New York

David M. Simpson, MD, MPH

New York, New York

Mark S. Wallace, MD San Diego, California

Donna S. Zhukovsky, MD Houston, Texas

Learning Objectives

At the completion of this initiative, participants should be better prepared to:

- Define, recognize, and independently assess breakthrough and persistent pain in patients with chronic pain syndromes
- Implement a multidimensional assessment of persistent and breakthrough pain based, in part, on the
 phenomenology and inferred pathophysiology of the pain syndrome, patient function, goals, and level of risk
- · Select appropriate patients for opioid-based management of persistent and breakthrough pain
- Employ multimodal opioid-based therapies for patients with persistent and breakthrough pain
- Explain the respective roles of long-acting, short-acting, and rapid-onset opioids in the management of persistent and breakthrough pain

Participation and Metrics

Total attendees and certifications issued to date: 34

Confidential Page 16 of 39

Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies



Course Evaluation

May 30, 2009 | San Francisco, California

Total Number of Attendees: 34

1. Did the learning objectives, which clarify specific steps to address educational gaps (current vs best practices), meet the overall purpose of the activity?

Response Rate

Objective 1: Define, recognize, and independently assess breakthrough and persistent pain in patients with

chronic pain syndromes

Yes 100% No 0%

Objective 2: Implement a multidimensional assessment of persistent and breakthrough pain based, in part, on

the phenomenology and inferred pathophysiology of the pain syndrome, patient function, goals,

and level of risk

Yes 100% No 0%

Objective 3: Select appropriate patients for opioid-based management of persistent and breakthrough pain

Yes 100% No 0%

Objective 4: Employ multimodal opioid-based therapies for patients with persistent and breakthrough pain

Yes 100% No 0%

Objective 5: Explain the respective roles of long-acting, short-acting, and rapid-onset opioids in the

management of persistent and breakthrough pain

Yes 100% No 0%

2. What percentage of the presentation was effective in teaching you something new?

90% 40% 70% 47% 50% 7% 30% 6% 10% 0%

3. This activity provided evidence-based information that will be useful to me in my job or practice.

Yes 100% No 0%

4. Did the information received today confirm how you treat/manage patients?

Yes 100% No 0%

Confidential Page 17 of 39

Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies



5. Will you make changes that will benefit patient care as a result of information received today? If yes, please describe.

Yes 67% No 33%

Comments

- 1. Less likely to image back pain patients; will try pregabalin
- 2. Consider using scales
- 3. Opioid dosing for chronic pain (x2)
- 4. Better use of screening tools
- 6. What subject matter not presented in this activity do you think should be included in future activities?

Comments

- 1. Providing scales (i.e., Brief Pain Inventory) would be helpful, so I can use them in my practice
- 7. Was this CME activity "free of commercial bias" for or against any product?

Yes 93% No 7%

Optional Questions

8. In comparison with other similar activities, how would you rate this activity?

 Excellent:
 67%

 Good:
 33%

 Average:
 0%

 Fair:
 0%

 Poor:
 0%

9. How would you rate this activity in the quality of its organization and professional manner in which it was conducted?

Excellent: 73%
Good: 27%
Average: 0%
Fair: 0%
Poor: 0%

My Customer Service Experience

10. Pre-/Off-site Registration

 Excellent:
 73%

 Good:
 27%

 Average:
 0%

 Fair:
 0%

 Poor:
 0%

Confidential

Page 18 of 39

Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies



11. Onsite Registration

Excellent:	60%
Good:	40%
Average:	0%
Fair:	0%
Poor:	0%

12. Interaction With Staff/Workshop Facilitators

Excellent:	86%
Good:	14%
Average:	0%
Fair:	0%
Poor:	0%

13. Conference Facilities

Excellent:	64%
Good:	29%
Average:	7%
Fair:	0%
Poor:	0%

14. Other:

Excellent:	100%
Good:	0%
Average:	0%
Fair:	0%
Poor:	0%

Comments

15. I wash my hands before and after each patient encounter.

Always:	79%
Most of the Time:	21%
Sometimes:	0%
Never:	0%

16. As of today, I will wash my hands before and after each patient encounter.

Always:	919
Most of the Time:	9%
Sometimes:	0%
Never:	0%

Confidential Page 19 of 39

^{1.} Good onsite signage directing participants to registration.



Speaker Evaluation

May 30, 2009 | San Francisco, CA

	Ability to Communicate	How Well Was Topic Covered?	Objectivity, Balance, & Scientific Rigor	Relevance to Your Practice
Michael J. Brenna	ın, MD			
Superior	29%	20%	20%	40%
Excellent	71%	80%	80%	60%
Satisfactory	0%	0%	0%	0%
Unsatisfactory	0%	0%	0%	0%
Perry G. Fine, MD				
Superior	60%	63%	63%	75%
Excellent	40%	37%	25%	25%
Satisfactory	0%	0%	12%	0%
Unsatisfactory	0%	0%	0%	0%
Scott M. Fishman	, MD			
Superior	50%	33%	33%	33%
Excellent	50%	67%	67%	67%
Satisfactory	0%	0%	0%	0%
Unsatisfactory	0%	0%	0%	0%
David M. Simpsor	n, MD, MPH			
Superior	40%	33%	33%	33%
Excellent	60%	67%	67%	67%
Satisfactory	0%	0%	0%	0%
Unsatisfactory	0%	0%	0%	0%
Mark S. Wallace, I	MD			
Superior	50%	50%	67%	67%
Excellent	50%	33%	33%	33%
Satisfactory	0%	17%	0%	0%
Unsatisfactory	0%	0%	0%	0%

Confidential Page 20 of 39

Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies

	Ability to Communicate	How Well Was Topic Covered?	Objectivity, Balance, & Scientific Rigor	Relevance to Your Practice
Donna S. Zhukovs	sky, MD			
Superior	100%	100%	100%	100%
Excellent	0%	0%	0%	0%
Satisfactory	0%	0%	0%	0%
Unsatisfactory	0%	0%	0%	0%

Confidential Page 21 of 39

Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies



Cases and Commentary™ Workshop

Friday, September 11, 2009 | 4:30 PM-8:30 PM
The Hyatt Regency Jacksonville Riverfront | Jacksonville, Florida

Faculty

B. Todd Sitzman, MD, MPH—PROGRAM CHAIR Hattiesburg, Mississippi

Paul M. Arnstein, RN, PhD Boston, Massachusetts

Patricia M. Bruckenthal, PhD, RN, ANP-C Stony Brook, New York

Deb B. Gordon, RN, MS Madison, Wisconsin

Keela A. Herr, PhD, RN lowa City, lowa

April Hazard Vallerand, PhD, RN Detroit, Michigan

CCME Reviewer David M. Kaufman, MD Bronx, New York



Learning Objectives

At the completion of this initiative, participants should be better prepared to:

- Define, recognize, and independently assess breakthrough and persistent pain in patients with chronic pain syndromes
- Perform multidimensional and continual assessments of persistent and breakthrough pain based, in part, on the phenomenology and inferred pathophysiology of the pain syndrome, as well as patient function and treatment goals
- Discuss important steps in the implementation, optimization, and long-term monitoring of multimodal opioid-based therapies for persistent and breakthrough pain with patients, families, caregivers, and physicians
- Explain the respective roles of long-acting, short-acting, and rapid-onset opioids in the management of persistent and breakthrough pain

Participation

Total attendees and certifications issued to date: 60

Confidential Page 22 of 39

Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies



Course Evaluation

September 11, 2009 | Jacksonville, Florida

Total Number of Attendees: 60

1. Did the learning objectives, which clarify specific steps to address educational gaps (current vs best practices), meet the overall purpose of the activity?

Response Rate

Objective 1: Define, recognize, and independently assess breakthrough and persistent pain in patients with

chronic pain syndromes

Yes 96% No 4%

Objective 2: Perform multidimensional and continual assessments of persistent and breakthrough pain based,

in part, on the phenomenology and inferred pathophysiology of the pain syndrome, as well as $\,$

patient function and treatment goals

Yes 96% No 4%

Objective 3: Discuss important steps in the implementation, optimization, and long-term monitoring of

multimodal opioid-based therapies for persistent and breakthrough pain with patients, families,

caregivers, and physicians

Yes 98% No 2%

Objective 4: Explain the respective roles of long-acting, short-acting, and rapid-onset opioids in the

management of persistent and breakthrough pain

Yes 96% No 4%

2. What percentage of the presentation was effective in teaching you something new?

90% 33% 70% 27% 50% 32% 30% 8% 10% 0%

3. This activity provided evidence-based information that will be useful to me in my job or practice.

Yes 100% No 0%

4. Did the information received today confirm how you treat/manage patients?

Yes 100% No 0%

Confidential Page 23 of 39

Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies



Will you make changes that will benefit patient care as a result of information received today?

Yes 89% No 11%

If yes, please describe.

Comments

- 1. Comprehensive risk assessments (x3)
- 2. Implement urine drug screening
- 3. Try to implement more specific pain rating questions
- 4. Use SOAPP-R and Passik's 5 A's
- 5. Implement opioid agreements for all patients (x2)
- 6. Use more pain evaluation tools
- 7. Better assessment of breakthrough pain (x2)
- 8. Try to question actual medication-taking protocol
- 9. Consider screening all patients, universally
- 10. Use new medications
- 11. Consider use of rapid-onset medications in lieu of short-acting opioids for breakthrough pain
- What subject matter not presented in this activity do you think should be included in future activities?

Comments

- 1. None (x4)
- 2. We had a great table—nothing!
- 3. Posttraumatic stress disorder and traumatic brain injury
- 4. Nursing/legal responsibilities in pain management
- 5. Chemical dependency and mental illness in pain management
- 6. Nonopioid management of chronic pain
- 7. Was this CME activity "free of commercial bias" for or against any product?

Yes

100%

No

0%

8. The provider of the activity has disclosed in writing or verbally the conflict of interest or lack thereof declared by the planners and presenters/content specialists.

Yes

100%

No

0%

Optional Questions

9. In comparison with other similar activities, how would you rate this activity?

Excellent:

88%

Good:

10%

Average:

Fair:

2%

Poor:

0% 0%

Confidential

Page 24 of 39

Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies



10. How would you rate this activity in the quality of its organization and professional manner in which it was conducted?

Excellent:	73%
Good:	27%
Average:	0%
Fair:	0%
Poor:	0%

My Customer Service Experience

11. Pre-/Off-site Registration

Excellent:	65%
Good:	31%
Average:	4%
Fair:	0%
Poor:	0%

12. Onsite Registration

Excellent:	76%
Good:	19%
Average:	5%
Fair:	0%
Poor:	0%

13. Interaction With Staff/Workshop Facilitators

Excellent:	70%
Good:	28%
Average:	2%
Fair:	0%
Poor:	0%

14. Conference Facilities

Excellent:	77%
Good:	19%
Average:	2%
Fair:	2%
Poor.	0%

15. Other:

Excellent:	100%
Good:	0%
Average:	0%
Fair:	0%
Poor:	0%

Confidential Page 25 of 39

Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies



Comments

- 1. Excellent method of teaching
- 2. Dr Sitzman was excellent and encouraged our group to maximize our learning
- 3. This was fun!
- 16. I wash my hands before and after each patient encounter.

Always:

84%

Most of the Time:

16%

Sometimes:

0%

Never:

0%

If you did not answer "Always," please list any factors acting as barriers.

- 1. Not when I meet patients in the hall
- 2. Emergency situations
- 3. Short on time
- 4. Also use topical antiseptics
- 17. As of today, I will wash my hands before and after each patient encounter.

Always:

93%

Most of the Time:

7%

Sometimes:

0%

Never:

0%

Confidential

Page 26 of 39



Speaker Evaluation

	Ability to Communicate	How Well Was Topic Covered?	Objectivity, Balance, & Scientific Rigor	Relevance to Your Practice
Paul M. Arnstein,	RN, PhD			
Superior	56%	50%	78%	63%
Excellent	44%	50%	22%	37%
Satisfactory	0%	0%	0%	0%
Unsatisfactory	0%	0%	0%	0%
Patricia M. Brucke	enthal, PhD, RN, ANP-	-C		
Superior	88%	88%	88%	88%
Excellent	12%	12%	12%	12%
Satisfactory	0%	0%	12%	0%
Unsatisfactory	0%	0%	0%	0%
Deb B. Gordon, R	N, MS			
Superior	50%	60%	50%	50%
Excellent	50%	40%	50%	50%
Satisfactory	0%	0%	0%	0%
Unsatisfactory	0%	0%	0%	0%
Keela A. Herr, Phi	D, RN			
Superior	91%	100%	82%	82%
Excellent	9%	0%	18%	18%
Satisfactory	0%	0%	0%	0%
Unsatisfactory	0%	0%	0%	0%
April Hazard Valle	erand, PhD, RN			
Superior	71%	61%	71%	65%
Excellent	29%	33%	29%	35%
Satisfactory	0%	6%	0%	0%
Unsatisfactory	0%	0%	0%	0%
B. Todd Sitzman,	MD, MPH			
Superior	60%	60%	70%	70%
Excellent	40%	40%	30%	30%
Satisfactory	0%	0%	0%	0%
Unsatisfactory	0%	0%	0%	0%

Confidential Page 27 of 39

Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies



Full-Day Regional Meeting

Saturday, June 13, 2009 | 8:00 AM-3:05 PM
The Grand Hyatt | New York, New York

Faculty

Russell K. Portenoy, MD—PROGRAM CHAIR New York, New York

Michael J. Brennan, MD Fairfield, Connecticut

Nathan I. Cherny, MBBS Jerusalem, Israel

Subhash Jain, MD New York, New York

Srinivas Nalamachu, MD Overland Park, Kansas

CCME Reviewer
David M. Kaufman, MD

Bronx, New York

Steven D. Passik, PhD New York, New York

David M. Simpson, MD, MPH

New York, New York

Steven P. Stanos, DO Chicago, Illinois

Theodore Wein, MD Montréal, Québec, Canada

Sharon M. Weinstein, MD Salt Lake City, Utah

Learning Objectives

At the completion of this initiative, participants should be better prepared to:

- · Define, recognize, and independently assess breakthrough and persistent pain in cancer survivors
- Implement a multidimensional, continual, and vigilant assessment of persistent and breakthrough pain based, in
 part, on the phenomenology and inferred pathophysiology of the pain syndrome, patient function, goals, and level
 of risk
- Select appropriate patients for opioid-based management of cancer- or treatment-related persistent and breakthrough pain
- Employ multimodal opioid-based therapies tailored to the multidimensional pain assessment of patients with persistent and breakthrough pain
- Explain the respective roles of long-acting, short-acting, and rapid-onset opioids in the management of persistent and breakthrough pain

Participation

Total attendees and certifications issued to date: 80

Confidential Page 28 of 39

Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies



Course Evaluation

June 13, 2009 | The Grand Hyatt | New York, New York

Total Number of Attendees: 80

 Did the learning objectives, which clarify specific steps to address educational gaps (current vs best practices) meet the overall purpose of the activity?

Response Rate

Objective 1: Define, recognize, and independently assess breakthrough and persistent pain in cancer survivors

Yes 100% No 0%

Objective 2: Implement a multidimensional, continual, and vigilant assessment of persistent and breakthrough

pain based, in part, on the phenomenology and inferred pathophysiology of the pain syndrome,

patient function, goals, and level of risk

Yes 100% No 0%

Objective 3: Select appropriate patients for opioid-based management of cancer- or treatment-related persistent

and breakthrough pain

Yes 100% No 0%

Objective 4: Employ multimodal opioid-based therapies tailored to the multidimensional pain assessment of

patients with persistent and breakthrough pain

Yes 98% No 2%

Objective 5: Explain the respective roles of long-acting, short-acting, and rapid-onset opioids in the

management of persistent and breakthrough pain

Yes 100% No 0%

2. What percentage of the presentation was effective in teaching you something new?

 90% effective
 30%

 70% effective
 32%

 50% effective
 21%

 30% effective
 14%

 10% effective
 3%

3. This activity provided evidence-based information that will be useful to me in my job or practice.

Yes 96% No 4%

4. Did the information received today confirm how you treat/manage patients?

Yes 98% No 2%

Confidential Page 29 of 39

Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies



5. Will you make changes that will benefit patient care as a result of information received?

Yes

83%

Νo

17%

If yes, please describe.

Comments

- 1. Assess risk for opioid abuse and addiction
- 2. Use multiple adjuvants
- 3. Use of new mandatory tools
- 4. Use of many newer agents to modify patient's pain
- 5. I treat patients who are on opioids for various reasons but I do not prescribe them myself
- 6. More likely to use a contract
- 7. More specific classification of patient application of modalities
- 8. Use of risk stratification
- 9. Risk stratify patients with chronic organic illness or BTP that will need opioid treatment
- 10. Maximize therapeutic regimen
- 11. Increased efficacy of therapy
- 12. Goal setting/evaluation of pain, even in long-time pain patients with chronic opioid use
- 13. Prescribe lower opioid dose in patients with uncertain etiology of pain
- 14. Evaluation of risk factors for potential abuse
- 15. Ceiling of opioid dosage
- 16. Fibromyalgia and migraine headache
- 17. Consider use of opioid risk tool
- 18. Improve risk stratification process; reassess for risk
- 19. Re-examine discharge and exit policy
- 20. APS-AAPM guidelines recommendations will help patients
- 21. Use risk assessment tools
- 22. Review treatment of patients in which risk outweighs benefit
- 23. Manage cancer pain
- 24. Will question patients about adherence
- 25. Thoroughly apply new guidelines
- 26. Will evaluate prior history of addiction and psychological problems
- 27. Start regularly using SOAPP
- 28. Increased frequency of UDT
- 29. Better assessment of addiction, diversion
- 30. Manage chronic cancer pain with baseline long-acting opioid analgesic

6. What subject matter not presented in this activity do you think should be included in future activities?

Comments

- 1. Additional presenters that incorporate other modalities that affect pain and its management
- 2. Very satisfied with program
- 3. Review of drug testing
- 4. How to communicate exit strategies to patients
- 5. Neuropathic pain
- 6. Specific prescription treatment for types of chronic pain
- 7. Use of adjunctive medications that can reduce dose of opioids

Confidential

Page 30 of 39

Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies



- 8. PCA and intrathecal pumps
- 9. Practicality of information in real life
- 10. Pain practice
- 11. Treatment of acute pain
- 12. Noncancer pain management
- 13. Hospice pain
- 7. Was this CME activity "free of commercial bias" for or against any product?

Yes

98%

Nο

2%

Optional Questions

8. In comparison with other similar activities, how would you rate this activity?

Excellent:

58%

Good:

35%

Average:

5% 2%

Fair: Poor:

0%

9. How would you rate this activity in the quality of its organization and professional manner in which it was conducted?

Excellent:

69%

Good:

27%

Average:

4%

Fair:

0%

Poor:

0%

My Customer Service Experience

10. Pre-/Off-site Registration

Excellent:

63%

Good:

Average:

32%

Fair:

4%

Poor:

0% 0%

11. Onsite Registration

Excellent:

Good:

60% 36%

Average:

Fair:

4%

Poor:

0% 0%

Confidential

Page 31 of 39



12. Interaction With Staff/Workshop Facilitators

Excellent:	58%
Good:	38%
Average:	4%
Fair:	0%
Poor:	0%

13. Conference Facilities

Excellent:	63%
Good:	29%
Average:	7%
Fair:	1%
Poor:	0%

14. Other

Excellent:	50%
Good:	50%
Average:	0%
Fair:	0%
Poor:	0%

15. I wash my hands before and after each patient encounter.

Always:	73%
Most of the Time:	20%
Sometimes:	5%
Never	2%

16. As of today, I will wash my hands before and after each patient encounter.

Always:	78%
Most of the Time:	20%
Sometimes:	0%
Never:	2%

Page 32 of 39 Confidential

Persistent and Breakthrough Pain Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies



Speaker Evaluation

June 13, 2009 | The Grand Hyatt | New York, New York

	Ability to Communicate	How Well Was Topic Covered?	Objectivity, Balance, & Scientific Rigor	Relevance to Your Practice
Michael J. Brennaı	n, MD			
Superior	38%	31%	38%	38%
Excellent	44%	49%	42%	44%
Satisfactory	18%	20%	20%	18%
Unsatisfactory	0%	0%	0%	0%
Nathan I. Cherny, I	MBBS			
Superior	25%	18%	24%	22%
Excellent	44%	52%	46%	53%
Satisfactory	31%	30%	30%	25%
Unsatisfactory	0%	0%	0%	0%
Subhash Jain, MD				
Superior	31%	28%	28%	33%
Excellent	44%	44%	47%	39%
Satisfactory	23%	28%	25%	28%
Unsatisfactory	2%	0%	0%	0%
Srinivas Nalamach	nu, MĐ			
Superior	27%	24%	21%	17%
Excellent	52%	52%	52%	52%
Satisfactory	18%	24%	27%	31%
Unsatisfactory	3%	0%	0%	0%
Steven D. Passik, I	PhD			
Superior	62%	52%	52%	52%
Excellent	35%	44%	42%	35%
Satisfactory	3%	4%	6%	13%
Unsatisfactory	0%	0%	0%	0%

Confidential Page 33 of 39

Persistent and Breakthrough Pain Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies

	•	-

	Ability to Communicate	How Well Was Topic Covered?	Objectivity, Balance, & Scientific Rigor	Relevance to Your Practice
Russell K. Porteno	y, MD			
Superior	55%	52%	52%	54%
Excellent	37%	38%	35%	31%
Satisfactory	8%	10%	13%	15%
Unsatisfactory	0%	0%	0%	0%
David M. Simpson,	MD, MPH			
Superior	31%	23%	27%	24%
Excellent	55%	57%	57%	59%
Satisfactory	15%	20%	16%	17%
Unsatisfactory	0%	0%	0%	0%
Steven P. Stanos, I	00			
Superior	32%	27%	27%	20%
Excellent	54%	57%	57%	63%
Satisfactory	14%	16%	16%	17%
Unsatisfactory	0%	0%	0%	0%
Theodore Wein, MD)			
Superior	27%	21%	21%	28%
Excellent	59%	62%	59%	55%
Satisfactory	14%	17%	20%	17%
Unsatisfactory	0%	0%	0%	0%
Sharon M. Weinste	in, MD			
Superior	38%	36%	36%	37%
Excellent	45%	45%	47%	43%
Satisfactory	17%	19%	17%	20%
Unsatisfactory	0%	0%	0%	0%

Confidential Page 34 of 39

Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies



International Experts Forum

Tuesday, September 1, 2009 | 8:00 AM-2:00 PM
Asante Communications, LLC | New York, New York

Stage I Faculty

Perry G. Fine, MD—PROGRAM CO-CHAIR Salt Lake City, Utah

Russell K. Portenoy, MD—PROGRAM CO-CHAIR Boston, Massachusetts

Stage II Faculty

Andrew Davies, MD, MBBS Surrey, United Kingdom

Sebastiano Mercadante, MD

Palermo, Italy

Christine A. Miaskowski, RN, PhD San Francisco, California

CCME Reviewer

David M. Kaufman, MD

Bronx, New York

Roger Chou, MD Portland, Oregon

Thomas Smith, MD Richmond, Virginia

Giovambattista Zeppetella, MD *Essex, United Kingdom*

Jan Sondon. S. Subjec.

Confidential Page 35 of 39

Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies



Full-Day Regional Meeting Satellite Webcast

Faculty

Russell K. Portenoy, MD—PROGRAM CHAIR New York, New York

Steven D. Passik, PhD New York, New York

Michael J. Brennan, MD Fairfield, Connecticut

CCME Reviewer David M. Kaufman, MD Bronx, New York

Learning Objectives

At the completion of this initiative, participants should be better prepared to:

- Define, recognize, and independently assess breakthrough and persistent pain in cancer survivors
- Implement a multidimensional, continual, and vigilant assessment of persistent and breakthrough pain based, in
 part, on the phenomenology and inferred pathophysiology of the pain syndrome, patient function, goals, and level
 of risk
- Select appropriate patients for opioid-based management of cancer- or treatment-related persistent and breakthrough pain
- Employ multimodal opioid-based therapies tailored to the multidimensional pain assessment of patients with persistent and breakthrough pain
- Explain the respective roles of long-acting, short-acting, and rapid-onset opioids in the management of persistent and breakthrough pain

Confidential Page 36 of 39

Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies



Durable Outcomes Study Webcast Series

Monday, August 17, 2009 | 2:00 PM-2:30 PM Monday, August 31, 2009 | 2:00 PM-2:30 PM Monday, September 14, 2009 | 2:00 PM-2:30 PM

David M. Simpson, MD

New York, New York

S-10 fel live

S-10 fel live

Mar less surfactive

Dro were

Faculty

Perry G. Fine, MD Salt Lake City, Utah

Michael J. Brennan, MD Fairfield, Connecticut

CCME Reviewer David M. Kaufman, MD Bronx, New York

Learning Objectives

At the completion of this initiative, participants should be better prepared to:

- Define, recognize, and independently assess breakthrough and persistent pain in patients with chronic pain syndromes
- Implement a multidimensional assessment of persistent and breakthrough pain based, in part, on the
 phenomenology and inferred pathophysiology of the pain syndrome, patient function, goals, and level of risk
- · Select appropriate patients for opioid-based management of persistent and breakthrough pain
- Employ multimodal opioid-based therapies for patients with persistent and breakthrough pain
- Explain the respective roles of long-acting, short-acting, and rapid-onset opioids in the management of persistent and breakthrough pain

Confidential Page 37 of 39

Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies



PAINClinician.com™

Overview

PAINClinician.com™ is an independently funded forum committed to improving clinician access to high quality pain education. PAINClinician.com™ provides clinicians with an opportunity to share their insights and experience managing patients with debilitating acute and chronic pain disorders. By consolidating resources already available and generating new educational materials tailored to the needs of the community-all identified through ongoing surveys posted throughout the site—this forum will, we believe, facilitate the exchange of ideas, help clinicians practice the art and science of pain medicine, and ultimately improve patient care. Primary care physicians, pain specialists, emergency room clinicians, surgeons, physiatrists, anesthesiologists, neurologists, pharmacists, physician assistants, nurse practitioners, nurses, and the countless other healthcare providers who treat pain are all invited to participate in this global community.

Editorial Board

Charles E. Argoff, MD Albany, New York

Jennifer Bolen, JD Knoxville, Tennessee

Michael J. Brennan, MD Fairfield, Connecticut

F. Michael Ferrante, MD Los Angeles, California

Perry G. Fine, MD Salt Lake City, Utah

Scott M. Fishman, MD Davis, California

Keela A. Herr, PhD, RN Iowa City, Iowa

Kenneth L. Kirsh, PhD Lexington, Kentucky

Bill H. McCarberg, MD San Diego, California

Video Interviews

Christine A. Miaskowski, PhD, RN San Francisco, California

Visit www.painclinician.com to access our library of video commentary.

Srinivas Nalamachu, MD Overland Park, Kansas

Judith A. Paice, PhD, RN

Chicago, Illinois

Steven D. Passik, PhD New York, New York

Russell K. Portenoy, MD New York, New York

Joshua P. Prager, MD, MS Los Angeles, California

Steven D. Silberstein, MD Philadelphia, Pennsylvania

B. Todd Sitzman, MD, MPH Hattiesburg, Mississippi

Steven P. Stanos, DO Chicago, Illinois

Lynn R. Webster, MD, FACPM, FASAM Salt Lake City, Utah

Page 38 of 39 Confidentia

Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies



Contact Information

Albert Einstein College of Medicine

Steven Feld

Associate Director, CME (718) 920-6674, ext. 232 sfeld@montefiore.org

Asante Communications, LLC

David Clark, MS

Account Supervisor (646) 253-0896 dclark@asanteglobal.com

Philip Compton

Account Executive (646) 253-0887 pcompton@asanteglobal.com

Peter Hurwitz

President, Managing Director (646) 253-0888 phurwitz@asanteglobal.com

Jim Kappler, PhD

Vice President, Scientific Services (646) 253-0881 jkappler@asanteglobal.com

John Lapolla

Executive Vice President (646) 253-0884 ilapolla@asanteglobal.com

James Shannon

Account Supervisor (646) 253-0894 jshannon@asanteglobal.com

Ryan Raffel

Scientific Research Associate (646) 253-0897 rraffel@asanteglobal.com

Confidential Page 39 of 39